id	sid	tid	token	lemma	pos
dpc-1945	1	1	dermatology	dermatology	NOUN
dpc-1945	1	2	:	:	PUNCT
dpc-1945	1	3	practical	practical	ADJ
dpc-1945	1	4	and	and	CCONJ
dpc-1945	1	5	conceptual	conceptual	ADJ
dpc-1945	1	6	cutaneous	cutaneous	ADJ
dpc-1945	1	7	squamous	squamous	ADJ
dpc-1945	1	8	cell	cell	NOUN
dpc-1945	1	9	carcinoma	carcinoma	NOUN
dpc-1945	1	10	:	:	PUNCT
dpc-1945	1	11	an	an	DET
dpc-1945	1	12	update	update	NOUN
dpc-1945	1	13	on	on	ADP
dpc-1945	1	14	diagnosis	diagnosis	NOUN
dpc-1945	1	15	and	and	CCONJ
dpc-1945	1	16	treatment	treatment	NOUN
dpc-1945	1	17	table	table	NOUN
dpc-1945	1	18	of	of	ADP
dpc-1945	1	19	contents	content	NOUN
dpc-1945	1	20	risk	risk	NOUN
dpc-1945	1	21	factors	factor	NOUN
dpc-1945	1	22	and	and	CCONJ
dpc-1945	1	23	diagnosis	diagnosis	NOUN
dpc-1945	1	24	of	of	ADP
dpc-1945	1	25	advanced	advanced	ADJ
dpc-1945	1	26	cutaneous	cutaneous	ADJ
dpc-1945	1	27	squamous	squamous	ADJ
dpc-1945	1	28	cell	cell	NOUN
dpc-1945	1	29	carcinoma	carcinoma	NOUN
dpc-1945	1	30	gabriella	gabriella	PROPN
dpc-1945	1	31	brancaccio	brancaccio	PROPN
dpc-1945	1	32	,	,	PUNCT
dpc-1945	1	33	giulia	giulia	PROPN
dpc-1945	1	34	briatico	briatico	PROPN
dpc-1945	1	35	,	,	PUNCT
dpc-1945	1	36	cristina	cristina	PROPN
dpc-1945	1	37	pellegrini	pellegrini	PROPN
dpc-1945	1	38	,	,	PUNCT
dpc-1945	1	39	tea	tea	NOUN
dpc-1945	1	40	rocco	rocco	NOUN
dpc-1945	1	41	,	,	PUNCT
dpc-1945	1	42	elvira	elvira	PROPN
dpc-1945	1	43	moscarella	moscarella	PROPN
dpc-1945	1	44	,	,	PUNCT
dpc-1945	1	45	maria	maria	PROPN
dpc-1945	1	46	concetta	concetta	PROPN
dpc-1945	1	47	fargnoli	fargnoli	VERB
dpc-1945	1	48	surgery	surgery	NOUN
dpc-1945	1	49	for	for	ADP
dpc-1945	1	50	cutaneous	cutaneous	ADJ
dpc-1945	1	51	squamous	squamous	ADJ
dpc-1945	1	52	cell	cell	NOUN
dpc-1945	1	53	carcinoma	carcinoma	NOUN
dpc-1945	1	54	and	and	CCONJ
dpc-1945	1	55	its	its	PRON
dpc-1945	1	56	limits	limit	NOUN
dpc-1945	1	57	in	in	ADP
dpc-1945	1	58	advanced	advanced	ADJ
dpc-1945	1	59	disease	disease	NOUN
dpc-1945	1	60	david	david	PROPN
dpc-1945	1	61	moreno	moreno	PROPN
dpc-1945	1	62	-	-	PUNCT
dpc-1945	1	63	ramírez	ramírez	PROPN
dpc-1945	1	64	,	,	PUNCT
dpc-1945	1	65	francisca	francisca	PROPN
dpc-1945	1	66	silva	silva	PROPN
dpc-1945	1	67	-	-	PUNCT
dpc-1945	1	68	clavería	clavería	PROPN
dpc-1945	1	69	,	,	PUNCT
dpc-1945	1	70	almudena	almudena	PROPN
dpc-1945	1	71	fernández	fernández	PROPN
dpc-1945	1	72	-	-	PUNCT
dpc-1945	1	73	orland	orland	PROPN
dpc-1945	1	74	,	,	PUNCT
dpc-1945	1	75	noemí	noemí	PROPN
dpc-1945	1	76	eiris	eiris	PROPN
dpc-1945	1	77	,	,	PUNCT
dpc-1945	1	78	andrés	andrés	PROPN
dpc-1945	1	79	ruiz	ruiz	PROPN
dpc-1945	1	80	de	de	PROPN
dpc-1945	1	81	casas	casas	PROPN
dpc-1945	1	82	,	,	PUNCT
dpc-1945	1	83	lara	lara	PROPN
dpc-1945	1	84	ferrándiz	ferrándiz	PROPN
dpc-1945	1	85	radiotherapy	radiotherapy	PROPN
dpc-1945	1	86	in	in	ADP
dpc-1945	1	87	the	the	DET
dpc-1945	1	88	adjuvant	adjuvant	NOUN
dpc-1945	1	89	and	and	CCONJ
dpc-1945	1	90	advanced	advanced	ADJ
dpc-1945	1	91	setting	setting	NOUN
dpc-1945	1	92	of	of	ADP
dpc-1945	1	93	cscc	cscc	ADJ
dpc-1945	1	94	paolo	paolo	PROPN
dpc-1945	1	95	muto	muto	PROPN
dpc-1945	1	96	and	and	CCONJ
dpc-1945	1	97	francesco	francesco	PROPN
dpc-1945	1	98	pastore	pastore	PROPN
dpc-1945	1	99	immunotherapy	immunotherapy	NOUN
dpc-1945	1	100	and	and	CCONJ
dpc-1945	1	101	systemic	systemic	ADJ
dpc-1945	1	102	treatment	treatment	NOUN
dpc-1945	1	103	of	of	ADP
dpc-1945	1	104	cutaneous	cutaneous	ADJ
dpc-1945	1	105	squamous	squamous	ADJ
dpc-1945	1	106	cell	cell	NOUN
dpc-1945	1	107	carcinoma	carcinoma	NOUN
dpc-1945	1	108	nader	nader	VERB
dpc-1945	1	109	aboul	aboul	NOUN
dpc-1945	1	110	-	-	PUNCT
dpc-1945	1	111	fettouh	fettouh	PROPN
dpc-1945	1	112	,	,	PUNCT
dpc-1945	1	113	daniel	daniel	PROPN
dpc-1945	1	114	morse	morse	PROPN
dpc-1945	1	115	,	,	PUNCT
dpc-1945	1	116	jigar	jigar	PROPN
dpc-1945	1	117	patel	patel	PROPN
dpc-1945	1	118	,	,	PUNCT
dpc-1945	1	119	michael	michael	PROPN
dpc-1945	1	120	r.	r.	PROPN
dpc-1945	1	121	migden	migden	PROPN
dpc-1945	1	122	treatment	treatment	NOUN
dpc-1945	1	123	of	of	ADP
dpc-1945	1	124	cutaneous	cutaneous	ADJ
dpc-1945	1	125	squamous	squamous	ADJ
dpc-1945	1	126	cell	cell	NOUN
dpc-1945	1	127	carcinoma	carcinoma	NOUN
dpc-1945	1	128	with	with	ADP
dpc-1945	1	129	immune	immune	ADJ
dpc-1945	1	130	checkpoint	checkpoint	NOUN
dpc-1945	1	131	inhibitors	inhibitor	NOUN
dpc-1945	1	132	in	in	ADP
dpc-1945	1	133	special	special	ADJ
dpc-1945	1	134	populations	population	NOUN
dpc-1945	1	135	paolo	paolo	PROPN
dpc-1945	1	136	bossi	bossi	PROPN
dpc-1945	1	137	,	,	PUNCT
dpc-1945	1	138	luigi	luigi	PROPN
dpc-1945	1	139	lorini	lorini	PROPN
dpc-1945	1	140	mattioli	mattioli	PROPN
dpc-1945	1	141	1885	1885	NUM
dpc-1945	1	142	www.mattioli1885.com	www.mattioli1885.com	NOUN
dpc-1945	1	143	chief	chief	ADJ
dpc-1945	1	144	editor	editor	NOUN
dpc-1945	1	145	prof	prof	NOUN
dpc-1945	1	146	.	.	PUNCT
dpc-1945	2	1	giuseppe	giuseppe	PROPN
dpc-1945	2	2	argenziano	argenziano	PROPN
dpc-1945	2	3	,	,	PUNCT
dpc-1945	2	4	md	md	PROPN
dpc-1945	2	5	dermatology	dermatology	NOUN
dpc-1945	2	6	unit	unit	NOUN
dpc-1945	2	7	,	,	PUNCT
dpc-1945	2	8	university	university	PROPN
dpc-1945	2	9	of	of	ADP
dpc-1945	2	10	campania	campania	PROPN
dpc-1945	2	11	luigi	luigi	PROPN
dpc-1945	2	12	vanvitelli	vanvitelli	PROPN
dpc-1945	2	13	,	,	PUNCT
dpc-1945	2	14	naples	naples	PROPN
dpc-1945	2	15	,	,	PUNCT
dpc-1945	2	16	italy	italy	PROPN
dpc-1945	2	17	guest	guest	PROPN
dpc-1945	2	18	editors	editors	PROPN
dpc-1945	2	19	prof	prof	PROPN
dpc-1945	2	20	.	.	PUNCT
dpc-1945	3	1	luc	luc	PROPN
dpc-1945	3	2	thomas	thomas	PROPN
dpc-1945	3	3	,	,	PUNCT
dpc-1945	3	4	md	md	PROPN
dpc-1945	3	5	,	,	PUNCT
dpc-1945	3	6	phd	phd	NOUN
dpc-1945	3	7	full	full	ADJ
dpc-1945	3	8	professor	professor	NOUN
dpc-1945	3	9	and	and	CCONJ
dpc-1945	3	10	vice	vice	NOUN
dpc-1945	3	11	-	-	NOUN
dpc-1945	3	12	chair	chair	NOUN
dpc-1945	3	13	,	,	PUNCT
dpc-1945	3	14	department	department	NOUN
dpc-1945	3	15	of	of	ADP
dpc-1945	3	16	dermatology	dermatology	NOUN
dpc-1945	3	17	,	,	PUNCT
dpc-1945	3	18	lyon	lyon	PROPN
dpc-1945	3	19	cancer	cancer	PROPN
dpc-1945	3	20	research	research	PROPN
dpc-1945	3	21	center	center	PROPN
dpc-1945	3	22	,	,	PUNCT
dpc-1945	3	23	lyon	lyon	PROPN
dpc-1945	3	24	1	1	NUM
dpc-1945	3	25	university	university	NOUN
dpc-1945	3	26	,	,	PUNCT
dpc-1945	3	27	centre	centre	PROPN
dpc-1945	3	28	hospitalier	hospitalier	PROPN
dpc-1945	3	29	lyon	lyon	PROPN
dpc-1945	3	30	sud	sud	PROPN
dpc-1945	3	31	,	,	PUNCT
dpc-1945	3	32	france	france	PROPN
dpc-1945	3	33	.	.	PUNCT
dpc-1945	4	1	prof	prof	PROPN
dpc-1945	4	2	.	.	PUNCT
dpc-1945	5	1	ketty	ketty	PROPN
dpc-1945	5	2	peris	peris	PROPN
dpc-1945	5	3	,	,	PUNCT
dpc-1945	5	4	md	md	PROPN
dpc-1945	5	5	full	full	ADJ
dpc-1945	5	6	professor	professor	NOUN
dpc-1945	5	7	of	of	ADP
dpc-1945	5	8	dermatology	dermatology	NOUN
dpc-1945	5	9	,	,	PUNCT
dpc-1945	5	10	chief	chief	NOUN
dpc-1945	5	11	of	of	ADP
dpc-1945	5	12	the	the	DET
dpc-1945	5	13	complex	complex	ADJ
dpc-1945	5	14	operative	operative	ADJ
dpc-1945	5	15	unit	unit	NOUN
dpc-1945	5	16	of	of	ADP
dpc-1945	5	17	dermatology	dermatology	NOUN
dpc-1945	5	18	director	director	NOUN
dpc-1945	5	19	of	of	ADP
dpc-1945	5	20	the	the	DET
dpc-1945	5	21	dermatology	dermatology	NOUN
dpc-1945	5	22	and	and	CCONJ
dpc-1945	5	23	venereology	venereology	NOUN
dpc-1945	5	24	postgraduate	postgraduate	PROPN
dpc-1945	5	25	school	school	PROPN
dpc-1945	5	26	catholic	catholic	PROPN
dpc-1945	5	27	university	university	PROPN
dpc-1945	5	28	of	of	ADP
dpc-1945	5	29	rome	rome	PROPN
dpc-1945	5	30	fondazione	fondazione	PROPN
dpc-1945	5	31	policlinico	policlinico	PROPN
dpc-1945	5	32	universitario	universitario	PROPN
dpc-1945	5	33	agostino	agostino	PROPN
dpc-1945	5	34	gemelli	gemelli	PROPN
dpc-1945	5	35	irccs	irccs	PROPN
dpc-1945	5	36	rome	rome	PROPN
dpc-1945	5	37	,	,	PUNCT
dpc-1945	5	38	italy	italy	PROPN
dpc-1945	5	39	.	.	PUNCT
dpc-1945	6	1	dermatology	dermatology	PROPN
dpc-1945	6	2	practical	practical	ADJ
dpc-1945	6	3	&	&	CCONJ
dpc-1945	6	4	conceptual	conceptual	ADJ
dpc-1945	6	5	review	review	NOUN
dpc-1945	6	6	|	|	ADV
dpc-1945	6	7	dermatol	dermatol	ADJ
dpc-1945	6	8	pract	pract	NOUN
dpc-1945	6	9	concept	concept	NOUN
dpc-1945	6	10	.	.	PUNCT
dpc-1945	7	1	2021	2021	NUM
dpc-1945	7	2	;	;	PUNCT
dpc-1945	7	3	11(s2	11(s2	NUM
dpc-1945	7	4	):	):	PUNCT
dpc-1945	7	5	e2021169s	e2021169s	NOUN
dpc-1945	7	6	1	1	NUM
dpc-1945	7	7	immunotherapy	immunotherapy	NOUN
dpc-1945	7	8	and	and	CCONJ
dpc-1945	7	9	systemic	systemic	ADJ
dpc-1945	7	10	treatment	treatment	NOUN
dpc-1945	7	11	of	of	ADP
dpc-1945	7	12	cutaneous	cutaneous	ADJ
dpc-1945	7	13	squamous	squamous	ADJ
dpc-1945	7	14	cell	cell	NOUN
dpc-1945	7	15	carcinoma	carcinoma	NOUN
dpc-1945	7	16	nader	nader	VERB
dpc-1945	7	17	aboul	aboul	PROPN
dpc-1945	7	18	-	-	PUNCT
dpc-1945	7	19	fettouh1	fettouh1	PROPN
dpc-1945	7	20	,	,	PUNCT
dpc-1945	7	21	daniel	daniel	PROPN
dpc-1945	7	22	morse1	morse1	PROPN
dpc-1945	7	23	,	,	PUNCT
dpc-1945	7	24	jigar	jigar	PROPN
dpc-1945	7	25	patel2	patel2	PROPN
dpc-1945	7	26	,	,	PUNCT
dpc-1945	7	27	michael	michael	PROPN
dpc-1945	7	28	r.	r.	PROPN
dpc-1945	7	29	migden3	migden3	PROPN
dpc-1945	7	30	1	1	NUM
dpc-1945	7	31	department	department	NOUN
dpc-1945	7	32	of	of	ADP
dpc-1945	7	33	dermatology	dermatology	NOUN
dpc-1945	7	34	,	,	PUNCT
dpc-1945	7	35	the	the	DET
dpc-1945	7	36	university	university	PROPN
dpc-1945	7	37	of	of	ADP
dpc-1945	7	38	texas	texas	PROPN
dpc-1945	7	39	mcgovern	mcgovern	PROPN
dpc-1945	7	40	medical	medical	PROPN
dpc-1945	7	41	school	school	PROPN
dpc-1945	7	42	at	at	ADP
dpc-1945	7	43	houston	houston	PROPN
dpc-1945	7	44	,	,	PUNCT
dpc-1945	7	45	houston	houston	PROPN
dpc-1945	7	46	,	,	PUNCT
dpc-1945	7	47	tx	tx	PROPN
dpc-1945	7	48	,	,	PUNCT
dpc-1945	7	49	usa	usa	PROPN
dpc-1945	7	50	2	2	NUM
dpc-1945	7	51	department	department	NOUN
dpc-1945	7	52	of	of	ADP
dpc-1945	7	53	dermatology	dermatology	NOUN
dpc-1945	7	54	,	,	PUNCT
dpc-1945	7	55	the	the	DET
dpc-1945	7	56	university	university	PROPN
dpc-1945	7	57	of	of	ADP
dpc-1945	7	58	texas	texas	PROPN
dpc-1945	7	59	md	md	PROPN
dpc-1945	7	60	anderson	anderson	PROPN
dpc-1945	7	61	cancer	cancer	PROPN
dpc-1945	7	62	center	center	PROPN
dpc-1945	7	63	,	,	PUNCT
dpc-1945	7	64	houston	houston	PROPN
dpc-1945	7	65	,	,	PUNCT
dpc-1945	7	66	tx	tx	PROPN
dpc-1945	7	67	,	,	PUNCT
dpc-1945	7	68	usa	usa	PROPN
dpc-1945	7	69	3	3	NUM
dpc-1945	7	70	departments	department	NOUN
dpc-1945	7	71	of	of	ADP
dpc-1945	7	72	dermatology	dermatology	NOUN
dpc-1945	7	73	and	and	CCONJ
dpc-1945	7	74	head	head	NOUN
dpc-1945	7	75	and	and	CCONJ
dpc-1945	7	76	neck	neck	NOUN
dpc-1945	7	77	surgery	surgery	NOUN
dpc-1945	7	78	,	,	PUNCT
dpc-1945	7	79	the	the	DET
dpc-1945	7	80	university	university	PROPN
dpc-1945	7	81	of	of	ADP
dpc-1945	7	82	texas	texas	PROPN
dpc-1945	7	83	md	md	PROPN
dpc-1945	7	84	anderson	anderson	PROPN
dpc-1945	7	85	cancer	cancer	PROPN
dpc-1945	7	86	center	center	PROPN
dpc-1945	7	87	,	,	PUNCT
dpc-1945	7	88	houston	houston	PROPN
dpc-1945	7	89	,	,	PUNCT
dpc-1945	7	90	tx	tx	PROPN
dpc-1945	7	91	,	,	PUNCT
dpc-1945	7	92	usa	usa	PROPN
dpc-1945	7	93	citation	citation	PROPN
dpc-1945	7	94	:	:	PUNCT
dpc-1945	7	95	aboul	aboul	ADJ
dpc-1945	7	96	-	-	PUNCT
dpc-1945	7	97	fettouh	fettouh	NOUN
dpc-1945	7	98	n	n	CCONJ
dpc-1945	7	99	,	,	PUNCT
dpc-1945	7	100	morse	morse	PROPN
dpc-1945	7	101	d	d	PROPN
dpc-1945	7	102	,	,	PUNCT
dpc-1945	7	103	patel	patel	PROPN
dpc-1945	7	104	j	j	PROPN
dpc-1945	7	105	,	,	PUNCT
dpc-1945	7	106	migden	migden	VERB
dpc-1945	7	107	mr	mr	PROPN
dpc-1945	7	108	.	.	PROPN
dpc-1945	7	109	immunotherapy	immunotherapy	PROPN
dpc-1945	7	110	and	and	CCONJ
dpc-1945	7	111	systemic	systemic	ADJ
dpc-1945	7	112	treatment	treatment	NOUN
dpc-1945	7	113	of	of	ADP
dpc-1945	7	114	cutaneous	cutaneous	ADJ
dpc-1945	7	115	squamous	squamous	ADJ
dpc-1945	7	116	cell	cell	NOUN
dpc-1945	7	117	carcinoma	carcinoma	NOUN
dpc-1945	7	118	.	.	PUNCT
dpc-1945	8	1	dermatol	dermatol	NOUN
dpc-1945	8	2	pract	pract	PROPN
dpc-1945	8	3	concept	concept	NOUN
dpc-1945	8	4	.	.	PUNCT
dpc-1945	9	1	2021	2021	NUM
dpc-1945	9	2	;	;	PUNCT
dpc-1945	9	3	11(s2	11(s2	NUM
dpc-1945	9	4	):	):	PUNCT
dpc-1945	10	1	e2021169s	e2021169s	NOUN
dpc-1945	10	2	.	.	PUNCT
dpc-1945	10	3	doi	doi	PROPN
dpc-1945	10	4	:	:	PUNCT
dpc-1945	10	5	https://doi.org/10.5826/dpc.11s2a169s	https://doi.org/10.5826/dpc.11s2a169s	PROPN
dpc-1945	10	6	accepted	accept	VERB
dpc-1945	10	7	:	:	PUNCT
dpc-1945	10	8	may	may	AUX
dpc-1945	10	9	17	17	NUM
dpc-1945	10	10	,	,	PUNCT
dpc-1945	10	11	2021	2021	NUM
dpc-1945	10	12	;	;	PUNCT
dpc-1945	10	13	published	publish	VERB
dpc-1945	10	14	:	:	PUNCT
dpc-1945	11	1	october	october	PROPN
dpc-1945	11	2	2021	2021	NUM
dpc-1945	11	3	copyright	copyright	NOUN
dpc-1945	11	4	:	:	PUNCT
dpc-1945	11	5	©	©	PROPN
dpc-1945	11	6	2021	2021	NUM
dpc-1945	11	7	aboul	aboul	PROPN
dpc-1945	11	8	-	-	PUNCT
dpc-1945	11	9	fettouh	fettouh	NOUN
dpc-1945	11	10	et	et	PROPN
dpc-1945	11	11	al	al	PROPN
dpc-1945	11	12	.	.	PUNCT
dpc-1945	12	1	this	this	PRON
dpc-1945	12	2	is	be	AUX
dpc-1945	12	3	an	an	DET
dpc-1945	12	4	open	open	ADJ
dpc-1945	12	5	-	-	PUNCT
dpc-1945	12	6	access	access	NOUN
dpc-1945	12	7	article	article	NOUN
dpc-1945	12	8	distributed	distribute	VERB
dpc-1945	12	9	under	under	ADP
dpc-1945	12	10	the	the	DET
dpc-1945	12	11	terms	term	NOUN
dpc-1945	12	12	of	of	ADP
dpc-1945	12	13	the	the	DET
dpc-1945	12	14	creative	creative	ADJ
dpc-1945	12	15	commons	common	NOUN
dpc-1945	12	16	attribution	attribution	NOUN
dpc-1945	12	17	license	license	NOUN
dpc-1945	12	18	by	by	ADP
dpc-1945	12	19	-	-	PUNCT
dpc-1945	12	20	nc-4.0	nc-4.0	NOUN
dpc-1945	12	21	,	,	PUNCT
dpc-1945	12	22	which	which	PRON
dpc-1945	12	23	permits	permit	VERB
dpc-1945	12	24	unrestricted	unrestricted	ADJ
dpc-1945	12	25	noncommercial	noncommercial	ADJ
dpc-1945	12	26	use	use	NOUN
dpc-1945	12	27	,	,	PUNCT
dpc-1945	12	28	distribution	distribution	NOUN
dpc-1945	12	29	,	,	PUNCT
dpc-1945	12	30	and	and	CCONJ
dpc-1945	12	31	reproduction	reproduction	NOUN
dpc-1945	12	32	in	in	ADP
dpc-1945	12	33	any	any	DET
dpc-1945	12	34	medium	medium	NOUN
dpc-1945	12	35	,	,	PUNCT
dpc-1945	12	36	provided	provide	VERB
dpc-1945	12	37	the	the	DET
dpc-1945	12	38	original	original	ADJ
dpc-1945	12	39	authors	author	NOUN
dpc-1945	12	40	and	and	CCONJ
dpc-1945	12	41	source	source	NOUN
dpc-1945	12	42	are	be	AUX
dpc-1945	12	43	credited	credit	VERB
dpc-1945	12	44	.	.	PUNCT
dpc-1945	13	1	funding	funding	NOUN
dpc-1945	13	2	.	.	PUNCT
dpc-1945	14	1	none	none	NOUN
dpc-1945	14	2	.	.	PUNCT
dpc-1945	15	1	competing	compete	VERB
dpc-1945	15	2	interests	interest	NOUN
dpc-1945	15	3	:	:	PUNCT
dpc-1945	15	4	none	none	NOUN
dpc-1945	15	5	.	.	PUNCT
dpc-1945	16	1	this	this	DET
dpc-1945	16	2	report	report	NOUN
dpc-1945	16	3	has	have	AUX
dpc-1945	16	4	not	not	PART
dpc-1945	16	5	been	be	AUX
dpc-1945	16	6	presented	present	VERB
dpc-1945	16	7	or	or	CCONJ
dpc-1945	16	8	published	publish	VERB
dpc-1945	16	9	previously	previously	ADV
dpc-1945	16	10	.	.	PUNCT
dpc-1945	17	1	authorship	authorship	NOUN
dpc-1945	17	2	:	:	PUNCT
dpc-1945	17	3	all	all	DET
dpc-1945	17	4	authors	author	NOUN
dpc-1945	17	5	have	have	AUX
dpc-1945	17	6	contributed	contribute	VERB
dpc-1945	17	7	significantly	significantly	ADV
dpc-1945	17	8	to	to	ADP
dpc-1945	17	9	this	this	DET
dpc-1945	17	10	publication	publication	NOUN
dpc-1945	17	11	.	.	PUNCT
dpc-1945	18	1	corresponding	correspond	VERB
dpc-1945	18	2	author	author	NOUN
dpc-1945	18	3	:	:	PUNCT
dpc-1945	18	4	michael	michael	PROPN
dpc-1945	18	5	r.	r.	PROPN
dpc-1945	18	6	migden	migden	PROPN
dpc-1945	18	7	,	,	PUNCT
dpc-1945	18	8	md	md	PROPN
dpc-1945	18	9	,	,	PUNCT
dpc-1945	18	10	professor	professor	NOUN
dpc-1945	18	11	,	,	PUNCT
dpc-1945	18	12	departments	department	NOUN
dpc-1945	18	13	of	of	ADP
dpc-1945	18	14	dermatology	dermatology	NOUN
dpc-1945	18	15	and	and	CCONJ
dpc-1945	18	16	head	head	NOUN
dpc-1945	18	17	and	and	CCONJ
dpc-1945	18	18	neck	neck	NOUN
dpc-1945	18	19	surgery	surgery	NOUN
dpc-1945	18	20	,	,	PUNCT
dpc-1945	18	21	the	the	DET
dpc-1945	18	22	university	university	PROPN
dpc-1945	18	23	of	of	ADP
dpc-1945	18	24	texas	texas	PROPN
dpc-1945	18	25	md	md	PROPN
dpc-1945	18	26	anderson	anderson	PROPN
dpc-1945	18	27	cancer	cancer	PROPN
dpc-1945	18	28	center	center	PROPN
dpc-1945	18	29	,	,	PUNCT
dpc-1945	18	30	houston	houston	PROPN
dpc-1945	18	31	,	,	PUNCT
dpc-1945	18	32	tx	tx	PROPN
dpc-1945	18	33	,	,	PUNCT
dpc-1945	18	34	usa	usa	PROPN
dpc-1945	18	35	.	.	PROPN
dpc-1945	18	36	email	email	NOUN
dpc-1945	18	37	:	:	PUNCT
dpc-1945	19	1	mrmigden@mdanderson.org	mrmigden@mdanderson.org	X
dpc-1945	19	2	this	this	DET
dpc-1945	19	3	article	article	NOUN
dpc-1945	19	4	is	be	AUX
dpc-1945	19	5	part	part	NOUN
dpc-1945	19	6	of	of	ADP
dpc-1945	19	7	the	the	DET
dpc-1945	19	8	dpc	dpc	PROPN
dpc-1945	19	9	journal	journal	PROPN
dpc-1945	19	10	special	special	ADJ
dpc-1945	19	11	issue	issue	NOUN
dpc-1945	19	12	cutaneous	cutaneous	ADJ
dpc-1945	19	13	squamous	squamous	ADJ
dpc-1945	19	14	cell	cell	NOUN
dpc-1945	19	15	carcinoma	carcinoma	NOUN
dpc-1945	19	16	:	:	PUNCT
dpc-1945	19	17	an	an	DET
dpc-1945	19	18	update	update	NOUN
dpc-1945	19	19	on	on	ADP
dpc-1945	19	20	diagnosis	diagnosis	NOUN
dpc-1945	19	21	and	and	CCONJ
dpc-1945	19	22	treatment	treatment	NOUN
dpc-1945	19	23	guest	guest	NOUN
dpc-1945	19	24	editors	editor	NOUN
dpc-1945	19	25	prof	prof	PROPN
dpc-1945	19	26	.	.	PUNCT
dpc-1945	20	1	luc	luc	PROPN
dpc-1945	20	2	thomas	thomas	PROPN
dpc-1945	20	3	,	,	PUNCT
dpc-1945	20	4	md	md	PROPN
dpc-1945	20	5	,	,	PUNCT
dpc-1945	20	6	phd	phd	NOUN
dpc-1945	20	7	full	full	ADJ
dpc-1945	20	8	professor	professor	NOUN
dpc-1945	20	9	and	and	CCONJ
dpc-1945	20	10	vice	vice	NOUN
dpc-1945	20	11	-	-	NOUN
dpc-1945	20	12	chair	chair	NOUN
dpc-1945	20	13	,	,	PUNCT
dpc-1945	20	14	department	department	NOUN
dpc-1945	20	15	of	of	ADP
dpc-1945	20	16	dermatology	dermatology	NOUN
dpc-1945	20	17	,	,	PUNCT
dpc-1945	20	18	lyon	lyon	PROPN
dpc-1945	20	19	cancer	cancer	PROPN
dpc-1945	20	20	research	research	PROPN
dpc-1945	20	21	center	center	PROPN
dpc-1945	20	22	,	,	PUNCT
dpc-1945	20	23	lyon	lyon	PROPN
dpc-1945	20	24	1	1	NUM
dpc-1945	20	25	university	university	NOUN
dpc-1945	20	26	,	,	PUNCT
dpc-1945	20	27	centre	centre	PROPN
dpc-1945	20	28	hospitalier	hospitalier	PROPN
dpc-1945	20	29	lyon	lyon	PROPN
dpc-1945	20	30	sud	sud	PROPN
dpc-1945	20	31	,	,	PUNCT
dpc-1945	20	32	france	france	PROPN
dpc-1945	20	33	.	.	PUNCT
dpc-1945	21	1	prof	prof	PROPN
dpc-1945	21	2	.	.	PUNCT
dpc-1945	22	1	ketty	ketty	PROPN
dpc-1945	22	2	peris	peris	PROPN
dpc-1945	22	3	,	,	PUNCT
dpc-1945	22	4	md	md	PROPN
dpc-1945	22	5	full	full	ADJ
dpc-1945	22	6	professor	professor	NOUN
dpc-1945	22	7	of	of	ADP
dpc-1945	22	8	dermatology	dermatology	NOUN
dpc-1945	22	9	,	,	PUNCT
dpc-1945	22	10	chief	chief	NOUN
dpc-1945	22	11	of	of	ADP
dpc-1945	22	12	the	the	DET
dpc-1945	22	13	complex	complex	ADJ
dpc-1945	22	14	operative	operative	ADJ
dpc-1945	22	15	unit	unit	NOUN
dpc-1945	22	16	of	of	ADP
dpc-1945	22	17	dermatology	dermatology	NOUN
dpc-1945	22	18	director	director	NOUN
dpc-1945	22	19	of	of	ADP
dpc-1945	22	20	the	the	DET
dpc-1945	22	21	dermatology	dermatology	NOUN
dpc-1945	22	22	and	and	CCONJ
dpc-1945	22	23	venereology	venereology	NOUN
dpc-1945	22	24	postgraduate	postgraduate	PROPN
dpc-1945	22	25	school	school	PROPN
dpc-1945	22	26	catholic	catholic	PROPN
dpc-1945	22	27	university	university	PROPN
dpc-1945	22	28	of	of	ADP
dpc-1945	22	29	rome	rome	PROPN
dpc-1945	22	30	fondazione	fondazione	PROPN
dpc-1945	22	31	policlinico	policlinico	PROPN
dpc-1945	22	32	universitario	universitario	PROPN
dpc-1945	22	33	agostino	agostino	PROPN
dpc-1945	22	34	gemelli	gemelli	PROPN
dpc-1945	22	35	irccs	irccs	PROPN
dpc-1945	22	36	rome	rome	PROPN
dpc-1945	22	37	,	,	PUNCT
dpc-1945	22	38	italy	italy	PROPN
dpc-1945	22	39	.	.	PUNCT
dpc-1945	23	1	cutaneous	cutaneous	ADJ
dpc-1945	23	2	squamous	squamous	ADJ
dpc-1945	23	3	cell	cell	NOUN
dpc-1945	23	4	carcinomas	carcinoma	NOUN
dpc-1945	23	5	(	(	PUNCT
dpc-1945	23	6	cscc	cscc	ADJ
dpc-1945	23	7	)	)	PUNCT
dpc-1945	23	8	represent	represent	VERB
dpc-1945	23	9	one	one	NUM
dpc-1945	23	10	of	of	ADP
dpc-1945	23	11	the	the	DET
dpc-1945	23	12	most	most	ADV
dpc-1945	23	13	diagnosed	diagnose	VERB
dpc-1945	23	14	non	non	ADJ
dpc-1945	23	15	-	-	ADJ
dpc-1945	23	16	melanoma	melanoma	ADJ
dpc-1945	23	17	skin	skin	NOUN
dpc-1945	23	18	cancers	cancer	NOUN
dpc-1945	23	19	and	and	CCONJ
dpc-1945	23	20	its	its	PRON
dpc-1945	23	21	incidence	incidence	NOUN
dpc-1945	23	22	is	be	AUX
dpc-1945	23	23	increasing	increase	VERB
dpc-1945	23	24	globally	globally	ADV
dpc-1945	23	25	.	.	PUNCT
dpc-1945	24	1	whereas	whereas	SCONJ
dpc-1945	24	2	early	early	ADJ
dpc-1945	24	3	stage	stage	NOUN
dpc-1945	24	4	and	and	CCONJ
dpc-1945	24	5	low	low	ADJ
dpc-1945	24	6	risk	risk	NOUN
dpc-1945	24	7	cscc	cscc	NOUN
dpc-1945	24	8	is	be	AUX
dpc-1945	24	9	typically	typically	ADV
dpc-1945	24	10	treated	treat	VERB
dpc-1945	24	11	with	with	ADP
dpc-1945	24	12	surgery	surgery	NOUN
dpc-1945	24	13	,	,	PUNCT
dpc-1945	24	14	and	and	CCONJ
dpc-1945	24	15	in	in	ADP
dpc-1945	24	16	some	some	DET
dpc-1945	24	17	cases	case	NOUN
dpc-1945	24	18	other	other	ADJ
dpc-1945	24	19	localized	localize	VERB
dpc-1945	24	20	therapeutic	therapeutic	ADJ
dpc-1945	24	21	modalities	modality	NOUN
dpc-1945	24	22	,	,	PUNCT
dpc-1945	24	23	locally	locally	ADV
dpc-1945	24	24	advanced	advanced	ADJ
dpc-1945	24	25	or	or	CCONJ
dpc-1945	24	26	metastatic	metastatic	ADJ
dpc-1945	24	27	cscc	cscc	NOUN
dpc-1945	24	28	is	be	AUX
dpc-1945	24	29	a	a	DET
dpc-1945	24	30	cause	cause	NOUN
dpc-1945	24	31	of	of	ADP
dpc-1945	24	32	significant	significant	ADJ
dpc-1945	24	33	morbidity	morbidity	NOUN
dpc-1945	24	34	and	and	CCONJ
dpc-1945	24	35	mortality	mortality	NOUN
dpc-1945	24	36	that	that	PRON
dpc-1945	24	37	requires	require	VERB
dpc-1945	24	38	a	a	DET
dpc-1945	24	39	different	different	ADJ
dpc-1945	24	40	approach	approach	NOUN
dpc-1945	24	41	to	to	ADP
dpc-1945	24	42	therapy	therapy	NOUN
dpc-1945	24	43	.	.	PUNCT
dpc-1945	25	1	therapeutic	therapeutic	ADJ
dpc-1945	25	2	attempts	attempt	NOUN
dpc-1945	25	3	at	at	ADP
dpc-1945	25	4	treating	treat	VERB
dpc-1945	25	5	advanced	advanced	ADJ
dpc-1945	25	6	cscc	cscc	ADJ
dpc-1945	25	7	include	include	VERB
dpc-1945	25	8	a	a	DET
dpc-1945	25	9	multi	multi	ADJ
dpc-1945	25	10	-	-	ADJ
dpc-1945	25	11	disciplinary	disciplinary	ADJ
dpc-1945	25	12	approach	approach	NOUN
dpc-1945	25	13	with	with	ADP
dpc-1945	25	14	considerations	consideration	NOUN
dpc-1945	25	15	for	for	ADP
dpc-1945	25	16	surgery	surgery	NOUN
dpc-1945	25	17	,	,	PUNCT
dpc-1945	25	18	radiation	radiation	NOUN
dpc-1945	25	19	,	,	PUNCT
dpc-1945	25	20	and	and	CCONJ
dpc-1945	25	21	systemic	systemic	ADJ
dpc-1945	25	22	therapies	therapy	NOUN
dpc-1945	25	23	.	.	PUNCT
dpc-1945	26	1	in	in	ADP
dpc-1945	26	2	this	this	DET
dpc-1945	26	3	review	review	NOUN
dpc-1945	26	4	,	,	PUNCT
dpc-1945	26	5	we	we	PRON
dpc-1945	26	6	will	will	AUX
dpc-1945	26	7	discuss	discuss	VERB
dpc-1945	26	8	the	the	DET
dpc-1945	26	9	various	various	ADJ
dpc-1945	26	10	systemic	systemic	ADJ
dpc-1945	26	11	therapies	therapy	NOUN
dpc-1945	26	12	that	that	PRON
dpc-1945	26	13	have	have	AUX
dpc-1945	26	14	been	be	AUX
dpc-1945	26	15	trialed	triale	VERB
dpc-1945	26	16	for	for	ADP
dpc-1945	26	17	advanced	advanced	ADJ
dpc-1945	26	18	cscc	cscc	ADJ
dpc-1945	26	19	,	,	PUNCT
dpc-1945	26	20	beginning	begin	VERB
dpc-1945	26	21	with	with	ADP
dpc-1945	26	22	the	the	DET
dpc-1945	26	23	early	early	ADJ
dpc-1945	26	24	cytotoxic	cytotoxic	ADJ
dpc-1945	26	25	and	and	CCONJ
dpc-1945	26	26	platinum	platinum	NOUN
dpc-1945	26	27	-	-	PUNCT
dpc-1945	26	28	based	base	VERB
dpc-1945	26	29	agents	agent	NOUN
dpc-1945	26	30	as	as	ADV
dpc-1945	26	31	well	well	ADV
dpc-1945	26	32	as	as	ADP
dpc-1945	26	33	their	their	PRON
dpc-1945	26	34	corresponding	corresponding	ADJ
dpc-1945	26	35	limitations	limitation	NOUN
dpc-1945	26	36	.	.	PUNCT
dpc-1945	27	1	we	we	PRON
dpc-1945	27	2	will	will	AUX
dpc-1945	27	3	then	then	ADV
dpc-1945	27	4	review	review	VERB
dpc-1945	27	5	the	the	DET
dpc-1945	27	6	targeted	target	VERB
dpc-1945	27	7	approaches	approach	NOUN
dpc-1945	27	8	using	use	VERB
dpc-1945	27	9	egfr	egfr	ADJ
dpc-1945	27	10	inhibitors	inhibitor	NOUN
dpc-1945	27	11	prior	prior	ADV
dpc-1945	27	12	to	to	ADP
dpc-1945	27	13	discussing	discuss	VERB
dpc-1945	27	14	the	the	DET
dpc-1945	27	15	more	more	ADV
dpc-1945	27	16	recent	recent	ADJ
dpc-1945	27	17	immunotherapeutics	immunotherapeutic	NOUN
dpc-1945	27	18	that	that	PRON
dpc-1945	27	19	have	have	AUX
dpc-1945	27	20	shown	show	VERB
dpc-1945	27	21	good	good	ADJ
dpc-1945	27	22	tumor	tumor	NOUN
dpc-1945	27	23	responses	response	NOUN
dpc-1945	27	24	in	in	ADP
dpc-1945	27	25	this	this	DET
dpc-1945	27	26	often	often	ADV
dpc-1945	27	27	-	-	PUNCT
dpc-1945	27	28	lethal	lethal	ADJ
dpc-1945	27	29	disease	disease	NOUN
dpc-1945	27	30	.	.	PUNCT
dpc-1945	28	1	abstract	abstract	ADJ
dpc-1945	28	2	2	2	NUM
dpc-1945	28	3	review	review	NOUN
dpc-1945	28	4	|	|	ADV
dpc-1945	28	5	dermatol	dermatol	ADJ
dpc-1945	28	6	pract	pract	NOUN
dpc-1945	28	7	concept	concept	NOUN
dpc-1945	28	8	.	.	PUNCT
dpc-1945	29	1	2021	2021	NUM
dpc-1945	29	2	;	;	PUNCT
dpc-1945	29	3	11(s2	11(s2	NUM
dpc-1945	29	4	):	):	PUNCT
dpc-1945	29	5	e2021169s	e2021169s	NOUN
dpc-1945	29	6	introduction	introduction	NOUN
dpc-1945	29	7	the	the	DET
dpc-1945	29	8	increasing	increase	VERB
dpc-1945	29	9	global	global	ADJ
dpc-1945	29	10	incidence	incidence	NOUN
dpc-1945	29	11	of	of	ADP
dpc-1945	29	12	cutaneous	cutaneous	ADJ
dpc-1945	29	13	squamous	squamous	ADJ
dpc-1945	29	14	cell	cell	NOUN
dpc-1945	29	15	carcinoma	carcinoma	NOUN
dpc-1945	29	16	(	(	PUNCT
dpc-1945	29	17	cscc	cscc	ADJ
dpc-1945	29	18	)	)	PUNCT
dpc-1945	29	19	is	be	AUX
dpc-1945	29	20	an	an	DET
dpc-1945	29	21	emerging	emerge	VERB
dpc-1945	29	22	health	health	NOUN
dpc-1945	29	23	crisis	crisis	NOUN
dpc-1945	30	1	[	[	X
dpc-1945	30	2	1	1	NUM
dpc-1945	30	3	,	,	PUNCT
dpc-1945	30	4	2	2	NUM
dpc-1945	30	5	]	]	PUNCT
dpc-1945	30	6	.	.	PUNCT
dpc-1945	31	1	studies	study	NOUN
dpc-1945	31	2	in	in	ADP
dpc-1945	31	3	the	the	DET
dpc-1945	31	4	united	united	PROPN
dpc-1945	31	5	kingdom	kingdom	PROPN
dpc-1945	31	6	,	,	PUNCT
dpc-1945	31	7	sweden	sweden	PROPN
dpc-1945	31	8	,	,	PUNCT
dpc-1945	31	9	and	and	CCONJ
dpc-1945	31	10	germany	germany	PROPN
dpc-1945	31	11	suggest	suggest	VERB
dpc-1945	31	12	an	an	DET
dpc-1945	31	13	incidence	incidence	NOUN
dpc-1945	31	14	of	of	ADP
dpc-1945	31	15	cscc	cscc	NOUN
dpc-1945	31	16	between	between	ADP
dpc-1945	31	17	9	9	NUM
dpc-1945	31	18	-	-	SYM
dpc-1945	31	19	96	96	NUM
dpc-1945	31	20	per	per	ADP
dpc-1945	31	21	100,000	100,000	NUM
dpc-1945	31	22	males	male	NOUN
dpc-1945	31	23	and	and	CCONJ
dpc-1945	31	24	5	5	NUM
dpc-1945	31	25	-	-	SYM
dpc-1945	31	26	68	68	NUM
dpc-1945	31	27	per	per	ADP
dpc-1945	31	28	100,000	100,000	NUM
dpc-1945	31	29	females	female	NOUN
dpc-1945	31	30	[	[	X
dpc-1945	31	31	3	3	NUM
dpc-1945	31	32	-	-	SYM
dpc-1945	31	33	5	5	NUM
dpc-1945	31	34	]	]	PUNCT
dpc-1945	31	35	,	,	PUNCT
dpc-1945	31	36	where	where	SCONJ
dpc-1945	31	37	australian	australian	ADJ
dpc-1945	31	38	data	datum	NOUN
dpc-1945	31	39	reveals	reveal	VERB
dpc-1945	31	40	an	an	DET
dpc-1945	31	41	even	even	ADV
dpc-1945	31	42	higher	high	ADJ
dpc-1945	31	43	incidence	incidence	NOUN
dpc-1945	31	44	of	of	ADP
dpc-1945	31	45	499	499	NUM
dpc-1945	31	46	per	per	ADP
dpc-1945	31	47	100,000	100,000	NUM
dpc-1945	31	48	males	male	NOUN
dpc-1945	31	49	and	and	CCONJ
dpc-1945	31	50	291	291	NUM
dpc-1945	31	51	per	per	ADP
dpc-1945	31	52	100,000	100,000	NUM
dpc-1945	31	53	females	female	NOUN
dpc-1945	31	54	[	[	X
dpc-1945	31	55	6	6	NUM
dpc-1945	31	56	]	]	PUNCT
dpc-1945	31	57	.	.	PUNCT
dpc-1945	32	1	variations	variation	NOUN
dpc-1945	32	2	in	in	ADP
dpc-1945	32	3	cscc	cscc	ADJ
dpc-1945	32	4	incidence	incidence	NOUN
dpc-1945	32	5	may	may	AUX
dpc-1945	32	6	be	be	AUX
dpc-1945	32	7	due	due	ADJ
dpc-1945	32	8	to	to	ADP
dpc-1945	32	9	differing	differ	VERB
dpc-1945	32	10	nosologic	nosologic	ADJ
dpc-1945	32	11	classifications	classification	NOUN
dpc-1945	32	12	of	of	ADP
dpc-1945	32	13	cscc	cscc	NOUN
dpc-1945	32	14	between	between	ADP
dpc-1945	32	15	regions	region	NOUN
dpc-1945	32	16	,	,	PUNCT
dpc-1945	32	17	which	which	PRON
dpc-1945	32	18	may	may	AUX
dpc-1945	32	19	include	include	VERB
dpc-1945	32	20	actinic	actinic	ADJ
dpc-1945	32	21	keratoses	keratose	NOUN
dpc-1945	32	22	or	or	CCONJ
dpc-1945	32	23	be	be	AUX
dpc-1945	32	24	limited	limit	VERB
dpc-1945	32	25	to	to	ADP
dpc-1945	32	26	only	only	ADV
dpc-1945	32	27	invasive	invasive	ADJ
dpc-1945	32	28	disease	disease	NOUN
dpc-1945	32	29	.	.	PUNCT
dpc-1945	33	1	a	a	DET
dpc-1945	33	2	population	population	NOUN
dpc-1945	33	3	-	-	PUNCT
dpc-1945	33	4	based	base	VERB
dpc-1945	33	5	study	study	NOUN
dpc-1945	33	6	by	by	ADP
dpc-1945	33	7	the	the	DET
dpc-1945	33	8	mayo	mayo	PROPN
dpc-1945	33	9	clinic	clinic	PROPN
dpc-1945	33	10	revealed	reveal	VERB
dpc-1945	33	11	that	that	SCONJ
dpc-1945	33	12	between	between	ADP
dpc-1945	33	13	1976	1976	NUM
dpc-1945	33	14	-	-	SYM
dpc-1945	33	15	1984	1984	NUM
dpc-1945	33	16	and	and	CCONJ
dpc-1945	33	17	2000	2000	NUM
dpc-1945	33	18	-	-	SYM
dpc-1945	33	19	2010	2010	NUM
dpc-1945	33	20	the	the	DET
dpc-1945	33	21	incidence	incidence	NOUN
dpc-1945	33	22	of	of	ADP
dpc-1945	33	23	cscc	cscc	NOUN
dpc-1945	33	24	increased	increase	VERB
dpc-1945	33	25	by	by	ADP
dpc-1945	33	26	263	263	NUM
dpc-1945	33	27	%	%	NOUN
dpc-1945	33	28	[	[	X
dpc-1945	33	29	7	7	NUM
dpc-1945	33	30	]	]	PUNCT
dpc-1945	33	31	.	.	PUNCT
dpc-1945	34	1	in	in	ADP
dpc-1945	34	2	addition	addition	NOUN
dpc-1945	34	3	,	,	PUNCT
dpc-1945	34	4	recent	recent	ADJ
dpc-1945	34	5	reports	report	NOUN
dpc-1945	34	6	show	show	VERB
dpc-1945	34	7	an	an	DET
dpc-1945	34	8	increasing	increase	VERB
dpc-1945	34	9	incidence	incidence	NOUN
dpc-1945	34	10	of	of	ADP
dpc-1945	34	11	scc	scc	PROPN
dpc-1945	34	12	relative	relative	ADJ
dpc-1945	34	13	to	to	ADP
dpc-1945	34	14	bcc	bcc	PROPN
dpc-1945	34	15	in	in	ADP
dpc-1945	34	16	the	the	DET
dpc-1945	34	17	aging	age	VERB
dpc-1945	34	18	population	population	NOUN
dpc-1945	34	19	[	[	X
dpc-1945	34	20	8	8	NUM
dpc-1945	34	21	]	]	PUNCT
dpc-1945	34	22	.	.	PUNCT
dpc-1945	35	1	the	the	DET
dpc-1945	35	2	majority	majority	NOUN
dpc-1945	35	3	of	of	ADP
dpc-1945	35	4	early	early	ADJ
dpc-1945	35	5	stage	stage	NOUN
dpc-1945	35	6	cscc	cscc	ADJ
dpc-1945	35	7	cases	case	NOUN
dpc-1945	35	8	are	be	AUX
dpc-1945	35	9	successfully	successfully	ADV
dpc-1945	35	10	treated	treat	VERB
dpc-1945	35	11	by	by	ADP
dpc-1945	35	12	surgery	surgery	NOUN
dpc-1945	35	13	.	.	PUNCT
dpc-1945	36	1	in	in	ADP
dpc-1945	36	2	some	some	DET
dpc-1945	36	3	cases	case	NOUN
dpc-1945	36	4	,	,	PUNCT
dpc-1945	36	5	other	other	ADJ
dpc-1945	36	6	localized	localize	VERB
dpc-1945	36	7	therapeutic	therapeutic	ADJ
dpc-1945	36	8	modalities	modality	NOUN
dpc-1945	36	9	may	may	AUX
dpc-1945	36	10	be	be	AUX
dpc-1945	36	11	used	use	VERB
dpc-1945	36	12	[	[	PUNCT
dpc-1945	36	13	9,10	9,10	NUM
dpc-1945	36	14	]	]	X
dpc-1945	36	15	.	.	PUNCT
dpc-1945	37	1	these	these	PRON
dpc-1945	37	2	include	include	VERB
dpc-1945	37	3	topical	topical	ADJ
dpc-1945	37	4	cytostatic	cytostatic	ADJ
dpc-1945	37	5	therapy	therapy	NOUN
dpc-1945	37	6	(	(	PUNCT
dpc-1945	37	7	5	5	NUM
dpc-1945	37	8	-	-	PUNCT
dpc-1945	37	9	fluorouracil	fluorouracil	NOUN
dpc-1945	37	10	)	)	PUNCT
dpc-1945	37	11	,	,	PUNCT
dpc-1945	37	12	topical	topical	ADJ
dpc-1945	37	13	immunotherapy	immunotherapy	NOUN
dpc-1945	37	14	(	(	PUNCT
dpc-1945	37	15	imiquimod	imiquimod	ADJ
dpc-1945	37	16	)	)	PUNCT
dpc-1945	37	17	,	,	PUNCT
dpc-1945	37	18	or	or	CCONJ
dpc-1945	37	19	intralesional	intralesional	ADJ
dpc-1945	37	20	injection	injection	NOUN
dpc-1945	37	21	(	(	PUNCT
dpc-1945	37	22	methotrexate	methotrexate	NOUN
dpc-1945	37	23	,	,	PUNCT
dpc-1945	37	24	bleomycin	bleomycin	PROPN
dpc-1945	37	25	)	)	PUNCT
dpc-1945	37	26	.	.	PUNCT
dpc-1945	38	1	destructive	destructive	ADJ
dpc-1945	38	2	methods	method	NOUN
dpc-1945	38	3	with	with	ADP
dpc-1945	38	4	cryosurgery	cryosurgery	NOUN
dpc-1945	38	5	,	,	PUNCT
dpc-1945	38	6	lasers	laser	NOUN
dpc-1945	38	7	,	,	PUNCT
dpc-1945	38	8	photodynamic	photodynamic	ADJ
dpc-1945	38	9	therapy	therapy	NOUN
dpc-1945	38	10	,	,	PUNCT
dpc-1945	38	11	radiotherapy	radiotherapy	NOUN
dpc-1945	38	12	,	,	PUNCT
dpc-1945	38	13	or	or	CCONJ
dpc-1945	38	14	curettage	curettage	NOUN
dpc-1945	38	15	and	and	CCONJ
dpc-1945	38	16	electrodessication	electrodessication	NOUN
dpc-1945	38	17	may	may	AUX
dpc-1945	38	18	also	also	ADV
dpc-1945	38	19	be	be	AUX
dpc-1945	38	20	used	use	VERB
dpc-1945	38	21	in	in	ADP
dpc-1945	38	22	the	the	DET
dpc-1945	38	23	appropriate	appropriate	ADJ
dpc-1945	38	24	clinical	clinical	ADJ
dpc-1945	38	25	context	context	NOUN
dpc-1945	38	26	.	.	PUNCT
dpc-1945	39	1	approximately	approximately	ADV
dpc-1945	39	2	5	5	NUM
dpc-1945	39	3	%	%	NOUN
dpc-1945	39	4	of	of	ADP
dpc-1945	39	5	cscc	cscc	ADJ
dpc-1945	39	6	progress	progress	NOUN
dpc-1945	39	7	into	into	ADP
dpc-1945	39	8	advanced	advanced	ADJ
dpc-1945	39	9	cscc	cscc	NOUN
dpc-1945	39	10	[	[	X
dpc-1945	39	11	11	11	NUM
dpc-1945	39	12	]	]	PUNCT
dpc-1945	39	13	.	.	PUNCT
dpc-1945	40	1	advanced	advanced	ADJ
dpc-1945	40	2	cscc	cscc	NOUN
dpc-1945	40	3	is	be	AUX
dpc-1945	40	4	comprised	comprise	VERB
dpc-1945	40	5	of	of	ADP
dpc-1945	40	6	locally	locally	ADV
dpc-1945	40	7	advanced	advance	VERB
dpc-1945	40	8	contiguous	contiguous	ADJ
dpc-1945	40	9	disease	disease	NOUN
dpc-1945	40	10	that	that	PRON
dpc-1945	40	11	is	be	AUX
dpc-1945	40	12	a	a	DET
dpc-1945	40	13	poor	poor	ADJ
dpc-1945	40	14	candidate	candidate	NOUN
dpc-1945	40	15	for	for	ADP
dpc-1945	40	16	surgery	surgery	NOUN
dpc-1945	40	17	,	,	PUNCT
dpc-1945	40	18	single	single	ADJ
dpc-1945	40	19	-	-	PUNCT
dpc-1945	40	20	modality	modality	NOUN
dpc-1945	40	21	radiation	radiation	NOUN
dpc-1945	40	22	,	,	PUNCT
dpc-1945	40	23	or	or	CCONJ
dpc-1945	40	24	a	a	DET
dpc-1945	40	25	combination	combination	NOUN
dpc-1945	40	26	of	of	ADP
dpc-1945	40	27	the	the	DET
dpc-1945	40	28	two	two	NUM
dpc-1945	40	29	;	;	PUNCT
dpc-1945	40	30	and	and	CCONJ
dpc-1945	40	31	metastatic	metastatic	ADJ
dpc-1945	40	32	cscc	cscc	NOUN
dpc-1945	40	33	.	.	PUNCT
dpc-1945	41	1	in	in	ADP
dpc-1945	41	2	cases	case	NOUN
dpc-1945	41	3	of	of	ADP
dpc-1945	41	4	larger	large	ADJ
dpc-1945	41	5	,	,	PUNCT
dpc-1945	41	6	more	more	ADV
dpc-1945	41	7	aggressive	aggressive	ADJ
dpc-1945	41	8	cscc	cscc	NOUN
dpc-1945	41	9	where	where	SCONJ
dpc-1945	41	10	surgery	surgery	NOUN
dpc-1945	41	11	can	can	AUX
dpc-1945	41	12	feasibly	feasibly	ADV
dpc-1945	41	13	remove	remove	VERB
dpc-1945	41	14	all	all	PRON
dpc-1945	41	15	of	of	ADP
dpc-1945	41	16	the	the	DET
dpc-1945	41	17	tumor	tumor	NOUN
dpc-1945	41	18	burden	burden	NOUN
dpc-1945	41	19	,	,	PUNCT
dpc-1945	41	20	it	it	PRON
dpc-1945	41	21	may	may	AUX
dpc-1945	41	22	come	come	VERB
dpc-1945	41	23	with	with	ADP
dpc-1945	41	24	the	the	DET
dpc-1945	41	25	cost	cost	NOUN
dpc-1945	41	26	of	of	ADP
dpc-1945	41	27	significant	significant	ADJ
dpc-1945	41	28	morbidity	morbidity	NOUN
dpc-1945	41	29	and/or	and/or	CCONJ
dpc-1945	41	30	disfigurement	disfigurement	NOUN
dpc-1945	41	31	from	from	ADP
dpc-1945	41	32	damage	damage	NOUN
dpc-1945	41	33	to	to	ADP
dpc-1945	41	34	nearby	nearby	ADJ
dpc-1945	41	35	anatomical	anatomical	ADJ
dpc-1945	41	36	structures	structure	NOUN
dpc-1945	41	37	and	and	CCONJ
dpc-1945	41	38	thus	thus	ADV
dpc-1945	41	39	is	be	AUX
dpc-1945	41	40	not	not	PART
dpc-1945	41	41	a	a	DET
dpc-1945	41	42	reasonable	reasonable	ADJ
dpc-1945	41	43	option	option	NOUN
dpc-1945	41	44	.	.	PUNCT
dpc-1945	42	1	treatment	treatment	NOUN
dpc-1945	42	2	of	of	ADP
dpc-1945	42	3	metastatic	metastatic	ADJ
dpc-1945	42	4	cscc	cscc	NOUN
dpc-1945	42	5	also	also	ADV
dpc-1945	42	6	presents	present	VERB
dpc-1945	42	7	major	major	ADJ
dpc-1945	42	8	challenges	challenge	NOUN
dpc-1945	42	9	.	.	PUNCT
dpc-1945	43	1	surgery	surgery	NOUN
dpc-1945	43	2	,	,	PUNCT
dpc-1945	43	3	radiotherapy	radiotherapy	NOUN
dpc-1945	43	4	,	,	PUNCT
dpc-1945	43	5	and	and	CCONJ
dpc-1945	43	6	systemic	systemic	ADJ
dpc-1945	43	7	therapy	therapy	NOUN
dpc-1945	43	8	may	may	AUX
dpc-1945	43	9	be	be	AUX
dpc-1945	43	10	used	use	VERB
dpc-1945	43	11	in	in	ADP
dpc-1945	43	12	an	an	DET
dpc-1945	43	13	attempt	attempt	NOUN
dpc-1945	43	14	to	to	PART
dpc-1945	43	15	control	control	VERB
dpc-1945	43	16	disease	disease	NOUN
dpc-1945	43	17	.	.	PUNCT
dpc-1945	44	1	surgery	surgery	NOUN
dpc-1945	44	2	can	can	AUX
dpc-1945	44	3	be	be	AUX
dpc-1945	44	4	used	use	VERB
dpc-1945	44	5	for	for	ADP
dpc-1945	44	6	tumor	tumor	NOUN
dpc-1945	44	7	debulking	debulking	NOUN
dpc-1945	44	8	as	as	ADV
dpc-1945	44	9	well	well	ADV
dpc-1945	44	10	as	as	ADP
dpc-1945	44	11	excision	excision	NOUN
dpc-1945	44	12	of	of	ADP
dpc-1945	44	13	isolated	isolated	ADJ
dpc-1945	44	14	metastatic	metastatic	ADJ
dpc-1945	44	15	lesions	lesion	NOUN
dpc-1945	44	16	or	or	CCONJ
dpc-1945	44	17	involved	involve	VERB
dpc-1945	44	18	lymph	lymph	NOUN
dpc-1945	44	19	nodes	node	NOUN
dpc-1945	44	20	.	.	PUNCT
dpc-1945	45	1	radiotherapy	radiotherapy	NOUN
dpc-1945	45	2	may	may	AUX
dpc-1945	45	3	be	be	AUX
dpc-1945	45	4	beneficial	beneficial	ADJ
dpc-1945	45	5	in	in	ADP
dpc-1945	45	6	treating	treat	VERB
dpc-1945	45	7	bone	bone	NOUN
dpc-1945	45	8	metastases	metastasis	NOUN
dpc-1945	45	9	and	and	CCONJ
dpc-1945	45	10	locally	locally	ADV
dpc-1945	45	11	advanced	advanced	ADJ
dpc-1945	45	12	symptomatic	symptomatic	ADJ
dpc-1945	45	13	tumors	tumor	NOUN
dpc-1945	45	14	.	.	PUNCT
dpc-1945	46	1	in	in	ADP
dpc-1945	46	2	certain	certain	ADJ
dpc-1945	46	3	circumstances	circumstance	NOUN
dpc-1945	46	4	,	,	PUNCT
dpc-1945	46	5	these	these	DET
dpc-1945	46	6	modalities	modality	NOUN
dpc-1945	46	7	can	can	AUX
dpc-1945	46	8	be	be	AUX
dpc-1945	46	9	used	use	VERB
dpc-1945	46	10	with	with	ADP
dpc-1945	46	11	a	a	DET
dpc-1945	46	12	palliative	palliative	ADJ
dpc-1945	46	13	intent	intent	NOUN
dpc-1945	46	14	in	in	ADP
dpc-1945	46	15	order	order	NOUN
dpc-1945	46	16	to	to	PART
dpc-1945	46	17	improve	improve	VERB
dpc-1945	46	18	a	a	DET
dpc-1945	46	19	patient	patient	NOUN
dpc-1945	46	20	’s	’s	PART
dpc-1945	46	21	quality	quality	NOUN
dpc-1945	46	22	of	of	ADP
dpc-1945	46	23	life	life	NOUN
dpc-1945	46	24	.	.	PUNCT
dpc-1945	47	1	combining	combine	VERB
dpc-1945	47	2	surgery	surgery	NOUN
dpc-1945	47	3	and	and	CCONJ
dpc-1945	47	4	radiotherapy	radiotherapy	NOUN
dpc-1945	47	5	with	with	ADP
dpc-1945	47	6	systemic	systemic	ADJ
dpc-1945	47	7	therapy	therapy	NOUN
dpc-1945	47	8	can	can	AUX
dpc-1945	47	9	be	be	AUX
dpc-1945	47	10	helpful	helpful	ADJ
dpc-1945	47	11	,	,	PUNCT
dpc-1945	47	12	as	as	ADP
dpc-1945	47	13	complete	complete	ADJ
dpc-1945	47	14	remission	remission	NOUN
dpc-1945	47	15	of	of	ADP
dpc-1945	47	16	disease	disease	NOUN
dpc-1945	47	17	with	with	ADP
dpc-1945	47	18	purely	purely	ADV
dpc-1945	47	19	systemic	systemic	ADJ
dpc-1945	47	20	therapy	therapy	NOUN
dpc-1945	47	21	is	be	AUX
dpc-1945	47	22	not	not	PART
dpc-1945	47	23	guaranteed	guarantee	VERB
dpc-1945	47	24	.	.	PUNCT
dpc-1945	48	1	until	until	ADP
dpc-1945	48	2	recently	recently	ADV
dpc-1945	48	3	,	,	PUNCT
dpc-1945	48	4	systemic	systemic	ADJ
dpc-1945	48	5	treatment	treatment	NOUN
dpc-1945	48	6	for	for	ADP
dpc-1945	48	7	cscc	cscc	NOUN
dpc-1945	48	8	was	be	AUX
dpc-1945	48	9	not	not	PART
dpc-1945	48	10	highly	highly	ADV
dpc-1945	48	11	effective	effective	ADJ
dpc-1945	48	12	and	and	CCONJ
dpc-1945	48	13	often	often	ADV
dpc-1945	48	14	difficult	difficult	ADJ
dpc-1945	48	15	to	to	PART
dpc-1945	48	16	tolerate	tolerate	VERB
dpc-1945	48	17	,	,	PUNCT
dpc-1945	48	18	thus	thus	ADV
dpc-1945	48	19	negatively	negatively	ADV
dpc-1945	48	20	impacting	impact	VERB
dpc-1945	48	21	patient	patient	NOUN
dpc-1945	48	22	’s	’s	PART
dpc-1945	48	23	quality	quality	NOUN
dpc-1945	48	24	of	of	ADP
dpc-1945	48	25	life	life	NOUN
dpc-1945	48	26	.	.	PUNCT
dpc-1945	49	1	in	in	ADP
dpc-1945	49	2	this	this	DET
dpc-1945	49	3	article	article	NOUN
dpc-1945	49	4	,	,	PUNCT
dpc-1945	49	5	we	we	PRON
dpc-1945	49	6	will	will	AUX
dpc-1945	49	7	review	review	VERB
dpc-1945	49	8	the	the	DET
dpc-1945	49	9	various	various	ADJ
dpc-1945	49	10	systemic	systemic	ADJ
dpc-1945	49	11	agents	agent	NOUN
dpc-1945	49	12	that	that	PRON
dpc-1945	49	13	have	have	AUX
dpc-1945	49	14	been	be	AUX
dpc-1945	49	15	used	use	VERB
dpc-1945	49	16	to	to	PART
dpc-1945	49	17	treat	treat	VERB
dpc-1945	49	18	advanced	advanced	ADJ
dpc-1945	49	19	cscc	cscc	ADJ
dpc-1945	49	20	.	.	PUNCT
dpc-1945	50	1	our	our	PRON
dpc-1945	50	2	discussion	discussion	NOUN
dpc-1945	50	3	will	will	AUX
dpc-1945	50	4	range	range	VERB
dpc-1945	50	5	from	from	ADP
dpc-1945	50	6	the	the	DET
dpc-1945	50	7	older	old	ADJ
dpc-1945	50	8	,	,	PUNCT
dpc-1945	50	9	more	more	ADV
dpc-1945	50	10	antiquated	antiquated	ADJ
dpc-1945	50	11	,	,	PUNCT
dpc-1945	50	12	therapies	therapy	NOUN
dpc-1945	50	13	,	,	PUNCT
dpc-1945	50	14	to	to	ADP
dpc-1945	50	15	modern	modern	ADJ
dpc-1945	50	16	small	small	ADJ
dpc-1945	50	17	molecule	molecule	NOUN
dpc-1945	50	18	targeted	target	VERB
dpc-1945	50	19	therapies	therapy	NOUN
dpc-1945	50	20	and	and	CCONJ
dpc-1945	50	21	immunotherapies	immunotherapy	NOUN
dpc-1945	50	22	,	,	PUNCT
dpc-1945	50	23	of	of	ADP
dpc-1945	50	24	which	which	PRON
dpc-1945	50	25	pd-1	pd-1	ADP
dpc-1945	50	26	inhibitors	inhibitor	NOUN
dpc-1945	50	27	have	have	AUX
dpc-1945	50	28	shown	show	VERB
dpc-1945	50	29	adequate	adequate	ADJ
dpc-1945	50	30	tumor	tumor	NOUN
dpc-1945	50	31	responses	response	NOUN
dpc-1945	50	32	for	for	ADP
dpc-1945	50	33	locally	locally	ADV
dpc-1945	50	34	advanced	advanced	ADJ
dpc-1945	50	35	or	or	CCONJ
dpc-1945	50	36	metastatic	metastatic	ADJ
dpc-1945	50	37	cscc	cscc	NOUN
dpc-1945	50	38	.	.	PUNCT
dpc-1945	51	1	we	we	PRON
dpc-1945	51	2	will	will	AUX
dpc-1945	51	3	re	re	VERB
dpc-1945	51	4	-	-	VERB
dpc-1945	51	5	examine	examine	VERB
dpc-1945	51	6	the	the	DET
dpc-1945	51	7	systemic	systemic	ADJ
dpc-1945	51	8	agents	agent	NOUN
dpc-1945	51	9	that	that	PRON
dpc-1945	51	10	have	have	AUX
dpc-1945	51	11	been	be	AUX
dpc-1945	51	12	trialed	triale	VERB
dpc-1945	51	13	for	for	ADP
dpc-1945	51	14	advanced	advanced	ADJ
dpc-1945	51	15	cscc	cscc	VERB
dpc-1945	51	16	,	,	PUNCT
dpc-1945	51	17	discuss	discuss	VERB
dpc-1945	51	18	the	the	DET
dpc-1945	51	19	limitations	limitation	NOUN
dpc-1945	51	20	of	of	ADP
dpc-1945	51	21	each	each	DET
dpc-1945	51	22	agent	agent	NOUN
dpc-1945	51	23	,	,	PUNCT
dpc-1945	51	24	and	and	CCONJ
dpc-1945	51	25	highlight	highlight	VERB
dpc-1945	51	26	future	future	ADJ
dpc-1945	51	27	considerations	consideration	NOUN
dpc-1945	51	28	and	and	CCONJ
dpc-1945	51	29	investigations	investigation	NOUN
dpc-1945	51	30	needed	need	VERB
dpc-1945	51	31	to	to	PART
dpc-1945	51	32	optimize	optimize	VERB
dpc-1945	51	33	systemic	systemic	ADJ
dpc-1945	51	34	treatment	treatment	NOUN
dpc-1945	51	35	for	for	ADP
dpc-1945	51	36	advanced	advanced	ADJ
dpc-1945	51	37	cscc	cscc	ADJ
dpc-1945	51	38	.	.	PUNCT
dpc-1945	52	1	cytotoxic	cytotoxic	ADJ
dpc-1945	52	2	chemotherapy	chemotherapy	NOUN
dpc-1945	52	3	for	for	ADP
dpc-1945	52	4	cscc	cscc	ADJ
dpc-1945	52	5	prior	prior	ADV
dpc-1945	52	6	to	to	ADP
dpc-1945	52	7	the	the	DET
dpc-1945	52	8	development	development	NOUN
dpc-1945	52	9	of	of	ADP
dpc-1945	52	10	more	more	ADJ
dpc-1945	52	11	modern	modern	ADJ
dpc-1945	52	12	systemic	systemic	ADJ
dpc-1945	52	13	agents	agent	NOUN
dpc-1945	52	14	used	use	VERB
dpc-1945	52	15	today	today	NOUN
dpc-1945	52	16	,	,	PUNCT
dpc-1945	52	17	cytotoxic	cytotoxic	ADJ
dpc-1945	52	18	chemotherapy	chemotherapy	NOUN
dpc-1945	52	19	and	and	CCONJ
dpc-1945	52	20	platinum	platinum	NOUN
dpc-1945	52	21	-	-	PUNCT
dpc-1945	52	22	based	base	VERB
dpc-1945	52	23	agents	agent	NOUN
dpc-1945	52	24	were	be	AUX
dpc-1945	52	25	the	the	DET
dpc-1945	52	26	mainstay	mainstay	NOUN
dpc-1945	52	27	of	of	ADP
dpc-1945	52	28	therapy	therapy	NOUN
dpc-1945	52	29	for	for	ADP
dpc-1945	52	30	advanced	advanced	ADJ
dpc-1945	52	31	cscc	cscc	ADJ
dpc-1945	52	32	.	.	PUNCT
dpc-1945	53	1	numerous	numerous	ADJ
dpc-1945	53	2	agents	agent	NOUN
dpc-1945	53	3	,	,	PUNCT
dpc-1945	53	4	including	include	VERB
dpc-1945	53	5	cisplatin	cisplatin	NOUN
dpc-1945	53	6	,	,	PUNCT
dpc-1945	53	7	bleomycin	bleomycin	PROPN
dpc-1945	53	8	,	,	PUNCT
dpc-1945	53	9	interferon	interferon	ADJ
dpc-1945	53	10	,	,	PUNCT
dpc-1945	53	11	5	5	NUM
dpc-1945	53	12	-	-	PUNCT
dpc-1945	53	13	fluorouracil	fluorouracil	NOUN
dpc-1945	53	14	and	and	CCONJ
dpc-1945	53	15	doxorubicin	doxorubicin	PROPN
dpc-1945	53	16	had	have	AUX
dpc-1945	53	17	been	be	AUX
dpc-1945	53	18	trialed	triale	VERB
dpc-1945	53	19	;	;	PUNCT
dpc-1945	53	20	many	many	ADJ
dpc-1945	53	21	were	be	AUX
dpc-1945	53	22	published	publish	VERB
dpc-1945	53	23	as	as	ADP
dpc-1945	53	24	case	case	NOUN
dpc-1945	53	25	reports	report	NOUN
dpc-1945	53	26	or	or	CCONJ
dpc-1945	53	27	case	case	NOUN
dpc-1945	53	28	series	series	NOUN
dpc-1945	53	29	.	.	PUNCT
dpc-1945	54	1	these	these	DET
dpc-1945	54	2	articles	article	NOUN
dpc-1945	54	3	reported	report	VERB
dpc-1945	54	4	widely	widely	ADV
dpc-1945	54	5	varying	vary	VERB
dpc-1945	54	6	response	response	NOUN
dpc-1945	54	7	rates	rate	NOUN
dpc-1945	54	8	from	from	ADP
dpc-1945	54	9	17%-84	17%-84	NUM
dpc-1945	54	10	%	%	NOUN
dpc-1945	54	11	[	[	X
dpc-1945	54	12	1214	1214	NUM
dpc-1945	54	13	]	]	PUNCT
dpc-1945	54	14	.	.	PUNCT
dpc-1945	55	1	very	very	ADV
dpc-1945	55	2	few	few	ADJ
dpc-1945	55	3	adequately	adequately	ADV
dpc-1945	55	4	powered	power	VERB
dpc-1945	55	5	randomized	randomize	VERB
dpc-1945	55	6	controlled	control	VERB
dpc-1945	55	7	trials	trial	NOUN
dpc-1945	55	8	were	be	AUX
dpc-1945	55	9	available	available	ADJ
dpc-1945	55	10	to	to	PART
dpc-1945	55	11	guide	guide	VERB
dpc-1945	55	12	treatment	treatment	NOUN
dpc-1945	55	13	regimens	regimen	NOUN
dpc-1945	55	14	and	and	CCONJ
dpc-1945	55	15	there	there	PRON
dpc-1945	55	16	were	be	VERB
dpc-1945	55	17	no	no	DET
dpc-1945	55	18	formal	formal	ADJ
dpc-1945	55	19	treatment	treatment	NOUN
dpc-1945	55	20	recommendations	recommendation	NOUN
dpc-1945	55	21	.	.	PUNCT
dpc-1945	56	1	in	in	ADP
dpc-1945	56	2	many	many	ADJ
dpc-1945	56	3	cases	case	NOUN
dpc-1945	56	4	,	,	PUNCT
dpc-1945	56	5	these	these	DET
dpc-1945	56	6	agents	agent	NOUN
dpc-1945	56	7	were	be	AUX
dpc-1945	56	8	combined	combine	VERB
dpc-1945	56	9	with	with	ADP
dpc-1945	56	10	other	other	ADJ
dpc-1945	56	11	therapy	therapy	NOUN
dpc-1945	56	12	modalities	modality	NOUN
dpc-1945	56	13	such	such	ADJ
dpc-1945	56	14	as	as	ADP
dpc-1945	56	15	radiotherapy	radiotherapy	NOUN
dpc-1945	56	16	or	or	CCONJ
dpc-1945	56	17	surgery	surgery	NOUN
dpc-1945	56	18	which	which	PRON
dpc-1945	56	19	further	far	ADV
dpc-1945	56	20	confounded	confound	VERB
dpc-1945	56	21	long	long	ADJ
dpc-1945	56	22	term	term	NOUN
dpc-1945	56	23	data	data	NOUN
dpc-1945	56	24	evaluation	evaluation	NOUN
dpc-1945	56	25	of	of	ADP
dpc-1945	56	26	these	these	DET
dpc-1945	56	27	treatment	treatment	NOUN
dpc-1945	56	28	regimens	regimen	NOUN
dpc-1945	56	29	[	[	X
dpc-1945	56	30	15	15	NUM
dpc-1945	56	31	]	]	PUNCT
dpc-1945	56	32	.	.	PUNCT
dpc-1945	57	1	results	result	NOUN
dpc-1945	57	2	showed	show	VERB
dpc-1945	57	3	short	short	ADJ
dpc-1945	57	4	progression	progression	NOUN
dpc-1945	57	5	free	free	ADJ
dpc-1945	57	6	survival	survival	NOUN
dpc-1945	57	7	(	(	PUNCT
dpc-1945	57	8	pfs	pfs	PROPN
dpc-1945	57	9	)	)	PUNCT
dpc-1945	57	10	and/or	and/or	CCONJ
dpc-1945	57	11	overall	overall	ADJ
dpc-1945	57	12	survival	survival	NOUN
dpc-1945	57	13	(	(	PUNCT
dpc-1945	57	14	os	os	NOUN
dpc-1945	57	15	)	)	PUNCT
dpc-1945	57	16	.	.	PUNCT
dpc-1945	58	1	in	in	ADP
dpc-1945	58	2	several	several	ADJ
dpc-1945	58	3	cases	case	NOUN
dpc-1945	58	4	reporting	report	VERB
dpc-1945	58	5	long	long	ADJ
dpc-1945	58	6	-	-	PUNCT
dpc-1945	58	7	term	term	NOUN
dpc-1945	58	8	tumor	tumor	NOUN
dpc-1945	58	9	remission	remission	NOUN
dpc-1945	58	10	,	,	PUNCT
dpc-1945	58	11	patients	patient	NOUN
dpc-1945	58	12	had	have	AUX
dpc-1945	58	13	received	receive	VERB
dpc-1945	58	14	subsequent	subsequent	ADJ
dpc-1945	58	15	surgical	surgical	ADJ
dpc-1945	58	16	or	or	CCONJ
dpc-1945	58	17	radiation	radiation	NOUN
dpc-1945	58	18	therapy	therapy	NOUN
dpc-1945	58	19	.	.	PUNCT
dpc-1945	59	1	table	table	NOUN
dpc-1945	59	2	1	1	NUM
dpc-1945	59	3	summarizes	summarize	NOUN
dpc-1945	59	4	several	several	ADJ
dpc-1945	59	5	studies	study	NOUN
dpc-1945	59	6	investigating	investigate	VERB
dpc-1945	59	7	cytotoxic	cytotoxic	ADJ
dpc-1945	59	8	agents	agent	NOUN
dpc-1945	59	9	for	for	ADP
dpc-1945	59	10	treatment	treatment	NOUN
dpc-1945	59	11	of	of	ADP
dpc-1945	59	12	advanced	advanced	ADJ
dpc-1945	59	13	cscc	cscc	ADJ
dpc-1945	59	14	and	and	CCONJ
dpc-1945	59	15	their	their	PRON
dpc-1945	59	16	limitations	limitation	NOUN
dpc-1945	59	17	.	.	PUNCT
dpc-1945	60	1	these	these	DET
dpc-1945	60	2	therapies	therapy	NOUN
dpc-1945	60	3	are	be	AUX
dpc-1945	60	4	frequent	frequent	ADJ
dpc-1945	60	5	causes	cause	NOUN
dpc-1945	60	6	of	of	ADP
dpc-1945	60	7	nausea	nausea	NOUN
dpc-1945	60	8	and	and	CCONJ
dpc-1945	60	9	emesis	emesis	NOUN
dpc-1945	60	10	,	,	PUNCT
dpc-1945	60	11	and	and	CCONJ
dpc-1945	60	12	at	at	ADP
dpc-1945	60	13	times	time	NOUN
dpc-1945	60	14	severe	severe	ADJ
dpc-1945	60	15	hematological	hematological	ADJ
dpc-1945	60	16	toxicities	toxicity	NOUN
dpc-1945	60	17	including	include	VERB
dpc-1945	60	18	neutropenia	neutropenia	NOUN
dpc-1945	60	19	,	,	PUNCT
dpc-1945	60	20	thrombocytopenia	thrombocytopenia	PROPN
dpc-1945	60	21	,	,	PUNCT
dpc-1945	60	22	and	and	CCONJ
dpc-1945	60	23	anemia	anemia	NOUN
dpc-1945	60	24	[	[	X
dpc-1945	60	25	16	16	NUM
dpc-1945	60	26	]	]	PUNCT
dpc-1945	60	27	.	.	PUNCT
dpc-1945	61	1	the	the	DET
dpc-1945	61	2	use	use	NOUN
dpc-1945	61	3	of	of	ADP
dpc-1945	61	4	cisplatin	cisplatin	NOUN
dpc-1945	61	5	in	in	ADP
dpc-1945	61	6	combination	combination	NOUN
dpc-1945	61	7	with	with	ADP
dpc-1945	61	8	5	5	NUM
dpc-1945	61	9	-	-	PUNCT
dpc-1945	61	10	fu	fu	NOUN
dpc-1945	61	11	and	and	CCONJ
dpc-1945	61	12	bleomycin	bleomycin	PROPN
dpc-1945	61	13	showed	show	VERB
dpc-1945	61	14	an	an	DET
dpc-1945	61	15	objective	objective	ADJ
dpc-1945	61	16	response	response	NOUN
dpc-1945	61	17	rate	rate	NOUN
dpc-1945	61	18	(	(	PUNCT
dpc-1945	61	19	orr	orr	PROPN
dpc-1945	61	20	)	)	PUNCT
dpc-1945	61	21	of	of	ADP
dpc-1945	61	22	84	84	NUM
dpc-1945	61	23	%	%	NOUN
dpc-1945	61	24	[	[	X
dpc-1945	61	25	13	13	NUM
dpc-1945	61	26	]	]	PUNCT
dpc-1945	61	27	but	but	CCONJ
dpc-1945	61	28	these	these	DET
dpc-1945	61	29	types	type	NOUN
dpc-1945	61	30	of	of	ADP
dpc-1945	61	31	regimens	regimen	NOUN
dpc-1945	61	32	are	be	AUX
dpc-1945	61	33	not	not	PART
dpc-1945	61	34	commonly	commonly	ADV
dpc-1945	61	35	used	use	VERB
dpc-1945	61	36	due	due	ADP
dpc-1945	61	37	to	to	ADP
dpc-1945	61	38	the	the	DET
dpc-1945	61	39	significant	significant	ADJ
dpc-1945	61	40	toxicity	toxicity	NOUN
dpc-1945	61	41	that	that	PRON
dpc-1945	61	42	is	be	AUX
dpc-1945	61	43	not	not	PART
dpc-1945	61	44	tolerable	tolerable	ADJ
dpc-1945	61	45	in	in	ADP
dpc-1945	61	46	the	the	DET
dpc-1945	61	47	elderly	elderly	ADJ
dpc-1945	61	48	population	population	NOUN
dpc-1945	61	49	which	which	PRON
dpc-1945	61	50	makes	make	VERB
dpc-1945	61	51	up	up	ADP
dpc-1945	61	52	a	a	DET
dpc-1945	61	53	large	large	ADJ
dpc-1945	61	54	portion	portion	NOUN
dpc-1945	61	55	of	of	ADP
dpc-1945	61	56	the	the	DET
dpc-1945	61	57	cscc	cscc	ADJ
dpc-1945	61	58	population	population	NOUN
dpc-1945	61	59	.	.	PUNCT
dpc-1945	62	1	in	in	ADP
dpc-1945	62	2	this	this	DET
dpc-1945	62	3	small	small	ADJ
dpc-1945	62	4	combination	combination	NOUN
dpc-1945	62	5	study	study	NOUN
dpc-1945	62	6	,	,	PUNCT
dpc-1945	62	7	the	the	DET
dpc-1945	62	8	median	median	ADJ
dpc-1945	62	9	age	age	NOUN
dpc-1945	62	10	of	of	ADP
dpc-1945	62	11	the	the	DET
dpc-1945	62	12	14	14	NUM
dpc-1945	62	13	patients	patient	NOUN
dpc-1945	62	14	enrolled	enrol	VERB
dpc-1945	62	15	was	be	AUX
dpc-1945	62	16	59	59	NUM
dpc-1945	62	17	,	,	PUNCT
dpc-1945	62	18	patients	patient	NOUN
dpc-1945	62	19	had	have	AUX
dpc-1945	62	20	only	only	ADV
dpc-1945	62	21	locally	locally	ADV
dpc-1945	62	22	developed	develop	VERB
dpc-1945	62	23	tumors	tumor	NOUN
dpc-1945	62	24	(	(	PUNCT
dpc-1945	62	25	none	none	NOUN
dpc-1945	62	26	with	with	ADP
dpc-1945	62	27	metastasis	metastasis	NOUN
dpc-1945	62	28	)	)	PUNCT
dpc-1945	62	29	,	,	PUNCT
dpc-1945	62	30	and	and	CCONJ
dpc-1945	62	31	10	10	NUM
dpc-1945	62	32	patients	patient	NOUN
dpc-1945	62	33	received	receive	VERB
dpc-1945	62	34	adjuvant	adjuvant	ADJ
dpc-1945	62	35	surgery	surgery	NOUN
dpc-1945	62	36	or	or	CCONJ
dpc-1945	62	37	radiotherapy	radiotherapy	NOUN
dpc-1945	62	38	.	.	PUNCT
dpc-1945	63	1	it	it	PRON
dpc-1945	63	2	is	be	AUX
dpc-1945	63	3	worthwhile	worthwhile	ADJ
dpc-1945	63	4	to	to	PART
dpc-1945	63	5	note	note	VERB
dpc-1945	63	6	that	that	SCONJ
dpc-1945	63	7	these	these	DET
dpc-1945	63	8	therapies	therapy	NOUN
dpc-1945	63	9	continue	continue	VERB
dpc-1945	63	10	to	to	PART
dpc-1945	63	11	be	be	AUX
dpc-1945	63	12	under	under	ADP
dpc-1945	63	13	investigation	investigation	NOUN
dpc-1945	63	14	in	in	ADP
dpc-1945	63	15	combination	combination	NOUN
dpc-1945	63	16	with	with	ADP
dpc-1945	63	17	more	more	ADJ
dpc-1945	63	18	modern	modern	ADJ
dpc-1945	63	19	small	small	ADJ
dpc-1945	63	20	molecule	molecule	NOUN
dpc-1945	63	21	targeted	target	VERB
dpc-1945	63	22	therapies	therapy	NOUN
dpc-1945	63	23	and	and	CCONJ
dpc-1945	63	24	immunotherapies	immunotherapy	NOUN
dpc-1945	63	25	that	that	PRON
dpc-1945	63	26	are	be	AUX
dpc-1945	63	27	the	the	DET
dpc-1945	63	28	mainstay	mainstay	NOUN
dpc-1945	63	29	of	of	ADP
dpc-1945	63	30	our	our	PRON
dpc-1945	63	31	discussion	discussion	NOUN
dpc-1945	63	32	in	in	ADP
dpc-1945	63	33	this	this	DET
dpc-1945	63	34	article	article	NOUN
dpc-1945	63	35	[	[	X
dpc-1945	63	36	17	17	NUM
dpc-1945	63	37	]	]	PUNCT
dpc-1945	63	38	.	.	PUNCT
dpc-1945	64	1	targeted	target	VERB
dpc-1945	64	2	therapy	therapy	NOUN
dpc-1945	64	3	for	for	ADP
dpc-1945	64	4	advanced	advanced	ADJ
dpc-1945	64	5	cscc	cscc	ADJ
dpc-1945	64	6	epidermal	epidermal	ADJ
dpc-1945	64	7	growth	growth	NOUN
dpc-1945	64	8	factor	factor	NOUN
dpc-1945	64	9	receptor	receptor	NOUN
dpc-1945	64	10	(	(	PUNCT
dpc-1945	64	11	egfr	egfr	X
dpc-1945	64	12	)	)	PUNCT
dpc-1945	64	13	is	be	AUX
dpc-1945	64	14	a	a	DET
dpc-1945	64	15	member	member	NOUN
dpc-1945	64	16	of	of	ADP
dpc-1945	64	17	the	the	DET
dpc-1945	64	18	erbb	erbb	PROPN
dpc-1945	64	19	family	family	PROPN
dpc-1945	64	20	of	of	ADP
dpc-1945	64	21	tyrosine	tyrosine	PROPN
dpc-1945	64	22	kinase	kinase	PROPN
dpc-1945	64	23	(	(	PUNCT
dpc-1945	64	24	rtks	rtks	NOUN
dpc-1945	64	25	)	)	PUNCT
dpc-1945	64	26	receptors	receptor	NOUN
dpc-1945	64	27	and	and	CCONJ
dpc-1945	64	28	transmits	transmit	VERB
dpc-1945	64	29	a	a	DET
dpc-1945	64	30	growth	growth	NOUN
dpc-1945	64	31	-	-	PUNCT
dpc-1945	64	32	inducing	induce	VERB
dpc-1945	64	33	signal	signal	NOUN
dpc-1945	64	34	to	to	ADP
dpc-1945	64	35	cells	cell	NOUN
dpc-1945	64	36	when	when	SCONJ
dpc-1945	64	37	stimulated	stimulate	VERB
dpc-1945	64	38	by	by	ADP
dpc-1945	64	39	an	an	DET
dpc-1945	64	40	egfr	egfr	ADJ
dpc-1945	64	41	ligand	ligand	NOUN
dpc-1945	65	1	[	[	X
dpc-1945	65	2	18	18	NUM
dpc-1945	65	3	]	]	PUNCT
dpc-1945	65	4	.	.	PUNCT
dpc-1945	65	5	egfr	egfr	PROPN
dpc-1945	65	6	is	be	AUX
dpc-1945	65	7	expressed	express	VERB
dpc-1945	65	8	in	in	ADP
dpc-1945	65	9	multiple	multiple	ADJ
dpc-1945	65	10	organs	organ	NOUN
dpc-1945	65	11	and	and	CCONJ
dpc-1945	65	12	plays	play	VERB
dpc-1945	65	13	important	important	ADJ
dpc-1945	65	14	roles	role	NOUN
dpc-1945	65	15	in	in	ADP
dpc-1945	65	16	proliferation	proliferation	NOUN
dpc-1945	65	17	,	,	PUNCT
dpc-1945	65	18	survival	survival	NOUN
dpc-1945	65	19	,	,	PUNCT
dpc-1945	65	20	and	and	CCONJ
dpc-1945	65	21	differentiation	differentiation	NOUN
dpc-1945	65	22	of	of	ADP
dpc-1945	65	23	cells	cell	NOUN
dpc-1945	65	24	in	in	ADP
dpc-1945	65	25	both	both	CCONJ
dpc-1945	65	26	physiology	physiology	NOUN
dpc-1945	65	27	and	and	CCONJ
dpc-1945	65	28	tumor	tumor	NOUN
dpc-1945	65	29	development	development	NOUN
dpc-1945	65	30	[	[	X
dpc-1945	65	31	19	19	NUM
dpc-1945	65	32	]	]	PUNCT
dpc-1945	65	33	.	.	PUNCT
dpc-1945	66	1	the	the	DET
dpc-1945	66	2	activation	activation	NOUN
dpc-1945	66	3	of	of	ADP
dpc-1945	66	4	egfr	egfr	NOUN
dpc-1945	66	5	affects	affect	VERB
dpc-1945	66	6	numerous	numerous	ADJ
dpc-1945	66	7	biochemical	biochemical	ADJ
dpc-1945	66	8	pathways	pathway	NOUN
dpc-1945	66	9	including	include	VERB
dpc-1945	66	10	ras	ras	NOUN
dpc-1945	66	11	-	-	PUNCT
dpc-1945	66	12	raf	raf	PROPN
dpc-1945	66	13	-	-	PUNCT
dpc-1945	66	14	mek	mek	PROPN
dpc-1945	66	15	-	-	PUNCT
dpc-1945	66	16	mapk	mapk	PROPN
dpc-1945	66	17	,	,	PUNCT
dpc-1945	66	18	plc	plc	PROPN
dpc-1945	66	19	-	-	NOUN
dpc-1945	66	20	gamma	gamma	NOUN
dpc-1945	66	21	/	/	SYM
dpc-1945	66	22	pkc	pkc	PROPN
dpc-1945	66	23	review	review	NOUN
dpc-1945	66	24	|	|	ADV
dpc-1945	66	25	dermatol	dermatol	ADJ
dpc-1945	66	26	pract	pract	NOUN
dpc-1945	66	27	concept	concept	NOUN
dpc-1945	66	28	.	.	PUNCT
dpc-1945	67	1	2021	2021	NUM
dpc-1945	67	2	;	;	PUNCT
dpc-1945	68	1	11(s2	11(s2	NUM
dpc-1945	68	2	):	):	PUNCT
dpc-1945	68	3	e2021169s	e2021169s	PROPN
dpc-1945	68	4	3	3	NUM
dpc-1945	68	5	and	and	CCONJ
dpc-1945	68	6	pi3k	pi3k	PROPN
dpc-1945	68	7	/	/	SYM
dpc-1945	68	8	akt	akt	PROPN
dpc-1945	68	9	/	/	SYM
dpc-1945	68	10	mtor	mtor	PROPN
dpc-1945	68	11	,	,	PUNCT
dpc-1945	68	12	stat	stat	PROPN
dpc-1945	68	13	and	and	CCONJ
dpc-1945	68	14	nfkb	nfkb	PROPN
dpc-1945	68	15	[	[	X
dpc-1945	68	16	20	20	NUM
dpc-1945	68	17	]	]	PUNCT
dpc-1945	68	18	.	.	PUNCT
dpc-1945	69	1	these	these	DET
dpc-1945	69	2	pathways	pathway	NOUN
dpc-1945	69	3	,	,	PUNCT
dpc-1945	69	4	frequently	frequently	ADV
dpc-1945	69	5	altered	alter	VERB
dpc-1945	69	6	in	in	ADP
dpc-1945	69	7	cscc	cscc	NOUN
dpc-1945	69	8	,	,	PUNCT
dpc-1945	69	9	allow	allow	VERB
dpc-1945	69	10	for	for	ADP
dpc-1945	69	11	increased	increase	VERB
dpc-1945	69	12	tumor	tumor	NOUN
dpc-1945	69	13	cell	cell	NOUN
dpc-1945	69	14	proliferation	proliferation	NOUN
dpc-1945	69	15	,	,	PUNCT
dpc-1945	69	16	migration	migration	NOUN
dpc-1945	69	17	,	,	PUNCT
dpc-1945	69	18	survival	survival	NOUN
dpc-1945	69	19	,	,	PUNCT
dpc-1945	69	20	altered	altered	ADJ
dpc-1945	69	21	differentiation	differentiation	NOUN
dpc-1945	69	22	,	,	PUNCT
dpc-1945	69	23	and	and	CCONJ
dpc-1945	69	24	resistance	resistance	NOUN
dpc-1945	69	25	to	to	ADP
dpc-1945	69	26	apoptosis	apoptosis	NOUN
dpc-1945	69	27	[	[	X
dpc-1945	69	28	21	21	NUM
dpc-1945	69	29	]	]	PUNCT
dpc-1945	69	30	.	.	PUNCT
dpc-1945	70	1	differences	difference	NOUN
dpc-1945	70	2	in	in	ADP
dpc-1945	70	3	expression	expression	NOUN
dpc-1945	70	4	of	of	ADP
dpc-1945	70	5	egfr	egfr	NOUN
dpc-1945	70	6	between	between	ADP
dpc-1945	70	7	primary	primary	ADJ
dpc-1945	70	8	and	and	CCONJ
dpc-1945	70	9	metastatic	metastatic	ADJ
dpc-1945	70	10	lesions	lesion	NOUN
dpc-1945	70	11	of	of	ADP
dpc-1945	70	12	cscc	cscc	PROPN
dpc-1945	70	13	have	have	AUX
dpc-1945	70	14	been	be	AUX
dpc-1945	70	15	reported	report	VERB
dpc-1945	70	16	,	,	PUNCT
dpc-1945	70	17	although	although	SCONJ
dpc-1945	70	18	egfr	egfr	ADJ
dpc-1945	70	19	expression	expression	NOUN
dpc-1945	70	20	is	be	AUX
dpc-1945	70	21	not	not	PART
dpc-1945	70	22	always	always	ADV
dpc-1945	70	23	a	a	DET
dpc-1945	70	24	requirement	requirement	NOUN
dpc-1945	70	25	for	for	ADP
dpc-1945	70	26	cscc	cscc	ADJ
dpc-1945	70	27	carcinogenesis	carcinogenesis	NOUN
dpc-1945	70	28	[	[	X
dpc-1945	70	29	22	22	NUM
dpc-1945	70	30	]	]	PUNCT
dpc-1945	70	31	.	.	PUNCT
dpc-1945	71	1	egfr	egfr	ADJ
dpc-1945	71	2	inhibitors	inhibitor	NOUN
dpc-1945	71	3	were	be	AUX
dpc-1945	71	4	one	one	NUM
dpc-1945	71	5	of	of	ADP
dpc-1945	71	6	the	the	DET
dpc-1945	71	7	earliest	early	ADJ
dpc-1945	71	8	systemic	systemic	ADJ
dpc-1945	71	9	targeted	target	VERB
dpc-1945	71	10	therapies	therapy	NOUN
dpc-1945	71	11	for	for	ADP
dpc-1945	71	12	the	the	DET
dpc-1945	71	13	treatment	treatment	NOUN
dpc-1945	71	14	of	of	ADP
dpc-1945	71	15	advanced	advanced	ADJ
dpc-1945	71	16	cscc	cscc	ADJ
dpc-1945	71	17	.	.	PUNCT
dpc-1945	72	1	both	both	DET
dpc-1945	72	2	monoclonal	monoclonal	NOUN
dpc-1945	72	3	antibodies	antibodie	VERB
dpc-1945	72	4	against	against	ADP
dpc-1945	72	5	the	the	DET
dpc-1945	72	6	ligand	ligand	ADJ
dpc-1945	72	7	binding	bind	VERB
dpc-1945	72	8	domain	domain	NOUN
dpc-1945	72	9	of	of	ADP
dpc-1945	72	10	egfr	egfr	NOUN
dpc-1945	72	11	,	,	PUNCT
dpc-1945	72	12	as	as	ADV
dpc-1945	72	13	well	well	ADV
dpc-1945	72	14	as	as	ADP
dpc-1945	72	15	small	small	ADJ
dpc-1945	72	16	tyrosine	tyrosine	NOUN
dpc-1945	72	17	kinase	kinase	PROPN
dpc-1945	72	18	inhibitors	inhibitor	NOUN
dpc-1945	72	19	(	(	PUNCT
dpc-1945	72	20	tki)molecules	tki)molecules	PROPN
dpc-1945	72	21	,	,	PUNCT
dpc-1945	72	22	have	have	AUX
dpc-1945	72	23	been	be	AUX
dpc-1945	72	24	trialed	triale	VERB
dpc-1945	72	25	.	.	PUNCT
dpc-1945	73	1	cetuximab	cetuximab	NOUN
dpc-1945	73	2	,	,	PUNCT
dpc-1945	73	3	a	a	DET
dpc-1945	73	4	human	human	NOUN
dpc-1945	73	5	/	/	SYM
dpc-1945	73	6	mouse	mouse	NOUN
dpc-1945	73	7	chimeric	chimeric	ADJ
dpc-1945	73	8	monoclonal	monoclonal	NOUN
dpc-1945	73	9	antibody	antibody	NOUN
dpc-1945	73	10	,	,	PUNCT
dpc-1945	73	11	competitively	competitively	ADV
dpc-1945	73	12	binds	bind	VERB
dpc-1945	73	13	and	and	CCONJ
dpc-1945	73	14	inhibits	inhibit	VERB
dpc-1945	73	15	the	the	DET
dpc-1945	73	16	ligand	ligand	ADJ
dpc-1945	73	17	binding	bind	VERB
dpc-1945	73	18	domain	domain	NOUN
dpc-1945	73	19	of	of	ADP
dpc-1945	73	20	egfr	egfr	NOUN
dpc-1945	73	21	thus	thus	ADV
dpc-1945	73	22	limiting	limit	VERB
dpc-1945	73	23	its	its	PRON
dpc-1945	73	24	interaction	interaction	NOUN
dpc-1945	73	25	with	with	ADP
dpc-1945	73	26	the	the	DET
dpc-1945	73	27	egfr	egfr	NOUN
dpc-1945	73	28	-	-	PUNCT
dpc-1945	73	29	ligand	ligand	NOUN
dpc-1945	73	30	.	.	PUNCT
dpc-1945	74	1	a	a	DET
dpc-1945	74	2	phase	phase	NOUN
dpc-1945	74	3	ii	ii	PROPN
dpc-1945	74	4	study	study	NOUN
dpc-1945	74	5	of	of	ADP
dpc-1945	74	6	cetuximab	cetuximab	NOUN
dpc-1945	74	7	as	as	ADP
dpc-1945	74	8	first	first	ADJ
dpc-1945	74	9	-	-	PUNCT
dpc-1945	74	10	line	line	NOUN
dpc-1945	74	11	single	single	ADJ
dpc-1945	74	12	-	-	PUNCT
dpc-1945	74	13	drug	drug	NOUN
dpc-1945	74	14	therapy	therapy	NOUN
dpc-1945	74	15	in	in	ADP
dpc-1945	74	16	patients	patient	NOUN
dpc-1945	74	17	with	with	ADP
dpc-1945	74	18	advanced	advanced	ADJ
dpc-1945	74	19	cscc	cscc	NOUN
dpc-1945	74	20	,	,	PUNCT
dpc-1945	74	21	conducted	conduct	VERB
dpc-1945	74	22	by	by	ADP
dpc-1945	74	23	maubec	maubec	NOUN
dpc-1945	74	24	and	and	CCONJ
dpc-1945	74	25	colleagues	colleague	NOUN
dpc-1945	74	26	[	[	X
dpc-1945	74	27	23	23	NUM
dpc-1945	74	28	]	]	PUNCT
dpc-1945	74	29	,	,	PUNCT
dpc-1945	74	30	included	include	VERB
dpc-1945	74	31	36	36	NUM
dpc-1945	74	32	patients	patient	NOUN
dpc-1945	74	33	that	that	PRON
dpc-1945	74	34	received	receive	VERB
dpc-1945	74	35	cetuximab	cetuximab	NOUN
dpc-1945	74	36	at	at	ADP
dpc-1945	74	37	an	an	DET
dpc-1945	74	38	initial	initial	ADJ
dpc-1945	74	39	dose	dose	NOUN
dpc-1945	74	40	of	of	ADP
dpc-1945	74	41	400	400	NUM
dpc-1945	74	42	mg	mg	NOUN
dpc-1945	74	43	/	/	SYM
dpc-1945	74	44	m2	m2	PROPN
dpc-1945	74	45	followed	follow	VERB
dpc-1945	74	46	by	by	ADP
dpc-1945	74	47	subsequent	subsequent	ADJ
dpc-1945	74	48	weekly	weekly	ADJ
dpc-1945	74	49	doses	dose	NOUN
dpc-1945	74	50	of	of	ADP
dpc-1945	74	51	250	250	NUM
dpc-1945	74	52	mg	mg	NOUN
dpc-1945	74	53	/	/	SYM
dpc-1945	74	54	m2	m2	PROPN
dpc-1945	74	55	for	for	ADP
dpc-1945	74	56	at	at	ADV
dpc-1945	74	57	least	least	ADV
dpc-1945	74	58	6	6	NUM
dpc-1945	74	59	weeks	week	NOUN
dpc-1945	74	60	with	with	ADP
dpc-1945	74	61	a	a	DET
dpc-1945	74	62	48	48	NUM
dpc-1945	74	63	week	week	NOUN
dpc-1945	74	64	follow	follow	VERB
dpc-1945	74	65	up	up	ADP
dpc-1945	74	66	.	.	PUNCT
dpc-1945	75	1	orr	orr	PROPN
dpc-1945	75	2	was	be	AUX
dpc-1945	75	3	28	28	NUM
dpc-1945	75	4	%	%	NOUN
dpc-1945	75	5	,	,	PUNCT
dpc-1945	75	6	with	with	ADP
dpc-1945	75	7	2	2	NUM
dpc-1945	75	8	complete	complete	ADJ
dpc-1945	75	9	remissions	remission	NOUN
dpc-1945	75	10	(	(	PUNCT
dpc-1945	75	11	6	6	NUM
dpc-1945	75	12	%	%	NOUN
dpc-1945	75	13	)	)	PUNCT
dpc-1945	75	14	and	and	CCONJ
dpc-1945	75	15	8	8	NUM
dpc-1945	75	16	partial	partial	ADJ
dpc-1945	75	17	responses	response	NOUN
dpc-1945	75	18	(	(	PUNCT
dpc-1945	75	19	22	22	NUM
dpc-1945	75	20	%	%	NOUN
dpc-1945	75	21	)	)	PUNCT
dpc-1945	75	22	,	,	PUNCT
dpc-1945	75	23	and	and	CCONJ
dpc-1945	75	24	a	a	DET
dpc-1945	75	25	short	short	ADJ
dpc-1945	75	26	mean	mean	NOUN
dpc-1945	75	27	os	os	NOUN
dpc-1945	75	28	of	of	ADP
dpc-1945	75	29	8.1	8.1	NUM
dpc-1945	75	30	months	month	NOUN
dpc-1945	75	31	.	.	PUNCT
dpc-1945	76	1	notably	notably	ADV
dpc-1945	76	2	,	,	PUNCT
dpc-1945	76	3	the	the	DET
dpc-1945	76	4	safety	safety	NOUN
dpc-1945	76	5	profile	profile	NOUN
dpc-1945	76	6	of	of	ADP
dpc-1945	76	7	the	the	DET
dpc-1945	76	8	study	study	NOUN
dpc-1945	76	9	was	be	AUX
dpc-1945	76	10	acceptable	acceptable	ADJ
dpc-1945	76	11	and	and	CCONJ
dpc-1945	76	12	similar	similar	ADJ
dpc-1945	76	13	to	to	ADP
dpc-1945	76	14	that	that	PRON
dpc-1945	76	15	of	of	ADP
dpc-1945	76	16	other	other	ADJ
dpc-1945	76	17	studies	study	NOUN
dpc-1945	76	18	.	.	PUNCT
dpc-1945	77	1	a	a	DET
dpc-1945	77	2	larger	large	ADJ
dpc-1945	77	3	retrospective	retrospective	ADJ
dpc-1945	77	4	clinical	clinical	ADJ
dpc-1945	77	5	trial	trial	NOUN
dpc-1945	77	6	by	by	ADP
dpc-1945	77	7	montaudié	montaudié	NOUN
dpc-1945	77	8	and	and	CCONJ
dpc-1945	77	9	colleagues	colleague	NOUN
dpc-1945	77	10	,	,	PUNCT
dpc-1945	77	11	showed	show	VERB
dpc-1945	77	12	an	an	DET
dpc-1945	77	13	orr	orr	NOUN
dpc-1945	77	14	of	of	ADP
dpc-1945	77	15	42	42	NUM
dpc-1945	77	16	%	%	NOUN
dpc-1945	77	17	and	and	CCONJ
dpc-1945	77	18	70	70	NUM
dpc-1945	77	19	%	%	NOUN
dpc-1945	77	20	disease	disease	NOUN
dpc-1945	77	21	control	control	NOUN
dpc-1945	77	22	rate	rate	NOUN
dpc-1945	77	23	(	(	PUNCT
dpc-1945	77	24	dcr	dcr	PROPN
dpc-1945	77	25	)	)	PUNCT
dpc-1945	77	26	at	at	ADP
dpc-1945	77	27	12	12	NUM
dpc-1945	77	28	weeks	week	NOUN
dpc-1945	77	29	in	in	ADP
dpc-1945	77	30	chemotherapy	chemotherapy	NOUN
dpc-1945	77	31	-	-	ADJ
dpc-1945	77	32	naïve	naïve	ADJ
dpc-1945	77	33	patients	patient	NOUN
dpc-1945	77	34	treated	treat	VERB
dpc-1945	77	35	with	with	ADP
dpc-1945	77	36	cetuximab	cetuximab	NOUN
dpc-1945	77	37	for	for	ADP
dpc-1945	77	38	advanced	advanced	ADJ
dpc-1945	77	39	cscc	cscc	ADJ
dpc-1945	77	40	.	.	PUNCT
dpc-1945	78	1	median	median	PROPN
dpc-1945	78	2	os	os	PROPN
dpc-1945	78	3	was	be	AUX
dpc-1945	78	4	17.5	17.5	NUM
dpc-1945	78	5	months	month	NOUN
dpc-1945	78	6	,	,	PUNCT
dpc-1945	78	7	and	and	CCONJ
dpc-1945	78	8	the	the	DET
dpc-1945	78	9	majority	majority	NOUN
dpc-1945	78	10	of	of	ADP
dpc-1945	78	11	adverse	adverse	ADJ
dpc-1945	78	12	events	event	NOUN
dpc-1945	78	13	were	be	AUX
dpc-1945	78	14	grade	grade	NOUN
dpc-1945	78	15	1	1	NUM
dpc-1945	78	16	to	to	ADP
dpc-1945	78	17	2	2	NUM
dpc-1945	78	18	.	.	PUNCT
dpc-1945	79	1	notably	notably	ADV
dpc-1945	79	2	,	,	PUNCT
dpc-1945	79	3	this	this	DET
dpc-1945	79	4	trial	trial	NOUN
dpc-1945	79	5	included	include	VERB
dpc-1945	79	6	a	a	DET
dpc-1945	79	7	large	large	ADJ
dpc-1945	79	8	proportion	proportion	NOUN
dpc-1945	79	9	of	of	ADP
dpc-1945	79	10	immunocompromised	immunocompromise	VERB
dpc-1945	79	11	patients	patient	NOUN
dpc-1945	79	12	(	(	PUNCT
dpc-1945	79	13	~33	~33	ADP
dpc-1945	79	14	%	%	NOUN
dpc-1945	79	15	of	of	ADP
dpc-1945	79	16	the	the	DET
dpc-1945	79	17	58	58	NUM
dpc-1945	79	18	-	-	PUNCT
dpc-1945	79	19	patient	patient	NOUN
dpc-1945	79	20	cohort	cohort	NOUN
dpc-1945	79	21	)	)	PUNCT
dpc-1945	79	22	which	which	PRON
dpc-1945	79	23	are	be	AUX
dpc-1945	79	24	typically	typically	ADV
dpc-1945	79	25	excluded	exclude	VERB
dpc-1945	79	26	from	from	ADP
dpc-1945	79	27	clinical	clinical	ADJ
dpc-1945	79	28	trials	trial	NOUN
dpc-1945	79	29	.	.	PUNCT
dpc-1945	80	1	the	the	DET
dpc-1945	80	2	authors	author	NOUN
dpc-1945	80	3	did	do	AUX
dpc-1945	80	4	note	note	VERB
dpc-1945	80	5	that	that	SCONJ
dpc-1945	80	6	their	their	PRON
dpc-1945	80	7	trial	trial	NOUN
dpc-1945	80	8	included	include	VERB
dpc-1945	80	9	a	a	DET
dpc-1945	80	10	significantly	significantly	ADV
dpc-1945	80	11	higher	high	ADJ
dpc-1945	80	12	table	table	NOUN
dpc-1945	80	13	1	1	NUM
dpc-1945	80	14	.	.	PUNCT
dpc-1945	80	15	cytotoxic	cytotoxic	ADJ
dpc-1945	80	16	chemotherapy	chemotherapy	NOUN
dpc-1945	80	17	for	for	ADP
dpc-1945	80	18	the	the	DET
dpc-1945	80	19	treatment	treatment	NOUN
dpc-1945	80	20	of	of	ADP
dpc-1945	80	21	cscc	cscc	ADJ
dpc-1945	80	22	study	study	NOUN
dpc-1945	80	23	regimen	regimen	NOUN
dpc-1945	80	24	line	line	NOUN
dpc-1945	80	25	of	of	ADP
dpc-1945	80	26	therapy	therapy	NOUN
dpc-1945	80	27	pts	pts	X
dpc-1945	80	28	(	(	PUNCT
dpc-1945	80	29	n	n	CCONJ
dpc-1945	80	30	)	)	PUNCT
dpc-1945	80	31	response	response	NOUN
dpc-1945	80	32	rate	rate	NOUN
dpc-1945	80	33	duration	duration	NOUN
dpc-1945	80	34	of	of	ADP
dpc-1945	80	35	response	response	NOUN
dpc-1945	80	36	notes	note	NOUN
dpc-1945	80	37	/	/	SYM
dpc-1945	80	38	limitations	limitation	NOUN
dpc-1945	81	1	guthrie	guthrie	PROPN
dpc-1945	81	2	t	t	PROPN
dpc-1945	81	3	et	et	PROPN
dpc-1945	81	4	al	al	PROPN
dpc-1945	81	5	.	.	PROPN
dpc-1945	81	6	1985(75	1985(75	NUM
dpc-1945	81	7	)	)	PUNCT
dpc-1945	81	8	cisplatin	cisplatin	NOUN
dpc-1945	81	9	+	+	CCONJ
dpc-1945	81	10	doxorubicin	doxorubicin	PROPN
dpc-1945	81	11	mixed	mix	VERB
dpc-1945	81	12	first/	first/	NUM
dpc-1945	81	13	second+	second+	NOUN
dpc-1945	81	14	4	4	NUM
dpc-1945	81	15	cr	cr	SYM
dpc-1945	81	16	25	25	NUM
dpc-1945	81	17	%	%	NOUN
dpc-1945	81	18	pr	pr	NOUN
dpc-1945	81	19	50	50	NUM
dpc-1945	81	20	%	%	NOUN
dpc-1945	81	21	orr	orr	NOUN
dpc-1945	81	22	75	75	NUM
dpc-1945	81	23	%	%	NOUN
dpc-1945	81	24	3–24	3–24	PROPN
dpc-1945	81	25	months	month	NOUN
dpc-1945	81	26	one	one	NUM
dpc-1945	81	27	patient	patient	NOUN
dpc-1945	81	28	had	have	VERB
dpc-1945	81	29	subsequent	subsequent	ADJ
dpc-1945	81	30	st	st	PROPN
dpc-1945	81	31	guthrie	guthrie	PROPN
dpc-1945	81	32	t	t	PROPN
dpc-1945	81	33	et	et	PROPN
dpc-1945	81	34	al	al	PROPN
dpc-1945	81	35	.	.	PROPN
dpc-1945	81	36	1990(14	1990(14	NUM
dpc-1945	81	37	)	)	PUNCT
dpc-1945	81	38	cisplatin	cisplatin	NOUN
dpc-1945	81	39	+	+	CCONJ
dpc-1945	81	40	doxorubicin	doxorubicin	PROPN
dpc-1945	81	41	mixed	mix	VERB
dpc-1945	81	42	first/	first/	NUM
dpc-1945	81	43	second+	second+	ADJ
dpc-1945	81	44	12	12	NUM
dpc-1945	81	45	cr	cr	NUM
dpc-1945	81	46	33	33	NUM
dpc-1945	81	47	%	%	NOUN
dpc-1945	82	1	pr	pr	NOUN
dpc-1945	82	2	25	25	NUM
dpc-1945	82	3	%	%	NOUN
dpc-1945	82	4	orr	orr	NOUN
dpc-1945	82	5	58	58	NUM
dpc-1945	82	6	%	%	NOUN
dpc-1945	82	7	sole	sole	ADJ
dpc-1945	82	8	therapy	therapy	NOUN
dpc-1945	82	9	(	(	PUNCT
dpc-1945	82	10	7	7	NUM
dpc-1945	82	11	)	)	PUNCT
dpc-1945	82	12	or	or	CCONJ
dpc-1945	82	13	neoadjuvant	neoadjuvant	ADJ
dpc-1945	82	14	(	(	PUNCT
dpc-1945	82	15	5	5	NUM
dpc-1945	82	16	)	)	PUNCT
dpc-1945	82	17	receiving	receive	VERB
dpc-1945	82	18	rt	rt	PROPN
dpc-1945	82	19	or	or	CCONJ
dpc-1945	82	20	st	st	PROPN
dpc-1945	82	21	sadek	sadek	PROPN
dpc-1945	82	22	h	h	PROPN
dpc-1945	82	23	et	et	PROPN
dpc-1945	82	24	al	al	PROPN
dpc-1945	82	25	.	.	PROPN
dpc-1945	82	26	1990(13	1990(13	NUM
dpc-1945	82	27	)	)	PUNCT
dpc-1945	82	28	cisplatin	cisplatin	NOUN
dpc-1945	82	29	+	+	CCONJ
dpc-1945	82	30	5	5	NUM
dpc-1945	82	31	-	-	PUNCT
dpc-1945	82	32	fluorouracil†	fluorouracil†	NOUN
dpc-1945	82	33	+	+	CCONJ
dpc-1945	82	34	bleomycin	bleomycin	NOUN
dpc-1945	82	35	second+	second+	ADJ
dpc-1945	82	36	13	13	NUM
dpc-1945	82	37	cr	cr	NUM
dpc-1945	82	38	30	30	NUM
dpc-1945	82	39	%	%	NOUN
dpc-1945	82	40	pr	pr	NOUN
dpc-1945	83	1	54	54	NUM
dpc-1945	83	2	%	%	NOUN
dpc-1945	83	3	orr	orr	NOUN
dpc-1945	83	4	84	84	NUM
dpc-1945	83	5	%	%	NOUN
dpc-1945	83	6	almost	almost	ADV
dpc-1945	83	7	all	all	PRON
dpc-1945	83	8	pts	pt	NOUN
dpc-1945	83	9	received	receive	VERB
dpc-1945	83	10	subsequent	subsequent	ADJ
dpc-1945	83	11	st	st	PROPN
dpc-1945	83	12	/	/	SYM
dpc-1945	83	13	rt	rt	PROPN
dpc-1945	83	14	khansur	khansur	PROPN
dpc-1945	83	15	t	t	PROPN
dpc-1945	83	16	et	et	PROPN
dpc-1945	83	17	al	al	PROPN
dpc-1945	83	18	.	.	PROPN
dpc-1945	83	19	1991(76	1991(76	NUM
dpc-1945	83	20	)	)	PUNCT
dpc-1945	83	21	cisplatin	cisplatin	NOUN
dpc-1945	83	22	+	+	CCONJ
dpc-1945	83	23	5	5	NUM
dpc-1945	83	24	-	-	PUNCT
dpc-1945	83	25	fluorouracil	fluorouracil	NOUN
dpc-1945	83	26	first	first	ADJ
dpc-1945	83	27	line	line	NOUN
dpc-1945	83	28	7	7	NUM
dpc-1945	83	29	cr	cr	PART
dpc-1945	83	30	43	43	NUM
dpc-1945	83	31	%	%	NOUN
dpc-1945	83	32	pr	pr	NOUN
dpc-1945	83	33	43	43	NUM
dpc-1945	83	34	%	%	NOUN
dpc-1945	83	35	orr	orr	NOUN
dpc-1945	83	36	86	86	NUM
dpc-1945	83	37	%	%	NOUN
dpc-1945	83	38	one	one	NUM
dpc-1945	83	39	patient	patient	NOUN
dpc-1945	83	40	received	receive	VERB
dpc-1945	83	41	subsequent	subsequent	ADJ
dpc-1945	83	42	st	st	PROPN
dpc-1945	83	43	.	.	PROPN
dpc-1945	83	44	several	several	ADJ
dpc-1945	83	45	patients	patient	NOUN
dpc-1945	83	46	lost	lose	VERB
dpc-1945	83	47	to	to	PART
dpc-1945	83	48	follow	follow	VERB
dpc-1945	83	49	up	up	ADP
dpc-1945	83	50	merimsky	merimsky	ADJ
dpc-1945	83	51	o	o	INTJ
dpc-1945	83	52	et	et	PROPN
dpc-1945	83	53	al	al	PROPN
dpc-1945	83	54	.	.	PROPN
dpc-1945	83	55	1992(77	1992(77	NUM
dpc-1945	83	56	)	)	PUNCT
dpc-1945	83	57	adriamycin	adriamycin	NOUN
dpc-1945	83	58	+	+	CCONJ
dpc-1945	83	59	cisplatin	cisplatin	NOUN
dpc-1945	83	60	second+	second+	ADJ
dpc-1945	83	61	line	line	NOUN
dpc-1945	83	62	2	2	NUM
dpc-1945	83	63	cr	cr	PART
dpc-1945	83	64	50	50	NUM
dpc-1945	83	65	%	%	NOUN
dpc-1945	83	66	pr	pr	NOUN
dpc-1945	83	67	50	50	NUM
dpc-1945	83	68	%	%	NOUN
dpc-1945	83	69	orr	orr	NOUN
dpc-1945	83	70	100	100	NUM
dpc-1945	83	71	%	%	NOUN
dpc-1945	83	72	both	both	DET
dpc-1945	83	73	patients	patient	NOUN
dpc-1945	83	74	had	have	VERB
dpc-1945	83	75	only	only	ADV
dpc-1945	83	76	locally	locally	ADV
dpc-1945	83	77	advanced	advanced	ADJ
dpc-1945	83	78	disease	disease	NOUN
dpc-1945	83	79	.	.	PUNCT
dpc-1945	84	1	cartei	cartei	NOUN
dpc-1945	84	2	g	g	PROPN
dpc-1945	84	3	et	et	PROPN
dpc-1945	84	4	al	al	PROPN
dpc-1945	84	5	.	.	PROPN
dpc-1945	84	6	2000(78	2000(78	NUM
dpc-1945	84	7	)	)	PUNCT
dpc-1945	85	1	oral	oral	ADJ
dpc-1945	85	2	5	5	NUM
dpc-1945	85	3	-	-	PUNCT
dpc-1945	85	4	fluorouracil	fluorouracil	NOUN
dpc-1945	85	5	second+	second+	ADJ
dpc-1945	85	6	line	line	NOUN
dpc-1945	85	7	14	14	NUM
dpc-1945	85	8	cr	cr	SYM
dpc-1945	85	9	0	0	NUM
dpc-1945	85	10	%	%	NOUN
dpc-1945	85	11	pr	pr	NOUN
dpc-1945	85	12	14	14	NUM
dpc-1945	85	13	%	%	NOUN
dpc-1945	85	14	orr	orr	NOUN
dpc-1945	85	15	14	14	NUM
dpc-1945	85	16	%	%	NOUN
dpc-1945	85	17	median	median	NOUN
dpc-1945	85	18	30	30	NUM
dpc-1945	85	19	weeks	week	NOUN
dpc-1945	85	20	none	none	NOUN
dpc-1945	85	21	had	have	VERB
dpc-1945	85	22	distant	distant	ADJ
dpc-1945	85	23	metastasis	metastasis	NOUN
dpc-1945	85	24	.	.	PUNCT
dpc-1945	86	1	some	some	PRON
dpc-1945	86	2	received	receive	VERB
dpc-1945	86	3	oral	oral	ADJ
dpc-1945	86	4	+	+	CCONJ
dpc-1945	86	5	topical	topical	ADJ
dpc-1945	86	6	5	5	NUM
dpc-1945	86	7	-	-	PUNCT
dpc-1945	86	8	fu	fu	NOUN
dpc-1945	86	9	shin	shin	NOUN
dpc-1945	86	10	dm	dm	X
dpc-1945	86	11	et	et	NOUN
dpc-1945	86	12	al	al	PROPN
dpc-1945	86	13	.	.	PROPN
dpc-1945	86	14	2002(79	2002(79	NUM
dpc-1945	86	15	)	)	PUNCT
dpc-1945	86	16	ifn	ifn	NOUN
dpc-1945	86	17	-	-	PUNCT
dpc-1945	86	18	alpha	alpha	NOUN
dpc-1945	86	19	and	and	CCONJ
dpc-1945	86	20	13	13	NUM
dpc-1945	86	21	-	-	PUNCT
dpc-1945	86	22	cis	cis	NOUN
dpc-1945	86	23	-	-	PUNCT
dpc-1945	86	24	retinoic	retinoic	NOUN
dpc-1945	86	25	acid	acid	NOUN
dpc-1945	86	26	and	and	CCONJ
dpc-1945	86	27	cisplatin	cisplatin	NOUN
dpc-1945	86	28	mixed	mix	VERB
dpc-1945	86	29	first/	first/	NUM
dpc-1945	86	30	second+	second+	NOUN
dpc-1945	86	31	39	39	NUM
dpc-1945	86	32	cr	cr	NUM
dpc-1945	86	33	17	17	NUM
dpc-1945	86	34	%	%	NOUN
dpc-1945	86	35	pr	pr	NOUN
dpc-1945	86	36	17	17	NUM
dpc-1945	86	37	%	%	NOUN
dpc-1945	86	38	orr	orr	NOUN
dpc-1945	86	39	34	34	NUM
dpc-1945	86	40	%	%	NOUN
dpc-1945	86	41	median	median	NOUN
dpc-1945	86	42	9	9	NUM
dpc-1945	86	43	months	month	NOUN
dpc-1945	86	44	none	none	NOUN
dpc-1945	86	45	had	have	VERB
dpc-1945	86	46	distant	distant	ADJ
dpc-1945	86	47	metastasis	metastasis	NOUN
dpc-1945	86	48	.	.	PUNCT
dpc-1945	87	1	median	median	ADJ
dpc-1945	87	2	survival	survival	NOUN
dpc-1945	87	3	14.6	14.6	NUM
dpc-1945	87	4	months	month	NOUN
dpc-1945	87	5	.	.	PUNCT
dpc-1945	88	1	fujisawa	fujisawa	PROPN
dpc-1945	89	1	y	y	PROPN
dpc-1945	89	2	et	et	PROPN
dpc-1945	89	3	al	al	PROPN
dpc-1945	89	4	.	.	PROPN
dpc-1945	89	5	2006(80	2006(80	PROPN
dpc-1945	89	6	)	)	PUNCT
dpc-1945	90	1	cisplatin	cisplatin	NOUN
dpc-1945	90	2	+	+	CCONJ
dpc-1945	90	3	5	5	NUM
dpc-1945	90	4	-	-	PUNCT
dpc-1945	90	5	fluorouracil	fluorouracil	NOUN
dpc-1945	90	6	+	+	CCONJ
dpc-1945	90	7	rt	rt	PROPN
dpc-1945	90	8	first	first	ADJ
dpc-1945	90	9	line	line	NOUN
dpc-1945	90	10	2	2	NUM
dpc-1945	90	11	cr100	cr100	NOUN
dpc-1945	90	12	%	%	NOUN
dpc-1945	90	13	pr	pr	NOUN
dpc-1945	90	14	0	0	NUM
dpc-1945	90	15	%	%	NOUN
dpc-1945	90	16	orr	orr	NOUN
dpc-1945	90	17	100	100	NUM
dpc-1945	90	18	%	%	NOUN
dpc-1945	90	19	both	both	DET
dpc-1945	90	20	patients	patient	NOUN
dpc-1945	90	21	had	have	VERB
dpc-1945	90	22	only	only	ADV
dpc-1945	90	23	locally	locally	ADV
dpc-1945	90	24	advanced	advanced	ADJ
dpc-1945	90	25	disease	disease	NOUN
dpc-1945	90	26	.	.	PUNCT
dpc-1945	91	1	nottage	nottage	NOUN
dpc-1945	91	2	mk	mk	PROPN
dpc-1945	91	3	et	et	PROPN
dpc-1945	91	4	al	al	PROPN
dpc-1945	91	5	.	.	PROPN
dpc-1945	91	6	2017(15	2017(15	NUM
dpc-1945	91	7	)	)	PUNCT
dpc-1945	91	8	(	(	PUNCT
dpc-1945	91	9	cisplatin	cisplatin	NOUN
dpc-1945	91	10	or	or	CCONJ
dpc-1945	91	11	carboplatin	carboplatin	NOUN
dpc-1945	91	12	)	)	PUNCT
dpc-1945	92	1	+	+	CCONJ
dpc-1945	92	2	rt	rt	PROPN
dpc-1945	92	3	first	first	ADJ
dpc-1945	92	4	line	line	NOUN
dpc-1945	92	5	19	19	NUM
dpc-1945	92	6	cr	cr	SYM
dpc-1945	92	7	53	53	NUM
dpc-1945	92	8	%	%	NOUN
dpc-1945	92	9	pr	pr	NOUN
dpc-1945	92	10	47	47	NUM
dpc-1945	92	11	%	%	NOUN
dpc-1945	92	12	orr	orr	NOUN
dpc-1945	92	13	100	100	NUM
dpc-1945	92	14	%	%	NOUN
dpc-1945	92	15	median	median	ADJ
dpc-1945	92	16	survival	survival	NOUN
dpc-1945	92	17	just	just	ADV
dpc-1945	92	18	over	over	ADP
dpc-1945	92	19	24	24	NUM
dpc-1945	92	20	months	month	NOUN
dpc-1945	92	21	note	note	VERB
dpc-1945	92	22	this	this	DET
dpc-1945	92	23	table	table	NOUN
dpc-1945	92	24	is	be	AUX
dpc-1945	92	25	just	just	ADV
dpc-1945	92	26	a	a	DET
dpc-1945	92	27	limited	limited	ADJ
dpc-1945	92	28	sampling	sampling	NOUN
dpc-1945	92	29	of	of	ADP
dpc-1945	92	30	published	publish	VERB
dpc-1945	92	31	reports	report	NOUN
dpc-1945	92	32	including	include	VERB
dpc-1945	92	33	cytotoxic	cytotoxic	ADJ
dpc-1945	92	34	chemotherapy	chemotherapy	NOUN
dpc-1945	92	35	for	for	ADP
dpc-1945	92	36	advanced	advanced	ADJ
dpc-1945	92	37	cutaneous	cutaneous	ADJ
dpc-1945	92	38	scc	scc	PROPN
dpc-1945	92	39	.	.	PUNCT
dpc-1945	93	1	cr=	cr=	PROPN
dpc-1945	93	2	complete	complete	ADJ
dpc-1945	93	3	response	response	NOUN
dpc-1945	93	4	;	;	PUNCT
dpc-1945	93	5	pr	pr	NOUN
dpc-1945	93	6	=	=	PUNCT
dpc-1945	93	7	partial	partial	ADJ
dpc-1945	93	8	response	response	NOUN
dpc-1945	93	9	;	;	PUNCT
dpc-1945	94	1	orr	orr	PROPN
dpc-1945	94	2	=	=	PUNCT
dpc-1945	94	3	overall	overall	ADJ
dpc-1945	94	4	response	response	NOUN
dpc-1945	94	5	rate	rate	NOUN
dpc-1945	94	6	;	;	PUNCT
dpc-1945	94	7	st	st	NOUN
dpc-1945	94	8	=	=	ADJ
dpc-1945	94	9	surgical	surgical	ADJ
dpc-1945	94	10	therapy	therapy	NOUN
dpc-1945	94	11	;	;	PUNCT
dpc-1945	94	12	rt	rt	NOUN
dpc-1945	94	13	=	=	NOUN
dpc-1945	94	14	radiation	radiation	NOUN
dpc-1945	94	15	therapy	therapy	NOUN
dpc-1945	94	16	;	;	PUNCT
dpc-1945	94	17	pts	pt	NOUN
dpc-1945	94	18	=	=	NOUN
dpc-1945	94	19	patients	patient	NOUN
dpc-1945	94	20	;	;	PUNCT
dpc-1945	94	21	ifn	ifn	ADJ
dpc-1945	94	22	-	-	PUNCT
dpc-1945	94	23	alpha	alpha	NOUN
dpc-1945	94	24	=	=	PUNCT
dpc-1945	94	25	interferon	interferon	ADJ
dpc-1945	94	26	alpha	alpha	NOUN
dpc-1945	94	27	4	4	NUM
dpc-1945	94	28	review	review	NOUN
dpc-1945	94	29	|	|	ADV
dpc-1945	94	30	dermatol	dermatol	ADJ
dpc-1945	94	31	pract	pract	NOUN
dpc-1945	94	32	concept	concept	NOUN
dpc-1945	94	33	.	.	PUNCT
dpc-1945	94	34	2021	2021	NUM
dpc-1945	94	35	;	;	PUNCT
dpc-1945	94	36	11(s2	11(s2	NUM
dpc-1945	94	37	):	):	PUNCT
dpc-1945	94	38	e2021169s	e2021169s	NOUN
dpc-1945	94	39	portion	portion	NOUN
dpc-1945	94	40	of	of	ADP
dpc-1945	94	41	patients	patient	NOUN
dpc-1945	94	42	with	with	ADP
dpc-1945	94	43	only	only	ADJ
dpc-1945	94	44	local	local	ADJ
dpc-1945	94	45	disease	disease	NOUN
dpc-1945	94	46	(	(	PUNCT
dpc-1945	94	47	~66	~66	NOUN
dpc-1945	94	48	%	%	NOUN
dpc-1945	94	49	)	)	PUNCT
dpc-1945	94	50	compared	compare	VERB
dpc-1945	94	51	to	to	ADP
dpc-1945	94	52	that	that	PRON
dpc-1945	94	53	of	of	ADP
dpc-1945	94	54	the	the	DET
dpc-1945	94	55	maubec	maubec	ADJ
dpc-1945	94	56	study	study	NOUN
dpc-1945	94	57	(	(	PUNCT
dpc-1945	94	58	39	39	NUM
dpc-1945	94	59	%	%	NOUN
dpc-1945	94	60	)	)	PUNCT
dpc-1945	94	61	.	.	PUNCT
dpc-1945	95	1	this	this	DET
dpc-1945	95	2	same	same	ADJ
dpc-1945	95	3	group	group	NOUN
dpc-1945	95	4	had	have	AUX
dpc-1945	95	5	also	also	ADV
dpc-1945	95	6	reported	report	VERB
dpc-1945	95	7	an	an	DET
dpc-1945	95	8	orr	orr	NOUN
dpc-1945	95	9	of	of	ADP
dpc-1945	95	10	48	48	NUM
dpc-1945	95	11	%	%	NOUN
dpc-1945	95	12	and	and	CCONJ
dpc-1945	95	13	dcr	dcr	PROPN
dpc-1945	95	14	of	of	ADP
dpc-1945	95	15	68	68	NUM
dpc-1945	95	16	%	%	NOUN
dpc-1945	95	17	at	at	ADP
dpc-1945	95	18	six	six	NUM
dpc-1945	95	19	weeks	week	NOUN
dpc-1945	95	20	in	in	ADP
dpc-1945	95	21	a	a	DET
dpc-1945	95	22	separate	separate	ADJ
dpc-1945	95	23	retrospective	retrospective	ADJ
dpc-1945	95	24	cohort	cohort	NOUN
dpc-1945	95	25	of	of	ADP
dpc-1945	95	26	31	31	NUM
dpc-1945	95	27	patients	patient	NOUN
dpc-1945	95	28	treated	treat	VERB
dpc-1945	95	29	with	with	ADP
dpc-1945	95	30	cetuximab	cetuximab	NOUN
dpc-1945	95	31	,	,	PUNCT
dpc-1945	95	32	with	with	ADP
dpc-1945	95	33	47	47	NUM
dpc-1945	95	34	%	%	NOUN
dpc-1945	95	35	of	of	ADP
dpc-1945	95	36	patients	patient	NOUN
dpc-1945	95	37	having	have	VERB
dpc-1945	95	38	local	local	ADJ
dpc-1945	95	39	disease	disease	NOUN
dpc-1945	95	40	rather	rather	ADV
dpc-1945	95	41	than	than	ADP
dpc-1945	95	42	metastatic	metastatic	ADJ
dpc-1945	95	43	[	[	X
dpc-1945	95	44	24	24	NUM
dpc-1945	95	45	]	]	PUNCT
dpc-1945	95	46	.	.	PUNCT
dpc-1945	96	1	panitumumab	panitumumab	NOUN
dpc-1945	96	2	,	,	PUNCT
dpc-1945	96	3	a	a	DET
dpc-1945	96	4	fully	fully	ADV
dpc-1945	96	5	humanized	humanize	VERB
dpc-1945	96	6	monoclonal	monoclonal	NOUN
dpc-1945	96	7	antibody	antibody	NOUN
dpc-1945	96	8	targeted	target	VERB
dpc-1945	96	9	at	at	ADP
dpc-1945	96	10	the	the	DET
dpc-1945	96	11	egfr	egfr	NOUN
dpc-1945	96	12	,	,	PUNCT
dpc-1945	96	13	reported	report	VERB
dpc-1945	96	14	a	a	DET
dpc-1945	96	15	31	31	NUM
dpc-1945	96	16	%	%	NOUN
dpc-1945	96	17	orr	orr	NOUN
dpc-1945	96	18	in	in	ADP
dpc-1945	96	19	a	a	DET
dpc-1945	96	20	phase	phase	NOUN
dpc-1945	96	21	ii	ii	NOUN
dpc-1945	96	22	clinical	clinical	ADJ
dpc-1945	96	23	trial	trial	NOUN
dpc-1945	96	24	by	by	ADP
dpc-1945	96	25	foote	foote	NOUN
dpc-1945	96	26	and	and	CCONJ
dpc-1945	96	27	colleagues	colleague	NOUN
dpc-1945	96	28	[	[	X
dpc-1945	96	29	25	25	NUM
dpc-1945	96	30	]	]	PUNCT
dpc-1945	96	31	.	.	PUNCT
dpc-1945	97	1	this	this	DET
dpc-1945	97	2	cohort	cohort	NOUN
dpc-1945	97	3	of	of	ADP
dpc-1945	97	4	patients	patient	NOUN
dpc-1945	97	5	only	only	ADV
dpc-1945	97	6	included	include	VERB
dpc-1945	97	7	16	16	NUM
dpc-1945	97	8	patients	patient	NOUN
dpc-1945	97	9	,	,	PUNCT
dpc-1945	97	10	with	with	ADP
dpc-1945	97	11	14	14	NUM
dpc-1945	97	12	patients	patient	NOUN
dpc-1945	97	13	receiving	receive	VERB
dpc-1945	97	14	previous	previous	ADJ
dpc-1945	97	15	radiotherapy	radiotherapy	NOUN
dpc-1945	97	16	and	and	CCONJ
dpc-1945	97	17	7	7	NUM
dpc-1945	97	18	patients	patient	NOUN
dpc-1945	97	19	having	having	AUX
dpc-1945	97	20	received	receive	VERB
dpc-1945	97	21	prior	prior	ADJ
dpc-1945	97	22	cytotoxic	cytotoxic	ADJ
dpc-1945	97	23	chemotherapy	chemotherapy	NOUN
dpc-1945	97	24	.	.	PUNCT
dpc-1945	98	1	progression	progression	NOUN
dpc-1945	98	2	-	-	PUNCT
dpc-1945	98	3	free	free	ADJ
dpc-1945	98	4	survival	survival	NOUN
dpc-1945	98	5	(	(	PUNCT
dpc-1945	98	6	pfs	pfs	PROPN
dpc-1945	98	7	)	)	PUNCT
dpc-1945	98	8	was	be	AUX
dpc-1945	98	9	8	8	NUM
dpc-1945	98	10	months	month	NOUN
dpc-1945	98	11	and	and	CCONJ
dpc-1945	98	12	median	median	ADJ
dpc-1945	98	13	os	os	PROPN
dpc-1945	98	14	was	be	AUX
dpc-1945	98	15	11	11	NUM
dpc-1945	98	16	months	month	NOUN
dpc-1945	98	17	.	.	PUNCT
dpc-1945	99	1	in	in	ADP
dpc-1945	99	2	a	a	DET
dpc-1945	99	3	translational	translational	ADJ
dpc-1945	99	4	sub	sub	NOUN
dpc-1945	99	5	-	-	NOUN
dpc-1945	99	6	study	study	ADJ
dpc-1945	99	7	,	,	PUNCT
dpc-1945	99	8	total	total	ADJ
dpc-1945	99	9	egfr	egfr	ADJ
dpc-1945	99	10	expression	expression	NOUN
dpc-1945	99	11	levels	level	NOUN
dpc-1945	99	12	were	be	AUX
dpc-1945	99	13	not	not	PART
dpc-1945	99	14	found	find	VERB
dpc-1945	99	15	to	to	PART
dpc-1945	99	16	be	be	AUX
dpc-1945	99	17	associated	associate	VERB
dpc-1945	99	18	with	with	ADP
dpc-1945	99	19	treatment	treatment	NOUN
dpc-1945	99	20	efficacy	efficacy	NOUN
dpc-1945	99	21	.	.	PUNCT
dpc-1945	100	1	gefitinib	gefitinib	NOUN
dpc-1945	100	2	and	and	CCONJ
dpc-1945	100	3	erlotinib	erlotinib	NOUN
dpc-1945	100	4	are	be	AUX
dpc-1945	100	5	small	small	ADJ
dpc-1945	100	6	tkis	tkis	NOUN
dpc-1945	100	7	molecules	molecule	NOUN
dpc-1945	100	8	targeting	target	VERB
dpc-1945	100	9	the	the	DET
dpc-1945	100	10	egfr	egfr	NOUN
dpc-1945	100	11	that	that	PRON
dpc-1945	100	12	have	have	AUX
dpc-1945	100	13	been	be	AUX
dpc-1945	100	14	studied	study	VERB
dpc-1945	100	15	in	in	ADP
dpc-1945	100	16	advanced	advanced	ADJ
dpc-1945	100	17	cscc	cscc	NOUN
dpc-1945	100	18	.	.	PUNCT
dpc-1945	101	1	gefitinib	gefitinib	NOUN
dpc-1945	101	2	showed	show	VERB
dpc-1945	101	3	an	an	DET
dpc-1945	101	4	orr	orr	NOUN
dpc-1945	101	5	of	of	ADP
dpc-1945	101	6	16	16	NUM
dpc-1945	101	7	%	%	NOUN
dpc-1945	101	8	and	and	CCONJ
dpc-1945	101	9	dcr	dcr	PROPN
dpc-1945	101	10	of	of	ADP
dpc-1945	101	11	51	51	NUM
dpc-1945	101	12	%	%	NOUN
dpc-1945	101	13	as	as	ADP
dpc-1945	101	14	monotherapy	monotherapy	NOUN
dpc-1945	101	15	for	for	ADP
dpc-1945	101	16	advanced	advanced	ADJ
dpc-1945	101	17	cscc	cscc	NOUN
dpc-1945	102	1	[	[	X
dpc-1945	102	2	26	26	NUM
dpc-1945	102	3	]	]	PUNCT
dpc-1945	102	4	but	but	CCONJ
dpc-1945	102	5	had	have	VERB
dpc-1945	102	6	a	a	DET
dpc-1945	102	7	notably	notably	ADV
dpc-1945	102	8	improved	improve	VERB
dpc-1945	102	9	45.5	45.5	NUM
dpc-1945	102	10	%	%	NOUN
dpc-1945	102	11	orr	orr	NOUN
dpc-1945	102	12	when	when	SCONJ
dpc-1945	102	13	used	use	VERB
dpc-1945	102	14	as	as	ADP
dpc-1945	102	15	neoadjuvant	neoadjuvant	ADJ
dpc-1945	102	16	therapy	therapy	NOUN
dpc-1945	102	17	where	where	SCONJ
dpc-1945	102	18	treatment	treatment	NOUN
dpc-1945	102	19	included	include	VERB
dpc-1945	102	20	standard	standard	ADJ
dpc-1945	102	21	surgery	surgery	NOUN
dpc-1945	102	22	or	or	CCONJ
dpc-1945	102	23	radiotherapy	radiotherapy	NOUN
dpc-1945	103	1	[	[	X
dpc-1945	103	2	27	27	NUM
dpc-1945	103	3	]	]	PUNCT
dpc-1945	103	4	.	.	PUNCT
dpc-1945	104	1	erlotinib	erlotinib	PROPN
dpc-1945	104	2	has	have	AUX
dpc-1945	104	3	also	also	ADV
dpc-1945	104	4	failed	fail	VERB
dpc-1945	104	5	to	to	PART
dpc-1945	104	6	show	show	VERB
dpc-1945	104	7	great	great	ADJ
dpc-1945	104	8	efficacy	efficacy	NOUN
dpc-1945	104	9	as	as	ADP
dpc-1945	104	10	monotherapy	monotherapy	NOUN
dpc-1945	104	11	,	,	PUNCT
dpc-1945	104	12	with	with	ADP
dpc-1945	104	13	a	a	DET
dpc-1945	104	14	single	single	ADJ
dpc-1945	104	15	-	-	PUNCT
dpc-1945	104	16	arm	arm	NOUN
dpc-1945	104	17	phase	phase	NOUN
dpc-1945	104	18	ii	ii	NOUN
dpc-1945	104	19	trial	trial	NOUN
dpc-1945	104	20	reporting	report	VERB
dpc-1945	104	21	an	an	DET
dpc-1945	104	22	orr	orr	NOUN
dpc-1945	104	23	of	of	ADP
dpc-1945	104	24	10	10	NUM
dpc-1945	104	25	%	%	NOUN
dpc-1945	104	26	(	(	PUNCT
dpc-1945	104	27	all	all	DET
dpc-1945	104	28	partial	partial	ADJ
dpc-1945	104	29	responses	response	NOUN
dpc-1945	104	30	)	)	PUNCT
dpc-1945	104	31	although	although	SCONJ
dpc-1945	104	32	there	there	PRON
dpc-1945	104	33	was	be	VERB
dpc-1945	104	34	a	a	DET
dpc-1945	104	35	notable	notable	ADJ
dpc-1945	104	36	dcr	dcr	NOUN
dpc-1945	104	37	of	of	ADP
dpc-1945	104	38	72	72	NUM
dpc-1945	104	39	%	%	NOUN
dpc-1945	104	40	[	[	X
dpc-1945	104	41	28	28	NUM
dpc-1945	104	42	]	]	PUNCT
dpc-1945	104	43	.	.	PUNCT
dpc-1945	105	1	erolitinib	erolitinib	VERB
dpc-1945	105	2	combined	combine	VERB
dpc-1945	105	3	with	with	ADP
dpc-1945	105	4	surgery	surgery	NOUN
dpc-1945	105	5	and	and	CCONJ
dpc-1945	105	6	postoperative	postoperative	ADJ
dpc-1945	105	7	adjuvant	adjuvant	ADJ
dpc-1945	105	8	radiation	radiation	NOUN
dpc-1945	105	9	therapy	therapy	NOUN
dpc-1945	105	10	in	in	ADP
dpc-1945	105	11	a	a	DET
dpc-1945	105	12	phase	phase	NOUN
dpc-1945	105	13	i	i	PRON
dpc-1945	105	14	trial	trial	NOUN
dpc-1945	105	15	showed	show	VERB
dpc-1945	105	16	a	a	DET
dpc-1945	105	17	recurrence	recurrence	NOUN
dpc-1945	105	18	rate	rate	NOUN
dpc-1945	105	19	of	of	ADP
dpc-1945	105	20	26.7	26.7	NUM
dpc-1945	105	21	%	%	NOUN
dpc-1945	105	22	with	with	ADP
dpc-1945	105	23	mean	mean	ADJ
dpc-1945	105	24	time	time	NOUN
dpc-1945	105	25	to	to	PART
dpc-1945	105	26	recurrence	recurrence	VERB
dpc-1945	105	27	in	in	ADP
dpc-1945	105	28	10.5	10.5	NUM
dpc-1945	105	29	months	month	NOUN
dpc-1945	105	30	,	,	PUNCT
dpc-1945	105	31	again	again	ADV
dpc-1945	105	32	highlighting	highlight	VERB
dpc-1945	105	33	the	the	DET
dpc-1945	105	34	use	use	NOUN
dpc-1945	105	35	of	of	ADP
dpc-1945	105	36	these	these	DET
dpc-1945	105	37	agents	agent	NOUN
dpc-1945	105	38	in	in	ADP
dpc-1945	105	39	combination	combination	NOUN
dpc-1945	105	40	with	with	ADP
dpc-1945	105	41	other	other	ADJ
dpc-1945	105	42	systemic	systemic	ADJ
dpc-1945	105	43	agents	agent	NOUN
dpc-1945	105	44	or	or	CCONJ
dpc-1945	105	45	therapeutic	therapeutic	ADJ
dpc-1945	105	46	modalities	modality	NOUN
dpc-1945	105	47	[	[	X
dpc-1945	105	48	29	29	NUM
dpc-1945	105	49	]	]	PUNCT
dpc-1945	105	50	.	.	PUNCT
dpc-1945	106	1	lapatinib	lapatinib	PROPN
dpc-1945	106	2	,	,	PUNCT
dpc-1945	106	3	a	a	DET
dpc-1945	106	4	tki	tki	NOUN
dpc-1945	106	5	that	that	PRON
dpc-1945	106	6	blocks	block	VERB
dpc-1945	106	7	the	the	DET
dpc-1945	106	8	her2	her2	PROPN
dpc-1945	106	9	receptor	receptor	NOUN
dpc-1945	106	10	,	,	PUNCT
dpc-1945	106	11	has	have	AUX
dpc-1945	106	12	been	be	AUX
dpc-1945	106	13	found	find	VERB
dpc-1945	106	14	to	to	PART
dpc-1945	106	15	be	be	AUX
dpc-1945	106	16	anecdotally	anecdotally	ADV
dpc-1945	106	17	effective	effective	ADJ
dpc-1945	106	18	in	in	ADP
dpc-1945	106	19	treatment	treatment	NOUN
dpc-1945	106	20	of	of	ADP
dpc-1945	106	21	advanced	advanced	ADJ
dpc-1945	106	22	cscc	cscc	NOUN
dpc-1945	107	1	[	[	X
dpc-1945	107	2	30	30	NUM
dpc-1945	107	3	]	]	PUNCT
dpc-1945	107	4	,	,	PUNCT
dpc-1945	107	5	prompting	prompt	VERB
dpc-1945	107	6	larger	large	ADJ
dpc-1945	107	7	trials	trial	NOUN
dpc-1945	107	8	to	to	PART
dpc-1945	107	9	investigate	investigate	VERB
dpc-1945	107	10	its	its	PRON
dpc-1945	107	11	efficacy	efficacy	NOUN
dpc-1945	107	12	in	in	ADP
dpc-1945	107	13	larger	large	ADJ
dpc-1945	107	14	cohorts	cohort	NOUN
dpc-1945	107	15	[	[	X
dpc-1945	107	16	31	31	NUM
dpc-1945	107	17	]	]	PUNCT
dpc-1945	107	18	.	.	PUNCT
dpc-1945	108	1	egfr	egfr	ADJ
dpc-1945	108	2	-	-	PUNCT
dpc-1945	108	3	targeted	target	VERB
dpc-1945	108	4	therapies	therapy	NOUN
dpc-1945	108	5	are	be	AUX
dpc-1945	108	6	typically	typically	ADV
dpc-1945	108	7	more	more	ADV
dpc-1945	108	8	tolerable	tolerable	ADJ
dpc-1945	108	9	with	with	ADP
dpc-1945	108	10	adverse	adverse	ADJ
dpc-1945	108	11	effects	effect	NOUN
dpc-1945	108	12	being	be	AUX
dpc-1945	108	13	less	less	ADV
dpc-1945	108	14	severe	severe	ADJ
dpc-1945	108	15	when	when	SCONJ
dpc-1945	108	16	compared	compare	VERB
dpc-1945	108	17	to	to	ADP
dpc-1945	108	18	cytotoxic	cytotoxic	ADJ
dpc-1945	108	19	agents	agent	NOUN
dpc-1945	108	20	.	.	PUNCT
dpc-1945	109	1	cutaneous	cutaneous	ADJ
dpc-1945	109	2	adverse	adverse	ADJ
dpc-1945	109	3	events	event	NOUN
dpc-1945	109	4	are	be	AUX
dpc-1945	109	5	incredibly	incredibly	ADV
dpc-1945	109	6	frequent	frequent	ADJ
dpc-1945	109	7	,	,	PUNCT
dpc-1945	109	8	occurring	occur	VERB
dpc-1945	109	9	from	from	ADP
dpc-1945	109	10	50	50	NUM
dpc-1945	109	11	-	-	SYM
dpc-1945	109	12	100	100	NUM
dpc-1945	109	13	%	%	NOUN
dpc-1945	109	14	of	of	ADP
dpc-1945	109	15	the	the	DET
dpc-1945	109	16	time	time	NOUN
dpc-1945	109	17	in	in	ADP
dpc-1945	109	18	reported	report	VERB
dpc-1945	109	19	clinical	clinical	ADJ
dpc-1945	109	20	trials	trial	NOUN
dpc-1945	109	21	using	use	VERB
dpc-1945	109	22	these	these	DET
dpc-1945	109	23	agents	agent	NOUN
dpc-1945	109	24	,	,	PUNCT
dpc-1945	109	25	and	and	CCONJ
dpc-1945	109	26	can	can	AUX
dpc-1945	109	27	be	be	AUX
dpc-1945	109	28	a	a	DET
dpc-1945	109	29	cause	cause	NOUN
dpc-1945	109	30	of	of	ADP
dpc-1945	109	31	poor	poor	ADJ
dpc-1945	109	32	drug	drug	NOUN
dpc-1945	109	33	compliance	compliance	NOUN
dpc-1945	109	34	and/or	and/or	CCONJ
dpc-1945	109	35	drug	drug	NOUN
dpc-1945	109	36	cessation	cessation	NOUN
dpc-1945	109	37	[	[	X
dpc-1945	109	38	32	32	NUM
dpc-1945	109	39	]	]	PUNCT
dpc-1945	109	40	.	.	PUNCT
dpc-1945	110	1	acneiform	acneiform	ADJ
dpc-1945	110	2	eruptions	eruption	NOUN
dpc-1945	110	3	in	in	ADP
dpc-1945	110	4	seborrheic	seborrheic	ADJ
dpc-1945	110	5	areas	area	NOUN
dpc-1945	110	6	are	be	AUX
dpc-1945	110	7	common	common	ADJ
dpc-1945	110	8	,	,	PUNCT
dpc-1945	110	9	but	but	CCONJ
dpc-1945	110	10	patients	patient	NOUN
dpc-1945	110	11	may	may	AUX
dpc-1945	110	12	also	also	ADV
dpc-1945	110	13	develop	develop	VERB
dpc-1945	110	14	xerosis	xerosis	NOUN
dpc-1945	110	15	,	,	PUNCT
dpc-1945	110	16	paronychia	paronychia	NOUN
dpc-1945	110	17	,	,	PUNCT
dpc-1945	110	18	and	and	CCONJ
dpc-1945	110	19	other	other	ADJ
dpc-1945	110	20	cutaneous	cutaneous	ADJ
dpc-1945	110	21	toxicities	toxicity	NOUN
dpc-1945	110	22	.	.	PUNCT
dpc-1945	111	1	there	there	PRON
dpc-1945	111	2	is	be	VERB
dpc-1945	111	3	a	a	DET
dpc-1945	111	4	positive	positive	ADJ
dpc-1945	111	5	correlation	correlation	NOUN
dpc-1945	111	6	between	between	ADP
dpc-1945	111	7	the	the	DET
dpc-1945	111	8	occurrence	occurrence	NOUN
dpc-1945	111	9	and	and	CCONJ
dpc-1945	111	10	severity	severity	NOUN
dpc-1945	111	11	of	of	ADP
dpc-1945	111	12	cutaneous	cutaneous	ADJ
dpc-1945	111	13	adverse	adverse	ADJ
dpc-1945	111	14	effects	effect	NOUN
dpc-1945	111	15	and	and	CCONJ
dpc-1945	111	16	tumor	tumor	NOUN
dpc-1945	111	17	response	response	NOUN
dpc-1945	111	18	,	,	PUNCT
dpc-1945	111	19	which	which	PRON
dpc-1945	111	20	can	can	AUX
dpc-1945	111	21	be	be	AUX
dpc-1945	111	22	a	a	DET
dpc-1945	111	23	supporting	support	VERB
dpc-1945	111	24	detail	detail	NOUN
dpc-1945	111	25	to	to	PART
dpc-1945	111	26	discuss	discuss	VERB
dpc-1945	111	27	with	with	ADP
dpc-1945	111	28	patients	patient	NOUN
dpc-1945	111	29	when	when	SCONJ
dpc-1945	111	30	helping	helping	AUX
dpc-1945	111	31	manage	manage	VERB
dpc-1945	111	32	these	these	DET
dpc-1945	111	33	skin	skin	NOUN
dpc-1945	111	34	toxicities	toxicity	NOUN
dpc-1945	111	35	[	[	X
dpc-1945	111	36	33	33	NUM
dpc-1945	111	37	]	]	PUNCT
dpc-1945	111	38	.	.	PUNCT
dpc-1945	112	1	due	due	ADP
dpc-1945	112	2	to	to	ADP
dpc-1945	112	3	significant	significant	ADJ
dpc-1945	112	4	egfr	egfr	ADJ
dpc-1945	112	5	expression	expression	NOUN
dpc-1945	112	6	in	in	ADP
dpc-1945	112	7	epithelial	epithelial	ADJ
dpc-1945	112	8	cells	cell	NOUN
dpc-1945	112	9	of	of	ADP
dpc-1945	112	10	the	the	DET
dpc-1945	112	11	gastrointestinal	gastrointestinal	ADJ
dpc-1945	112	12	tract	tract	NOUN
dpc-1945	112	13	,	,	PUNCT
dpc-1945	112	14	diarrhea	diarrhea	NOUN
dpc-1945	112	15	is	be	AUX
dpc-1945	112	16	a	a	DET
dpc-1945	112	17	common	common	ADJ
dpc-1945	112	18	adverse	adverse	ADJ
dpc-1945	112	19	event	event	NOUN
dpc-1945	112	20	of	of	ADP
dpc-1945	112	21	egfr	egfr	ADJ
dpc-1945	112	22	targeted	target	VERB
dpc-1945	112	23	agents	agent	NOUN
dpc-1945	112	24	,	,	PUNCT
dpc-1945	112	25	with	with	ADP
dpc-1945	112	26	incidence	incidence	NOUN
dpc-1945	112	27	varying	vary	VERB
dpc-1945	112	28	from	from	ADP
dpc-1945	112	29	27	27	NUM
dpc-1945	112	30	%	%	NOUN
dpc-1945	112	31	to	to	ADP
dpc-1945	112	32	87	87	NUM
dpc-1945	112	33	%	%	NOUN
dpc-1945	112	34	in	in	ADP
dpc-1945	112	35	various	various	ADJ
dpc-1945	112	36	phase	phase	NOUN
dpc-1945	112	37	iii	iii	NUM
dpc-1945	112	38	clinical	clinical	ADJ
dpc-1945	112	39	trials	trial	NOUN
dpc-1945	112	40	for	for	ADP
dpc-1945	112	41	various	various	ADJ
dpc-1945	112	42	malignancies	malignancy	NOUN
dpc-1945	112	43	[	[	X
dpc-1945	112	44	34	34	NUM
dpc-1945	112	45	]	]	PUNCT
dpc-1945	112	46	.	.	PUNCT
dpc-1945	113	1	nevertheless	nevertheless	ADV
dpc-1945	113	2	,	,	PUNCT
dpc-1945	113	3	these	these	DET
dpc-1945	113	4	adverse	adverse	ADJ
dpc-1945	113	5	events	event	NOUN
dpc-1945	113	6	are	be	AUX
dpc-1945	113	7	more	more	ADV
dpc-1945	113	8	manageable	manageable	ADJ
dpc-1945	113	9	in	in	ADP
dpc-1945	113	10	comparison	comparison	NOUN
dpc-1945	113	11	to	to	ADP
dpc-1945	113	12	the	the	DET
dpc-1945	113	13	severe	severe	ADJ
dpc-1945	113	14	side	side	NOUN
dpc-1945	113	15	effects	effect	NOUN
dpc-1945	113	16	that	that	PRON
dpc-1945	113	17	can	can	AUX
dpc-1945	113	18	occur	occur	VERB
dpc-1945	113	19	with	with	ADP
dpc-1945	113	20	cytotoxic	cytotoxic	ADJ
dpc-1945	113	21	therapies	therapy	NOUN
dpc-1945	113	22	.	.	PUNCT
dpc-1945	114	1	intrinsic	intrinsic	ADJ
dpc-1945	114	2	and	and	CCONJ
dpc-1945	114	3	acquired	acquire	VERB
dpc-1945	114	4	resistance	resistance	NOUN
dpc-1945	114	5	to	to	ADP
dpc-1945	114	6	egfr	egfr	VERB
dpc-1945	114	7	inhibitors	inhibitor	NOUN
dpc-1945	114	8	is	be	AUX
dpc-1945	114	9	well	well	ADV
dpc-1945	114	10	recognized	recognize	VERB
dpc-1945	114	11	[	[	X
dpc-1945	114	12	35	35	NUM
dpc-1945	114	13	]	]	PUNCT
dpc-1945	114	14	.	.	PUNCT
dpc-1945	115	1	several	several	ADJ
dpc-1945	115	2	mechanisms	mechanism	NOUN
dpc-1945	115	3	of	of	ADP
dpc-1945	115	4	resistance	resistance	NOUN
dpc-1945	115	5	in	in	ADP
dpc-1945	115	6	advanced	advanced	ADJ
dpc-1945	115	7	malignancies	malignancy	NOUN
dpc-1945	115	8	have	have	AUX
dpc-1945	115	9	been	be	AUX
dpc-1945	115	10	described	describe	VERB
dpc-1945	115	11	and	and	CCONJ
dpc-1945	115	12	many	many	ADJ
dpc-1945	115	13	include	include	VERB
dpc-1945	115	14	genomic	genomic	ADJ
dpc-1945	115	15	alterations	alteration	NOUN
dpc-1945	115	16	in	in	ADP
dpc-1945	115	17	downstream	downstream	ADJ
dpc-1945	115	18	effectors	effector	NOUN
dpc-1945	115	19	of	of	ADP
dpc-1945	115	20	the	the	DET
dpc-1945	115	21	egfr	egfr	NOUN
dpc-1945	115	22	signaling	signal	VERB
dpc-1945	115	23	pathway	pathway	NOUN
dpc-1945	116	1	[	[	X
dpc-1945	116	2	36	36	NUM
dpc-1945	116	3	]	]	PUNCT
dpc-1945	116	4	.	.	PUNCT
dpc-1945	117	1	these	these	PRON
dpc-1945	117	2	may	may	AUX
dpc-1945	117	3	arise	arise	VERB
dpc-1945	117	4	either	either	CCONJ
dpc-1945	117	5	as	as	ADP
dpc-1945	117	6	new	new	ADJ
dpc-1945	117	7	genetic	genetic	ADJ
dpc-1945	117	8	alterations	alteration	NOUN
dpc-1945	117	9	in	in	ADP
dpc-1945	117	10	the	the	DET
dpc-1945	117	11	tumor	tumor	NOUN
dpc-1945	117	12	after	after	ADP
dpc-1945	117	13	start	start	NOUN
dpc-1945	117	14	of	of	ADP
dpc-1945	117	15	therapy	therapy	NOUN
dpc-1945	117	16	,	,	PUNCT
dpc-1945	117	17	or	or	CCONJ
dpc-1945	117	18	through	through	ADP
dpc-1945	117	19	positive	positive	ADJ
dpc-1945	117	20	selection	selection	NOUN
dpc-1945	117	21	pressure	pressure	NOUN
dpc-1945	117	22	of	of	ADP
dpc-1945	117	23	anti	anti	ADJ
dpc-1945	117	24	-	-	ADJ
dpc-1945	117	25	egfr	egfr	ADJ
dpc-1945	117	26	therapies	therapy	NOUN
dpc-1945	117	27	on	on	ADP
dpc-1945	117	28	an	an	DET
dpc-1945	117	29	already	already	ADV
dpc-1945	117	30	-	-	PUNCT
dpc-1945	117	31	present	present	ADJ
dpc-1945	117	32	group	group	NOUN
dpc-1945	117	33	of	of	ADP
dpc-1945	117	34	egfr	egfr	ADJ
dpc-1945	117	35	-	-	PUNCT
dpc-1945	117	36	resistant	resistant	ADJ
dpc-1945	117	37	cells	cell	NOUN
dpc-1945	117	38	present	present	ADJ
dpc-1945	117	39	at	at	ADP
dpc-1945	117	40	time	time	NOUN
dpc-1945	117	41	of	of	ADP
dpc-1945	117	42	treatment	treatment	NOUN
dpc-1945	117	43	initiation	initiation	NOUN
dpc-1945	117	44	[	[	X
dpc-1945	117	45	37	37	NUM
dpc-1945	117	46	]	]	PUNCT
dpc-1945	117	47	.	.	PUNCT
dpc-1945	118	1	strategies	strategy	NOUN
dpc-1945	118	2	to	to	PART
dpc-1945	118	3	combat	combat	VERB
dpc-1945	118	4	anti	anti	ADJ
dpc-1945	118	5	-	-	ADJ
dpc-1945	118	6	egfr	egfr	ADJ
dpc-1945	118	7	resistance	resistance	NOUN
dpc-1945	118	8	include	include	VERB
dpc-1945	118	9	the	the	DET
dpc-1945	118	10	use	use	NOUN
dpc-1945	118	11	of	of	ADP
dpc-1945	118	12	combination	combination	NOUN
dpc-1945	118	13	therapy	therapy	NOUN
dpc-1945	118	14	with	with	ADP
dpc-1945	118	15	other	other	ADJ
dpc-1945	118	16	therapeutic	therapeutic	ADJ
dpc-1945	118	17	modalities	modality	NOUN
dpc-1945	118	18	such	such	ADJ
dpc-1945	118	19	as	as	ADP
dpc-1945	118	20	radiotherapies	radiotherapy	NOUN
dpc-1945	118	21	,	,	PUNCT
dpc-1945	118	22	or	or	CCONJ
dpc-1945	118	23	combination	combination	NOUN
dpc-1945	118	24	therapies	therapy	NOUN
dpc-1945	118	25	with	with	ADP
dpc-1945	118	26	other	other	ADJ
dpc-1945	118	27	systemic	systemic	ADJ
dpc-1945	118	28	agents	agent	NOUN
dpc-1945	118	29	including	include	VERB
dpc-1945	118	30	traditional	traditional	ADJ
dpc-1945	118	31	cytotoxic	cytotoxic	ADJ
dpc-1945	118	32	chemotherapy	chemotherapy	NOUN
dpc-1945	119	1	[	[	X
dpc-1945	119	2	38	38	NUM
dpc-1945	119	3	]	]	PUNCT
dpc-1945	119	4	.	.	PUNCT
dpc-1945	120	1	table	table	NOUN
dpc-1945	120	2	2	2	NUM
dpc-1945	120	3	summarizes	summarize	NOUN
dpc-1945	120	4	a	a	DET
dpc-1945	120	5	small	small	ADJ
dpc-1945	120	6	sample	sample	NOUN
dpc-1945	120	7	of	of	ADP
dpc-1945	120	8	studies	study	NOUN
dpc-1945	120	9	investigating	investigate	VERB
dpc-1945	120	10	targeted	target	VERB
dpc-1945	120	11	therapies	therapy	NOUN
dpc-1945	120	12	for	for	ADP
dpc-1945	120	13	treatment	treatment	NOUN
dpc-1945	120	14	of	of	ADP
dpc-1945	120	15	advanced	advanced	ADJ
dpc-1945	120	16	cscc	cscc	ADJ
dpc-1945	120	17	.	.	PUNCT
dpc-1945	121	1	treatment	treatment	NOUN
dpc-1945	121	2	with	with	ADP
dpc-1945	121	3	these	these	DET
dpc-1945	121	4	agents	agent	NOUN
dpc-1945	121	5	may	may	AUX
dpc-1945	121	6	be	be	AUX
dpc-1945	121	7	limited	limit	VERB
dpc-1945	121	8	due	due	ADP
dpc-1945	121	9	to	to	ADP
dpc-1945	121	10	short	short	ADJ
dpc-1945	121	11	durations	duration	NOUN
dpc-1945	121	12	of	of	ADP
dpc-1945	121	13	response	response	NOUN
dpc-1945	121	14	and	and	CCONJ
dpc-1945	121	15	progression	progression	NOUN
dpc-1945	121	16	free	free	ADJ
dpc-1945	121	17	survival	survival	NOUN
dpc-1945	121	18	.	.	PUNCT
dpc-1945	122	1	table	table	NOUN
dpc-1945	122	2	2	2	NUM
dpc-1945	122	3	.	.	NUM
dpc-1945	122	4	targeted	target	VERB
dpc-1945	122	5	therapies	therapy	NOUN
dpc-1945	122	6	for	for	ADP
dpc-1945	122	7	the	the	DET
dpc-1945	122	8	treatment	treatment	NOUN
dpc-1945	122	9	of	of	ADP
dpc-1945	122	10	advanced	advanced	ADJ
dpc-1945	122	11	cutaneous	cutaneous	ADJ
dpc-1945	122	12	scc	scc	PROPN
dpc-1945	122	13	study	study	NOUN
dpc-1945	122	14	regimen	regimen	NOUN
dpc-1945	122	15	line	line	NOUN
dpc-1945	122	16	of	of	ADP
dpc-1945	122	17	therapy	therapy	NOUN
dpc-1945	122	18	pts	pts	X
dpc-1945	122	19	(	(	PUNCT
dpc-1945	122	20	n	n	CCONJ
dpc-1945	122	21	)	)	PUNCT
dpc-1945	122	22	response	response	NOUN
dpc-1945	122	23	rate	rate	NOUN
dpc-1945	122	24	duration	duration	NOUN
dpc-1945	122	25	of	of	ADP
dpc-1945	122	26	response	response	NOUN
dpc-1945	122	27	notes	note	NOUN
dpc-1945	122	28	/	/	SYM
dpc-1945	122	29	limitations	limitation	NOUN
dpc-1945	122	30	maubec	maubec	NOUN
dpc-1945	122	31	e	e	PROPN
dpc-1945	122	32	et	et	NOUN
dpc-1945	122	33	al	al	PROPN
dpc-1945	122	34	.	.	PUNCT
dpc-1945	123	1	2011(23	2011(23	NOUN
dpc-1945	123	2	)	)	PUNCT
dpc-1945	123	3	cetuximab	cetuximab	NOUN
dpc-1945	123	4	first	first	ADJ
dpc-1945	123	5	line	line	NOUN
dpc-1945	123	6	(	(	PUNCT
dpc-1945	123	7	42	42	NUM
dpc-1945	123	8	%	%	NOUN
dpc-1945	123	9	)	)	PUNCT
dpc-1945	123	10	second+	second+	NOUN
dpc-1945	123	11	line	line	NOUN
dpc-1945	123	12	(	(	PUNCT
dpc-1945	123	13	58	58	NUM
dpc-1945	123	14	%	%	NOUN
dpc-1945	123	15	)	)	PUNCT
dpc-1945	123	16	36	36	NUM
dpc-1945	123	17	cr	cr	NOUN
dpc-1945	123	18	6	6	NUM
dpc-1945	123	19	%	%	NOUN
dpc-1945	123	20	pr	pr	NOUN
dpc-1945	123	21	22	22	NUM
dpc-1945	123	22	%	%	NOUN
dpc-1945	123	23	orr	orr	NOUN
dpc-1945	123	24	28	28	NUM
dpc-1945	123	25	%	%	NOUN
dpc-1945	123	26	mean	mean	NOUN
dpc-1945	123	27	6.8	6.8	NUM
dpc-1945	123	28	months	month	NOUN
dpc-1945	123	29	mean	mean	VERB
dpc-1945	123	30	os	os	NOUN
dpc-1945	123	31	8.1	8.1	NUM
dpc-1945	123	32	months	month	NOUN
dpc-1945	123	33	median	median	PROPN
dpc-1945	123	34	pfs	pf	VERB
dpc-1945	123	35	4.1	4.1	NUM
dpc-1945	123	36	months	month	NOUN
dpc-1945	123	37	dcr	dcr	PROPN
dpc-1945	123	38	of	of	ADP
dpc-1945	123	39	69	69	NUM
dpc-1945	123	40	%	%	NOUN
dpc-1945	123	41	some	some	DET
dpc-1945	123	42	patients	patient	NOUN
dpc-1945	123	43	received	receive	VERB
dpc-1945	123	44	subsequent	subsequent	ADJ
dpc-1945	123	45	surgical	surgical	ADJ
dpc-1945	123	46	excision	excision	NOUN
dpc-1945	123	47	montauedié	montauedié	PROPN
dpc-1945	123	48	h	h	PROPN
dpc-1945	123	49	et	et	PROPN
dpc-1945	123	50	al	al	PROPN
dpc-1945	123	51	.	.	PROPN
dpc-1945	124	1	2020(24	2020(24	NUM
dpc-1945	124	2	)	)	PUNCT
dpc-1945	124	3	cetuximab	cetuximab	NOUN
dpc-1945	124	4	first	first	ADJ
dpc-1945	124	5	line	line	NOUN
dpc-1945	124	6	(	(	PUNCT
dpc-1945	124	7	36	36	NUM
dpc-1945	124	8	%	%	NOUN
dpc-1945	124	9	)	)	PUNCT
dpc-1945	125	1	second+	second+	NOUN
dpc-1945	125	2	line	line	NOUN
dpc-1945	125	3	(	(	PUNCT
dpc-1945	125	4	64	64	NUM
dpc-1945	125	5	%	%	NOUN
dpc-1945	125	6	)	)	PUNCT
dpc-1945	125	7	58	58	NUM
dpc-1945	125	8	cr	cr	NOUN
dpc-1945	125	9	2	2	NUM
dpc-1945	125	10	%	%	NOUN
dpc-1945	125	11	pr	pr	NOUN
dpc-1945	125	12	40	40	NUM
dpc-1945	125	13	%	%	NOUN
dpc-1945	125	14	orr	orr	NOUN
dpc-1945	125	15	42	42	NUM
dpc-1945	125	16	%	%	NOUN
dpc-1945	125	17	retrospective	retrospective	ADJ
dpc-1945	125	18	study	study	NOUN
dpc-1945	125	19	dcr	dcr	PROPN
dpc-1945	125	20	at	at	ADP
dpc-1945	125	21	12	12	NUM
dpc-1945	125	22	weeks	week	NOUN
dpc-1945	125	23	70	70	NUM
dpc-1945	125	24	%	%	NOUN
dpc-1945	125	25	median	median	NOUN
dpc-1945	125	26	pfs	pfs	PROPN
dpc-1945	125	27	9.7	9.7	NUM
dpc-1945	125	28	months	month	NOUN
dpc-1945	125	29	median	median	PROPN
dpc-1945	125	30	os	os	NOUN
dpc-1945	125	31	17.5	17.5	NUM
dpc-1945	125	32	months	month	NOUN
dpc-1945	125	33	hillen	hillen	ADJ
dpc-1945	125	34	u.	u.	PROPN
dpc-1945	125	35	et	et	PROPN
dpc-1945	125	36	al	al	PROPN
dpc-1945	125	37	.	.	PROPN
dpc-1945	125	38	2018(81	2018(81	NUM
dpc-1945	125	39	)	)	PUNCT
dpc-1945	125	40	cetuximab	cetuximab	NOUN
dpc-1945	125	41	majority	majority	NOUN
dpc-1945	125	42	second+	second+	ADJ
dpc-1945	125	43	line	line	NOUN
dpc-1945	125	44	15	15	NUM
dpc-1945	125	45	cr	cr	NOUN
dpc-1945	125	46	6	6	NUM
dpc-1945	125	47	%	%	NOUN
dpc-1945	125	48	pr	pr	NOUN
dpc-1945	125	49	13	13	NUM
dpc-1945	125	50	%	%	NOUN
dpc-1945	125	51	orr	orr	NOUN
dpc-1945	125	52	20	20	NUM
dpc-1945	125	53	%	%	NOUN
dpc-1945	125	54	mean	mean	NOUN
dpc-1945	125	55	7	7	NUM
dpc-1945	125	56	months	month	NOUN
dpc-1945	125	57	retrospective	retrospective	ADJ
dpc-1945	125	58	study	study	NOUN
dpc-1945	125	59	table	table	NOUN
dpc-1945	125	60	2	2	NUM
dpc-1945	125	61	continues	continue	VERB
dpc-1945	125	62	review	review	NOUN
dpc-1945	125	63	|	|	ADV
dpc-1945	125	64	dermatol	dermatol	ADJ
dpc-1945	125	65	pract	pract	NOUN
dpc-1945	125	66	concept	concept	NOUN
dpc-1945	125	67	.	.	PUNCT
dpc-1945	126	1	2021	2021	NUM
dpc-1945	126	2	;	;	PUNCT
dpc-1945	126	3	11(s2	11(s2	NUM
dpc-1945	126	4	):	):	PUNCT
dpc-1945	126	5	e2021169s	e2021169s	PROPN
dpc-1945	126	6	5	5	NUM
dpc-1945	126	7	systemic	systemic	ADJ
dpc-1945	126	8	immunotherapy	immunotherapy	NOUN
dpc-1945	126	9	for	for	ADP
dpc-1945	126	10	advanced	advanced	ADJ
dpc-1945	126	11	cscc	cscc	ADJ
dpc-1945	126	12	immunogenicity	immunogenicity	NOUN
dpc-1945	126	13	of	of	ADP
dpc-1945	126	14	cutaneous	cutaneous	ADJ
dpc-1945	126	15	squamous	squamous	ADJ
dpc-1945	126	16	cell	cell	NOUN
dpc-1945	126	17	carcinoma	carcinoma	NOUN
dpc-1945	126	18	a	a	DET
dpc-1945	126	19	discussion	discussion	NOUN
dpc-1945	126	20	of	of	ADP
dpc-1945	126	21	the	the	DET
dpc-1945	126	22	immune	immune	ADJ
dpc-1945	126	23	system	system	NOUN
dpc-1945	126	24	’s	’s	PART
dpc-1945	126	25	role	role	NOUN
dpc-1945	126	26	in	in	ADP
dpc-1945	126	27	development	development	NOUN
dpc-1945	126	28	of	of	ADP
dpc-1945	126	29	cscc	cscc	ADJ
dpc-1945	126	30	and	and	CCONJ
dpc-1945	126	31	tumor	tumor	NOUN
dpc-1945	126	32	progression	progression	NOUN
dpc-1945	126	33	is	be	AUX
dpc-1945	126	34	essential	essential	ADJ
dpc-1945	126	35	to	to	ADP
dpc-1945	126	36	understanding	understand	VERB
dpc-1945	126	37	how	how	SCONJ
dpc-1945	126	38	immunotherapy	immunotherapy	NOUN
dpc-1945	126	39	acts	act	VERB
dpc-1945	126	40	and	and	CCONJ
dpc-1945	126	41	mediates	mediate	VERB
dpc-1945	126	42	destruction	destruction	NOUN
dpc-1945	126	43	of	of	ADP
dpc-1945	126	44	target	target	NOUN
dpc-1945	126	45	tumor	tumor	NOUN
dpc-1945	126	46	cells	cell	NOUN
dpc-1945	126	47	.	.	PUNCT
dpc-1945	127	1	it	it	PRON
dpc-1945	127	2	is	be	AUX
dpc-1945	127	3	known	know	VERB
dpc-1945	127	4	that	that	SCONJ
dpc-1945	127	5	immunosuppression	immunosuppression	NOUN
dpc-1945	127	6	significantly	significantly	ADV
dpc-1945	127	7	increases	increase	VERB
dpc-1945	127	8	the	the	DET
dpc-1945	127	9	incidence	incidence	NOUN
dpc-1945	127	10	of	of	ADP
dpc-1945	127	11	non	non	ADJ
dpc-1945	127	12	-	-	ADJ
dpc-1945	127	13	melanoma	melanoma	ADJ
dpc-1945	127	14	skin	skin	NOUN
dpc-1945	127	15	cancer	cancer	NOUN
dpc-1945	127	16	including	include	VERB
dpc-1945	127	17	cscc	cscc	PROPN
dpc-1945	127	18	which	which	PRON
dpc-1945	127	19	occurs	occur	VERB
dpc-1945	127	20	65	65	NUM
dpc-1945	127	21	-	-	SYM
dpc-1945	127	22	250	250	NUM
dpc-1945	127	23	times	time	NOUN
dpc-1945	127	24	more	more	ADV
dpc-1945	127	25	frequently	frequently	ADV
dpc-1945	127	26	in	in	ADP
dpc-1945	127	27	patients	patient	NOUN
dpc-1945	127	28	after	after	ADP
dpc-1945	127	29	organ	organ	NOUN
dpc-1945	127	30	transplantation	transplantation	NOUN
dpc-1945	127	31	compared	compare	VERB
dpc-1945	127	32	to	to	ADP
dpc-1945	127	33	the	the	DET
dpc-1945	127	34	general	general	ADJ
dpc-1945	127	35	population	population	NOUN
dpc-1945	128	1	[	[	X
dpc-1945	128	2	39	39	NUM
dpc-1945	128	3	]	]	PUNCT
dpc-1945	128	4	.	.	PUNCT
dpc-1945	129	1	in	in	ADP
dpc-1945	129	2	addition	addition	NOUN
dpc-1945	129	3	,	,	PUNCT
dpc-1945	129	4	cscc	cscc	ADJ
dpc-1945	129	5	in	in	ADP
dpc-1945	129	6	the	the	DET
dpc-1945	129	7	organ	organ	NOUN
dpc-1945	129	8	transplant	transplant	NOUN
dpc-1945	129	9	population	population	NOUN
dpc-1945	129	10	tend	tend	VERB
dpc-1945	129	11	to	to	PART
dpc-1945	129	12	be	be	AUX
dpc-1945	129	13	more	more	ADV
dpc-1945	129	14	aggressive	aggressive	ADJ
dpc-1945	129	15	with	with	ADP
dpc-1945	129	16	an	an	DET
dpc-1945	129	17	increased	increase	VERB
dpc-1945	129	18	risk	risk	NOUN
dpc-1945	129	19	of	of	ADP
dpc-1945	129	20	local	local	ADJ
dpc-1945	129	21	recurrence	recurrence	NOUN
dpc-1945	129	22	,	,	PUNCT
dpc-1945	129	23	regional	regional	ADJ
dpc-1945	129	24	and	and	CCONJ
dpc-1945	129	25	distant	distant	ADJ
dpc-1945	129	26	metastasis	metastasis	NOUN
dpc-1945	129	27	,	,	PUNCT
dpc-1945	129	28	and	and	CCONJ
dpc-1945	129	29	mortality	mortality	NOUN
dpc-1945	130	1	[	[	X
dpc-1945	130	2	40	40	NUM
dpc-1945	130	3	]	]	PUNCT
dpc-1945	130	4	.	.	PUNCT
dpc-1945	131	1	chronic	chronic	ADJ
dpc-1945	131	2	immunosuppression	immunosuppression	NOUN
dpc-1945	131	3	impairs	impair	VERB
dpc-1945	131	4	normal	normal	ADJ
dpc-1945	131	5	immune	immune	ADJ
dpc-1945	131	6	surveillance	surveillance	NOUN
dpc-1945	131	7	and	and	CCONJ
dpc-1945	131	8	eradication	eradication	NOUN
dpc-1945	131	9	of	of	ADP
dpc-1945	131	10	carcinogenic	carcinogenic	ADJ
dpc-1945	131	11	changes	change	NOUN
dpc-1945	131	12	within	within	ADP
dpc-1945	131	13	tumor	tumor	NOUN
dpc-1945	131	14	cells	cell	NOUN
dpc-1945	131	15	.	.	PUNCT
dpc-1945	132	1	ultraviolet	ultraviolet	NOUN
dpc-1945	132	2	(	(	PUNCT
dpc-1945	132	3	uv	uv	NOUN
dpc-1945	132	4	)	)	PUNCT
dpc-1945	132	5	radiation	radiation	NOUN
dpc-1945	132	6	,	,	PUNCT
dpc-1945	132	7	a	a	DET
dpc-1945	132	8	primary	primary	ADJ
dpc-1945	132	9	pathogenic	pathogenic	ADJ
dpc-1945	132	10	factor	factor	NOUN
dpc-1945	132	11	for	for	ADP
dpc-1945	132	12	development	development	NOUN
dpc-1945	132	13	of	of	ADP
dpc-1945	132	14	squamous	squamous	ADJ
dpc-1945	132	15	cell	cell	NOUN
dpc-1945	132	16	carcinoma	carcinoma	NOUN
dpc-1945	132	17	,	,	PUNCT
dpc-1945	132	18	directly	directly	ADV
dpc-1945	132	19	causes	cause	VERB
dpc-1945	132	20	uv	uv	NOUN
dpc-1945	132	21	-	-	PUNCT
dpc-1945	132	22	specific	specific	ADJ
dpc-1945	132	23	mutations	mutation	NOUN
dpc-1945	132	24	in	in	ADP
dpc-1945	132	25	keratinocytes	keratinocyte	NOUN
dpc-1945	132	26	as	as	ADV
dpc-1945	132	27	well	well	ADV
dpc-1945	132	28	as	as	ADP
dpc-1945	132	29	a	a	DET
dpc-1945	132	30	functional	functional	ADJ
dpc-1945	132	31	and	and	CCONJ
dpc-1945	132	32	quantitative	quantitative	ADJ
dpc-1945	132	33	reduction	reduction	NOUN
dpc-1945	132	34	in	in	ADP
dpc-1945	132	35	the	the	DET
dpc-1945	132	36	cutaneous	cutaneous	ADJ
dpc-1945	132	37	immune	immune	ADJ
dpc-1945	132	38	response	response	NOUN
dpc-1945	132	39	,	,	PUNCT
dpc-1945	132	40	which	which	PRON
dpc-1945	132	41	in	in	ADP
dpc-1945	132	42	turn	turn	NOUN
dpc-1945	132	43	suppresses	suppress	VERB
dpc-1945	132	44	the	the	DET
dpc-1945	132	45	cutaneous	cutaneous	ADJ
dpc-1945	132	46	antigen	antigen	ADJ
dpc-1945	132	47	presentation	presentation	NOUN
dpc-1945	132	48	and	and	CCONJ
dpc-1945	132	49	recognition	recognition	NOUN
dpc-1945	132	50	in	in	ADP
dpc-1945	132	51	the	the	DET
dpc-1945	132	52	cutaneous	cutaneous	ADJ
dpc-1945	132	53	environment	environment	NOUN
dpc-1945	132	54	[	[	X
dpc-1945	132	55	41	41	NUM
dpc-1945	132	56	]	]	PUNCT
dpc-1945	132	57	.	.	PUNCT
dpc-1945	133	1	cutaneous	cutaneous	ADJ
dpc-1945	133	2	scc	scc	PROPN
dpc-1945	133	3	has	have	VERB
dpc-1945	133	4	one	one	NUM
dpc-1945	133	5	of	of	ADP
dpc-1945	133	6	the	the	DET
dpc-1945	133	7	highest	high	ADJ
dpc-1945	133	8	mutational	mutational	ADJ
dpc-1945	133	9	burden	burden	NOUN
dpc-1945	133	10	(	(	PUNCT
dpc-1945	133	11	tmb	tmb	NOUN
dpc-1945	133	12	)	)	PUNCT
dpc-1945	133	13	of	of	ADP
dpc-1945	133	14	all	all	DET
dpc-1945	133	15	tumors	tumor	NOUN
dpc-1945	133	16	including	include	VERB
dpc-1945	133	17	melanoma	melanoma	NOUN
dpc-1945	133	18	and	and	CCONJ
dpc-1945	133	19	other	other	ADJ
dpc-1945	133	20	squamous	squamous	ADJ
dpc-1945	133	21	tumor	tumor	NOUN
dpc-1945	133	22	types	type	NOUN
dpc-1945	133	23	[	[	X
dpc-1945	133	24	42	42	NUM
dpc-1945	133	25	]	]	PUNCT
dpc-1945	133	26	.	.	PUNCT
dpc-1945	134	1	tmb	tmb	PROPN
dpc-1945	134	2	has	have	AUX
dpc-1945	134	3	shown	show	VERB
dpc-1945	134	4	to	to	PART
dpc-1945	134	5	have	have	VERB
dpc-1945	134	6	predictive	predictive	ADJ
dpc-1945	134	7	value	value	NOUN
dpc-1945	134	8	of	of	ADP
dpc-1945	134	9	tumor	tumor	NOUN
dpc-1945	134	10	response	response	NOUN
dpc-1945	134	11	using	use	VERB
dpc-1945	134	12	immune	immune	ADJ
dpc-1945	134	13	checkpoint	checkpoint	NOUN
dpc-1945	134	14	inhibitors	inhibitor	NOUN
dpc-1945	134	15	in	in	ADP
dpc-1945	134	16	advanced	advanced	ADJ
dpc-1945	134	17	malignancies	malignancy	NOUN
dpc-1945	134	18	[	[	X
dpc-1945	134	19	43	43	NUM
dpc-1945	134	20	]	]	PUNCT
dpc-1945	134	21	,	,	PUNCT
dpc-1945	134	22	making	make	VERB
dpc-1945	134	23	cscc	cscc	VERB
dpc-1945	134	24	an	an	DET
dpc-1945	134	25	ideal	ideal	ADJ
dpc-1945	134	26	candidate	candidate	NOUN
dpc-1945	134	27	for	for	ADP
dpc-1945	134	28	immunotherapy	immunotherapy	NOUN
dpc-1945	134	29	treatment	treatment	NOUN
dpc-1945	134	30	.	.	PUNCT
dpc-1945	135	1	tumor	tumor	NOUN
dpc-1945	135	2	cells	cell	NOUN
dpc-1945	135	3	attempt	attempt	VERB
dpc-1945	135	4	to	to	PART
dpc-1945	135	5	evade	evade	VERB
dpc-1945	135	6	the	the	DET
dpc-1945	135	7	immune	immune	ADJ
dpc-1945	135	8	system	system	NOUN
dpc-1945	135	9	through	through	ADP
dpc-1945	135	10	a	a	DET
dpc-1945	135	11	variety	variety	NOUN
dpc-1945	135	12	of	of	ADP
dpc-1945	135	13	mechanisms	mechanism	NOUN
dpc-1945	135	14	,	,	PUNCT
dpc-1945	135	15	and	and	CCONJ
dpc-1945	135	16	those	those	DET
dpc-1945	135	17	cells	cell	NOUN
dpc-1945	135	18	that	that	PRON
dpc-1945	135	19	succeed	succeed	VERB
dpc-1945	135	20	show	show	VERB
dpc-1945	135	21	a	a	DET
dpc-1945	135	22	loss	loss	NOUN
dpc-1945	135	23	of	of	ADP
dpc-1945	135	24	expression	expression	NOUN
dpc-1945	135	25	of	of	ADP
dpc-1945	135	26	immunogenic	immunogenic	ADJ
dpc-1945	135	27	tumor	tumor	NOUN
dpc-1945	135	28	-	-	PUNCT
dpc-1945	135	29	specific	specific	ADJ
dpc-1945	135	30	antigens	antigen	NOUN
dpc-1945	135	31	[	[	X
dpc-1945	135	32	44	44	NUM
dpc-1945	135	33	]	]	PUNCT
dpc-1945	135	34	.	.	PUNCT
dpc-1945	136	1	these	these	DET
dpc-1945	136	2	cells	cell	NOUN
dpc-1945	136	3	are	be	AUX
dpc-1945	136	4	admixed	admix	VERB
dpc-1945	136	5	with	with	ADP
dpc-1945	136	6	a	a	DET
dpc-1945	136	7	variety	variety	NOUN
dpc-1945	136	8	of	of	ADP
dpc-1945	136	9	infiltrating	infiltrating	ADJ
dpc-1945	136	10	leukocytes	leukocyte	NOUN
dpc-1945	136	11	of	of	ADP
dpc-1945	136	12	both	both	CCONJ
dpc-1945	136	13	innate	innate	ADJ
dpc-1945	136	14	and	and	CCONJ
dpc-1945	136	15	adaptive	adaptive	ADJ
dpc-1945	136	16	origin	origin	NOUN
dpc-1945	136	17	in	in	ADP
dpc-1945	136	18	what	what	PRON
dpc-1945	136	19	is	be	AUX
dpc-1945	136	20	called	call	VERB
dpc-1945	136	21	a	a	DET
dpc-1945	136	22	tumor	tumor	NOUN
dpc-1945	136	23	microenvironment	microenvironment	NOUN
dpc-1945	136	24	(	(	PUNCT
dpc-1945	136	25	tme	tme	NOUN
dpc-1945	136	26	)	)	PUNCT
dpc-1945	136	27	.	.	PUNCT
dpc-1945	137	1	this	this	DET
dpc-1945	137	2	microenvironment	microenvironment	NOUN
dpc-1945	137	3	includes	include	VERB
dpc-1945	137	4	many	many	ADJ
dpc-1945	137	5	complex	complex	ADJ
dpc-1945	137	6	and	and	CCONJ
dpc-1945	137	7	dynamic	dynamic	ADJ
dpc-1945	137	8	interactions	interaction	NOUN
dpc-1945	137	9	between	between	ADP
dpc-1945	137	10	tumor	tumor	NOUN
dpc-1945	137	11	cells	cell	NOUN
dpc-1945	137	12	and	and	CCONJ
dpc-1945	137	13	the	the	DET
dpc-1945	137	14	immune	immune	ADJ
dpc-1945	137	15	cells	cell	NOUN
dpc-1945	137	16	,	,	PUNCT
dpc-1945	137	17	including	include	VERB
dpc-1945	137	18	t	t	NOUN
dpc-1945	137	19	-	-	PUNCT
dpc-1945	137	20	cells	cell	NOUN
dpc-1945	137	21	which	which	PRON
dpc-1945	137	22	constitute	constitute	VERB
dpc-1945	137	23	a	a	DET
dpc-1945	137	24	major	major	ADJ
dpc-1945	137	25	cell	cell	NOUN
dpc-1945	137	26	type	type	NOUN
dpc-1945	137	27	found	find	VERB
dpc-1945	137	28	in	in	ADP
dpc-1945	137	29	this	this	DET
dpc-1945	137	30	microenvistudy	microenvistudy	NOUN
dpc-1945	137	31	regimen	regimen	NOUN
dpc-1945	137	32	line	line	NOUN
dpc-1945	137	33	of	of	ADP
dpc-1945	137	34	therapy	therapy	NOUN
dpc-1945	137	35	pts	pts	X
dpc-1945	137	36	(	(	PUNCT
dpc-1945	137	37	n	n	CCONJ
dpc-1945	137	38	)	)	PUNCT
dpc-1945	137	39	response	response	NOUN
dpc-1945	137	40	rate	rate	NOUN
dpc-1945	137	41	duration	duration	NOUN
dpc-1945	137	42	of	of	ADP
dpc-1945	137	43	response	response	NOUN
dpc-1945	137	44	notes	note	NOUN
dpc-1945	137	45	/	/	SYM
dpc-1945	137	46	limitations	limitation	NOUN
dpc-1945	137	47	preneau	preneau	NOUN
dpc-1945	137	48	s	s	PROPN
dpc-1945	137	49	et	et	NOUN
dpc-1945	137	50	al	al	PROPN
dpc-1945	137	51	.	.	PROPN
dpc-1945	138	1	2014(82	2014(82	NUM
dpc-1945	138	2	)	)	PUNCT
dpc-1945	138	3	cetuximab	cetuximab	NOUN
dpc-1945	138	4	(	(	PUNCT
dpc-1945	138	5	6	6	NUM
dpc-1945	138	6	)	)	PUNCT
dpc-1945	138	7	,	,	PUNCT
dpc-1945	138	8	cetuximab	cetuximab	NOUN
dpc-1945	138	9	+	+	X
dpc-1945	138	10	rt	rt	PROPN
dpc-1945	138	11	(	(	PUNCT
dpc-1945	138	12	5	5	NUM
dpc-1945	138	13	)	)	PUNCT
dpc-1945	138	14	,	,	PUNCT
dpc-1945	138	15	cetuximab	cetuximab	NOUN
dpc-1945	138	16	+	+	CCONJ
dpc-1945	138	17	carboplatin	carboplatin	NOUN
dpc-1945	138	18	(	(	PUNCT
dpc-1945	138	19	9	9	NUM
dpc-1945	138	20	)	)	PUNCT
dpc-1945	138	21	first	first	ADJ
dpc-1945	138	22	line	line	NOUN
dpc-1945	138	23	(	(	PUNCT
dpc-1945	138	24	10	10	NUM
dpc-1945	138	25	%	%	NOUN
dpc-1945	138	26	)	)	PUNCT
dpc-1945	138	27	second+	second+	NOUN
dpc-1945	138	28	line	line	NOUN
dpc-1945	138	29	(	(	PUNCT
dpc-1945	138	30	90	90	NUM
dpc-1945	138	31	%	%	NOUN
dpc-1945	138	32	)	)	PUNCT
dpc-1945	138	33	20	20	NUM
dpc-1945	138	34	orr	orr	NOUN
dpc-1945	138	35	47	47	NUM
dpc-1945	138	36	%	%	NOUN
dpc-1945	138	37	os	os	NOUN
dpc-1945	138	38	11.1	11.1	NUM
dpc-1945	138	39	months	month	NOUN
dpc-1945	138	40	pfs	pfs	PROPN
dpc-1945	138	41	5.7	5.7	NUM
dpc-1945	138	42	months	month	NOUN
dpc-1945	138	43	orr	orr	PROPN
dpc-1945	138	44	:	:	PUNCT
dpc-1945	138	45	cetuximab	cetuximab	NOUN
dpc-1945	138	46	monotherapy	monotherapy	NOUN
dpc-1945	138	47	(	(	PUNCT
dpc-1945	138	48	33	33	NUM
dpc-1945	138	49	%	%	NOUN
dpc-1945	138	50	)	)	PUNCT
dpc-1945	138	51	,	,	PUNCT
dpc-1945	138	52	cetuximab	cetuximab	NOUN
dpc-1945	138	53	+	+	CCONJ
dpc-1945	138	54	carboplatin	carboplatin	NOUN
dpc-1945	138	55	(	(	PUNCT
dpc-1945	138	56	38	38	NUM
dpc-1945	138	57	%	%	NOUN
dpc-1945	138	58	)	)	PUNCT
dpc-1945	138	59	,	,	PUNCT
dpc-1945	138	60	cetuximab	cetuximab	NOUN
dpc-1945	138	61	+	+	X
dpc-1945	138	62	rt	rt	PROPN
dpc-1945	138	63	(	(	PUNCT
dpc-1945	138	64	80	80	NUM
dpc-1945	138	65	%	%	NOUN
dpc-1945	138	66	)	)	PUNCT
dpc-1945	139	1	reigneau	reigneau	NOUN
dpc-1945	139	2	m	m	VERB
dpc-1945	139	3	et	et	NOUN
dpc-1945	139	4	al	al	PROPN
dpc-1945	139	5	.	.	PROPN
dpc-1945	139	6	2015(83	2015(83	NUM
dpc-1945	139	7	)	)	PUNCT
dpc-1945	139	8	neoadjuvant	neoadjuvant	ADJ
dpc-1945	139	9	cetuximab	cetuximab	NOUN
dpc-1945	139	10	+	+	PROPN
dpc-1945	139	11	/(platinum	/(platinum	PUNCT
dpc-1945	139	12	based	base	VERB
dpc-1945	139	13	agent	agent	NOUN
dpc-1945	139	14	+	+	CCONJ
dpc-1945	139	15	5	5	NUM
dpc-1945	139	16	-	-	PUNCT
dpc-1945	139	17	fluorouracil	fluorouracil	NOUN
dpc-1945	139	18	)	)	PUNCT
dpc-1945	139	19	prior	prior	ADV
dpc-1945	139	20	to	to	ADP
dpc-1945	139	21	st	st	PROPN
dpc-1945	139	22	mixed	mixed	ADJ
dpc-1945	139	23	first	first	ADJ
dpc-1945	139	24	line	line	NOUN
dpc-1945	139	25	and	and	CCONJ
dpc-1945	139	26	second+	second+	ADJ
dpc-1945	139	27	line	line	NOUN
dpc-1945	139	28	34	34	NUM
dpc-1945	139	29	locally	locally	ADV
dpc-1945	139	30	advanced	advance	VERB
dpc-1945	139	31	scc	scc	NOUN
dpc-1945	139	32	only	only	ADV
dpc-1945	139	33	9	9	NUM
dpc-1945	139	34	pts	pt	NOUN
dpc-1945	139	35	received	receive	VERB
dpc-1945	139	36	cetuximab	cetuximab	NOUN
dpc-1945	139	37	monotherapy	monotherapy	NOUN
dpc-1945	139	38	tumors	tumor	NOUN
dpc-1945	139	39	became	become	VERB
dpc-1945	139	40	resectable	resectable	ADJ
dpc-1945	139	41	in	in	ADP
dpc-1945	139	42	28	28	NUM
dpc-1945	139	43	of	of	ADP
dpc-1945	139	44	34	34	NUM
dpc-1945	139	45	patients	patient	NOUN
dpc-1945	139	46	(	(	PUNCT
dpc-1945	139	47	82	82	NUM
dpc-1945	139	48	%	%	NOUN
dpc-1945	139	49	)	)	PUNCT
dpc-1945	139	50	some	some	DET
dpc-1945	139	51	patients	patient	NOUN
dpc-1945	139	52	received	receive	VERB
dpc-1945	139	53	adjuvant	adjuvant	PROPN
dpc-1945	139	54	rt	rt	PROPN
dpc-1945	139	55	galbiati	galbiati	PROPN
dpc-1945	139	56	d	d	PROPN
dpc-1945	139	57	et	et	PROPN
dpc-1945	139	58	al	al	PROPN
dpc-1945	139	59	.	.	PROPN
dpc-1945	139	60	2019(17	2019(17	NUM
dpc-1945	139	61	)	)	PUNCT
dpc-1945	139	62	cetuximab	cetuximab	NOUN
dpc-1945	139	63	+	+	CCONJ
dpc-1945	139	64	(	(	PUNCT
dpc-1945	139	65	cisplatin	cisplatin	NOUN
dpc-1945	139	66	or	or	CCONJ
dpc-1945	139	67	carboplatin	carboplatin	NOUN
dpc-1945	139	68	)	)	PUNCT
dpc-1945	140	1	second+	second+	NOUN
dpc-1945	140	2	line	line	NOUN
dpc-1945	140	3	12	12	NUM
dpc-1945	140	4	cr	cr	NUM
dpc-1945	140	5	8	8	NUM
dpc-1945	140	6	%	%	NOUN
dpc-1945	140	7	pr	pr	NOUN
dpc-1945	140	8	42	42	NUM
dpc-1945	140	9	%	%	NOUN
dpc-1945	140	10	orr	orr	NOUN
dpc-1945	140	11	50	50	NUM
dpc-1945	140	12	%	%	NOUN
dpc-1945	140	13	median	median	NOUN
dpc-1945	140	14	4.8	4.8	NUM
dpc-1945	140	15	months	month	NOUN
dpc-1945	140	16	median	median	PROPN
dpc-1945	140	17	pfs	pf	VERB
dpc-1945	140	18	6.6	6.6	NUM
dpc-1945	140	19	months	month	NOUN
dpc-1945	140	20	median	median	PROPN
dpc-1945	140	21	os	os	NOUN
dpc-1945	140	22	14.6	14.6	NUM
dpc-1945	140	23	months	month	NOUN
dpc-1945	140	24	some	some	DET
dpc-1945	140	25	patients	patient	NOUN
dpc-1945	140	26	subsequently	subsequently	ADV
dpc-1945	140	27	received	receive	VERB
dpc-1945	140	28	st	st	PROPN
dpc-1945	140	29	or	or	CCONJ
dpc-1945	140	30	rt	rt	PROPN
dpc-1945	140	31	foote	foote	PROPN
dpc-1945	140	32	mc	mc	PROPN
dpc-1945	140	33	et	et	PROPN
dpc-1945	140	34	al	al	PROPN
dpc-1945	140	35	.	.	PROPN
dpc-1945	141	1	2014(25	2014(25	NUM
dpc-1945	141	2	)	)	PUNCT
dpc-1945	141	3	panitumumab	panitumumab	VERB
dpc-1945	141	4	first	first	ADJ
dpc-1945	141	5	line	line	NOUN
dpc-1945	141	6	(	(	PUNCT
dpc-1945	141	7	6	6	NUM
dpc-1945	141	8	%	%	NOUN
dpc-1945	141	9	)	)	PUNCT
dpc-1945	142	1	second+	second+	NOUN
dpc-1945	142	2	line	line	NOUN
dpc-1945	142	3	(	(	PUNCT
dpc-1945	142	4	92	92	NUM
dpc-1945	142	5	%	%	NOUN
dpc-1945	142	6	)	)	PUNCT
dpc-1945	142	7	16	16	NUM
dpc-1945	142	8	cr	cr	PART
dpc-1945	142	9	12	12	NUM
dpc-1945	142	10	%	%	NOUN
dpc-1945	142	11	pr	pr	NOUN
dpc-1945	142	12	19	19	NUM
dpc-1945	142	13	%	%	NOUN
dpc-1945	142	14	orr	orr	NOUN
dpc-1945	142	15	31	31	NUM
dpc-1945	142	16	%	%	NOUN
dpc-1945	142	17	median	median	NOUN
dpc-1945	142	18	5	5	NUM
dpc-1945	142	19	months	month	NOUN
dpc-1945	142	20	median	median	PROPN
dpc-1945	142	21	pfs	pfs	PROPN
dpc-1945	142	22	8	8	NUM
dpc-1945	142	23	months	month	NOUN
dpc-1945	142	24	median	median	NOUN
dpc-1945	142	25	os	os	NOUN
dpc-1945	142	26	11	11	NUM
dpc-1945	142	27	months	month	NOUN
dpc-1945	142	28	william	william	PROPN
dpc-1945	142	29	wn	wn	PROPN
dpc-1945	142	30	et	et	PROPN
dpc-1945	142	31	al	al	PROPN
dpc-1945	142	32	.	.	PROPN
dpc-1945	142	33	2017(26	2017(26	NUM
dpc-1945	142	34	)	)	PUNCT
dpc-1945	142	35	gefitinib	gefitinib	NOUN
dpc-1945	142	36	second+	second+	PART
dpc-1945	142	37	line	line	NOUN
dpc-1945	142	38	37	37	NUM
dpc-1945	142	39	cr	cr	NOUN
dpc-1945	142	40	0	0	NUM
dpc-1945	142	41	%	%	NOUN
dpc-1945	142	42	pr	pr	NOUN
dpc-1945	142	43	16	16	NUM
dpc-1945	142	44	%	%	NOUN
dpc-1945	142	45	orr	orr	NOUN
dpc-1945	142	46	16	16	NUM
dpc-1945	142	47	%	%	NOUN
dpc-1945	142	48	median	median	NOUN
dpc-1945	142	49	31.4	31.4	NUM
dpc-1945	142	50	months	month	NOUN
dpc-1945	142	51	dcr	dcr	NOUN
dpc-1945	142	52	51	51	NUM
dpc-1945	142	53	%	%	NOUN
dpc-1945	142	54	median	median	NOUN
dpc-1945	142	55	os	os	NOUN
dpc-1945	142	56	12.9	12.9	NUM
dpc-1945	142	57	months	month	NOUN
dpc-1945	142	58	median	median	PROPN
dpc-1945	142	59	pfs	pfs	PROPN
dpc-1945	142	60	3.8	3.8	NUM
dpc-1945	142	61	months	month	NOUN
dpc-1945	142	62	lewis	lewis	PROPN
dpc-1945	142	63	et	et	PROPN
dpc-1945	142	64	al	al	PROPN
dpc-1945	142	65	.	.	PROPN
dpc-1945	142	66	2012(27	2012(27	NUM
dpc-1945	142	67	)	)	PUNCT
dpc-1945	142	68	neoadjuvant	neoadjuvant	ADJ
dpc-1945	142	69	gefinitib	gefinitib	PROPN
dpc-1945	142	70	prior	prior	ADV
dpc-1945	142	71	to	to	ADP
dpc-1945	142	72	st	st	PROPN
dpc-1945	142	73	and/or	and/or	CCONJ
dpc-1945	142	74	rt	rt	PROPN
dpc-1945	142	75	first	first	ADJ
dpc-1945	142	76	line	line	NOUN
dpc-1945	142	77	(	(	PUNCT
dpc-1945	142	78	43	43	NUM
dpc-1945	142	79	%	%	NOUN
dpc-1945	142	80	)	)	PUNCT
dpc-1945	142	81	second+	second+	NOUN
dpc-1945	142	82	line	line	NOUN
dpc-1945	142	83	(	(	PUNCT
dpc-1945	142	84	57	57	NUM
dpc-1945	142	85	%	%	NOUN
dpc-1945	142	86	)	)	PUNCT
dpc-1945	142	87	22	22	NUM
dpc-1945	142	88	cr	cr	NUM
dpc-1945	142	89	18	18	NUM
dpc-1945	142	90	%	%	NOUN
dpc-1945	142	91	pr	pr	NOUN
dpc-1945	142	92	27	27	NUM
dpc-1945	142	93	%	%	NOUN
dpc-1945	142	94	orr	orr	NOUN
dpc-1945	142	95	45	45	NUM
dpc-1945	142	96	%	%	NOUN
dpc-1945	142	97	2	2	NUM
dpc-1945	142	98	-	-	PUNCT
dpc-1945	142	99	year	year	NOUN
dpc-1945	142	100	os	os	NOUN
dpc-1945	142	101	72.1	72.1	NUM
dpc-1945	142	102	%	%	NOUN
dpc-1945	142	103	2	2	NUM
dpc-1945	142	104	-	-	PUNCT
dpc-1945	142	105	year	year	NOUN
dpc-1945	142	106	pfs	pfs	ADJ
dpc-1945	142	107	63.6	63.6	NUM
dpc-1945	142	108	%	%	NOUN
dpc-1945	142	109	gold	gold	NOUN
dpc-1945	142	110	et	et	PROPN
dpc-1945	142	111	al	al	PROPN
dpc-1945	142	112	.	.	PROPN
dpc-1945	142	113	2018(28	2018(28	NUM
dpc-1945	142	114	)	)	PUNCT
dpc-1945	142	115	erlotinib	erlotinib	NOUN
dpc-1945	142	116	second+	second+	PART
dpc-1945	142	117	line	line	NOUN
dpc-1945	142	118	29	29	NUM
dpc-1945	142	119	cr	cr	PART
dpc-1945	142	120	0	0	NUM
dpc-1945	142	121	%	%	NOUN
dpc-1945	142	122	pr	pr	NOUN
dpc-1945	142	123	10	10	NUM
dpc-1945	142	124	%	%	NOUN
dpc-1945	142	125	orr	orr	NOUN
dpc-1945	142	126	10	10	NUM
dpc-1945	142	127	%	%	NOUN
dpc-1945	142	128	dcr	dcr	NOUN
dpc-1945	142	129	72	72	NUM
dpc-1945	142	130	%	%	NOUN
dpc-1945	142	131	median	median	NOUN
dpc-1945	142	132	os	os	NOUN
dpc-1945	142	133	13	13	NUM
dpc-1945	142	134	months	month	NOUN
dpc-1945	142	135	median	median	PROPN
dpc-1945	142	136	pfs	pfs	PROPN
dpc-1945	142	137	4.7	4.7	NUM
dpc-1945	142	138	months	month	NOUN
dpc-1945	142	139	note	note	VERB
dpc-1945	142	140	this	this	DET
dpc-1945	142	141	table	table	NOUN
dpc-1945	142	142	is	be	AUX
dpc-1945	142	143	just	just	ADV
dpc-1945	142	144	a	a	DET
dpc-1945	142	145	limited	limited	ADJ
dpc-1945	142	146	sampling	sampling	NOUN
dpc-1945	142	147	of	of	ADP
dpc-1945	142	148	published	publish	VERB
dpc-1945	142	149	reports	report	NOUN
dpc-1945	142	150	including	include	VERB
dpc-1945	142	151	targeted	target	VERB
dpc-1945	142	152	therapies	therapy	NOUN
dpc-1945	142	153	for	for	ADP
dpc-1945	142	154	advanced	advanced	ADJ
dpc-1945	142	155	cutaneous	cutaneous	ADJ
dpc-1945	142	156	scc	scc	PROPN
dpc-1945	142	157	.	.	PUNCT
dpc-1945	143	1	cr=	cr=	PROPN
dpc-1945	143	2	complete	complete	ADJ
dpc-1945	143	3	response	response	NOUN
dpc-1945	143	4	;	;	PUNCT
dpc-1945	143	5	pr	pr	NOUN
dpc-1945	143	6	=	=	PUNCT
dpc-1945	143	7	partial	partial	ADJ
dpc-1945	143	8	response	response	NOUN
dpc-1945	143	9	;	;	PUNCT
dpc-1945	144	1	orr	orr	PROPN
dpc-1945	144	2	=	=	PUNCT
dpc-1945	144	3	overall	overall	ADJ
dpc-1945	144	4	response	response	NOUN
dpc-1945	144	5	rate	rate	NOUN
dpc-1945	144	6	;	;	PUNCT
dpc-1945	144	7	st	st	NOUN
dpc-1945	144	8	=	=	ADJ
dpc-1945	144	9	surgical	surgical	ADJ
dpc-1945	144	10	therapy	therapy	NOUN
dpc-1945	144	11	;	;	PUNCT
dpc-1945	144	12	rt	rt	NOUN
dpc-1945	144	13	=	=	NOUN
dpc-1945	144	14	radiation	radiation	NOUN
dpc-1945	144	15	therapy	therapy	NOUN
dpc-1945	144	16	;	;	PUNCT
dpc-1945	144	17	pts	pt	NOUN
dpc-1945	144	18	=	=	NOUN
dpc-1945	144	19	patients	patient	NOUN
dpc-1945	144	20	;	;	PUNCT
dpc-1945	144	21	dcr	dcr	PROPN
dpc-1945	144	22	=	=	PUNCT
dpc-1945	144	23	disease	disease	NOUN
dpc-1945	144	24	control	control	NOUN
dpc-1945	144	25	rate	rate	NOUN
dpc-1945	144	26	;	;	PUNCT
dpc-1945	144	27	scc	scc	NOUN
dpc-1945	144	28	=	=	PUNCT
dpc-1945	144	29	squamous	squamous	ADJ
dpc-1945	144	30	cell	cell	NOUN
dpc-1945	144	31	carcinoma	carcinoma	NOUN
dpc-1945	144	32	.	.	PUNCT
dpc-1945	145	1	6	6	NUM
dpc-1945	145	2	review	review	NOUN
dpc-1945	145	3	|	|	ADV
dpc-1945	145	4	dermatol	dermatol	ADJ
dpc-1945	145	5	pract	pract	NOUN
dpc-1945	145	6	concept	concept	NOUN
dpc-1945	145	7	.	.	PUNCT
dpc-1945	146	1	2021	2021	NUM
dpc-1945	146	2	;	;	PUNCT
dpc-1945	146	3	11(s2	11(s2	NUM
dpc-1945	146	4	):	):	PUNCT
dpc-1945	147	1	e2021169s	e2021169s	X
dpc-1945	147	2	ronment	ronment	NOUN
dpc-1945	147	3	[	[	X
dpc-1945	147	4	45	45	NUM
dpc-1945	147	5	]	]	PUNCT
dpc-1945	147	6	.	.	PUNCT
dpc-1945	148	1	tumor	tumor	NOUN
dpc-1945	148	2	cells	cell	NOUN
dpc-1945	148	3	can	can	AUX
dpc-1945	148	4	evade	evade	VERB
dpc-1945	148	5	the	the	DET
dpc-1945	148	6	immune	immune	ADJ
dpc-1945	148	7	system	system	NOUN
dpc-1945	148	8	in	in	ADP
dpc-1945	148	9	the	the	DET
dpc-1945	148	10	tme	tme	NOUN
dpc-1945	148	11	by	by	ADP
dpc-1945	148	12	t	t	PROPN
dpc-1945	148	13	-	-	PUNCT
dpc-1945	148	14	cell	cell	NOUN
dpc-1945	148	15	co	co	NOUN
dpc-1945	148	16	-	-	NOUN
dpc-1945	148	17	stimulation	stimulation	NOUN
dpc-1945	148	18	through	through	ADP
dpc-1945	148	19	tumor	tumor	NOUN
dpc-1945	148	20	cell	cell	NOUN
dpc-1945	148	21	upregulation	upregulation	NOUN
dpc-1945	148	22	of	of	ADP
dpc-1945	148	23	immune	immune	NOUN
dpc-1945	148	24	-	-	PUNCT
dpc-1945	148	25	checkpoint	checkpoint	NOUN
dpc-1945	148	26	co	co	ADJ
dpc-1945	148	27	-	-	ADJ
dpc-1945	148	28	signaling	signal	VERB
dpc-1945	148	29	proteins	protein	NOUN
dpc-1945	148	30	such	such	ADJ
dpc-1945	148	31	as	as	ADP
dpc-1945	148	32	cytotoxic	cytotoxic	ADJ
dpc-1945	148	33	t	t	PROPN
dpc-1945	148	34	-	-	PUNCT
dpc-1945	148	35	lymphocyte	lymphocyte	NOUN
dpc-1945	148	36	-	-	PUNCT
dpc-1945	148	37	associated	associate	VERB
dpc-1945	148	38	antigen	antigen	ADJ
dpc-1945	148	39	4	4	NUM
dpc-1945	148	40	(	(	PUNCT
dpc-1945	148	41	ctla-4	ctla-4	X
dpc-1945	148	42	)	)	PUNCT
dpc-1945	148	43	and	and	CCONJ
dpc-1945	148	44	programmed	program	VERB
dpc-1945	148	45	death-1	death-1	PROPN
dpc-1945	148	46	(	(	PUNCT
dpc-1945	148	47	pd-1	pd-1	ADJ
dpc-1945	148	48	)	)	PUNCT
dpc-1945	148	49	protein	protein	NOUN
dpc-1945	148	50	.	.	PUNCT
dpc-1945	149	1	these	these	DET
dpc-1945	149	2	act	act	NOUN
dpc-1945	149	3	as	as	ADP
dpc-1945	149	4	brakes	brake	NOUN
dpc-1945	149	5	on	on	ADP
dpc-1945	149	6	the	the	DET
dpc-1945	149	7	anti	anti	ADJ
dpc-1945	149	8	-	-	ADJ
dpc-1945	149	9	tumor	tumor	ADJ
dpc-1945	149	10	immune	immune	ADJ
dpc-1945	149	11	response	response	NOUN
dpc-1945	149	12	,	,	PUNCT
dpc-1945	149	13	and	and	CCONJ
dpc-1945	149	14	have	have	AUX
dpc-1945	149	15	become	become	VERB
dpc-1945	149	16	immunotherapeutic	immunotherapeutic	ADJ
dpc-1945	149	17	targets	target	NOUN
dpc-1945	149	18	in	in	ADP
dpc-1945	149	19	treatment	treatment	NOUN
dpc-1945	149	20	of	of	ADP
dpc-1945	149	21	cscc	cscc	NOUN
dpc-1945	149	22	.	.	PUNCT
dpc-1945	150	1	exploring	explore	VERB
dpc-1945	150	2	the	the	DET
dpc-1945	150	3	vast	vast	ADJ
dpc-1945	150	4	and	and	CCONJ
dpc-1945	150	5	intricate	intricate	ADJ
dpc-1945	150	6	interactions	interaction	NOUN
dpc-1945	150	7	between	between	ADP
dpc-1945	150	8	the	the	DET
dpc-1945	150	9	immune	immune	ADJ
dpc-1945	150	10	response	response	NOUN
dpc-1945	150	11	and	and	CCONJ
dpc-1945	150	12	cscc	cscc	NOUN
dpc-1945	150	13	is	be	AUX
dpc-1945	150	14	beyond	beyond	ADP
dpc-1945	150	15	the	the	DET
dpc-1945	150	16	scope	scope	NOUN
dpc-1945	150	17	of	of	ADP
dpc-1945	150	18	this	this	DET
dpc-1945	150	19	review	review	NOUN
dpc-1945	150	20	.	.	PUNCT
dpc-1945	151	1	nevertheless	nevertheless	ADV
dpc-1945	151	2	,	,	PUNCT
dpc-1945	151	3	a	a	DET
dpc-1945	151	4	strong	strong	ADJ
dpc-1945	151	5	emphasis	emphasis	NOUN
dpc-1945	151	6	should	should	AUX
dpc-1945	151	7	be	be	AUX
dpc-1945	151	8	placed	place	VERB
dpc-1945	151	9	on	on	ADP
dpc-1945	151	10	recognizing	recognize	VERB
dpc-1945	151	11	that	that	SCONJ
dpc-1945	151	12	these	these	DET
dpc-1945	151	13	interactions	interaction	NOUN
dpc-1945	151	14	form	form	VERB
dpc-1945	151	15	the	the	DET
dpc-1945	151	16	backbone	backbone	NOUN
dpc-1945	151	17	from	from	ADP
dpc-1945	151	18	which	which	PRON
dpc-1945	151	19	modern	modern	ADJ
dpc-1945	151	20	immunotherapeutics	immunotherapeutic	NOUN
dpc-1945	151	21	have	have	AUX
dpc-1945	151	22	been	be	AUX
dpc-1945	151	23	designed	design	VERB
dpc-1945	151	24	and	and	CCONJ
dpc-1945	151	25	developed	develop	VERB
dpc-1945	151	26	.	.	PUNCT
dpc-1945	152	1	pd-1	pd-1	ADP
dpc-1945	152	2	inhibitors	inhibitor	NOUN
dpc-1945	152	3	pd-1	pd-1	ADP
dpc-1945	152	4	inhibitors	inhibitor	NOUN
dpc-1945	152	5	have	have	AUX
dpc-1945	152	6	become	become	VERB
dpc-1945	152	7	a	a	DET
dpc-1945	152	8	mainstream	mainstream	NOUN
dpc-1945	152	9	approach	approach	NOUN
dpc-1945	152	10	for	for	ADP
dpc-1945	152	11	the	the	DET
dpc-1945	152	12	treatment	treatment	NOUN
dpc-1945	152	13	of	of	ADP
dpc-1945	152	14	a	a	DET
dpc-1945	152	15	variety	variety	NOUN
dpc-1945	152	16	of	of	ADP
dpc-1945	152	17	cancers	cancer	NOUN
dpc-1945	152	18	including	include	VERB
dpc-1945	152	19	,	,	PUNCT
dpc-1945	152	20	but	but	CCONJ
dpc-1945	152	21	not	not	PART
dpc-1945	152	22	limited	limit	VERB
dpc-1945	152	23	to	to	ADP
dpc-1945	152	24	,	,	PUNCT
dpc-1945	152	25	non	non	ADJ
dpc-1945	152	26	-	-	ADJ
dpc-1945	152	27	small	small	ADJ
dpc-1945	152	28	cell	cell	NOUN
dpc-1945	152	29	lung	lung	NOUN
dpc-1945	152	30	cancer	cancer	NOUN
dpc-1945	152	31	,	,	PUNCT
dpc-1945	152	32	metastatic	metastatic	ADJ
dpc-1945	152	33	melanoma	melanoma	NOUN
dpc-1945	152	34	,	,	PUNCT
dpc-1945	152	35	colorectal	colorectal	ADJ
dpc-1945	152	36	cancer	cancer	NOUN
dpc-1945	152	37	,	,	PUNCT
dpc-1945	152	38	as	as	ADV
dpc-1945	152	39	well	well	ADV
dpc-1945	152	40	as	as	ADP
dpc-1945	152	41	advanced	advanced	ADJ
dpc-1945	152	42	cscc	cscc	ADJ
dpc-1945	152	43	[	[	X
dpc-1945	152	44	46	46	NUM
dpc-1945	152	45	]	]	PUNCT
dpc-1945	152	46	.	.	PUNCT
dpc-1945	153	1	the	the	DET
dpc-1945	153	2	pd-1	pd-1	ADJ
dpc-1945	153	3	receptor	receptor	NOUN
dpc-1945	153	4	protein	protein	NOUN
dpc-1945	153	5	on	on	ADP
dpc-1945	153	6	t	t	PROPN
dpc-1945	153	7	-	-	PUNCT
dpc-1945	153	8	cells	cell	NOUN
dpc-1945	153	9	interacts	interact	VERB
dpc-1945	153	10	with	with	ADP
dpc-1945	153	11	its	its	PRON
dpc-1945	153	12	corresponding	correspond	VERB
dpc-1945	153	13	ligand	ligand	NOUN
dpc-1945	153	14	,	,	PUNCT
dpc-1945	153	15	pd	pd	PROPN
dpc-1945	153	16	-	-	PROPN
dpc-1945	153	17	l1	l1	PROPN
dpc-1945	153	18	or	or	CCONJ
dpc-1945	153	19	pd	pd	NOUN
dpc-1945	153	20	-	-	PUNCT
dpc-1945	153	21	l2	l2	NOUN
dpc-1945	153	22	,	,	PUNCT
dpc-1945	153	23	which	which	PRON
dpc-1945	153	24	may	may	AUX
dpc-1945	153	25	be	be	AUX
dpc-1945	153	26	expressed	express	VERB
dpc-1945	153	27	on	on	ADP
dpc-1945	153	28	tumor	tumor	NOUN
dpc-1945	153	29	cells	cell	NOUN
dpc-1945	153	30	or	or	CCONJ
dpc-1945	153	31	tumor	tumor	NOUN
dpc-1945	153	32	infiltrating	infiltrate	VERB
dpc-1945	153	33	lymphocytes	lymphocyte	NOUN
dpc-1945	153	34	that	that	PRON
dpc-1945	153	35	may	may	AUX
dpc-1945	153	36	be	be	AUX
dpc-1945	153	37	in	in	ADP
dpc-1945	153	38	the	the	DET
dpc-1945	153	39	tme	tme	NOUN
dpc-1945	153	40	.	.	PUNCT
dpc-1945	154	1	this	this	DET
dpc-1945	154	2	interaction	interaction	NOUN
dpc-1945	154	3	transmits	transmit	VERB
dpc-1945	154	4	downstream	downstream	ADJ
dpc-1945	154	5	signals	signal	NOUN
dpc-1945	154	6	that	that	PRON
dpc-1945	154	7	inhibit	inhibit	VERB
dpc-1945	154	8	t	t	NOUN
dpc-1945	154	9	-	-	PUNCT
dpc-1945	154	10	cell	cell	NOUN
dpc-1945	154	11	proliferation	proliferation	NOUN
dpc-1945	154	12	,	,	PUNCT
dpc-1945	154	13	cytokine	cytokine	ADJ
dpc-1945	154	14	production	production	NOUN
dpc-1945	154	15	,	,	PUNCT
dpc-1945	154	16	and	and	CCONJ
dpc-1945	154	17	cytolytic	cytolytic	ADJ
dpc-1945	154	18	function	function	NOUN
dpc-1945	154	19	,	,	PUNCT
dpc-1945	154	20	thus	thus	ADV
dpc-1945	154	21	inhibiting	inhibit	VERB
dpc-1945	154	22	the	the	DET
dpc-1945	154	23	immunogenic	immunogenic	ADJ
dpc-1945	154	24	antitumor	antitumor	PROPN
dpc-1945	154	25	response	response	NOUN
dpc-1945	155	1	[	[	X
dpc-1945	155	2	47	47	NUM
dpc-1945	155	3	-	-	SYM
dpc-1945	155	4	49	49	NUM
dpc-1945	155	5	]	]	PUNCT
dpc-1945	155	6	.	.	PUNCT
dpc-1945	156	1	pd-1	pd-1	VERB
dpc-1945	156	2	inhibitors	inhibitor	NOUN
dpc-1945	156	3	are	be	AUX
dpc-1945	156	4	one	one	NUM
dpc-1945	156	5	type	type	NOUN
dpc-1945	156	6	of	of	ADP
dpc-1945	156	7	immune	immune	ADJ
dpc-1945	156	8	checkpoint	checkpoint	NOUN
dpc-1945	156	9	inhibitor	inhibitor	NOUN
dpc-1945	156	10	that	that	PRON
dpc-1945	156	11	blocks	block	VERB
dpc-1945	156	12	the	the	DET
dpc-1945	156	13	pd-1	pd-1	NOUN
dpc-1945	156	14	/	/	SYM
dpc-1945	156	15	pd	pd	ADJ
dpc-1945	156	16	-	-	PUNCT
dpc-1945	156	17	l1	l1	PROPN
dpc-1945	156	18	interaction	interaction	NOUN
dpc-1945	156	19	and	and	CCONJ
dpc-1945	156	20	allows	allow	VERB
dpc-1945	156	21	for	for	ADP
dpc-1945	156	22	enhanced	enhanced	ADJ
dpc-1945	156	23	immune	immune	ADJ
dpc-1945	156	24	surveillance	surveillance	NOUN
dpc-1945	156	25	and	and	CCONJ
dpc-1945	156	26	destruction	destruction	NOUN
dpc-1945	156	27	of	of	ADP
dpc-1945	156	28	tumor	tumor	NOUN
dpc-1945	156	29	cells	cell	NOUN
dpc-1945	156	30	.	.	PUNCT
dpc-1945	157	1	pembrolizumab	pembrolizumab	NOUN
dpc-1945	157	2	,	,	PUNCT
dpc-1945	157	3	nivolumab	nivolumab	NOUN
dpc-1945	157	4	,	,	PUNCT
dpc-1945	157	5	and	and	CCONJ
dpc-1945	157	6	most	most	ADV
dpc-1945	157	7	recently	recently	ADV
dpc-1945	157	8	cemiplimab	cemiplimab	NOUN
dpc-1945	157	9	are	be	AUX
dpc-1945	157	10	anti	anti	ADJ
dpc-1945	157	11	-	-	ADJ
dpc-1945	157	12	pd1	pd1	ADJ
dpc-1945	157	13	monoclonal	monoclonal	NOUN
dpc-1945	157	14	antibodies	antibody	NOUN
dpc-1945	157	15	used	use	VERB
dpc-1945	157	16	in	in	ADP
dpc-1945	157	17	the	the	DET
dpc-1945	157	18	treatment	treatment	NOUN
dpc-1945	157	19	of	of	ADP
dpc-1945	157	20	advanced	advanced	ADJ
dpc-1945	157	21	malignancies	malignancy	NOUN
dpc-1945	157	22	.	.	PUNCT
dpc-1945	158	1	in	in	ADP
dpc-1945	158	2	2018	2018	NUM
dpc-1945	158	3	,	,	PUNCT
dpc-1945	158	4	registration	registration	NOUN
dpc-1945	158	5	trials	trial	NOUN
dpc-1945	158	6	by	by	ADP
dpc-1945	158	7	migden	migden	ADJ
dpc-1945	158	8	and	and	CCONJ
dpc-1945	158	9	colleagues	colleague	NOUN
dpc-1945	158	10	showed	show	VERB
dpc-1945	158	11	orrs	orr	NOUN
dpc-1945	158	12	of	of	ADP
dpc-1945	158	13	41.1	41.1	NUM
dpc-1945	158	14	-	-	SYM
dpc-1945	158	15	50	50	NUM
dpc-1945	158	16	%	%	NOUN
dpc-1945	158	17	in	in	ADP
dpc-1945	158	18	the	the	DET
dpc-1945	158	19	phase	phase	NOUN
dpc-1945	158	20	i	i	PRON
dpc-1945	158	21	and	and	CCONJ
dpc-1945	158	22	ii	ii	PROPN
dpc-1945	158	23	studies	study	NOUN
dpc-1945	158	24	that	that	PRON
dpc-1945	158	25	included	include	VERB
dpc-1945	158	26	patients	patient	NOUN
dpc-1945	158	27	with	with	ADP
dpc-1945	158	28	locally	locally	ADV
dpc-1945	158	29	advanced	advanced	ADJ
dpc-1945	158	30	or	or	CCONJ
dpc-1945	158	31	metastatic	metastatic	ADJ
dpc-1945	158	32	cscc	cscc	NOUN
dpc-1945	158	33	treated	treat	VERB
dpc-1945	158	34	with	with	ADP
dpc-1945	158	35	weight	weight	NOUN
dpc-1945	158	36	-	-	PUNCT
dpc-1945	158	37	based	base	VERB
dpc-1945	158	38	dosing	dosing	NOUN
dpc-1945	158	39	of	of	ADP
dpc-1945	158	40	cemiplimab	cemiplimab	NOUN
dpc-1945	158	41	(	(	PUNCT
dpc-1945	158	42	3mg	3mg	NOUN
dpc-1945	158	43	/	/	SYM
dpc-1945	158	44	kg	kg	NOUN
dpc-1945	158	45	q2weeks	q2week	NOUN
dpc-1945	158	46	)	)	PUNCT
dpc-1945	158	47	or	or	CCONJ
dpc-1945	158	48	a	a	DET
dpc-1945	158	49	fixed	fix	VERB
dpc-1945	158	50	dose	dose	NOUN
dpc-1945	158	51	(	(	PUNCT
dpc-1945	158	52	350	350	NUM
dpc-1945	158	53	mg	mg	NOUN
dpc-1945	158	54	q3weeks	q3week	NOUN
dpc-1945	158	55	)	)	PUNCT
dpc-1945	158	56	.	.	PUNCT
dpc-1945	159	1	disease	disease	NOUN
dpc-1945	159	2	control	control	NOUN
dpc-1945	159	3	rates	rate	NOUN
dpc-1945	159	4	ranged	range	VERB
dpc-1945	159	5	from	from	ADP
dpc-1945	159	6	62	62	NUM
dpc-1945	159	7	-	-	SYM
dpc-1945	159	8	71.2	71.2	NUM
dpc-1945	159	9	%	%	NOUN
dpc-1945	159	10	[	[	X
dpc-1945	159	11	5052	5052	NUM
dpc-1945	159	12	]	]	PUNCT
dpc-1945	159	13	.	.	PUNCT
dpc-1945	160	1	it	it	PRON
dpc-1945	160	2	is	be	AUX
dpc-1945	160	3	worthwhile	worthwhile	ADJ
dpc-1945	160	4	to	to	PART
dpc-1945	160	5	note	note	VERB
dpc-1945	160	6	that	that	SCONJ
dpc-1945	160	7	there	there	PRON
dpc-1945	160	8	were	be	VERB
dpc-1945	160	9	patients	patient	NOUN
dpc-1945	160	10	included	include	VERB
dpc-1945	160	11	in	in	ADP
dpc-1945	160	12	these	these	DET
dpc-1945	160	13	trials	trial	NOUN
dpc-1945	160	14	where	where	SCONJ
dpc-1945	160	15	partial	partial	ADJ
dpc-1945	160	16	response	response	NOUN
dpc-1945	160	17	was	be	AUX
dpc-1945	160	18	not	not	PART
dpc-1945	160	19	obtained	obtain	VERB
dpc-1945	160	20	until	until	ADP
dpc-1945	160	21	after	after	ADP
dpc-1945	160	22	6	6	NUM
dpc-1945	160	23	-	-	SYM
dpc-1945	160	24	10	10	NUM
dpc-1945	160	25	months	month	NOUN
dpc-1945	160	26	of	of	ADP
dpc-1945	160	27	treatment	treatment	NOUN
dpc-1945	160	28	and	and	CCONJ
dpc-1945	160	29	thus	thus	ADV
dpc-1945	160	30	only	only	ADV
dpc-1945	160	31	a	a	DET
dpc-1945	160	32	few	few	ADJ
dpc-1945	160	33	cycles	cycle	NOUN
dpc-1945	160	34	of	of	ADP
dpc-1945	160	35	therapy	therapy	NOUN
dpc-1945	160	36	seem	seem	VERB
dpc-1945	160	37	insufficient	insufficient	ADJ
dpc-1945	160	38	to	to	PART
dpc-1945	160	39	determine	determine	VERB
dpc-1945	160	40	response	response	NOUN
dpc-1945	160	41	.	.	PUNCT
dpc-1945	161	1	some	some	DET
dpc-1945	161	2	patients	patient	NOUN
dpc-1945	161	3	who	who	PRON
dpc-1945	161	4	initially	initially	ADV
dpc-1945	161	5	appeared	appear	VERB
dpc-1945	161	6	as	as	SCONJ
dpc-1945	161	7	non	non	NOUN
dpc-1945	161	8	-	-	NOUN
dpc-1945	161	9	responders	responder	NOUN
dpc-1945	161	10	later	later	ADV
dpc-1945	161	11	showed	show	VERB
dpc-1945	161	12	impressive	impressive	ADJ
dpc-1945	161	13	tumor	tumor	NOUN
dpc-1945	161	14	regression	regression	NOUN
dpc-1945	161	15	and	and	CCONJ
dpc-1945	161	16	at	at	ADP
dpc-1945	161	17	times	time	NOUN
dpc-1945	161	18	a	a	DET
dpc-1945	161	19	complete	complete	ADJ
dpc-1945	161	20	response	response	NOUN
dpc-1945	161	21	.	.	PUNCT
dpc-1945	162	1	the	the	DET
dpc-1945	162	2	keynote-629	keynote-629	ADJ
dpc-1945	162	3	trial	trial	NOUN
dpc-1945	162	4	by	by	ADP
dpc-1945	162	5	grob	grob	PROPN
dpc-1945	162	6	and	and	CCONJ
dpc-1945	162	7	colleagues	colleague	NOUN
dpc-1945	162	8	,	,	PUNCT
dpc-1945	162	9	a	a	DET
dpc-1945	162	10	single	single	ADJ
dpc-1945	162	11	arm	arm	NOUN
dpc-1945	162	12	phase	phase	NOUN
dpc-1945	162	13	ii	ii	NOUN
dpc-1945	162	14	trial	trial	NOUN
dpc-1945	162	15	that	that	PRON
dpc-1945	162	16	treated	treat	VERB
dpc-1945	162	17	105	105	NUM
dpc-1945	162	18	patients	patient	NOUN
dpc-1945	162	19	with	with	ADP
dpc-1945	162	20	200	200	NUM
dpc-1945	162	21	mg	mg	PROPN
dpc-1945	162	22	pembrolizumab	pembrolizumab	NOUN
dpc-1945	162	23	q3	q3	PROPN
dpc-1945	162	24	weeks	week	NOUN
dpc-1945	162	25	(	(	PUNCT
dpc-1945	162	26	q3w	q3w	NOUN
dpc-1945	162	27	)	)	PUNCT
dpc-1945	162	28	,	,	PUNCT
dpc-1945	162	29	observed	observe	VERB
dpc-1945	162	30	a	a	DET
dpc-1945	162	31	34.4	34.4	NUM
dpc-1945	162	32	%	%	NOUN
dpc-1945	162	33	orr	orr	NOUN
dpc-1945	162	34	with	with	ADP
dpc-1945	162	35	a	a	DET
dpc-1945	162	36	52.4	52.4	NUM
dpc-1945	162	37	%	%	NOUN
dpc-1945	162	38	dcr	dcr	NOUN
dpc-1945	163	1	[	[	X
dpc-1945	163	2	53	53	NUM
dpc-1945	163	3	]	]	PUNCT
dpc-1945	163	4	.	.	PUNCT
dpc-1945	164	1	it	it	PRON
dpc-1945	164	2	should	should	AUX
dpc-1945	164	3	be	be	AUX
dpc-1945	164	4	noted	note	VERB
dpc-1945	164	5	that	that	SCONJ
dpc-1945	164	6	in	in	ADP
dpc-1945	164	7	86.7	86.7	NUM
dpc-1945	164	8	%	%	NOUN
dpc-1945	164	9	of	of	ADP
dpc-1945	164	10	patients	patient	NOUN
dpc-1945	164	11	in	in	ADP
dpc-1945	164	12	the	the	DET
dpc-1945	164	13	keynote-629	keynote-629	ADJ
dpc-1945	164	14	trial	trial	NOUN
dpc-1945	164	15	,	,	PUNCT
dpc-1945	164	16	pembrolizumab	pembrolizumab	NOUN
dpc-1945	164	17	was	be	AUX
dpc-1945	164	18	at	at	ADP
dpc-1945	164	19	least	least	ADJ
dpc-1945	164	20	second	second	ADJ
dpc-1945	164	21	line	line	NOUN
dpc-1945	164	22	therapy	therapy	NOUN
dpc-1945	164	23	.	.	PUNCT
dpc-1945	165	1	maubec	maubec	NOUN
dpc-1945	165	2	and	and	CCONJ
dpc-1945	165	3	colleagues	colleague	NOUN
dpc-1945	165	4	reported	report	VERB
dpc-1945	165	5	a	a	DET
dpc-1945	165	6	slightly	slightly	ADV
dpc-1945	165	7	higher	high	ADJ
dpc-1945	165	8	orr	orr	NOUN
dpc-1945	165	9	of	of	ADP
dpc-1945	165	10	41	41	NUM
dpc-1945	165	11	%	%	NOUN
dpc-1945	165	12	and	and	CCONJ
dpc-1945	165	13	dcr	dcr	PROPN
dpc-1945	165	14	of	of	ADP
dpc-1945	165	15	54	54	NUM
dpc-1945	165	16	%	%	NOUN
dpc-1945	165	17	in	in	ADP
dpc-1945	165	18	a	a	DET
dpc-1945	165	19	phase	phase	NOUN
dpc-1945	165	20	ii	ii	NOUN
dpc-1945	165	21	study	study	NOUN
dpc-1945	165	22	of	of	ADP
dpc-1945	165	23	pembrolizumab	pembrolizumab	NOUN
dpc-1945	165	24	as	as	ADP
dpc-1945	165	25	first	first	ADJ
dpc-1945	165	26	-	-	PUNCT
dpc-1945	165	27	line	line	NOUN
dpc-1945	165	28	monotherapy	monotherapy	NOUN
dpc-1945	165	29	[	[	X
dpc-1945	165	30	54	54	NUM
dpc-1945	165	31	]	]	PUNCT
dpc-1945	165	32	.	.	PUNCT
dpc-1945	166	1	although	although	SCONJ
dpc-1945	166	2	nivolumab	nivolumab	NOUN
dpc-1945	166	3	lacks	lack	NOUN
dpc-1945	166	4	completed	complete	VERB
dpc-1945	166	5	large	large	ADJ
dpc-1945	166	6	scale	scale	NOUN
dpc-1945	166	7	phase	phase	NOUN
dpc-1945	166	8	i	i	PRON
dpc-1945	166	9	and	and	CCONJ
dpc-1945	166	10	ii	ii	NOUN
dpc-1945	166	11	trials	trial	NOUN
dpc-1945	166	12	for	for	ADP
dpc-1945	166	13	advanced	advanced	ADJ
dpc-1945	166	14	cscc	cscc	NOUN
dpc-1945	166	15	as	as	SCONJ
dpc-1945	166	16	seen	see	VERB
dpc-1945	166	17	with	with	ADP
dpc-1945	166	18	cemiplimab	cemiplimab	NOUN
dpc-1945	166	19	and	and	CCONJ
dpc-1945	166	20	pembrolizumab	pembrolizumab	NOUN
dpc-1945	166	21	,	,	PUNCT
dpc-1945	166	22	it	it	PRON
dpc-1945	166	23	has	have	AUX
dpc-1945	166	24	been	be	AUX
dpc-1945	166	25	used	use	VERB
dpc-1945	166	26	as	as	ADP
dpc-1945	166	27	therapy	therapy	NOUN
dpc-1945	166	28	for	for	ADP
dpc-1945	166	29	advanced	advanced	ADJ
dpc-1945	166	30	cscc	cscc	ADJ
dpc-1945	166	31	.	.	PUNCT
dpc-1945	167	1	table	table	NOUN
dpc-1945	167	2	3	3	NUM
dpc-1945	167	3	summarizes	summarize	NOUN
dpc-1945	167	4	several	several	ADJ
dpc-1945	167	5	studies	study	NOUN
dpc-1945	167	6	investigating	investigate	VERB
dpc-1945	167	7	anti	anti	ADJ
dpc-1945	167	8	-	-	ADJ
dpc-1945	167	9	pd1	pd1	VERB
dpc-1945	167	10	therapies	therapy	NOUN
dpc-1945	167	11	for	for	ADP
dpc-1945	167	12	advanced	advanced	ADJ
dpc-1945	167	13	cscc	cscc	ADJ
dpc-1945	167	14	.	.	PUNCT
dpc-1945	168	1	table	table	NOUN
dpc-1945	168	2	3	3	NUM
dpc-1945	168	3	.	.	PUNCT
dpc-1945	169	1	anti	anti	ADJ
dpc-1945	169	2	-	-	ADJ
dpc-1945	169	3	pd1	pd1	VERB
dpc-1945	169	4	therapies	therapy	NOUN
dpc-1945	169	5	for	for	ADP
dpc-1945	169	6	advanced	advanced	ADJ
dpc-1945	169	7	cscc	cscc	ADJ
dpc-1945	169	8	study	study	NOUN
dpc-1945	169	9	regimen	regimen	NOUN
dpc-1945	169	10	line	line	NOUN
dpc-1945	169	11	of	of	ADP
dpc-1945	169	12	therapy	therapy	NOUN
dpc-1945	169	13	pts	pts	X
dpc-1945	169	14	(	(	PUNCT
dpc-1945	169	15	n	n	CCONJ
dpc-1945	169	16	)	)	PUNCT
dpc-1945	169	17	response	response	NOUN
dpc-1945	169	18	rate	rate	NOUN
dpc-1945	169	19	duration	duration	NOUN
dpc-1945	169	20	of	of	ADP
dpc-1945	169	21	response	response	NOUN
dpc-1945	169	22	notes	note	NOUN
dpc-1945	169	23	/	/	SYM
dpc-1945	169	24	limitations	limitation	NOUN
dpc-1945	169	25	migden	migden	VERB
dpc-1945	169	26	mr	mr	PROPN
dpc-1945	169	27	et	et	PROPN
dpc-1945	169	28	al	al	PROPN
dpc-1945	169	29	.	.	PROPN
dpc-1945	169	30	2018	2018	NUM
dpc-1945	169	31	(	(	PUNCT
dpc-1945	169	32	50	50	NUM
dpc-1945	169	33	)	)	PUNCT
dpc-1945	169	34	cemiplimab	cemiplimab	NOUN
dpc-1945	169	35	first	first	ADJ
dpc-1945	169	36	line	line	NOUN
dpc-1945	169	37	(	(	PUNCT
dpc-1945	169	38	31	31	NUM
dpc-1945	169	39	%	%	NOUN
dpc-1945	169	40	)	)	PUNCT
dpc-1945	170	1	second+	second+	NOUN
dpc-1945	170	2	line	line	NOUN
dpc-1945	170	3	(	(	PUNCT
dpc-1945	170	4	69	69	NUM
dpc-1945	170	5	%	%	NOUN
dpc-1945	170	6	)	)	PUNCT
dpc-1945	170	7	26	26	NUM
dpc-1945	170	8	cr	cr	NOUN
dpc-1945	170	9	0	0	NUM
dpc-1945	170	10	%	%	NOUN
dpc-1945	170	11	pr	pr	NOUN
dpc-1945	170	12	50	50	NUM
dpc-1945	170	13	%	%	NOUN
dpc-1945	170	14	orr	orr	NOUN
dpc-1945	170	15	50	50	NUM
dpc-1945	170	16	%	%	NOUN
dpc-1945	170	17	median	median	NOUN
dpc-1945	170	18	nr	nr	NOUN
dpc-1945	170	19	expansion	expansion	NOUN
dpc-1945	170	20	cohorts	cohort	NOUN
dpc-1945	170	21	of	of	ADP
dpc-1945	170	22	phase	phase	NOUN
dpc-1945	170	23	i	i	PRON
dpc-1945	170	24	study	study	VERB
dpc-1945	170	25	including	include	VERB
dpc-1945	170	26	locally	locally	ADV
dpc-1945	170	27	advanced	advanced	ADJ
dpc-1945	170	28	or	or	CCONJ
dpc-1945	170	29	metastatic	metastatic	ADJ
dpc-1945	170	30	cscc	cscc	ADJ
dpc-1945	170	31	migden	migden	VERB
dpc-1945	170	32	mr	mr	PROPN
dpc-1945	170	33	et	et	PROPN
dpc-1945	170	34	al	al	PROPN
dpc-1945	170	35	.	.	PROPN
dpc-1945	170	36	2020(52	2020(52	NUM
dpc-1945	170	37	)	)	PUNCT
dpc-1945	170	38	cemiplimab	cemiplimab	NOUN
dpc-1945	170	39	first	first	ADV
dpc-1945	170	40	and	and	CCONJ
dpc-1945	170	41	second+	second+	ADJ
dpc-1945	170	42	line	line	NOUN
dpc-1945	170	43	78	78	NUM
dpc-1945	170	44	cr	cr	PART
dpc-1945	170	45	13	13	NUM
dpc-1945	170	46	%	%	NOUN
dpc-1945	170	47	pr	pr	NOUN
dpc-1945	170	48	31	31	NUM
dpc-1945	170	49	%	%	NOUN
dpc-1945	170	50	orr	orr	NOUN
dpc-1945	170	51	44	44	NUM
dpc-1945	170	52	%	%	NOUN
dpc-1945	170	53	median	median	NOUN
dpc-1945	170	54	nr	nr	PROPN
dpc-1945	170	55	km	km	PROPN
dpc-1945	170	56	dor	dor	PROPN
dpc-1945	170	57	89	89	NUM
dpc-1945	170	58	%	%	NOUN
dpc-1945	170	59	phase	phase	NOUN
dpc-1945	170	60	ii	ii	PROPN
dpc-1945	170	61	locally	locally	ADV
dpc-1945	170	62	advanced	advance	VERB
dpc-1945	170	63	cscc	cscc	ADJ
dpc-1945	170	64	cohort	cohort	NOUN
dpc-1945	170	65	km	km	NOUN
dpc-1945	170	66	1	1	NUM
dpc-1945	170	67	year	year	NOUN
dpc-1945	170	68	os	os	NOUN
dpc-1945	170	69	81	81	NUM
dpc-1945	170	70	%	%	NOUN
dpc-1945	170	71	km	km	NOUN
dpc-1945	170	72	1	1	NUM
dpc-1945	170	73	year	year	NOUN
dpc-1945	170	74	pfs	pf	VERB
dpc-1945	170	75	53	53	NUM
dpc-1945	170	76	%	%	NOUN
dpc-1945	170	77	richscin	richscin	NOUN
dpc-1945	170	78	d	d	NOUN
dpc-1945	170	79	et	et	NOUN
dpc-1945	170	80	al	al	PROPN
dpc-1945	170	81	.	.	PROPN
dpc-1945	171	1	2020(51	2020(51	NUM
dpc-1945	171	2	)	)	PUNCT
dpc-1945	171	3	cemiplimab	cemiplimab	NOUN
dpc-1945	171	4	first	first	ADV
dpc-1945	171	5	and	and	CCONJ
dpc-1945	171	6	second+	second+	ADJ
dpc-1945	171	7	line	line	NOUN
dpc-1945	171	8	71	71	NUM
dpc-1945	171	9	cr	cr	NUM
dpc-1945	171	10	11	11	NUM
dpc-1945	171	11	%	%	NOUN
dpc-1945	171	12	pr	pr	NOUN
dpc-1945	171	13	34	34	NUM
dpc-1945	171	14	%	%	NOUN
dpc-1945	171	15	orr	orr	NOUN
dpc-1945	171	16	45	45	NUM
dpc-1945	171	17	%	%	NOUN
dpc-1945	171	18	median	median	NOUN
dpc-1945	171	19	nr	nr	PROPN
dpc-1945	171	20	km	km	PROPN
dpc-1945	171	21	dor	dor	PROPN
dpc-1945	172	1	90	90	NUM
dpc-1945	172	2	%	%	NOUN
dpc-1945	172	3	dcr	dcr	NOUN
dpc-1945	172	4	68	68	NUM
dpc-1945	172	5	%	%	NOUN
dpc-1945	172	6	km	km	NOUN
dpc-1945	172	7	1	1	NUM
dpc-1945	172	8	year	year	NOUN
dpc-1945	172	9	os	os	NOUN
dpc-1945	172	10	81	81	NUM
dpc-1945	172	11	%	%	NOUN
dpc-1945	172	12	km	km	NOUN
dpc-1945	172	13	1	1	NUM
dpc-1945	172	14	year	year	NOUN
dpc-1945	172	15	pfs	pf	VERB
dpc-1945	172	16	51.2	51.2	NUM
dpc-1945	172	17	%	%	NOUN
dpc-1945	172	18	in	in	ADP
dpc-1945	172	19	gk	gk	PROPN
dpc-1945	172	20	et	et	PROPN
dpc-1945	172	21	al	al	PROPN
dpc-1945	172	22	.	.	PROPN
dpc-1945	172	23	2020(84	2020(84	NUM
dpc-1945	172	24	)	)	PUNCT
dpc-1945	172	25	cemiplimab	cemiplimab	NOUN
dpc-1945	172	26	(	(	PUNCT
dpc-1945	172	27	13	13	NUM
dpc-1945	172	28	)	)	PUNCT
dpc-1945	172	29	pembrolizumab	pembrolizumab	NOUN
dpc-1945	172	30	(	(	PUNCT
dpc-1945	172	31	7	7	X
dpc-1945	172	32	)	)	PUNCT
dpc-1945	172	33	nivolumab	nivolumab	NOUN
dpc-1945	172	34	(	(	PUNCT
dpc-1945	172	35	6	6	NUM
dpc-1945	172	36	)	)	PUNCT
dpc-1945	172	37	first	first	ADJ
dpc-1945	172	38	and	and	CCONJ
dpc-1945	172	39	second+	second+	ADJ
dpc-1945	172	40	line	line	NOUN
dpc-1945	172	41	26	26	NUM
dpc-1945	172	42	cr	cr	PART
dpc-1945	172	43	23	23	NUM
dpc-1945	172	44	%	%	NOUN
dpc-1945	172	45	pr	pr	NOUN
dpc-1945	172	46	19	19	NUM
dpc-1945	172	47	%	%	NOUN
dpc-1945	172	48	orr	orr	NOUN
dpc-1945	172	49	42	42	NUM
dpc-1945	172	50	%	%	NOUN
dpc-1945	172	51	median	median	NOUN
dpc-1945	172	52	7.6	7.6	NUM
dpc-1945	172	53	months	month	NOUN
dpc-1945	172	54	retrospective	retrospective	ADJ
dpc-1945	172	55	study	study	NOUN
dpc-1945	172	56	median	median	NOUN
dpc-1945	172	57	pfs	pfs	PROPN
dpc-1945	172	58	5.4	5.4	NUM
dpc-1945	172	59	months	month	NOUN
dpc-1945	172	60	maubec	maubec	ADP
dpc-1945	172	61	e	e	PROPN
dpc-1945	172	62	et	et	PROPN
dpc-1945	172	63	al	al	PROPN
dpc-1945	172	64	.	.	PROPN
dpc-1945	172	65	2020(54	2020(54	NUM
dpc-1945	172	66	)	)	PUNCT
dpc-1945	172	67	pembrolizumab	pembrolizumab	NOUN
dpc-1945	172	68	first	first	ADJ
dpc-1945	172	69	line	line	NOUN
dpc-1945	172	70	(	(	PUNCT
dpc-1945	172	71	31	31	NUM
dpc-1945	172	72	%	%	NOUN
dpc-1945	172	73	)	)	PUNCT
dpc-1945	172	74	second+	second+	NOUN
dpc-1945	172	75	line	line	NOUN
dpc-1945	172	76	(	(	PUNCT
dpc-1945	172	77	69	69	NUM
dpc-1945	172	78	%	%	NOUN
dpc-1945	172	79	)	)	PUNCT
dpc-1945	172	80	57	57	NUM
dpc-1945	172	81	cr	cr	SYM
dpc-1945	172	82	8	8	NUM
dpc-1945	172	83	%	%	NOUN
dpc-1945	172	84	pr	pr	NOUN
dpc-1945	172	85	33	33	NUM
dpc-1945	172	86	%	%	NOUN
dpc-1945	172	87	orr	orr	NOUN
dpc-1945	172	88	41	41	NUM
dpc-1945	172	89	%	%	NOUN
dpc-1945	172	90	median	median	PROPN
dpc-1945	172	91	nr	nr	PROPN
dpc-1945	172	92	dcr	dcr	PROPN
dpc-1945	172	93	60	60	NUM
dpc-1945	172	94	%	%	NOUN
dpc-1945	172	95	salzmann	salzmann	PROPN
dpc-1945	172	96	m	m	PROPN
dpc-1945	172	97	et	et	NOUN
dpc-1945	172	98	al	al	PROPN
dpc-1945	172	99	.	.	PROPN
dpc-1945	173	1	2020(85	2020(85	NUM
dpc-1945	173	2	)	)	PUNCT
dpc-1945	173	3	cemiplimab	cemiplimab	NOUN
dpc-1945	173	4	(	(	PUNCT
dpc-1945	173	5	8)	8)	NUM
dpc-1945	173	6	pembrolizumab	pembrolizumab	NOUN
dpc-1945	173	7	(	(	PUNCT
dpc-1945	173	8	28	28	NUM
dpc-1945	173	9	)	)	PUNCT
dpc-1945	173	10	nivolumab	nivolumab	NOUN
dpc-1945	173	11	(	(	PUNCT
dpc-1945	173	12	10	10	NUM
dpc-1945	173	13	)	)	PUNCT
dpc-1945	173	14	first	first	ADJ
dpc-1945	173	15	line	line	NOUN
dpc-1945	173	16	(	(	PUNCT
dpc-1945	173	17	67	67	NUM
dpc-1945	173	18	%	%	NOUN
dpc-1945	173	19	)	)	PUNCT
dpc-1945	173	20	second+	second+	NOUN
dpc-1945	173	21	line	line	NOUN
dpc-1945	173	22	(	(	PUNCT
dpc-1945	173	23	33	33	NUM
dpc-1945	173	24	%	%	NOUN
dpc-1945	173	25	)	)	PUNCT
dpc-1945	173	26	46	46	NUM
dpc-1945	173	27	cr	cr	NUM
dpc-1945	173	28	15	15	NUM
dpc-1945	173	29	%	%	NOUN
dpc-1945	173	30	pr	pr	NOUN
dpc-1945	173	31	44	44	NUM
dpc-1945	173	32	%	%	NOUN
dpc-1945	173	33	orr	orr	NOUN
dpc-1945	173	34	59	59	NUM
dpc-1945	173	35	%	%	NOUN
dpc-1945	173	36	retrospective	retrospective	ADJ
dpc-1945	173	37	study	study	NOUN
dpc-1945	173	38	dcr	dcr	NOUN
dpc-1945	173	39	80	80	NUM
dpc-1945	173	40	%	%	NOUN
dpc-1945	173	41	km	km	NOUN
dpc-1945	173	42	1	1	NUM
dpc-1945	173	43	year	year	NOUN
dpc-1945	173	44	pfs	pf	VERB
dpc-1945	173	45	59	59	NUM
dpc-1945	173	46	%	%	NOUN
dpc-1945	173	47	table	table	NOUN
dpc-1945	173	48	3	3	NUM
dpc-1945	173	49	continues	continue	VERB
dpc-1945	173	50	review	review	NOUN
dpc-1945	173	51	|	|	ADV
dpc-1945	173	52	dermatol	dermatol	ADJ
dpc-1945	173	53	pract	pract	NOUN
dpc-1945	173	54	concept	concept	NOUN
dpc-1945	173	55	.	.	PUNCT
dpc-1945	174	1	2021	2021	NUM
dpc-1945	174	2	;	;	PUNCT
dpc-1945	174	3	11(s2	11(s2	NUM
dpc-1945	174	4	):	):	PUNCT
dpc-1945	174	5	e2021169s	e2021169s	NOUN
dpc-1945	174	6	7	7	NUM
dpc-1945	174	7	immunotherapy	immunotherapy	NOUN
dpc-1945	174	8	brings	bring	VERB
dpc-1945	174	9	with	with	ADP
dpc-1945	174	10	it	it	PRON
dpc-1945	174	11	a	a	DET
dpc-1945	174	12	wide	wide	ADJ
dpc-1945	174	13	variety	variety	NOUN
dpc-1945	174	14	of	of	ADP
dpc-1945	174	15	possible	possible	ADJ
dpc-1945	174	16	immune	immune	ADJ
dpc-1945	174	17	related	relate	VERB
dpc-1945	174	18	adverse	adverse	ADJ
dpc-1945	174	19	events	event	NOUN
dpc-1945	174	20	(	(	PUNCT
dpc-1945	174	21	iraes	iraes	NOUN
dpc-1945	174	22	)	)	PUNCT
dpc-1945	174	23	involving	involve	VERB
dpc-1945	174	24	various	various	ADJ
dpc-1945	174	25	organ	organ	NOUN
dpc-1945	174	26	systems	system	NOUN
dpc-1945	174	27	that	that	PRON
dpc-1945	174	28	may	may	AUX
dpc-1945	174	29	be	be	AUX
dpc-1945	174	30	monitored	monitor	VERB
dpc-1945	174	31	,	,	PUNCT
dpc-1945	174	32	managed	manage	VERB
dpc-1945	174	33	symptomatically	symptomatically	ADV
dpc-1945	174	34	,	,	PUNCT
dpc-1945	174	35	or	or	CCONJ
dpc-1945	174	36	treated	treat	VERB
dpc-1945	174	37	with	with	ADP
dpc-1945	174	38	systemic	systemic	ADJ
dpc-1945	174	39	steroids	steroid	NOUN
dpc-1945	174	40	if	if	SCONJ
dpc-1945	174	41	grade	grade	NOUN
dpc-1945	174	42	3	3	NUM
dpc-1945	174	43	or	or	CCONJ
dpc-1945	174	44	higher	high	ADJ
dpc-1945	174	45	.	.	PUNCT
dpc-1945	175	1	in	in	ADP
dpc-1945	175	2	the	the	DET
dpc-1945	175	3	large	large	ADJ
dpc-1945	175	4	-	-	PUNCT
dpc-1945	175	5	scale	scale	NOUN
dpc-1945	175	6	trials	trial	NOUN
dpc-1945	175	7	of	of	ADP
dpc-1945	175	8	cemiplimab	cemiplimab	NOUN
dpc-1945	175	9	mentioned	mention	VERB
dpc-1945	175	10	above	above	ADV
dpc-1945	175	11	,	,	PUNCT
dpc-1945	175	12	the	the	DET
dpc-1945	175	13	most	most	ADV
dpc-1945	175	14	reported	reported	ADJ
dpc-1945	175	15	side	side	NOUN
dpc-1945	175	16	effects	effect	NOUN
dpc-1945	175	17	in	in	ADP
dpc-1945	175	18	the	the	DET
dpc-1945	175	19	study	study	NOUN
dpc-1945	175	20	were	be	AUX
dpc-1945	175	21	diarrhea	diarrhea	NOUN
dpc-1945	175	22	and	and	CCONJ
dpc-1945	175	23	fatigue	fatigue	NOUN
dpc-1945	175	24	,	,	PUNCT
dpc-1945	175	25	experienced	experience	VERB
dpc-1945	175	26	by	by	ADP
dpc-1945	175	27	25	25	NUM
dpc-1945	175	28	%	%	NOUN
dpc-1945	175	29	of	of	ADP
dpc-1945	175	30	enrolled	enrol	VERB
dpc-1945	175	31	patients	patient	NOUN
dpc-1945	175	32	,	,	PUNCT
dpc-1945	175	33	of	of	ADP
dpc-1945	175	34	which	which	PRON
dpc-1945	175	35	the	the	DET
dpc-1945	175	36	majority	majority	NOUN
dpc-1945	175	37	were	be	AUX
dpc-1945	175	38	low	low	ADJ
dpc-1945	175	39	grade	grade	NOUN
dpc-1945	175	40	[	[	X
dpc-1945	175	41	50	50	NUM
dpc-1945	175	42	]	]	PUNCT
dpc-1945	175	43	.	.	PUNCT
dpc-1945	176	1	patients	patient	NOUN
dpc-1945	176	2	should	should	AUX
dpc-1945	176	3	be	be	AUX
dpc-1945	176	4	very	very	ADV
dpc-1945	176	5	closely	closely	ADV
dpc-1945	176	6	monitored	monitor	VERB
dpc-1945	176	7	and	and	CCONJ
dpc-1945	176	8	informed	inform	VERB
dpc-1945	176	9	to	to	PART
dpc-1945	176	10	report	report	VERB
dpc-1945	176	11	even	even	ADV
dpc-1945	176	12	the	the	DET
dpc-1945	176	13	mildest	mild	ADJ
dpc-1945	176	14	of	of	ADP
dpc-1945	176	15	symptoms	symptom	NOUN
dpc-1945	176	16	,	,	PUNCT
dpc-1945	176	17	as	as	ADP
dpc-1945	176	18	life	life	NOUN
dpc-1945	176	19	-	-	PUNCT
dpc-1945	176	20	threatening	threaten	VERB
dpc-1945	176	21	irae	irae	NOUN
dpc-1945	176	22	such	such	ADJ
dpc-1945	176	23	as	as	ADP
dpc-1945	176	24	colitis	colitis	NOUN
dpc-1945	176	25	,	,	PUNCT
dpc-1945	176	26	pneumonitis	pneumonitis	NOUN
dpc-1945	176	27	,	,	PUNCT
dpc-1945	176	28	and	and	CCONJ
dpc-1945	176	29	hepatitis	hepatitis	NOUN
dpc-1945	176	30	represent	represent	VERB
dpc-1945	176	31	a	a	DET
dpc-1945	176	32	possible	possible	ADJ
dpc-1945	176	33	downside	downside	NOUN
dpc-1945	176	34	of	of	ADP
dpc-1945	176	35	immunotherapy	immunotherapy	NOUN
dpc-1945	176	36	.	.	PUNCT
dpc-1945	177	1	most	most	ADJ
dpc-1945	177	2	clinical	clinical	ADJ
dpc-1945	177	3	trials	trial	NOUN
dpc-1945	177	4	involving	involve	VERB
dpc-1945	177	5	immunotherapy	immunotherapy	NOUN
dpc-1945	177	6	have	have	AUX
dpc-1945	177	7	excluded	exclude	VERB
dpc-1945	177	8	patients	patient	NOUN
dpc-1945	177	9	with	with	ADP
dpc-1945	177	10	a	a	DET
dpc-1945	177	11	prior	prior	ADJ
dpc-1945	177	12	history	history	NOUN
dpc-1945	177	13	of	of	ADP
dpc-1945	177	14	autoimmune	autoimmune	ADJ
dpc-1945	177	15	disease	disease	NOUN
dpc-1945	177	16	.	.	PUNCT
dpc-1945	178	1	those	those	PRON
dpc-1945	178	2	that	that	PRON
dpc-1945	178	3	included	include	VERB
dpc-1945	178	4	patients	patient	NOUN
dpc-1945	178	5	with	with	ADP
dpc-1945	178	6	a	a	DET
dpc-1945	178	7	history	history	NOUN
dpc-1945	178	8	of	of	ADP
dpc-1945	178	9	autoimmune	autoimmune	ADJ
dpc-1945	178	10	disease	disease	NOUN
dpc-1945	178	11	showed	show	VERB
dpc-1945	178	12	that	that	SCONJ
dpc-1945	178	13	anti	anti	ADJ
dpc-1945	178	14	-	-	ADJ
dpc-1945	178	15	pd1	pd1	ADJ
dpc-1945	178	16	agents	agent	NOUN
dpc-1945	178	17	may	may	AUX
dpc-1945	178	18	cause	cause	VERB
dpc-1945	178	19	disease	disease	NOUN
dpc-1945	178	20	flares	flare	NOUN
dpc-1945	178	21	.	.	PUNCT
dpc-1945	179	1	although	although	SCONJ
dpc-1945	179	2	some	some	DET
dpc-1945	179	3	patients	patient	NOUN
dpc-1945	179	4	did	do	AUX
dpc-1945	179	5	experience	experience	VERB
dpc-1945	179	6	significant	significant	ADJ
dpc-1945	179	7	anti	anti	ADJ
dpc-1945	179	8	-	-	ADJ
dpc-1945	179	9	tumor	tumor	ADJ
dpc-1945	179	10	activity	activity	NOUN
dpc-1945	179	11	,	,	PUNCT
dpc-1945	179	12	the	the	DET
dpc-1945	179	13	degree	degree	NOUN
dpc-1945	179	14	of	of	ADP
dpc-1945	179	15	flares	flare	NOUN
dpc-1945	179	16	did	do	AUX
dpc-1945	179	17	not	not	PART
dpc-1945	179	18	correlate	correlate	VERB
dpc-1945	179	19	with	with	ADP
dpc-1945	179	20	degree	degree	NOUN
dpc-1945	179	21	of	of	ADP
dpc-1945	179	22	response	response	NOUN
dpc-1945	179	23	[	[	X
dpc-1945	179	24	55	55	NUM
dpc-1945	179	25	]	]	PUNCT
dpc-1945	179	26	.	.	PUNCT
dpc-1945	180	1	pd-1	pd-1	VERB
dpc-1945	180	2	inhibitors	inhibitor	NOUN
dpc-1945	180	3	are	be	AUX
dpc-1945	180	4	not	not	PART
dpc-1945	180	5	excluded	exclude	VERB
dpc-1945	180	6	from	from	ADP
dpc-1945	180	7	the	the	DET
dpc-1945	180	8	shortfalls	shortfall	NOUN
dpc-1945	180	9	of	of	ADP
dpc-1945	180	10	intrinsic	intrinsic	ADJ
dpc-1945	180	11	or	or	CCONJ
dpc-1945	180	12	acquired	acquire	VERB
dpc-1945	180	13	tumor	tumor	NOUN
dpc-1945	180	14	resistance	resistance	NOUN
dpc-1945	180	15	.	.	PUNCT
dpc-1945	181	1	in	in	ADP
dpc-1945	181	2	the	the	DET
dpc-1945	181	3	open	open	ADJ
dpc-1945	181	4	-	-	PUNCT
dpc-1945	181	5	label	label	NOUN
dpc-1945	181	6	,	,	PUNCT
dpc-1945	181	7	multicohort	multicohort	NOUN
dpc-1945	181	8	phase	phase	NOUN
dpc-1945	181	9	1b	1b	NUM
dpc-1945	181	10	clinical	clinical	ADJ
dpc-1945	181	11	trial	trial	NOUN
dpc-1945	181	12	for	for	ADP
dpc-1945	181	13	patients	patient	NOUN
dpc-1945	181	14	with	with	ADP
dpc-1945	181	15	metastatic	metastatic	ADJ
dpc-1945	181	16	melanoma	melanoma	NOUN
dpc-1945	181	17	,	,	PUNCT
dpc-1945	181	18	25	25	NUM
dpc-1945	181	19	%	%	NOUN
dpc-1945	181	20	of	of	ADP
dpc-1945	181	21	patients	patient	NOUN
dpc-1945	181	22	treated	treat	VERB
dpc-1945	181	23	with	with	ADP
dpc-1945	181	24	pd-1	pd-1	ADJ
dpc-1945	181	25	inhibitors	inhibitor	NOUN
dpc-1945	181	26	who	who	PRON
dpc-1945	181	27	demonstrated	demonstrate	VERB
dpc-1945	181	28	an	an	DET
dpc-1945	181	29	objective	objective	ADJ
dpc-1945	181	30	response	response	NOUN
dpc-1945	181	31	later	later	ADV
dpc-1945	181	32	developed	develop	VERB
dpc-1945	181	33	disease	disease	NOUN
dpc-1945	181	34	progression	progression	NOUN
dpc-1945	181	35	[	[	X
dpc-1945	181	36	56	56	NUM
dpc-1945	181	37	]	]	PUNCT
dpc-1945	181	38	.	.	PUNCT
dpc-1945	182	1	mechanisms	mechanism	NOUN
dpc-1945	182	2	of	of	ADP
dpc-1945	182	3	resistance	resistance	NOUN
dpc-1945	182	4	are	be	AUX
dpc-1945	182	5	believed	believe	VERB
dpc-1945	182	6	to	to	PART
dpc-1945	182	7	include	include	VERB
dpc-1945	182	8	loss	loss	NOUN
dpc-1945	182	9	of	of	ADP
dpc-1945	182	10	cell	cell	NOUN
dpc-1945	182	11	function	function	NOUN
dpc-1945	182	12	,	,	PUNCT
dpc-1945	182	13	disruption	disruption	NOUN
dpc-1945	182	14	of	of	ADP
dpc-1945	182	15	antigen	antigen	ADJ
dpc-1945	182	16	presentation	presentation	NOUN
dpc-1945	182	17	,	,	PUNCT
dpc-1945	182	18	as	as	ADV
dpc-1945	182	19	well	well	ADV
dpc-1945	182	20	as	as	ADP
dpc-1945	182	21	several	several	ADJ
dpc-1945	182	22	other	other	ADJ
dpc-1945	182	23	immune	immune	NOUN
dpc-1945	182	24	-	-	PUNCT
dpc-1945	182	25	associated	associate	VERB
dpc-1945	182	26	factors	factor	NOUN
dpc-1945	182	27	[	[	X
dpc-1945	182	28	57	57	NUM
dpc-1945	182	29	]	]	PUNCT
dpc-1945	182	30	.	.	PUNCT
dpc-1945	183	1	acquired	acquire	VERB
dpc-1945	183	2	resistance	resistance	NOUN
dpc-1945	183	3	of	of	ADP
dpc-1945	183	4	pd-1	pd-1	ADJ
dpc-1945	183	5	inhibitors	inhibitor	NOUN
dpc-1945	183	6	in	in	ADP
dpc-1945	183	7	non	non	ADJ
dpc-1945	183	8	-	-	ADJ
dpc-1945	183	9	melanoma	melanoma	ADJ
dpc-1945	183	10	skin	skin	NOUN
dpc-1945	183	11	cancer	cancer	NOUN
dpc-1945	183	12	has	have	AUX
dpc-1945	183	13	not	not	PART
dpc-1945	183	14	been	be	AUX
dpc-1945	183	15	frequently	frequently	ADV
dpc-1945	183	16	reported	report	VERB
dpc-1945	183	17	or	or	CCONJ
dpc-1945	183	18	characterized	characterize	VERB
dpc-1945	183	19	at	at	ADP
dpc-1945	183	20	this	this	DET
dpc-1945	183	21	time	time	NOUN
dpc-1945	183	22	,	,	PUNCT
dpc-1945	183	23	but	but	CCONJ
dpc-1945	183	24	may	may	AUX
dpc-1945	183	25	be	be	AUX
dpc-1945	183	26	revealed	reveal	VERB
dpc-1945	183	27	as	as	SCONJ
dpc-1945	183	28	additional	additional	ADJ
dpc-1945	183	29	larger	large	ADJ
dpc-1945	183	30	trials	trial	NOUN
dpc-1945	183	31	with	with	ADP
dpc-1945	183	32	these	these	DET
dpc-1945	183	33	agents	agent	NOUN
dpc-1945	183	34	are	be	AUX
dpc-1945	183	35	completed	complete	VERB
dpc-1945	183	36	.	.	PUNCT
dpc-1945	184	1	intralesional	intralesional	ADJ
dpc-1945	184	2	therapy	therapy	NOUN
dpc-1945	184	3	of	of	ADP
dpc-1945	184	4	immune	immune	ADJ
dpc-1945	184	5	checkpoint	checkpoint	NOUN
dpc-1945	184	6	inhibitors	inhibitor	NOUN
dpc-1945	184	7	are	be	AUX
dpc-1945	184	8	an	an	DET
dpc-1945	184	9	appealing	appealing	ADJ
dpc-1945	184	10	approach	approach	NOUN
dpc-1945	184	11	to	to	ADP
dpc-1945	184	12	treatment	treatment	NOUN
dpc-1945	184	13	.	.	PUNCT
dpc-1945	185	1	this	this	PRON
dpc-1945	185	2	may	may	AUX
dpc-1945	185	3	allow	allow	VERB
dpc-1945	185	4	for	for	ADP
dpc-1945	185	5	higher	high	ADJ
dpc-1945	185	6	local	local	ADJ
dpc-1945	185	7	tissue	tissue	NOUN
dpc-1945	185	8	concentrations	concentration	NOUN
dpc-1945	185	9	of	of	ADP
dpc-1945	185	10	the	the	DET
dpc-1945	185	11	agent	agent	NOUN
dpc-1945	185	12	within	within	ADP
dpc-1945	185	13	the	the	DET
dpc-1945	185	14	tumor	tumor	NOUN
dpc-1945	185	15	site	site	NOUN
dpc-1945	185	16	,	,	PUNCT
dpc-1945	185	17	with	with	ADP
dpc-1945	185	18	limited	limited	ADJ
dpc-1945	185	19	systemic	systemic	ADJ
dpc-1945	185	20	exposure	exposure	NOUN
dpc-1945	185	21	and	and	CCONJ
dpc-1945	185	22	possibly	possibly	ADV
dpc-1945	185	23	lower	low	ADJ
dpc-1945	185	24	systemic	systemic	ADJ
dpc-1945	185	25	toxicity	toxicity	NOUN
dpc-1945	185	26	.	.	PUNCT
dpc-1945	186	1	a	a	DET
dpc-1945	186	2	study	study	NOUN
dpc-1945	186	3	investigating	investigate	VERB
dpc-1945	186	4	intralesional	intralesional	ADJ
dpc-1945	186	5	pd-1	pd-1	ADP
dpc-1945	186	6	inhibitor	inhibitor	NOUN
dpc-1945	186	7	therapy	therapy	NOUN
dpc-1945	186	8	for	for	ADP
dpc-1945	186	9	recurrent	recurrent	ADJ
dpc-1945	186	10	cscc	cscc	NOUN
dpc-1945	186	11	is	be	AUX
dpc-1945	186	12	currently	currently	ADV
dpc-1945	186	13	underway	underway	ADJ
dpc-1945	186	14	[	[	X
dpc-1945	186	15	58	58	NUM
dpc-1945	186	16	]	]	PUNCT
dpc-1945	186	17	.	.	PUNCT
dpc-1945	187	1	pd1	pd1	NOUN
dpc-1945	187	2	/	/	SYM
dpc-1945	187	3	pd	pd	NOUN
dpc-1945	187	4	-	-	PUNCT
dpc-1945	187	5	l1	l1	PROPN
dpc-1945	187	6	expression	expression	NOUN
dpc-1945	187	7	and	and	CCONJ
dpc-1945	187	8	tumor	tumor	NOUN
dpc-1945	187	9	response	response	NOUN
dpc-1945	187	10	identification	identification	NOUN
dpc-1945	187	11	of	of	ADP
dpc-1945	187	12	tumors	tumor	NOUN
dpc-1945	187	13	that	that	PRON
dpc-1945	187	14	are	be	AUX
dpc-1945	187	15	most	most	ADV
dpc-1945	187	16	likely	likely	ADJ
dpc-1945	187	17	to	to	PART
dpc-1945	187	18	respond	respond	VERB
dpc-1945	187	19	to	to	ADP
dpc-1945	187	20	anti	anti	ADJ
dpc-1945	187	21	-	-	ADJ
dpc-1945	187	22	pd1	pd1	ADJ
dpc-1945	187	23	agents	agent	NOUN
dpc-1945	187	24	has	have	AUX
dpc-1945	187	25	been	be	AUX
dpc-1945	187	26	difficult	difficult	ADJ
dpc-1945	187	27	.	.	PUNCT
dpc-1945	188	1	studies	study	NOUN
dpc-1945	188	2	on	on	ADP
dpc-1945	188	3	pd1	pd1	VERB
dpc-1945	188	4	inhibitors	inhibitor	NOUN
dpc-1945	188	5	for	for	ADP
dpc-1945	188	6	the	the	DET
dpc-1945	188	7	treatment	treatment	NOUN
dpc-1945	188	8	of	of	ADP
dpc-1945	188	9	various	various	ADJ
dpc-1945	188	10	advanced	advanced	ADJ
dpc-1945	188	11	malignancies	malignancy	NOUN
dpc-1945	188	12	have	have	AUX
dpc-1945	188	13	shown	show	VERB
dpc-1945	188	14	that	that	SCONJ
dpc-1945	188	15	pretreatment	pretreatment	NOUN
dpc-1945	188	16	tumor	tumor	NOUN
dpc-1945	188	17	pd	pd	PROPN
dpc-1945	188	18	-	-	PROPN
dpc-1945	188	19	l1	l1	PROPN
dpc-1945	188	20	expression	expression	NOUN
dpc-1945	188	21	has	have	VERB
dpc-1945	188	22	a	a	DET
dpc-1945	188	23	potential	potential	ADJ
dpc-1945	188	24	association	association	NOUN
dpc-1945	188	25	with	with	ADP
dpc-1945	188	26	response	response	NOUN
dpc-1945	188	27	to	to	ADP
dpc-1945	188	28	the	the	DET
dpc-1945	188	29	pd-1	pd-1	ADJ
dpc-1945	188	30	pathway	pathway	NOUN
dpc-1945	188	31	blockade	blockade	NOUN
dpc-1945	188	32	[	[	X
dpc-1945	188	33	59	59	NUM
dpc-1945	188	34	]	]	PUNCT
dpc-1945	188	35	.	.	PUNCT
dpc-1945	189	1	however	however	ADV
dpc-1945	189	2	,	,	PUNCT
dpc-1945	189	3	in	in	ADP
dpc-1945	189	4	other	other	ADJ
dpc-1945	189	5	cases	case	NOUN
dpc-1945	189	6	,	,	PUNCT
dpc-1945	189	7	pd	pd	PROPN
dpc-1945	189	8	-	-	PROPN
dpc-1945	189	9	l1	l1	PROPN
dpc-1945	189	10	negative	negative	ADJ
dpc-1945	189	11	patients	patient	NOUN
dpc-1945	189	12	showed	show	VERB
dpc-1945	189	13	excellent	excellent	ADJ
dpc-1945	189	14	response	response	NOUN
dpc-1945	189	15	to	to	ADP
dpc-1945	189	16	treatment	treatment	NOUN
dpc-1945	189	17	whereas	whereas	SCONJ
dpc-1945	189	18	pd	pd	PROPN
dpc-1945	189	19	-	-	PROPN
dpc-1945	189	20	l1	l1	PROPN
dpc-1945	189	21	positive	positive	ADJ
dpc-1945	189	22	patients	patient	NOUN
dpc-1945	189	23	showed	show	VERB
dpc-1945	189	24	no	no	DET
dpc-1945	189	25	response	response	NOUN
dpc-1945	189	26	to	to	ADP
dpc-1945	189	27	therapy	therapy	NOUN
dpc-1945	189	28	[	[	X
dpc-1945	189	29	6062	6062	NUM
dpc-1945	189	30	]	]	PUNCT
dpc-1945	189	31	.	.	PUNCT
dpc-1945	190	1	there	there	PRON
dpc-1945	190	2	are	be	VERB
dpc-1945	190	3	no	no	DET
dpc-1945	190	4	established	establish	VERB
dpc-1945	190	5	guidelines	guideline	NOUN
dpc-1945	190	6	,	,	PUNCT
dpc-1945	190	7	understandably	understandably	ADV
dpc-1945	190	8	,	,	PUNCT
dpc-1945	190	9	when	when	SCONJ
dpc-1945	190	10	considering	consider	VERB
dpc-1945	190	11	how	how	SCONJ
dpc-1945	190	12	and	and	CCONJ
dpc-1945	190	13	when	when	SCONJ
dpc-1945	190	14	to	to	PART
dpc-1945	190	15	biopsy	biopsy	VERB
dpc-1945	190	16	a	a	DET
dpc-1945	190	17	tumor	tumor	NOUN
dpc-1945	190	18	sample	sample	NOUN
dpc-1945	190	19	.	.	PUNCT
dpc-1945	191	1	small	small	ADJ
dpc-1945	191	2	needle	needle	NOUN
dpc-1945	191	3	biopsies	biopsy	NOUN
dpc-1945	191	4	versus	versus	ADP
dpc-1945	191	5	punch	punch	VERB
dpc-1945	191	6	biopsies	biopsy	NOUN
dpc-1945	191	7	of	of	ADP
dpc-1945	191	8	cutaneous	cutaneous	ADJ
dpc-1945	191	9	tumors	tumor	NOUN
dpc-1945	191	10	may	may	AUX
dpc-1945	191	11	provide	provide	VERB
dpc-1945	191	12	differing	differ	VERB
dpc-1945	191	13	results	result	NOUN
dpc-1945	191	14	.	.	PUNCT
dpc-1945	192	1	in	in	ADP
dpc-1945	192	2	addition	addition	NOUN
dpc-1945	192	3	,	,	PUNCT
dpc-1945	192	4	gene	gene	NOUN
dpc-1945	192	5	expression	expression	NOUN
dpc-1945	192	6	is	be	AUX
dpc-1945	192	7	not	not	PART
dpc-1945	192	8	uniform	uniform	ADJ
dpc-1945	192	9	throughout	throughout	ADP
dpc-1945	192	10	a	a	DET
dpc-1945	192	11	tumor	tumor	NOUN
dpc-1945	192	12	[	[	X
dpc-1945	192	13	63	63	NUM
dpc-1945	192	14	]	]	PUNCT
dpc-1945	192	15	and	and	CCONJ
dpc-1945	192	16	1	1	NUM
dpc-1945	192	17	biopsy	biopsy	NOUN
dpc-1945	192	18	alone	alone	ADV
dpc-1945	192	19	may	may	AUX
dpc-1945	192	20	be	be	AUX
dpc-1945	192	21	far	far	ADV
dpc-1945	192	22	from	from	ADP
dpc-1945	192	23	sufficient	sufficient	ADJ
dpc-1945	192	24	to	to	PART
dpc-1945	192	25	provide	provide	VERB
dpc-1945	192	26	adequate	adequate	ADJ
dpc-1945	192	27	sampling	sampling	NOUN
dpc-1945	192	28	.	.	PUNCT
dpc-1945	193	1	in	in	ADP
dpc-1945	193	2	some	some	DET
dpc-1945	193	3	instances	instance	NOUN
dpc-1945	193	4	,	,	PUNCT
dpc-1945	193	5	pd	pd	PROPN
dpc-1945	193	6	-	-	PUNCT
dpc-1945	193	7	l1	l1	PROPN
dpc-1945	193	8	expression	expression	NOUN
dpc-1945	193	9	is	be	AUX
dpc-1945	193	10	limited	limit	VERB
dpc-1945	193	11	or	or	CCONJ
dpc-1945	193	12	may	may	AUX
dpc-1945	193	13	even	even	ADV
dpc-1945	193	14	be	be	AUX
dpc-1945	193	15	absent	absent	ADJ
dpc-1945	193	16	in	in	ADP
dpc-1945	193	17	tumor	tumor	NOUN
dpc-1945	193	18	cells	cell	NOUN
dpc-1945	193	19	while	while	SCONJ
dpc-1945	193	20	significant	significant	ADJ
dpc-1945	193	21	expression	expression	NOUN
dpc-1945	193	22	of	of	ADP
dpc-1945	193	23	this	this	DET
dpc-1945	193	24	marker	marker	NOUN
dpc-1945	193	25	was	be	AUX
dpc-1945	193	26	noted	note	VERB
dpc-1945	193	27	in	in	ADP
dpc-1945	193	28	the	the	DET
dpc-1945	193	29	tumor	tumor	NOUN
dpc-1945	193	30	infiltrating	infiltrate	VERB
dpc-1945	193	31	lymphocytes	lymphocyte	NOUN
dpc-1945	193	32	.	.	PUNCT
dpc-1945	194	1	variations	variation	NOUN
dpc-1945	194	2	between	between	ADP
dpc-1945	194	3	methods	method	NOUN
dpc-1945	194	4	used	use	VERB
dpc-1945	194	5	including	include	VERB
dpc-1945	194	6	immunohistochemistry	immunohistochemistry	NOUN
dpc-1945	194	7	and	and	CCONJ
dpc-1945	194	8	staining	stain	VERB
dpc-1945	194	9	techniques	technique	NOUN
dpc-1945	194	10	,	,	PUNCT
dpc-1945	194	11	as	as	ADV
dpc-1945	194	12	well	well	ADV
dpc-1945	194	13	as	as	ADP
dpc-1945	194	14	definitions	definition	NOUN
dpc-1945	194	15	of	of	ADP
dpc-1945	194	16	pd	pd	PROPN
dpc-1945	194	17	-	-	PROPN
dpc-1945	194	18	l1	l1	PROPN
dpc-1945	194	19	‘	'	PUNCT
dpc-1945	194	20	positivity	positivity	NOUN
dpc-1945	194	21	’	'	PUNCT
dpc-1945	194	22	(	(	PUNCT
dpc-1945	194	23	cell	cell	NOUN
dpc-1945	194	24	surface	surface	NOUN
dpc-1945	194	25	expression	expression	NOUN
dpc-1945	194	26	,	,	PUNCT
dpc-1945	194	27	cytoplasmic	cytoplasmic	ADJ
dpc-1945	194	28	expression	expression	NOUN
dpc-1945	194	29	,	,	PUNCT
dpc-1945	194	30	by	by	ADP
dpc-1945	194	31	tumor	tumor	NOUN
dpc-1945	194	32	cells	cell	NOUN
dpc-1945	194	33	only	only	ADV
dpc-1945	194	34	,	,	PUNCT
dpc-1945	194	35	by	by	ADP
dpc-1945	194	36	immune	immune	ADJ
dpc-1945	194	37	related	related	ADJ
dpc-1945	194	38	cells	cell	NOUN
dpc-1945	194	39	,	,	PUNCT
dpc-1945	194	40	threshold	threshold	NOUN
dpc-1945	194	41	of	of	ADP
dpc-1945	194	42	positivity	positivity	NOUN
dpc-1945	194	43	)	)	PUNCT
dpc-1945	194	44	make	make	VERB
dpc-1945	194	45	for	for	ADP
dpc-1945	194	46	less	less	ADV
dpc-1945	194	47	conclusive	conclusive	ADJ
dpc-1945	194	48	predictive	predictive	ADJ
dpc-1945	194	49	value	value	NOUN
dpc-1945	194	50	of	of	ADP
dpc-1945	194	51	these	these	DET
dpc-1945	194	52	markers	marker	NOUN
dpc-1945	194	53	.	.	PUNCT
dpc-1945	195	1	there	there	PRON
dpc-1945	195	2	is	be	VERB
dpc-1945	195	3	much	much	ADV
dpc-1945	195	4	more	more	ADJ
dpc-1945	195	5	work	work	NOUN
dpc-1945	195	6	needed	need	VERB
dpc-1945	195	7	to	to	PART
dpc-1945	195	8	determine	determine	VERB
dpc-1945	195	9	the	the	DET
dpc-1945	195	10	validity	validity	NOUN
dpc-1945	195	11	and	and	CCONJ
dpc-1945	195	12	reliability	reliability	NOUN
dpc-1945	195	13	of	of	ADP
dpc-1945	195	14	pd	pd	PROPN
dpc-1945	195	15	-	-	PROPN
dpc-1945	195	16	l1	l1	PROPN
dpc-1945	195	17	expression	expression	NOUN
dpc-1945	195	18	as	as	ADP
dpc-1945	195	19	a	a	DET
dpc-1945	195	20	predictor	predictor	NOUN
dpc-1945	195	21	of	of	ADP
dpc-1945	195	22	tumor	tumor	NOUN
dpc-1945	195	23	response	response	NOUN
dpc-1945	195	24	.	.	PUNCT
dpc-1945	196	1	anti	anti	ADJ
dpc-1945	196	2	-	-	ADJ
dpc-1945	196	3	pdl1	pdl1	ADJ
dpc-1945	196	4	agents	agent	NOUN
dpc-1945	196	5	complementing	complement	VERB
dpc-1945	196	6	the	the	DET
dpc-1945	196	7	anti	anti	ADJ
dpc-1945	196	8	-	-	ADJ
dpc-1945	196	9	pd1	pd1	ADJ
dpc-1945	196	10	agents	agent	NOUN
dpc-1945	196	11	discussed	discuss	VERB
dpc-1945	196	12	above	above	ADV
dpc-1945	196	13	,	,	PUNCT
dpc-1945	196	14	antipdl1	antipdl1	ADJ
dpc-1945	196	15	agents	agent	NOUN
dpc-1945	196	16	have	have	AUX
dpc-1945	196	17	been	be	AUX
dpc-1945	196	18	developed	develop	VERB
dpc-1945	196	19	in	in	ADP
dpc-1945	196	20	hopes	hope	NOUN
dpc-1945	196	21	of	of	ADP
dpc-1945	196	22	adding	add	VERB
dpc-1945	196	23	yet	yet	ADV
dpc-1945	196	24	another	another	DET
dpc-1945	196	25	agent	agent	NOUN
dpc-1945	196	26	in	in	ADP
dpc-1945	196	27	our	our	PRON
dpc-1945	196	28	fight	fight	NOUN
dpc-1945	196	29	against	against	ADP
dpc-1945	196	30	advanced	advanced	ADJ
dpc-1945	196	31	malignancies	malignancy	NOUN
dpc-1945	196	32	.	.	PUNCT
dpc-1945	197	1	atezolizumab	atezolizumab	PROPN
dpc-1945	197	2	,	,	PUNCT
dpc-1945	197	3	avelumab	avelumab	ADV
dpc-1945	197	4	,	,	PUNCT
dpc-1945	197	5	and	and	CCONJ
dpc-1945	197	6	durvalumab	durvalumab	NOUN
dpc-1945	197	7	are	be	AUX
dpc-1945	197	8	igg1	igg1	NOUN
dpc-1945	197	9	antibodies	antibody	NOUN
dpc-1945	197	10	targeting	target	VERB
dpc-1945	197	11	against	against	ADP
dpc-1945	197	12	the	the	DET
dpc-1945	197	13	pd	pd	PROPN
dpc-1945	197	14	-	-	PROPN
dpc-1945	197	15	l1	l1	PROPN
dpc-1945	197	16	ligand	ligand	NOUN
dpc-1945	197	17	.	.	PUNCT
dpc-1945	198	1	these	these	DET
dpc-1945	198	2	agents	agent	NOUN
dpc-1945	198	3	have	have	AUX
dpc-1945	198	4	been	be	AUX
dpc-1945	198	5	used	use	VERB
dpc-1945	198	6	for	for	ADP
dpc-1945	198	7	treatment	treatment	NOUN
dpc-1945	198	8	of	of	ADP
dpc-1945	198	9	various	various	ADJ
dpc-1945	198	10	malignancies	malignancy	NOUN
dpc-1945	198	11	including	include	VERB
dpc-1945	198	12	urothelial	urothelial	ADJ
dpc-1945	198	13	carcinoma	carcinoma	NOUN
dpc-1945	198	14	,	,	PUNCT
dpc-1945	198	15	non	non	ADJ
dpc-1945	198	16	-	-	ADJ
dpc-1945	198	17	small	small	ADJ
dpc-1945	198	18	cell	cell	NOUN
dpc-1945	198	19	lung	lung	NOUN
dpc-1945	198	20	cancer	cancer	NOUN
dpc-1945	198	21	,	,	PUNCT
dpc-1945	198	22	and	and	CCONJ
dpc-1945	198	23	metastatic	metastatic	ADJ
dpc-1945	198	24	merkel	merkel	NOUN
dpc-1945	198	25	-	-	PUNCT
dpc-1945	198	26	cell	cell	NOUN
dpc-1945	198	27	carcinoma	carcinoma	NOUN
dpc-1945	198	28	.	.	PUNCT
dpc-1945	199	1	in	in	ADP
dpc-1945	199	2	2017	2017	NUM
dpc-1945	199	3	,	,	PUNCT
dpc-1945	199	4	there	there	PRON
dpc-1945	199	5	were	be	VERB
dpc-1945	199	6	117	117	NUM
dpc-1945	199	7	ongoing	ongoing	ADJ
dpc-1945	199	8	clinical	clinical	ADJ
dpc-1945	199	9	trials	trial	NOUN
dpc-1945	199	10	that	that	PRON
dpc-1945	199	11	involved	involve	VERB
dpc-1945	199	12	atezolizumab	atezolizumab	NOUN
dpc-1945	199	13	[	[	X
dpc-1945	199	14	64	64	NUM
dpc-1945	199	15	]	]	PUNCT
dpc-1945	199	16	.	.	PUNCT
dpc-1945	200	1	although	although	SCONJ
dpc-1945	200	2	there	there	PRON
dpc-1945	200	3	study	study	VERB
dpc-1945	200	4	regimen	regimen	NOUN
dpc-1945	200	5	line	line	NOUN
dpc-1945	200	6	of	of	ADP
dpc-1945	200	7	therapy	therapy	NOUN
dpc-1945	200	8	pts	pts	X
dpc-1945	200	9	(	(	PUNCT
dpc-1945	200	10	n	n	CCONJ
dpc-1945	200	11	)	)	PUNCT
dpc-1945	200	12	response	response	NOUN
dpc-1945	200	13	rate	rate	NOUN
dpc-1945	200	14	duration	duration	NOUN
dpc-1945	200	15	of	of	ADP
dpc-1945	200	16	response	response	NOUN
dpc-1945	200	17	notes	note	NOUN
dpc-1945	200	18	/	/	SYM
dpc-1945	200	19	limitations	limitation	NOUN
dpc-1945	200	20	grob	grob	PROPN
dpc-1945	200	21	jj	jj	PROPN
dpc-1945	200	22	et	et	PROPN
dpc-1945	200	23	al	al	PROPN
dpc-1945	200	24	.	.	PROPN
dpc-1945	200	25	2020(53	2020(53	NUM
dpc-1945	200	26	)	)	PUNCT
dpc-1945	200	27	pembrolizumab	pembrolizumab	NOUN
dpc-1945	200	28	first	first	ADJ
dpc-1945	200	29	line	line	NOUN
dpc-1945	200	30	(	(	PUNCT
dpc-1945	200	31	13	13	NUM
dpc-1945	200	32	%	%	NOUN
dpc-1945	200	33	)	)	PUNCT
dpc-1945	201	1	second+	second+	NOUN
dpc-1945	201	2	line	line	NOUN
dpc-1945	201	3	(	(	PUNCT
dpc-1945	201	4	87	87	NUM
dpc-1945	201	5	%	%	NOUN
dpc-1945	201	6	)	)	PUNCT
dpc-1945	201	7	105	105	NUM
dpc-1945	201	8	cr	cr	NOUN
dpc-1945	201	9	4	4	NUM
dpc-1945	201	10	%	%	NOUN
dpc-1945	201	11	pr	pr	NOUN
dpc-1945	201	12	31	31	NUM
dpc-1945	201	13	%	%	NOUN
dpc-1945	201	14	orr	orr	NOUN
dpc-1945	201	15	34	34	NUM
dpc-1945	201	16	%	%	NOUN
dpc-1945	201	17	median	median	PROPN
dpc-1945	201	18	nr	nr	PROPN
dpc-1945	201	19	dcr	dcr	PROPN
dpc-1945	201	20	52.4	52.4	NUM
dpc-1945	201	21	%	%	NOUN
dpc-1945	201	22	median	median	NOUN
dpc-1945	201	23	pfs	pfs	PROPN
dpc-1945	201	24	6.9	6.9	NUM
dpc-1945	201	25	months	month	NOUN
dpc-1945	201	26	median	median	PROPN
dpc-1945	201	27	os	os	PROPN
dpc-1945	201	28	nr	nr	PROPN
dpc-1945	201	29	eton	eton	PROPN
dpc-1945	201	30	o	o	PROPN
dpc-1945	201	31	et	et	PROPN
dpc-1945	201	32	al	al	PROPN
dpc-1945	201	33	.	.	PROPN
dpc-1945	201	34	2020(86	2020(86	NOUN
dpc-1945	201	35	)	)	PUNCT
dpc-1945	201	36	pembrolizumab	pembrolizumab	NOUN
dpc-1945	201	37	+	+	CCONJ
dpc-1945	201	38	panitumumab	panitumumab	NOUN
dpc-1945	201	39	(	(	PUNCT
dpc-1945	201	40	1	1	NUM
dpc-1945	201	41	)	)	PUNCT
dpc-1945	201	42	nivolumab	nivolumab	NOUN
dpc-1945	201	43	+	+	CCONJ
dpc-1945	201	44	panitumumab	panitumumab	X
dpc-1945	201	45	(	(	PUNCT
dpc-1945	201	46	1	1	NUM
dpc-1945	201	47	)	)	PUNCT
dpc-1945	201	48	second+	second+	NOUN
dpc-1945	201	49	line	line	NOUN
dpc-1945	201	50	2	2	NUM
dpc-1945	201	51	cr	cr	PART
dpc-1945	201	52	100	100	NUM
dpc-1945	201	53	%	%	NOUN
dpc-1945	201	54	orr	orr	PROPN
dpc-1945	201	55	100	100	NUM
dpc-1945	201	56	%	%	NOUN
dpc-1945	201	57	case	case	NOUN
dpc-1945	201	58	series	series	NOUN
dpc-1945	201	59	note	note	VERB
dpc-1945	201	60	this	this	DET
dpc-1945	201	61	table	table	NOUN
dpc-1945	201	62	is	be	AUX
dpc-1945	201	63	just	just	ADV
dpc-1945	201	64	a	a	DET
dpc-1945	201	65	limited	limited	ADJ
dpc-1945	201	66	sampling	sampling	NOUN
dpc-1945	201	67	of	of	ADP
dpc-1945	201	68	published	publish	VERB
dpc-1945	201	69	reports	report	NOUN
dpc-1945	201	70	including	include	VERB
dpc-1945	201	71	pd-1	pd-1	ADP
dpc-1945	201	72	inhibitor	inhibitor	NOUN
dpc-1945	201	73	therapies	therapy	NOUN
dpc-1945	201	74	for	for	ADP
dpc-1945	201	75	advanced	advanced	ADJ
dpc-1945	201	76	cutaneous	cutaneous	ADJ
dpc-1945	201	77	scc	scc	PROPN
dpc-1945	201	78	.	.	PUNCT
dpc-1945	202	1	cr=	cr=	PROPN
dpc-1945	202	2	complete	complete	ADJ
dpc-1945	202	3	response	response	NOUN
dpc-1945	202	4	;	;	PUNCT
dpc-1945	202	5	pr	pr	NOUN
dpc-1945	202	6	=	=	PUNCT
dpc-1945	202	7	partial	partial	ADJ
dpc-1945	202	8	response	response	NOUN
dpc-1945	202	9	;	;	PUNCT
dpc-1945	203	1	orr	orr	PROPN
dpc-1945	203	2	=	=	PUNCT
dpc-1945	203	3	overall	overall	ADJ
dpc-1945	203	4	response	response	NOUN
dpc-1945	203	5	rate	rate	NOUN
dpc-1945	203	6	;	;	PUNCT
dpc-1945	203	7	st	st	NOUN
dpc-1945	203	8	=	=	ADJ
dpc-1945	203	9	surgical	surgical	ADJ
dpc-1945	203	10	therapy	therapy	NOUN
dpc-1945	203	11	;	;	PUNCT
dpc-1945	203	12	rt	rt	NOUN
dpc-1945	203	13	=	=	NOUN
dpc-1945	203	14	radiation	radiation	NOUN
dpc-1945	203	15	therapy	therapy	NOUN
dpc-1945	203	16	;	;	PUNCT
dpc-1945	203	17	pts	pt	NOUN
dpc-1945	203	18	=	=	NOUN
dpc-1945	203	19	patients	patient	NOUN
dpc-1945	203	20	;	;	PUNCT
dpc-1945	203	21	dcr	dcr	PROPN
dpc-1945	203	22	=	=	PUNCT
dpc-1945	203	23	disease	disease	NOUN
dpc-1945	203	24	control	control	NOUN
dpc-1945	203	25	rate	rate	NOUN
dpc-1945	203	26	;	;	PUNCT
dpc-1945	203	27	dor=	dor=	NOUN
dpc-1945	203	28	duration	duration	NOUN
dpc-1945	203	29	of	of	ADP
dpc-1945	203	30	response	response	NOUN
dpc-1945	203	31	;	;	PUNCT
dpc-1945	203	32	cscc	cscc	ADJ
dpc-1945	203	33	=	=	PUNCT
dpc-1945	203	34	cutaneous	cutaneous	ADJ
dpc-1945	203	35	squamous	squamous	ADJ
dpc-1945	203	36	cell	cell	NOUN
dpc-1945	203	37	carcinoma	carcinoma	NOUN
dpc-1945	203	38	;	;	PUNCT
dpc-1945	203	39	nr=	nr=	VERB
dpc-1945	203	40	not	not	PART
dpc-1945	203	41	reached	reach	VERB
dpc-1945	203	42	;	;	PUNCT
dpc-1945	203	43	kr	kr	PROPN
dpc-1945	203	44	=	=	PROPN
dpc-1945	203	45	kaplan	kaplan	PROPN
dpc-1945	203	46	-	-	PUNCT
dpc-1945	203	47	meier	meier	PROPN
dpc-1945	203	48	estimate	estimate	VERB
dpc-1945	203	49	12	12	NUM
dpc-1945	203	50	-	-	PUNCT
dpc-1945	203	51	month	month	NOUN
dpc-1945	203	52	estimate	estimate	NOUN
dpc-1945	203	53	8	8	NUM
dpc-1945	203	54	review	review	NOUN
dpc-1945	203	55	|	|	ADV
dpc-1945	203	56	dermatol	dermatol	ADJ
dpc-1945	203	57	pract	pract	NOUN
dpc-1945	203	58	concept	concept	NOUN
dpc-1945	203	59	.	.	PUNCT
dpc-1945	204	1	2021	2021	NUM
dpc-1945	204	2	;	;	PUNCT
dpc-1945	204	3	11(s2	11(s2	NUM
dpc-1945	204	4	):	):	PUNCT
dpc-1945	204	5	e2021169s	e2021169s	NOUN
dpc-1945	204	6	are	be	AUX
dpc-1945	204	7	studies	study	NOUN
dpc-1945	204	8	using	use	VERB
dpc-1945	204	9	anti	anti	ADJ
dpc-1945	204	10	-	-	ADJ
dpc-1945	204	11	pdl1	pdl1	ADJ
dpc-1945	204	12	agents	agent	NOUN
dpc-1945	204	13	for	for	ADP
dpc-1945	204	14	advanced	advanced	ADJ
dpc-1945	204	15	cscc	cscc	VERB
dpc-1945	204	16	,	,	PUNCT
dpc-1945	204	17	there	there	PRON
dpc-1945	204	18	is	be	VERB
dpc-1945	204	19	no	no	DET
dpc-1945	204	20	data	datum	NOUN
dpc-1945	204	21	published	publish	VERB
dpc-1945	204	22	at	at	ADP
dpc-1945	204	23	this	this	DET
dpc-1945	204	24	time	time	NOUN
dpc-1945	204	25	.	.	PUNCT
dpc-1945	205	1	the	the	DET
dpc-1945	205	2	second	second	ADJ
dpc-1945	205	3	pd-1	pd-1	ADP
dpc-1945	205	4	ligand	ligand	ADJ
dpc-1945	205	5	,	,	PUNCT
dpc-1945	205	6	pd	pd	NOUN
dpc-1945	205	7	-	-	NOUN
dpc-1945	205	8	l2	l2	NOUN
dpc-1945	205	9	,	,	PUNCT
dpc-1945	205	10	is	be	AUX
dpc-1945	205	11	selectively	selectively	ADV
dpc-1945	205	12	expressed	express	VERB
dpc-1945	205	13	on	on	ADP
dpc-1945	205	14	monocytes	monocyte	NOUN
dpc-1945	205	15	and	and	CCONJ
dpc-1945	205	16	dendritic	dendritic	ADJ
dpc-1945	205	17	cells	cell	NOUN
dpc-1945	205	18	and	and	CCONJ
dpc-1945	205	19	could	could	AUX
dpc-1945	205	20	similarly	similarly	ADV
dpc-1945	205	21	be	be	AUX
dpc-1945	205	22	another	another	DET
dpc-1945	205	23	molecular	molecular	ADJ
dpc-1945	205	24	target	target	NOUN
dpc-1945	205	25	[	[	X
dpc-1945	205	26	65	65	NUM
dpc-1945	205	27	]	]	PUNCT
dpc-1945	205	28	.	.	PUNCT
dpc-1945	206	1	rp1	rp1	PROPN
dpc-1945	206	2	monotherapy	monotherapy	NOUN
dpc-1945	206	3	and	and	CCONJ
dpc-1945	206	4	in	in	ADP
dpc-1945	206	5	combination	combination	NOUN
dpc-1945	206	6	with	with	ADP
dpc-1945	206	7	pd-1	pd-1	VERB
dpc-1945	206	8	inhibitors	inhibitor	NOUN
dpc-1945	206	9	oncolytic	oncolytic	ADJ
dpc-1945	206	10	virotherapy	virotherapy	NOUN
dpc-1945	206	11	(	(	PUNCT
dpc-1945	206	12	ov	ov	PROPN
dpc-1945	206	13	)	)	PUNCT
dpc-1945	206	14	is	be	AUX
dpc-1945	206	15	the	the	DET
dpc-1945	206	16	use	use	NOUN
dpc-1945	206	17	of	of	ADP
dpc-1945	206	18	a	a	DET
dpc-1945	206	19	replication	replication	NOUN
dpc-1945	206	20	-	-	PUNCT
dpc-1945	206	21	competent	competent	ADJ
dpc-1945	206	22	virus	virus	NOUN
dpc-1945	206	23	for	for	ADP
dpc-1945	206	24	the	the	DET
dpc-1945	206	25	treatment	treatment	NOUN
dpc-1945	206	26	of	of	ADP
dpc-1945	206	27	cancer	cancer	NOUN
dpc-1945	206	28	.	.	PUNCT
dpc-1945	207	1	ov	ov	PROPN
dpc-1945	207	2	must	must	AUX
dpc-1945	207	3	be	be	AUX
dpc-1945	207	4	non	non	ADJ
dpc-1945	207	5	-	-	ADJ
dpc-1945	207	6	pathogenic	pathogenic	ADJ
dpc-1945	207	7	to	to	ADP
dpc-1945	207	8	normal	normal	ADJ
dpc-1945	207	9	cells	cell	NOUN
dpc-1945	207	10	and	and	CCONJ
dpc-1945	207	11	can	can	AUX
dpc-1945	207	12	work	work	VERB
dpc-1945	207	13	in	in	ADP
dpc-1945	207	14	a	a	DET
dpc-1945	207	15	variety	variety	NOUN
dpc-1945	207	16	of	of	ADP
dpc-1945	207	17	mechanisms	mechanism	NOUN
dpc-1945	207	18	to	to	PART
dpc-1945	207	19	selectively	selectively	ADV
dpc-1945	207	20	kill	kill	VERB
dpc-1945	207	21	tumor	tumor	NOUN
dpc-1945	207	22	cells	cell	NOUN
dpc-1945	207	23	.	.	PUNCT
dpc-1945	208	1	in	in	ADP
dpc-1945	208	2	the	the	DET
dpc-1945	208	3	last	last	ADJ
dpc-1945	208	4	few	few	ADJ
dpc-1945	208	5	decades	decade	NOUN
dpc-1945	208	6	,	,	PUNCT
dpc-1945	208	7	commercially	commercially	ADV
dpc-1945	208	8	available	available	ADJ
dpc-1945	208	9	ovs	ovs	NOUN
dpc-1945	208	10	have	have	AUX
dpc-1945	208	11	been	be	AUX
dpc-1945	208	12	used	use	VERB
dpc-1945	208	13	in	in	ADP
dpc-1945	208	14	a	a	DET
dpc-1945	208	15	variety	variety	NOUN
dpc-1945	208	16	of	of	ADP
dpc-1945	208	17	cancers	cancer	NOUN
dpc-1945	208	18	including	include	VERB
dpc-1945	208	19	metastatic	metastatic	ADJ
dpc-1945	208	20	melanoma	melanoma	NOUN
dpc-1945	208	21	[	[	X
dpc-1945	208	22	66	66	NUM
dpc-1945	208	23	]	]	PUNCT
dpc-1945	208	24	.	.	PUNCT
dpc-1945	209	1	ov	ov	PROPN
dpc-1945	209	2	has	have	VERB
dpc-1945	209	3	the	the	DET
dpc-1945	209	4	ability	ability	NOUN
dpc-1945	209	5	to	to	PART
dpc-1945	209	6	stimulate	stimulate	VERB
dpc-1945	209	7	an	an	DET
dpc-1945	209	8	anti	anti	ADJ
dpc-1945	209	9	-	-	ADJ
dpc-1945	209	10	cancer	cancer	ADJ
dpc-1945	209	11	immune	immune	ADJ
dpc-1945	209	12	response	response	NOUN
dpc-1945	209	13	,	,	PUNCT
dpc-1945	209	14	increasing	increase	VERB
dpc-1945	209	15	the	the	DET
dpc-1945	209	16	immune	immune	ADJ
dpc-1945	209	17	activity	activity	NOUN
dpc-1945	209	18	within	within	ADP
dpc-1945	209	19	the	the	DET
dpc-1945	209	20	tme	tme	NOUN
dpc-1945	209	21	.	.	PUNCT
dpc-1945	210	1	by	by	ADP
dpc-1945	210	2	enhancing	enhance	VERB
dpc-1945	210	3	this	this	DET
dpc-1945	210	4	immune	immune	ADJ
dpc-1945	210	5	response	response	NOUN
dpc-1945	210	6	,	,	PUNCT
dpc-1945	210	7	targeting	target	VERB
dpc-1945	210	8	tumor	tumor	NOUN
dpc-1945	210	9	cells	cell	NOUN
dpc-1945	210	10	,	,	PUNCT
dpc-1945	210	11	and	and	CCONJ
dpc-1945	210	12	exposing	expose	VERB
dpc-1945	210	13	tumor	tumor	NOUN
dpc-1945	210	14	neoantigens	neoantigen	NOUN
dpc-1945	210	15	,	,	PUNCT
dpc-1945	210	16	ov	ov	PRON
dpc-1945	210	17	could	could	AUX
dpc-1945	210	18	provide	provide	VERB
dpc-1945	210	19	a	a	DET
dpc-1945	210	20	logistical	logistical	ADJ
dpc-1945	210	21	complement	complement	NOUN
dpc-1945	210	22	to	to	ADP
dpc-1945	210	23	immune	immune	ADJ
dpc-1945	210	24	checkpoint	checkpoint	NOUN
dpc-1945	210	25	inhibition	inhibition	NOUN
dpc-1945	210	26	.	.	PUNCT
dpc-1945	211	1	unfortunately	unfortunately	ADV
dpc-1945	211	2	,	,	PUNCT
dpc-1945	211	3	a	a	DET
dpc-1945	211	4	detailed	detailed	ADJ
dpc-1945	211	5	discussion	discussion	NOUN
dpc-1945	211	6	of	of	ADP
dpc-1945	211	7	ovs	ovs	NOUN
dpc-1945	211	8	and	and	CCONJ
dpc-1945	211	9	their	their	PRON
dpc-1945	211	10	effects	effect	NOUN
dpc-1945	211	11	on	on	ADP
dpc-1945	211	12	the	the	DET
dpc-1945	211	13	tme	tme	NOUN
dpc-1945	211	14	is	be	AUX
dpc-1945	211	15	beyond	beyond	ADP
dpc-1945	211	16	the	the	DET
dpc-1945	211	17	scope	scope	NOUN
dpc-1945	211	18	of	of	ADP
dpc-1945	211	19	this	this	DET
dpc-1945	211	20	review	review	NOUN
dpc-1945	211	21	.	.	PUNCT
dpc-1945	212	1	an	an	DET
dpc-1945	212	2	open	open	ADJ
dpc-1945	212	3	-	-	PUNCT
dpc-1945	212	4	label	label	NOUN
dpc-1945	212	5	,	,	PUNCT
dpc-1945	212	6	single	single	ADJ
dpc-1945	212	7	-	-	PUNCT
dpc-1945	212	8	arm	arm	NOUN
dpc-1945	212	9	phase	phase	NOUN
dpc-1945	212	10	ii	ii	NOUN
dpc-1945	212	11	clinical	clinical	ADJ
dpc-1945	212	12	trial	trial	NOUN
dpc-1945	212	13	of	of	ADP
dpc-1945	212	14	the	the	DET
dpc-1945	212	15	oncolytic	oncolytic	ADJ
dpc-1945	212	16	hsv	hsv	PROPN
dpc-1945	212	17	rp1	rp1	NOUN
dpc-1945	212	18	in	in	ADP
dpc-1945	212	19	combination	combination	NOUN
dpc-1945	212	20	with	with	ADP
dpc-1945	212	21	nivolumab	nivolumab	NOUN
dpc-1945	212	22	has	have	AUX
dpc-1945	212	23	shown	show	VERB
dpc-1945	212	24	early	early	ADJ
dpc-1945	212	25	promising	promising	ADJ
dpc-1945	212	26	results	result	NOUN
dpc-1945	212	27	,	,	PUNCT
dpc-1945	212	28	with	with	SCONJ
dpc-1945	212	29	5	5	NUM
dpc-1945	212	30	of	of	ADP
dpc-1945	212	31	6	6	NUM
dpc-1945	212	32	metastatic	metastatic	ADJ
dpc-1945	212	33	cscc	cscc	ADJ
dpc-1945	212	34	patients	patient	NOUN
dpc-1945	212	35	enrolled	enrol	VERB
dpc-1945	212	36	showing	show	VERB
dpc-1945	212	37	disease	disease	NOUN
dpc-1945	212	38	response	response	NOUN
dpc-1945	212	39	and	and	CCONJ
dpc-1945	212	40	3	3	NUM
dpc-1945	212	41	complete	complete	ADJ
dpc-1945	212	42	responses	response	NOUN
dpc-1945	212	43	[	[	X
dpc-1945	212	44	67	67	NUM
dpc-1945	212	45	]	]	PUNCT
dpc-1945	212	46	.	.	PUNCT
dpc-1945	213	1	larger	large	ADJ
dpc-1945	213	2	ongoing	ongoing	ADJ
dpc-1945	213	3	studies	study	NOUN
dpc-1945	213	4	will	will	AUX
dpc-1945	213	5	evaluate	evaluate	VERB
dpc-1945	213	6	the	the	DET
dpc-1945	213	7	efficacy	efficacy	NOUN
dpc-1945	213	8	and	and	CCONJ
dpc-1945	213	9	durability	durability	NOUN
dpc-1945	213	10	of	of	ADP
dpc-1945	213	11	responses	response	NOUN
dpc-1945	213	12	in	in	ADP
dpc-1945	213	13	patients	patient	NOUN
dpc-1945	213	14	with	with	ADP
dpc-1945	213	15	advanced	advanced	ADJ
dpc-1945	213	16	cscc	cscc	ADJ
dpc-1945	213	17	.	.	PUNCT
dpc-1945	214	1	ctla-4	ctla-4	NOUN
dpc-1945	214	2	inhibitors	inhibitor	NOUN
dpc-1945	214	3	ipilimumab	ipilimumab	VERB
dpc-1945	214	4	is	be	AUX
dpc-1945	214	5	a	a	DET
dpc-1945	214	6	ctla-4	ctla-4	NOUN
dpc-1945	214	7	blocking	block	VERB
dpc-1945	214	8	antibody	antibody	NOUN
dpc-1945	214	9	that	that	PRON
dpc-1945	214	10	became	become	VERB
dpc-1945	214	11	the	the	DET
dpc-1945	214	12	first	first	ADJ
dpc-1945	214	13	checkpoint	checkpoint	NOUN
dpc-1945	214	14	inhibitor	inhibitor	NOUN
dpc-1945	214	15	to	to	PART
dpc-1945	214	16	be	be	AUX
dpc-1945	214	17	tested	test	VERB
dpc-1945	214	18	and	and	CCONJ
dpc-1945	214	19	shown	show	VERB
dpc-1945	214	20	to	to	PART
dpc-1945	214	21	be	be	AUX
dpc-1945	214	22	effective	effective	ADJ
dpc-1945	214	23	for	for	ADP
dpc-1945	214	24	the	the	DET
dpc-1945	214	25	treatment	treatment	NOUN
dpc-1945	214	26	of	of	ADP
dpc-1945	214	27	cancer	cancer	NOUN
dpc-1945	214	28	patients	patient	NOUN
dpc-1945	214	29	,	,	PUNCT
dpc-1945	214	30	specifically	specifically	ADV
dpc-1945	214	31	metastatic	metastatic	ADJ
dpc-1945	214	32	melanoma	melanoma	NOUN
dpc-1945	214	33	[	[	X
dpc-1945	214	34	68	68	NUM
dpc-1945	214	35	]	]	PUNCT
dpc-1945	214	36	.	.	PUNCT
dpc-1945	215	1	in	in	ADP
dpc-1945	215	2	2015	2015	NUM
dpc-1945	215	3	,	,	PUNCT
dpc-1945	215	4	ipilimumab	ipilimumab	NOUN
dpc-1945	215	5	showed	show	VERB
dpc-1945	215	6	durable	durable	ADJ
dpc-1945	215	7	complete	complete	ADJ
dpc-1945	215	8	responses	response	NOUN
dpc-1945	215	9	in	in	ADP
dpc-1945	215	10	patients	patient	NOUN
dpc-1945	215	11	with	with	ADP
dpc-1945	215	12	metastatic	metastatic	ADJ
dpc-1945	215	13	melanoma	melanoma	NOUN
dpc-1945	215	14	and	and	CCONJ
dpc-1945	215	15	became	become	VERB
dpc-1945	215	16	a	a	DET
dpc-1945	215	17	standard	standard	NOUN
dpc-1945	215	18	-	-	PUNCT
dpc-1945	215	19	of	of	ADP
dpc-1945	215	20	-	-	PUNCT
dpc-1945	215	21	care	care	NOUN
dpc-1945	215	22	adjuvant	adjuvant	ADJ
dpc-1945	215	23	treatment	treatment	NOUN
dpc-1945	215	24	of	of	ADP
dpc-1945	215	25	resected	resect	VERB
dpc-1945	215	26	stage	stage	NOUN
dpc-1945	215	27	iii	iii	NUM
dpc-1945	215	28	melanoma	melanoma	NOUN
dpc-1945	216	1	[	[	X
dpc-1945	216	2	69	69	NUM
dpc-1945	216	3	]	]	PUNCT
dpc-1945	216	4	.	.	PUNCT
dpc-1945	217	1	day	day	NOUN
dpc-1945	217	2	and	and	CCONJ
dpc-1945	217	3	colleagues	colleague	NOUN
dpc-1945	217	4	reported	report	VERB
dpc-1945	217	5	a	a	DET
dpc-1945	217	6	durable	durable	ADJ
dpc-1945	217	7	response	response	NOUN
dpc-1945	217	8	in	in	ADP
dpc-1945	217	9	metastatic	metastatic	ADJ
dpc-1945	217	10	cscc	cscc	NOUN
dpc-1945	217	11	using	use	VERB
dpc-1945	217	12	ipilimumab	ipilimumab	NOUN
dpc-1945	217	13	,	,	PUNCT
dpc-1945	217	14	although	although	SCONJ
dpc-1945	217	15	larger	large	ADJ
dpc-1945	217	16	trials	trial	NOUN
dpc-1945	217	17	are	be	AUX
dpc-1945	217	18	needed	need	VERB
dpc-1945	217	19	to	to	PART
dpc-1945	217	20	fully	fully	ADV
dpc-1945	217	21	characterize	characterize	VERB
dpc-1945	217	22	ipilimumab	ipilimumab	NOUN
dpc-1945	217	23	’s	’s	PART
dpc-1945	217	24	safety	safety	NOUN
dpc-1945	217	25	and	and	CCONJ
dpc-1945	217	26	efficacy	efficacy	NOUN
dpc-1945	217	27	for	for	ADP
dpc-1945	217	28	this	this	DET
dpc-1945	217	29	cancer	cancer	NOUN
dpc-1945	218	1	[	[	X
dpc-1945	218	2	70	70	NUM
dpc-1945	218	3	]	]	PUNCT
dpc-1945	218	4	.	.	PUNCT
dpc-1945	219	1	the	the	DET
dpc-1945	219	2	combination	combination	NOUN
dpc-1945	219	3	of	of	ADP
dpc-1945	219	4	ipilimumab	ipilimumab	NOUN
dpc-1945	219	5	and	and	CCONJ
dpc-1945	219	6	nivolumab	nivolumab	NOUN
dpc-1945	219	7	has	have	AUX
dpc-1945	219	8	reported	report	VERB
dpc-1945	219	9	increased	increase	VERB
dpc-1945	219	10	efficacy	efficacy	NOUN
dpc-1945	219	11	over	over	ADP
dpc-1945	219	12	that	that	PRON
dpc-1945	219	13	of	of	ADP
dpc-1945	219	14	single	single	ADJ
dpc-1945	219	15	agent	agent	NOUN
dpc-1945	219	16	checkpoint	checkpoint	NOUN
dpc-1945	219	17	blockade	blockade	NOUN
dpc-1945	219	18	.	.	PUNCT
dpc-1945	220	1	these	these	DET
dpc-1945	220	2	effects	effect	NOUN
dpc-1945	220	3	were	be	AUX
dpc-1945	220	4	more	more	ADV
dpc-1945	220	5	durable	durable	ADJ
dpc-1945	220	6	and	and	CCONJ
dpc-1945	220	7	significantly	significantly	ADV
dpc-1945	220	8	prolonged	prolonged	ADJ
dpc-1945	220	9	survival	survival	NOUN
dpc-1945	220	10	of	of	ADP
dpc-1945	220	11	responsive	responsive	ADJ
dpc-1945	220	12	patients	patient	NOUN
dpc-1945	220	13	for	for	ADP
dpc-1945	220	14	various	various	ADJ
dpc-1945	220	15	malignancies	malignancy	NOUN
dpc-1945	220	16	[	[	X
dpc-1945	220	17	71	71	NUM
dpc-1945	220	18	]	]	PUNCT
dpc-1945	220	19	.	.	PUNCT
dpc-1945	221	1	this	this	DET
dpc-1945	221	2	combination	combination	NOUN
dpc-1945	221	3	therapy	therapy	NOUN
dpc-1945	221	4	is	be	AUX
dpc-1945	221	5	currently	currently	ADV
dpc-1945	221	6	under	under	ADP
dpc-1945	221	7	investigation	investigation	NOUN
dpc-1945	221	8	for	for	ADP
dpc-1945	221	9	the	the	DET
dpc-1945	221	10	treatment	treatment	NOUN
dpc-1945	221	11	of	of	ADP
dpc-1945	221	12	advanced	advanced	ADJ
dpc-1945	221	13	cscc	cscc	NOUN
dpc-1945	221	14	[	[	X
dpc-1945	221	15	72	72	NUM
dpc-1945	221	16	]	]	PUNCT
dpc-1945	221	17	.	.	PUNCT
dpc-1945	222	1	summary	summary	NOUN
dpc-1945	222	2	of	of	ADP
dpc-1945	222	3	systemic	systemic	ADJ
dpc-1945	222	4	therapy	therapy	NOUN
dpc-1945	222	5	for	for	ADP
dpc-1945	222	6	advanced	advanced	ADJ
dpc-1945	222	7	cscc	cscc	ADJ
dpc-1945	222	8	advanced	advanced	ADJ
dpc-1945	222	9	cscc	cscc	ADJ
dpc-1945	222	10	manifests	manifest	NOUN
dpc-1945	222	11	with	with	ADP
dpc-1945	222	12	highly	highly	ADV
dpc-1945	222	13	variable	variable	ADJ
dpc-1945	222	14	presentation	presentation	NOUN
dpc-1945	222	15	having	have	VERB
dpc-1945	222	16	many	many	ADJ
dpc-1945	222	17	patient	patient	NOUN
dpc-1945	222	18	-	-	PUNCT
dpc-1945	222	19	specific	specific	ADJ
dpc-1945	222	20	features	feature	NOUN
dpc-1945	222	21	and	and	CCONJ
dpc-1945	222	22	considerations	consideration	NOUN
dpc-1945	222	23	.	.	PUNCT
dpc-1945	223	1	although	although	SCONJ
dpc-1945	223	2	some	some	DET
dpc-1945	223	3	early	early	ADJ
dpc-1945	223	4	use	use	NOUN
dpc-1945	223	5	of	of	ADP
dpc-1945	223	6	cytotoxic	cytotoxic	ADJ
dpc-1945	223	7	chemotherapy	chemotherapy	NOUN
dpc-1945	223	8	agents	agent	NOUN
dpc-1945	223	9	for	for	ADP
dpc-1945	223	10	advanced	advanced	ADJ
dpc-1945	223	11	cscc	cscc	NOUN
dpc-1945	223	12	showed	show	VERB
dpc-1945	223	13	impressive	impressive	ADJ
dpc-1945	223	14	response	response	NOUN
dpc-1945	223	15	rates	rate	NOUN
dpc-1945	223	16	,	,	PUNCT
dpc-1945	223	17	many	many	ADJ
dpc-1945	223	18	of	of	ADP
dpc-1945	223	19	these	these	DET
dpc-1945	223	20	trials	trial	NOUN
dpc-1945	223	21	included	include	VERB
dpc-1945	223	22	a	a	DET
dpc-1945	223	23	combination	combination	NOUN
dpc-1945	223	24	of	of	ADP
dpc-1945	223	25	agents	agent	NOUN
dpc-1945	223	26	,	,	PUNCT
dpc-1945	223	27	as	as	ADV
dpc-1945	223	28	well	well	ADV
dpc-1945	223	29	as	as	ADP
dpc-1945	223	30	subsequent	subsequent	ADJ
dpc-1945	223	31	surgery	surgery	NOUN
dpc-1945	223	32	or	or	CCONJ
dpc-1945	223	33	radiation	radiation	NOUN
dpc-1945	223	34	therapy	therapy	NOUN
dpc-1945	223	35	.	.	PUNCT
dpc-1945	224	1	the	the	DET
dpc-1945	224	2	limitations	limitation	NOUN
dpc-1945	224	3	of	of	ADP
dpc-1945	224	4	cytotoxic	cytotoxic	ADJ
dpc-1945	224	5	chemotherapy	chemotherapy	NOUN
dpc-1945	224	6	include	include	VERB
dpc-1945	224	7	their	their	PRON
dpc-1945	224	8	significant	significant	ADJ
dpc-1945	224	9	and	and	CCONJ
dpc-1945	224	10	at	at	ADP
dpc-1945	224	11	times	time	NOUN
dpc-1945	224	12	lethal	lethal	ADJ
dpc-1945	224	13	side	side	NOUN
dpc-1945	224	14	effect	effect	NOUN
dpc-1945	224	15	profiles	profile	NOUN
dpc-1945	224	16	which	which	PRON
dpc-1945	224	17	is	be	AUX
dpc-1945	224	18	poorly	poorly	ADV
dpc-1945	224	19	tolerated	tolerate	VERB
dpc-1945	224	20	in	in	ADP
dpc-1945	224	21	the	the	DET
dpc-1945	224	22	elderly	elderly	ADJ
dpc-1945	224	23	population	population	NOUN
dpc-1945	224	24	that	that	PRON
dpc-1945	224	25	characterizes	characterize	VERB
dpc-1945	224	26	advanced	advanced	ADJ
dpc-1945	224	27	cscc	cscc	ADJ
dpc-1945	224	28	.	.	PUNCT
dpc-1945	225	1	egfr	egfr	PROPN
dpc-1945	225	2	targeted	target	VERB
dpc-1945	225	3	therapies	therapy	NOUN
dpc-1945	225	4	such	such	ADJ
dpc-1945	225	5	as	as	ADP
dpc-1945	225	6	cetuximab	cetuximab	NOUN
dpc-1945	225	7	showed	show	VERB
dpc-1945	225	8	reasonable	reasonable	ADJ
dpc-1945	225	9	responses	response	NOUN
dpc-1945	225	10	,	,	PUNCT
dpc-1945	225	11	with	with	ADP
dpc-1945	225	12	less	less	ADV
dpc-1945	225	13	toxic	toxic	ADJ
dpc-1945	225	14	side	side	NOUN
dpc-1945	225	15	effect	effect	NOUN
dpc-1945	225	16	profiles	profile	NOUN
dpc-1945	225	17	that	that	PRON
dpc-1945	225	18	included	include	VERB
dpc-1945	225	19	cutaneous	cutaneous	ADJ
dpc-1945	225	20	eruptions	eruption	NOUN
dpc-1945	225	21	and	and	CCONJ
dpc-1945	225	22	gastrointestinal	gastrointestinal	ADJ
dpc-1945	225	23	adverse	adverse	ADJ
dpc-1945	225	24	events	event	NOUN
dpc-1945	225	25	.	.	PUNCT
dpc-1945	226	1	however	however	ADV
dpc-1945	226	2	,	,	PUNCT
dpc-1945	226	3	the	the	DET
dpc-1945	226	4	durability	durability	NOUN
dpc-1945	226	5	of	of	ADP
dpc-1945	226	6	response	response	NOUN
dpc-1945	226	7	was	be	AUX
dpc-1945	226	8	suboptimal	suboptimal	ADJ
dpc-1945	226	9	with	with	ADP
dpc-1945	226	10	a	a	DET
dpc-1945	226	11	high	high	ADJ
dpc-1945	226	12	percentage	percentage	NOUN
dpc-1945	226	13	of	of	ADP
dpc-1945	226	14	tumor	tumor	NOUN
dpc-1945	226	15	recurrence	recurrence	NOUN
dpc-1945	226	16	and	and	CCONJ
dpc-1945	226	17	low	low	ADJ
dpc-1945	226	18	overall	overall	ADJ
dpc-1945	226	19	survival	survival	NOUN
dpc-1945	226	20	at	at	ADP
dpc-1945	226	21	the	the	DET
dpc-1945	226	22	2	2	NUM
dpc-1945	226	23	-	-	PUNCT
dpc-1945	226	24	year	year	NOUN
dpc-1945	226	25	mark	mark	NOUN
dpc-1945	226	26	.	.	PUNCT
dpc-1945	227	1	immunotherapy	immunotherapy	NOUN
dpc-1945	227	2	with	with	ADP
dpc-1945	227	3	pd-1	pd-1	VERB
dpc-1945	227	4	inhibitors	inhibitor	NOUN
dpc-1945	227	5	demonstrate	demonstrate	VERB
dpc-1945	227	6	good	good	ADJ
dpc-1945	227	7	response	response	NOUN
dpc-1945	227	8	rates	rate	NOUN
dpc-1945	227	9	and	and	CCONJ
dpc-1945	227	10	generally	generally	ADV
dpc-1945	227	11	good	good	ADJ
dpc-1945	227	12	tolerability	tolerability	NOUN
dpc-1945	227	13	.	.	PUNCT
dpc-1945	228	1	although	although	SCONJ
dpc-1945	228	2	severe	severe	ADJ
dpc-1945	228	3	iraes	irae	NOUN
dpc-1945	228	4	have	have	AUX
dpc-1945	228	5	occurred	occur	VERB
dpc-1945	228	6	,	,	PUNCT
dpc-1945	228	7	lower	low	ADJ
dpc-1945	228	8	grade	grade	NOUN
dpc-1945	228	9	adverse	adverse	ADJ
dpc-1945	228	10	events	event	NOUN
dpc-1945	228	11	are	be	AUX
dpc-1945	228	12	more	more	ADV
dpc-1945	228	13	common	common	ADJ
dpc-1945	228	14	.	.	PUNCT
dpc-1945	229	1	as	as	ADP
dpc-1945	229	2	monotherapy	monotherapy	NOUN
dpc-1945	229	3	,	,	PUNCT
dpc-1945	229	4	large	large	ADJ
dpc-1945	229	5	scale	scale	NOUN
dpc-1945	229	6	trials	trial	NOUN
dpc-1945	229	7	of	of	ADP
dpc-1945	229	8	pd1	pd1	NOUN
dpc-1945	229	9	inhibitors	inhibitor	NOUN
dpc-1945	229	10	showed	show	VERB
dpc-1945	229	11	orrs	orr	NOUN
dpc-1945	229	12	close	close	ADJ
dpc-1945	229	13	to	to	ADP
dpc-1945	229	14	50	50	NUM
dpc-1945	229	15	%	%	NOUN
dpc-1945	229	16	.	.	PUNCT
dpc-1945	230	1	while	while	SCONJ
dpc-1945	230	2	biomarkers	biomarker	NOUN
dpc-1945	230	3	are	be	AUX
dpc-1945	230	4	conceptually	conceptually	ADV
dpc-1945	230	5	well	well	ADV
dpc-1945	230	6	suited	suited	ADJ
dpc-1945	230	7	for	for	ADP
dpc-1945	230	8	deciding	decide	VERB
dpc-1945	230	9	which	which	PRON
dpc-1945	230	10	systemic	systemic	ADJ
dpc-1945	230	11	agents	agent	NOUN
dpc-1945	230	12	would	would	AUX
dpc-1945	230	13	provide	provide	VERB
dpc-1945	230	14	the	the	DET
dpc-1945	230	15	most	most	ADV
dpc-1945	230	16	clinical	clinical	ADJ
dpc-1945	230	17	benefit	benefit	NOUN
dpc-1945	230	18	,	,	PUNCT
dpc-1945	230	19	assessment	assessment	NOUN
dpc-1945	230	20	of	of	ADP
dpc-1945	230	21	these	these	PRON
dpc-1945	230	22	to	to	ADP
dpc-1945	230	23	date	date	NOUN
dpc-1945	230	24	has	have	AUX
dpc-1945	230	25	yielded	yield	VERB
dpc-1945	230	26	mostly	mostly	ADV
dpc-1945	230	27	inconsistent	inconsistent	ADJ
dpc-1945	230	28	results	result	NOUN
dpc-1945	230	29	.	.	PUNCT
dpc-1945	231	1	patients	patient	NOUN
dpc-1945	231	2	with	with	ADP
dpc-1945	231	3	advanced	advanced	ADJ
dpc-1945	231	4	cscc	cscc	PROPN
dpc-1945	231	5	treated	treat	VERB
dpc-1945	231	6	with	with	ADP
dpc-1945	231	7	cetuximab	cetuximab	NOUN
dpc-1945	231	8	showed	show	VERB
dpc-1945	231	9	efficacy	efficacy	NOUN
dpc-1945	231	10	in	in	ADP
dpc-1945	231	11	a	a	DET
dpc-1945	231	12	cohort	cohort	NOUN
dpc-1945	231	13	of	of	ADP
dpc-1945	231	14	patients	patient	NOUN
dpc-1945	231	15	that	that	PRON
dpc-1945	231	16	did	do	AUX
dpc-1945	231	17	not	not	PART
dpc-1945	231	18	reveal	reveal	VERB
dpc-1945	231	19	significant	significant	ADJ
dpc-1945	231	20	egfr	egfr	ADJ
dpc-1945	231	21	mutations	mutation	NOUN
dpc-1945	231	22	,	,	PUNCT
dpc-1945	231	23	although	although	SCONJ
dpc-1945	231	24	this	this	PRON
dpc-1945	231	25	is	be	AUX
dpc-1945	231	26	specific	specific	ADJ
dpc-1945	231	27	to	to	ADP
dpc-1945	231	28	the	the	DET
dpc-1945	231	29	investigated	investigate	VERB
dpc-1945	231	30	loci	locus	NOUN
dpc-1945	231	31	in	in	ADP
dpc-1945	231	32	the	the	DET
dpc-1945	231	33	study	study	NOUN
dpc-1945	231	34	by	by	ADP
dpc-1945	231	35	picard	picard	NOUN
dpc-1945	231	36	and	and	CCONJ
dpc-1945	231	37	colleagues	colleague	NOUN
dpc-1945	232	1	[	[	X
dpc-1945	232	2	73	73	NUM
dpc-1945	232	3	]	]	PUNCT
dpc-1945	232	4	.	.	PUNCT
dpc-1945	233	1	as	as	SCONJ
dpc-1945	233	2	noted	note	VERB
dpc-1945	233	3	above	above	ADV
dpc-1945	233	4	,	,	PUNCT
dpc-1945	233	5	similar	similar	ADJ
dpc-1945	233	6	findings	finding	NOUN
dpc-1945	233	7	have	have	AUX
dpc-1945	233	8	been	be	AUX
dpc-1945	233	9	noted	note	VERB
dpc-1945	233	10	with	with	ADP
dpc-1945	233	11	pd-1	pd-1	VERB
dpc-1945	233	12	inhibitors	inhibitor	NOUN
dpc-1945	233	13	where	where	SCONJ
dpc-1945	233	14	complete	complete	ADJ
dpc-1945	233	15	responses	response	NOUN
dpc-1945	233	16	occurred	occur	VERB
dpc-1945	233	17	in	in	ADP
dpc-1945	233	18	tumors	tumor	NOUN
dpc-1945	233	19	that	that	PRON
dpc-1945	233	20	lacked	lack	VERB
dpc-1945	233	21	tumor	tumor	NOUN
dpc-1945	233	22	and	and	CCONJ
dpc-1945	233	23	til	til	PROPN
dpc-1945	233	24	pd	pd	PROPN
dpc-1945	233	25	-	-	PROPN
dpc-1945	233	26	l1	l1	PROPN
dpc-1945	233	27	expression	expression	NOUN
dpc-1945	233	28	,	,	PUNCT
dpc-1945	233	29	or	or	CCONJ
dpc-1945	233	30	the	the	DET
dpc-1945	233	31	lack	lack	NOUN
dpc-1945	233	32	of	of	ADP
dpc-1945	233	33	response	response	NOUN
dpc-1945	233	34	was	be	AUX
dpc-1945	233	35	seen	see	VERB
dpc-1945	233	36	in	in	ADP
dpc-1945	233	37	tumors	tumor	NOUN
dpc-1945	233	38	that	that	PRON
dpc-1945	233	39	strongly	strongly	ADV
dpc-1945	233	40	expressed	express	VERB
dpc-1945	233	41	pd	pd	ADJ
dpc-1945	233	42	-	-	PUNCT
dpc-1945	233	43	l1[60	l1[60	NOUN
dpc-1945	233	44	-	-	NOUN
dpc-1945	233	45	62	62	NUM
dpc-1945	233	46	]	]	PUNCT
dpc-1945	233	47	.	.	PUNCT
dpc-1945	234	1	in	in	ADP
dpc-1945	234	2	addition	addition	NOUN
dpc-1945	234	3	,	,	PUNCT
dpc-1945	234	4	differences	difference	NOUN
dpc-1945	234	5	in	in	ADP
dpc-1945	234	6	the	the	DET
dpc-1945	234	7	methods	method	NOUN
dpc-1945	234	8	used	use	VERB
dpc-1945	234	9	for	for	ADP
dpc-1945	234	10	biomarker	biomarker	NOUN
dpc-1945	234	11	testing	testing	NOUN
dpc-1945	234	12	or	or	CCONJ
dpc-1945	234	13	other	other	ADJ
dpc-1945	234	14	assays	assay	NOUN
dpc-1945	234	15	further	far	ADV
dpc-1945	234	16	confound	confound	VERB
dpc-1945	234	17	the	the	DET
dpc-1945	234	18	interpretation	interpretation	NOUN
dpc-1945	234	19	of	of	ADP
dpc-1945	234	20	these	these	DET
dpc-1945	234	21	results	result	NOUN
dpc-1945	234	22	[	[	X
dpc-1945	234	23	74	74	NUM
dpc-1945	234	24	]	]	PUNCT
dpc-1945	234	25	.	.	PUNCT
dpc-1945	235	1	standardization	standardization	NOUN
dpc-1945	235	2	of	of	ADP
dpc-1945	235	3	biomarker	biomarker	NOUN
dpc-1945	235	4	testing	testing	NOUN
dpc-1945	235	5	in	in	ADP
dpc-1945	235	6	large	large	ADJ
dpc-1945	235	7	-	-	PUNCT
dpc-1945	235	8	scale	scale	NOUN
dpc-1945	235	9	trials	trial	NOUN
dpc-1945	235	10	may	may	AUX
dpc-1945	235	11	lead	lead	VERB
dpc-1945	235	12	to	to	ADP
dpc-1945	235	13	more	more	ADV
dpc-1945	235	14	conclusive	conclusive	ADJ
dpc-1945	235	15	findings	finding	NOUN
dpc-1945	235	16	of	of	ADP
dpc-1945	235	17	any	any	DET
dpc-1945	235	18	correlations	correlation	NOUN
dpc-1945	235	19	identified	identify	VERB
dpc-1945	235	20	.	.	PUNCT
dpc-1945	236	1	conclusions	conclusion	NOUN
dpc-1945	236	2	significant	significant	ADJ
dpc-1945	236	3	advances	advance	NOUN
dpc-1945	236	4	have	have	AUX
dpc-1945	236	5	been	be	AUX
dpc-1945	236	6	made	make	VERB
dpc-1945	236	7	in	in	ADP
dpc-1945	236	8	the	the	DET
dpc-1945	236	9	quest	quest	NOUN
dpc-1945	236	10	to	to	PART
dpc-1945	236	11	achieve	achieve	VERB
dpc-1945	236	12	durable	durable	ADJ
dpc-1945	236	13	tumor	tumor	NOUN
dpc-1945	236	14	responses	response	NOUN
dpc-1945	236	15	with	with	ADP
dpc-1945	236	16	limited	limited	ADJ
dpc-1945	236	17	systemic	systemic	ADJ
dpc-1945	236	18	toxicity	toxicity	NOUN
dpc-1945	236	19	in	in	ADP
dpc-1945	236	20	the	the	DET
dpc-1945	236	21	fight	fight	NOUN
dpc-1945	236	22	against	against	ADP
dpc-1945	236	23	advanced	advanced	ADJ
dpc-1945	236	24	cscc	cscc	NOUN
dpc-1945	236	25	.	.	PUNCT
dpc-1945	237	1	although	although	SCONJ
dpc-1945	237	2	we	we	PRON
dpc-1945	237	3	have	have	AUX
dpc-1945	237	4	reviewed	review	VERB
dpc-1945	237	5	numerous	numerous	ADJ
dpc-1945	237	6	agents	agent	NOUN
dpc-1945	237	7	and	and	CCONJ
dpc-1945	237	8	trials	trial	NOUN
dpc-1945	237	9	including	include	VERB
dpc-1945	237	10	cytotoxic	cytotoxic	ADJ
dpc-1945	237	11	chemotherapies	chemotherapy	NOUN
dpc-1945	237	12	,	,	PUNCT
dpc-1945	237	13	targeted	target	VERB
dpc-1945	237	14	agents	agent	NOUN
dpc-1945	237	15	,	,	PUNCT
dpc-1945	237	16	and	and	CCONJ
dpc-1945	237	17	immunotherapies	immunotherapy	NOUN
dpc-1945	237	18	,	,	PUNCT
dpc-1945	237	19	head	head	NOUN
dpc-1945	237	20	-	-	PUNCT
dpc-1945	237	21	to	to	ADP
dpc-1945	237	22	-	-	PUNCT
dpc-1945	237	23	head	head	NOUN
dpc-1945	237	24	comparisons	comparison	NOUN
dpc-1945	237	25	are	be	AUX
dpc-1945	237	26	not	not	PART
dpc-1945	237	27	appropriate	appropriate	ADJ
dpc-1945	237	28	due	due	ADP
dpc-1945	237	29	to	to	ADP
dpc-1945	237	30	the	the	DET
dpc-1945	237	31	differences	difference	NOUN
dpc-1945	237	32	in	in	ADP
dpc-1945	237	33	study	study	NOUN
dpc-1945	237	34	design	design	NOUN
dpc-1945	237	35	.	.	PUNCT
dpc-1945	238	1	there	there	PRON
dpc-1945	238	2	are	be	VERB
dpc-1945	238	3	substantial	substantial	ADJ
dpc-1945	238	4	differences	difference	NOUN
dpc-1945	238	5	of	of	ADP
dpc-1945	238	6	the	the	DET
dpc-1945	238	7	demographics	demographic	NOUN
dpc-1945	238	8	enrolled	enrol	VERB
dpc-1945	238	9	in	in	ADP
dpc-1945	238	10	these	these	DET
dpc-1945	238	11	studies	study	NOUN
dpc-1945	238	12	,	,	PUNCT
dpc-1945	238	13	and	and	CCONJ
dpc-1945	238	14	many	many	ADJ
dpc-1945	238	15	trials	trial	NOUN
dpc-1945	238	16	did	do	AUX
dpc-1945	238	17	not	not	PART
dpc-1945	238	18	involve	involve	VERB
dpc-1945	238	19	first	first	ADJ
dpc-1945	238	20	line	line	NOUN
dpc-1945	238	21	therapy	therapy	NOUN
dpc-1945	238	22	.	.	PUNCT
dpc-1945	239	1	although	although	SCONJ
dpc-1945	239	2	different	different	ADJ
dpc-1945	239	3	drugs	drug	NOUN
dpc-1945	239	4	within	within	ADP
dpc-1945	239	5	the	the	DET
dpc-1945	239	6	same	same	ADJ
dpc-1945	239	7	class	class	NOUN
dpc-1945	239	8	may	may	AUX
dpc-1945	239	9	work	work	VERB
dpc-1945	239	10	in	in	ADP
dpc-1945	239	11	a	a	DET
dpc-1945	239	12	similar	similar	ADJ
dpc-1945	239	13	fashion	fashion	NOUN
dpc-1945	239	14	,	,	PUNCT
dpc-1945	239	15	we	we	PRON
dpc-1945	239	16	can	can	AUX
dpc-1945	239	17	not	not	PART
dpc-1945	239	18	assume	assume	VERB
dpc-1945	239	19	that	that	SCONJ
dpc-1945	239	20	they	they	PRON
dpc-1945	239	21	are	be	AUX
dpc-1945	239	22	equivalent	equivalent	ADJ
dpc-1945	239	23	in	in	ADP
dpc-1945	239	24	efficacy	efficacy	NOUN
dpc-1945	239	25	or	or	CCONJ
dpc-1945	239	26	safety	safety	NOUN
dpc-1945	239	27	.	.	PUNCT
dpc-1945	240	1	nevertheless	nevertheless	ADV
dpc-1945	240	2	,	,	PUNCT
dpc-1945	240	3	the	the	DET
dpc-1945	240	4	rise	rise	NOUN
dpc-1945	240	5	of	of	ADP
dpc-1945	240	6	immunotherapy	immunotherapy	NOUN
dpc-1945	240	7	,	,	PUNCT
dpc-1945	240	8	specifically	specifically	ADV
dpc-1945	240	9	pd-1	pd-1	ADP
dpc-1945	240	10	inhibitors	inhibitor	NOUN
dpc-1945	240	11	,	,	PUNCT
dpc-1945	240	12	have	have	AUX
dpc-1945	240	13	shown	show	VERB
dpc-1945	240	14	adequate	adequate	ADJ
dpc-1945	240	15	tumor	tumor	NOUN
dpc-1945	240	16	responses	response	NOUN
dpc-1945	240	17	with	with	ADP
dpc-1945	240	18	less	less	ADV
dpc-1945	240	19	frequent	frequent	ADJ
dpc-1945	240	20	severe	severe	ADJ
dpc-1945	240	21	systemic	systemic	ADJ
dpc-1945	240	22	toxicities	toxicity	NOUN
dpc-1945	240	23	.	.	PUNCT
dpc-1945	241	1	cytotoxic	cytotoxic	ADJ
dpc-1945	241	2	agents	agent	NOUN
dpc-1945	241	3	and	and	CCONJ
dpc-1945	241	4	targeted	target	VERB
dpc-1945	241	5	based	base	VERB
dpc-1945	241	6	therapies	therapy	NOUN
dpc-1945	241	7	should	should	AUX
dpc-1945	241	8	not	not	PART
dpc-1945	241	9	be	be	AUX
dpc-1945	241	10	altogether	altogether	ADV
dpc-1945	241	11	forgotten	forget	VERB
dpc-1945	241	12	,	,	PUNCT
dpc-1945	241	13	and	and	CCONJ
dpc-1945	241	14	can	can	AUX
dpc-1945	241	15	continue	continue	VERB
dpc-1945	241	16	to	to	PART
dpc-1945	241	17	be	be	AUX
dpc-1945	241	18	considered	consider	VERB
dpc-1945	241	19	in	in	ADP
dpc-1945	241	20	specific	specific	ADJ
dpc-1945	241	21	cases	case	NOUN
dpc-1945	241	22	where	where	SCONJ
dpc-1945	241	23	immune	immune	ADJ
dpc-1945	241	24	checkpoint	checkpoint	NOUN
dpc-1945	241	25	inhibition	inhibition	NOUN
dpc-1945	241	26	is	be	AUX
dpc-1945	241	27	contraindicated	contraindicate	VERB
dpc-1945	241	28	.	.	PUNCT
dpc-1945	242	1	the	the	DET
dpc-1945	242	2	large	large	ADJ
dpc-1945	242	3	number	number	NOUN
dpc-1945	242	4	of	of	ADP
dpc-1945	242	5	trials	trial	NOUN
dpc-1945	242	6	in	in	ADP
dpc-1945	242	7	progress	progress	NOUN
dpc-1945	242	8	today	today	NOUN
dpc-1945	242	9	include	include	VERB
dpc-1945	242	10	adjuvant	adjuvant	ADJ
dpc-1945	242	11	,	,	PUNCT
dpc-1945	242	12	neoadjuvant	neoadjuvant	ADJ
dpc-1945	242	13	monotherapy	monotherapy	NOUN
dpc-1945	242	14	and	and	CCONJ
dpc-1945	242	15	combinations	combination	NOUN
dpc-1945	242	16	of	of	ADP
dpc-1945	242	17	the	the	DET
dpc-1945	242	18	agents	agent	NOUN
dpc-1945	242	19	discussed	discuss	VERB
dpc-1945	242	20	in	in	ADP
dpc-1945	242	21	this	this	DET
dpc-1945	242	22	review	review	NOUN
dpc-1945	242	23	.	.	PUNCT
dpc-1945	243	1	even	even	ADV
dpc-1945	243	2	so	so	ADV
dpc-1945	243	3	,	,	PUNCT
dpc-1945	243	4	much	much	ADJ
dpc-1945	243	5	work	work	NOUN
dpc-1945	243	6	is	be	AUX
dpc-1945	243	7	needed	need	VERB
dpc-1945	243	8	to	to	PART
dpc-1945	243	9	improve	improve	VERB
dpc-1945	243	10	outcomes	outcome	NOUN
dpc-1945	243	11	while	while	SCONJ
dpc-1945	243	12	review	review	VERB
dpc-1945	243	13	|	|	ADV
dpc-1945	243	14	dermatol	dermatol	ADJ
dpc-1945	243	15	pract	pract	NOUN
dpc-1945	243	16	concept	concept	NOUN
dpc-1945	243	17	.	.	PUNCT
dpc-1945	244	1	2021	2021	NUM
dpc-1945	244	2	;	;	PUNCT
dpc-1945	244	3	11(s2	11(s2	NUM
dpc-1945	244	4	):	):	PUNCT
dpc-1945	244	5	e2021169s	e2021169s	NOUN
dpc-1945	244	6	9	9	NUM
dpc-1945	244	7	decreasing	decrease	VERB
dpc-1945	244	8	risks	risk	NOUN
dpc-1945	244	9	from	from	ADP
dpc-1945	244	10	adverse	adverse	ADJ
dpc-1945	244	11	events	event	NOUN
dpc-1945	244	12	in	in	ADP
dpc-1945	244	13	the	the	DET
dpc-1945	244	14	fight	fight	NOUN
dpc-1945	244	15	against	against	ADP
dpc-1945	244	16	advanced	advanced	ADJ
dpc-1945	244	17	cscc	cscc	NOUN
dpc-1945	244	18	.	.	PUNCT
dpc-1945	245	1	references	reference	NOUN
dpc-1945	245	2	1	1	NUM
dpc-1945	245	3	.	.	PUNCT
dpc-1945	246	1	lomas	lomas	PROPN
dpc-1945	246	2	a	a	PRON
dpc-1945	246	3	,	,	PUNCT
dpc-1945	246	4	leonardi	leonardi	PROPN
dpc-1945	246	5	-	-	PUNCT
dpc-1945	246	6	bee	bee	PROPN
dpc-1945	246	7	j	j	PROPN
dpc-1945	246	8	,	,	PUNCT
dpc-1945	246	9	bath	bath	NOUN
dpc-1945	246	10	-	-	PUNCT
dpc-1945	246	11	hextall	hextall	NOUN
dpc-1945	246	12	f.	f.	PROPN
dpc-1945	246	13	a	a	DET
dpc-1945	246	14	systematic	systematic	ADJ
dpc-1945	246	15	review	review	NOUN
dpc-1945	246	16	of	of	ADP
dpc-1945	246	17	worldwide	worldwide	ADJ
dpc-1945	246	18	incidence	incidence	NOUN
dpc-1945	246	19	of	of	ADP
dpc-1945	246	20	nonmelanoma	nonmelanoma	ADJ
dpc-1945	246	21	skin	skin	NOUN
dpc-1945	246	22	cancer	cancer	NOUN
dpc-1945	246	23	.	.	PUNCT
dpc-1945	247	1	br	br	PROPN
dpc-1945	247	2	j	j	PROPN
dpc-1945	247	3	dermatol	dermatol	NOUN
dpc-1945	247	4	.	.	PUNCT
dpc-1945	248	1	(	(	PUNCT
dpc-1945	248	2	1951	1951	NUM
dpc-1945	248	3	)	)	PUNCT
dpc-1945	248	4	.	.	PUNCT
dpc-1945	249	1	2012;166(5):1069	2012;166(5):1069	NUM
dpc-1945	249	2	-	-	SYM
dpc-1945	249	3	80	80	NUM
dpc-1945	249	4	.	.	PUNCT
dpc-1945	250	1	doi	doi	NOUN
dpc-1945	250	2	:	:	PUNCT
dpc-1945	250	3	10.1111	10.1111	NUM
dpc-1945	250	4	/	/	SYM
dpc-1945	250	5	j.13652133.2012.10830.x	j.13652133.2012.10830.x	PROPN
dpc-1945	250	6	.	.	PUNCT
dpc-1945	251	1	pmid	pmid	NOUN
dpc-1945	251	2	:	:	PUNCT
dpc-1945	251	3	22251204	22251204	NUM
dpc-1945	251	4	.	.	PUNCT
dpc-1945	252	1	2	2	X
dpc-1945	252	2	.	.	X
dpc-1945	252	3	perera	perera	PROPN
dpc-1945	252	4	e	e	PROPN
dpc-1945	252	5	,	,	PUNCT
dpc-1945	252	6	gnaneswaran	gnaneswaran	NOUN
dpc-1945	252	7	n	n	CCONJ
dpc-1945	252	8	,	,	PUNCT
dpc-1945	252	9	staines	stain	VERB
dpc-1945	252	10	c	c	NOUN
dpc-1945	252	11	,	,	PUNCT
dpc-1945	252	12	win	win	PROPN
dpc-1945	252	13	ak	ak	PROPN
dpc-1945	252	14	,	,	PUNCT
dpc-1945	252	15	sinclair	sinclair	PROPN
dpc-1945	252	16	r.	r.	PROPN
dpc-1945	252	17	incidence	incidence	PROPN
dpc-1945	252	18	and	and	CCONJ
dpc-1945	252	19	prevalence	prevalence	NOUN
dpc-1945	252	20	of	of	ADP
dpc-1945	252	21	non	non	ADJ
dpc-1945	252	22	-	-	ADJ
dpc-1945	252	23	melanoma	melanoma	ADJ
dpc-1945	252	24	skin	skin	NOUN
dpc-1945	252	25	cancer	cancer	NOUN
dpc-1945	252	26	in	in	ADP
dpc-1945	252	27	australia	australia	PROPN
dpc-1945	252	28	:	:	PUNCT
dpc-1945	252	29	a	a	DET
dpc-1945	252	30	systematic	systematic	ADJ
dpc-1945	252	31	review	review	NOUN
dpc-1945	252	32	.	.	PUNCT
dpc-1945	253	1	australas	australas	PROPN
dpc-1945	253	2	j	j	PROPN
dpc-1945	253	3	dermatol	dermatol	NOUN
dpc-1945	253	4	.	.	PUNCT
dpc-1945	254	1	2015;56(4):258	2015;56(4):258	NUM
dpc-1945	254	2	-	-	SYM
dpc-1945	254	3	67	67	NUM
dpc-1945	254	4	.	.	PUNCT
dpc-1945	255	1	doi	doi	NOUN
dpc-1945	255	2	:	:	PUNCT
dpc-1945	255	3	10.1111	10.1111	NUM
dpc-1945	255	4	/	/	SYM
dpc-1945	255	5	ajd.12282	ajd.12282	PROPN
dpc-1945	255	6	.	.	PUNCT
dpc-1945	256	1	pmid	pmid	NOUN
dpc-1945	256	2	:	:	PUNCT
dpc-1945	256	3	25716064	25716064	NUM
dpc-1945	256	4	.	.	PUNCT
dpc-1945	257	1	3	3	X
dpc-1945	257	2	.	.	X
dpc-1945	257	3	brewster	brewster	PROPN
dpc-1945	257	4	dh	dh	PROPN
dpc-1945	257	5	,	,	PUNCT
dpc-1945	257	6	bhatti	bhatti	PROPN
dpc-1945	257	7	la	la	PROPN
dpc-1945	257	8	,	,	PUNCT
dpc-1945	257	9	inglis	inglis	PROPN
dpc-1945	257	10	jhc	jhc	PROPN
dpc-1945	257	11	,	,	PUNCT
dpc-1945	257	12	nairn	nairn	PROPN
dpc-1945	257	13	er	er	INTJ
dpc-1945	257	14	,	,	PUNCT
dpc-1945	257	15	doherty	doherty	PROPN
dpc-1945	257	16	vr	vr	PROPN
dpc-1945	257	17	.	.	PROPN
dpc-1945	257	18	recent	recent	ADJ
dpc-1945	257	19	trends	trend	NOUN
dpc-1945	257	20	in	in	ADP
dpc-1945	257	21	incidence	incidence	NOUN
dpc-1945	257	22	of	of	ADP
dpc-1945	257	23	nonmelanoma	nonmelanoma	ADJ
dpc-1945	257	24	skin	skin	NOUN
dpc-1945	257	25	cancers	cancer	NOUN
dpc-1945	257	26	in	in	ADP
dpc-1945	257	27	the	the	DET
dpc-1945	257	28	east	east	NOUN
dpc-1945	257	29	of	of	ADP
dpc-1945	257	30	scotland	scotland	PROPN
dpc-1945	257	31	,	,	PUNCT
dpc-1945	257	32	1992–2003	1992–2003	NUM
dpc-1945	257	33	.	.	PUNCT
dpc-1945	258	1	br	br	PROPN
dpc-1945	258	2	j	j	PROPN
dpc-1945	258	3	dermatol	dermatol	NOUN
dpc-1945	258	4	.	.	PUNCT
dpc-1945	259	1	2007;156(6):1295	2007;156(6):1295	NUM
dpc-1945	259	2	-	-	SYM
dpc-1945	259	3	300	300	NUM
dpc-1945	259	4	.	.	PUNCT
dpc-1945	259	5	doi	doi	NOUN
dpc-1945	259	6	:	:	PUNCT
dpc-1945	259	7	10.1111	10.1111	NUM
dpc-1945	259	8	/	/	SYM
dpc-1945	259	9	j.1365	j.1365	NOUN
dpc-1945	259	10	-	-	PUNCT
dpc-1945	259	11	2133.2007.07892.x	2133.2007.07892.x	NUM
dpc-1945	259	12	.	.	PUNCT
dpc-1945	260	1	pmid	pmid	NOUN
dpc-1945	260	2	:	:	PUNCT
dpc-1945	260	3	17535229	17535229	NUM
dpc-1945	260	4	.	.	PUNCT
dpc-1945	261	1	4	4	X
dpc-1945	261	2	.	.	X
dpc-1945	261	3	andersson	andersson	PROPN
dpc-1945	261	4	em	em	PRON
dpc-1945	261	5	,	,	PUNCT
dpc-1945	261	6	paoli	paoli	PROPN
dpc-1945	261	7	j	j	PROPN
dpc-1945	261	8	,	,	PUNCT
dpc-1945	261	9	wastensson	wastensson	PROPN
dpc-1945	261	10	g.	g.	PROPN
dpc-1945	261	11	incidence	incidence	NOUN
dpc-1945	261	12	of	of	ADP
dpc-1945	261	13	cutaneous	cutaneous	ADJ
dpc-1945	261	14	squamous	squamous	ADJ
dpc-1945	261	15	cell	cell	NOUN
dpc-1945	261	16	carcinoma	carcinoma	NOUN
dpc-1945	261	17	in	in	ADP
dpc-1945	261	18	coastal	coastal	ADJ
dpc-1945	261	19	and	and	CCONJ
dpc-1945	261	20	inland	inland	ADJ
dpc-1945	261	21	areas	area	NOUN
dpc-1945	261	22	of	of	ADP
dpc-1945	261	23	western	western	ADJ
dpc-1945	261	24	sweden	sweden	PROPN
dpc-1945	261	25	.	.	PUNCT
dpc-1945	262	1	cancer	cancer	NOUN
dpc-1945	262	2	epidemiol	epidemiol	PROPN
dpc-1945	262	3	.	.	PUNCT
dpc-1945	263	1	2011;35(6):e69	2011;35(6):e69	NUM
dpc-1945	263	2	-	-	SYM
dpc-1945	263	3	74	74	NUM
dpc-1945	263	4	.	.	PUNCT
dpc-1945	264	1	doi	doi	NOUN
dpc-1945	264	2	:	:	PUNCT
dpc-1945	264	3	10.1016	10.1016	NUM
dpc-1945	264	4	/	/	SYM
dpc-1945	264	5	j.	j.	PROPN
dpc-1945	264	6	canep.2011.05.006	canep.2011.05.006	PROPN
dpc-1945	264	7	.	.	PUNCT
dpc-1945	265	1	pmid	pmid	NOUN
dpc-1945	265	2	:	:	PUNCT
dpc-1945	265	3	21840282	21840282	NUM
dpc-1945	265	4	.	.	PUNCT
dpc-1945	266	1	5	5	X
dpc-1945	266	2	.	.	X
dpc-1945	266	3	katalinic	katalinic	VERB
dpc-1945	266	4	a	a	PRON
dpc-1945	266	5	,	,	PUNCT
dpc-1945	266	6	kunze	kunze	PROPN
dpc-1945	266	7	u	u	PROPN
dpc-1945	266	8	,	,	PUNCT
dpc-1945	266	9	schäfer	schäfer	NOUN
dpc-1945	266	10	t.	t.	NOUN
dpc-1945	266	11	epidemiology	epidemiology	NOUN
dpc-1945	266	12	of	of	ADP
dpc-1945	266	13	cutaneous	cutaneous	ADJ
dpc-1945	266	14	melanoma	melanoma	NOUN
dpc-1945	266	15	and	and	CCONJ
dpc-1945	266	16	non	non	ADJ
dpc-1945	266	17	-	-	ADJ
dpc-1945	266	18	melanoma	melanoma	ADJ
dpc-1945	266	19	skin	skin	NOUN
dpc-1945	266	20	cancer	cancer	NOUN
dpc-1945	266	21	in	in	ADP
dpc-1945	266	22	schleswig	schleswig	PROPN
dpc-1945	266	23	-	-	PUNCT
dpc-1945	266	24	holstein	holstein	PROPN
dpc-1945	266	25	,	,	PUNCT
dpc-1945	266	26	germany	germany	PROPN
dpc-1945	266	27	:	:	PUNCT
dpc-1945	266	28	incidence	incidence	NOUN
dpc-1945	266	29	,	,	PUNCT
dpc-1945	266	30	clinical	clinical	ADJ
dpc-1945	266	31	subtypes	subtype	NOUN
dpc-1945	266	32	,	,	PUNCT
dpc-1945	266	33	tumour	tumour	NOUN
dpc-1945	266	34	stages	stage	NOUN
dpc-1945	266	35	and	and	CCONJ
dpc-1945	266	36	localization	localization	NOUN
dpc-1945	266	37	(	(	PUNCT
dpc-1945	266	38	epidemiology	epidemiology	NOUN
dpc-1945	266	39	of	of	ADP
dpc-1945	266	40	skin	skin	NOUN
dpc-1945	266	41	cancer	cancer	NOUN
dpc-1945	266	42	)	)	PUNCT
dpc-1945	266	43	.	.	PUNCT
dpc-1945	267	1	br	br	PROPN
dpc-1945	267	2	j	j	PROPN
dpc-1945	267	3	dermatol	dermatol	NOUN
dpc-1945	267	4	.	.	PUNCT
dpc-1945	268	1	2003;149(6):12006	2003;149(6):12006	NUM
dpc-1945	268	2	.	.	PUNCT
dpc-1945	269	1	doi	doi	NOUN
dpc-1945	269	2	:	:	PUNCT
dpc-1945	269	3	10.1111	10.1111	NUM
dpc-1945	269	4	/	/	SYM
dpc-1945	269	5	j.1365	j.1365	NOUN
dpc-1945	269	6	-	-	PUNCT
dpc-1945	269	7	2133.2003.05554.x	2133.2003.05554.x	NUM
dpc-1945	269	8	.	.	PUNCT
dpc-1945	270	1	pmid	pmid	NOUN
dpc-1945	270	2	:	:	PUNCT
dpc-1945	270	3	14674897	14674897	NUM
dpc-1945	270	4	.	.	PUNCT
dpc-1945	271	1	6	6	X
dpc-1945	271	2	.	.	X
dpc-1945	271	3	staples	staples	PROPN
dpc-1945	271	4	mp	mp	PROPN
dpc-1945	271	5	,	,	PUNCT
dpc-1945	271	6	elwood	elwood	PROPN
dpc-1945	271	7	m	m	PROPN
dpc-1945	271	8	,	,	PUNCT
dpc-1945	271	9	burton	burton	PROPN
dpc-1945	271	10	rc	rc	PROPN
dpc-1945	271	11	,	,	PUNCT
dpc-1945	271	12	williams	williams	PROPN
dpc-1945	271	13	jl	jl	PROPN
dpc-1945	271	14	,	,	PUNCT
dpc-1945	271	15	marks	mark	VERB
dpc-1945	271	16	r	r	PROPN
dpc-1945	271	17	,	,	PUNCT
dpc-1945	271	18	giles	giles	PROPN
dpc-1945	271	19	gg	gg	PROPN
dpc-1945	271	20	.	.	PUNCT
dpc-1945	272	1	non	non	ADJ
dpc-1945	272	2	-	-	ADJ
dpc-1945	272	3	melanoma	melanoma	ADJ
dpc-1945	272	4	skin	skin	NOUN
dpc-1945	272	5	cancer	cancer	NOUN
dpc-1945	272	6	in	in	ADP
dpc-1945	272	7	australia	australia	PROPN
dpc-1945	272	8	:	:	PUNCT
dpc-1945	272	9	the	the	DET
dpc-1945	272	10	2002	2002	NUM
dpc-1945	272	11	national	national	ADJ
dpc-1945	272	12	survey	survey	NOUN
dpc-1945	272	13	and	and	CCONJ
dpc-1945	272	14	trends	trend	NOUN
dpc-1945	272	15	since	since	SCONJ
dpc-1945	272	16	1985	1985	NUM
dpc-1945	272	17	.	.	PUNCT
dpc-1945	273	1	med	med	PROPN
dpc-1945	273	2	j	j	PROPN
dpc-1945	273	3	aust	aust	PROPN
dpc-1945	273	4	.	.	PUNCT
dpc-1945	274	1	2006;184(1):6	2006;184(1):6	NUM
dpc-1945	274	2	-	-	SYM
dpc-1945	274	3	10	10	NUM
dpc-1945	274	4	.	.	PUNCT
dpc-1945	275	1	doi	doi	NOUN
dpc-1945	275	2	:	:	PUNCT
dpc-1945	275	3	10.5694	10.5694	NUM
dpc-1945	275	4	/	/	SYM
dpc-1945	275	5	j.1326	j.1326	NOUN
dpc-1945	275	6	-	-	PUNCT
dpc-1945	275	7	5377.2006.tb00086.x	5377.2006.tb00086.x	NUM
dpc-1945	275	8	.	.	PUNCT
dpc-1945	276	1	pmid	pmid	NOUN
dpc-1945	276	2	:	:	PUNCT
dpc-1945	276	3	16398622	16398622	NUM
dpc-1945	276	4	.	.	PUNCT
dpc-1945	277	1	7	7	X
dpc-1945	277	2	.	.	X
dpc-1945	277	3	muzic	muzic	PROPN
dpc-1945	277	4	jg	jg	PROPN
dpc-1945	277	5	,	,	PUNCT
dpc-1945	277	6	schmitt	schmitt	PROPN
dpc-1945	277	7	ar	ar	PROPN
dpc-1945	277	8	,	,	PUNCT
dpc-1945	277	9	wright	wright	PROPN
dpc-1945	277	10	ac	ac	PROPN
dpc-1945	277	11	,	,	PUNCT
dpc-1945	277	12	et	et	PROPN
dpc-1945	277	13	al	al	PROPN
dpc-1945	277	14	.	.	PROPN
dpc-1945	277	15	incidence	incidence	NOUN
dpc-1945	277	16	and	and	CCONJ
dpc-1945	277	17	trends	trend	NOUN
dpc-1945	277	18	of	of	ADP
dpc-1945	277	19	basal	basal	ADJ
dpc-1945	277	20	cell	cell	NOUN
dpc-1945	277	21	carcinoma	carcinoma	NOUN
dpc-1945	277	22	and	and	CCONJ
dpc-1945	277	23	cutaneous	cutaneous	ADJ
dpc-1945	277	24	squamous	squamous	ADJ
dpc-1945	277	25	cell	cell	NOUN
dpc-1945	277	26	carcinoma	carcinoma	NOUN
dpc-1945	277	27	:	:	PUNCT
dpc-1945	277	28	a	a	DET
dpc-1945	277	29	population	population	NOUN
dpc-1945	277	30	-	-	PUNCT
dpc-1945	277	31	based	base	VERB
dpc-1945	277	32	study	study	NOUN
dpc-1945	277	33	in	in	ADP
dpc-1945	277	34	olmsted	olmsted	PROPN
dpc-1945	277	35	county	county	PROPN
dpc-1945	277	36	,	,	PUNCT
dpc-1945	277	37	minnesota	minnesota	PROPN
dpc-1945	277	38	,	,	PUNCT
dpc-1945	277	39	2000	2000	NUM
dpc-1945	277	40	to	to	ADP
dpc-1945	277	41	2010	2010	NUM
dpc-1945	277	42	.	.	PUNCT
dpc-1945	278	1	mayo	mayo	PROPN
dpc-1945	278	2	clin	clin	PROPN
dpc-1945	278	3	proc	proc	PROPN
dpc-1945	278	4	.	.	PUNCT
dpc-1945	279	1	2017;92(6):890	2017;92(6):890	NUM
dpc-1945	279	2	-	-	SYM
dpc-1945	279	3	898	898	NUM
dpc-1945	279	4	.	.	PUNCT
dpc-1945	280	1	doi:10.1016	doi:10.1016	PROPN
dpc-1945	280	2	/	/	SYM
dpc-1945	280	3	j.	j.	PROPN
dpc-1945	280	4	mayocp.2017.02.015	mayocp.2017.02.015	PROPN
dpc-1945	280	5	.	.	PUNCT
dpc-1945	281	1	pmid	pmid	NOUN
dpc-1945	281	2	:	:	PUNCT
dpc-1945	281	3	28522111	28522111	NUM
dpc-1945	281	4	.	.	PUNCT
dpc-1945	282	1	8	8	X
dpc-1945	282	2	.	.	PUNCT
dpc-1945	282	3	rogers	rogers	PROPN
dpc-1945	282	4	hw	hw	PROPN
dpc-1945	282	5	,	,	PUNCT
dpc-1945	282	6	weinstock	weinstock	PROPN
dpc-1945	282	7	ma	ma	PROPN
dpc-1945	282	8	,	,	PUNCT
dpc-1945	282	9	feldman	feldman	PROPN
dpc-1945	282	10	sr	sr	PROPN
dpc-1945	282	11	,	,	PUNCT
dpc-1945	282	12	coldiron	coldiron	PROPN
dpc-1945	282	13	bm	bm	PROPN
dpc-1945	282	14	.	.	PUNCT
dpc-1945	282	15	incidence	incidence	ADJ
dpc-1945	282	16	estimate	estimate	NOUN
dpc-1945	282	17	of	of	ADP
dpc-1945	282	18	nonmelanoma	nonmelanoma	ADJ
dpc-1945	282	19	skin	skin	NOUN
dpc-1945	282	20	cancer	cancer	NOUN
dpc-1945	282	21	(	(	PUNCT
dpc-1945	282	22	keratinocyte	keratinocyte	NOUN
dpc-1945	282	23	carcinomas	carcinomas	PROPN
dpc-1945	282	24	)	)	PUNCT
dpc-1945	282	25	in	in	ADP
dpc-1945	282	26	the	the	DET
dpc-1945	282	27	u.s	u.s	PROPN
dpc-1945	282	28	.	.	PROPN
dpc-1945	282	29	population	population	NOUN
dpc-1945	282	30	,	,	PUNCT
dpc-1945	282	31	2012	2012	NUM
dpc-1945	282	32	.	.	PUNCT
dpc-1945	283	1	jama	jama	PROPN
dpc-1945	283	2	dermatol	dermatol	NOUN
dpc-1945	283	3	.	.	PUNCT
dpc-1945	284	1	2015;151(10):1081	2015;151(10):1081	NUM
dpc-1945	284	2	-	-	SYM
dpc-1945	284	3	1086	1086	NUM
dpc-1945	284	4	.	.	PUNCT
dpc-1945	285	1	doi:10.1001	doi:10.1001	PROPN
dpc-1945	285	2	/	/	SYM
dpc-1945	285	3	jamadermatol.2015.1187	jamadermatol.2015.1187	PROPN
dpc-1945	285	4	pmid	pmid	NOUN
dpc-1945	285	5	:	:	PUNCT
dpc-1945	285	6	25928283	25928283	NUM
dpc-1945	285	7	.	.	PUNCT
dpc-1945	286	1	9	9	X
dpc-1945	286	2	.	.	X
dpc-1945	286	3	lansbury	lansbury	PROPN
dpc-1945	286	4	l	l	PROPN
dpc-1945	286	5	,	,	PUNCT
dpc-1945	286	6	bath	bath	NOUN
dpc-1945	286	7	-	-	PUNCT
dpc-1945	286	8	hextall	hextall	NOUN
dpc-1945	286	9	f	f	PROPN
dpc-1945	286	10	,	,	PUNCT
dpc-1945	286	11	perkins	perkins	PROPN
dpc-1945	286	12	w	w	PROPN
dpc-1945	286	13	,	,	PUNCT
dpc-1945	286	14	stanton	stanton	PROPN
dpc-1945	286	15	w	w	PROPN
dpc-1945	286	16	,	,	PUNCT
dpc-1945	286	17	leonardi	leonardi	PROPN
dpc-1945	286	18	-	-	PUNCT
dpc-1945	286	19	bee	bee	PROPN
dpc-1945	286	20	j.	j.	PROPN
dpc-1945	286	21	interventions	intervention	NOUN
dpc-1945	286	22	for	for	ADP
dpc-1945	286	23	non	non	ADJ
dpc-1945	286	24	-	-	ADJ
dpc-1945	286	25	metastatic	metastatic	ADJ
dpc-1945	286	26	squamous	squamous	ADJ
dpc-1945	286	27	cell	cell	NOUN
dpc-1945	286	28	carcinoma	carcinoma	NOUN
dpc-1945	286	29	of	of	ADP
dpc-1945	286	30	the	the	DET
dpc-1945	286	31	skin	skin	NOUN
dpc-1945	286	32	:	:	PUNCT
dpc-1945	286	33	systematic	systematic	ADJ
dpc-1945	286	34	review	review	NOUN
dpc-1945	286	35	and	and	CCONJ
dpc-1945	286	36	pooled	pool	VERB
dpc-1945	286	37	analysis	analysis	NOUN
dpc-1945	286	38	of	of	ADP
dpc-1945	286	39	observational	observational	ADJ
dpc-1945	286	40	studies	study	NOUN
dpc-1945	286	41	.	.	PUNCT
dpc-1945	287	1	bmj	bmj	PROPN
dpc-1945	287	2	.	.	PUNCT
dpc-1945	288	1	2013;347	2013;347	NUM
dpc-1945	288	2	:	:	PUNCT
dpc-1945	288	3	f6153	f6153	VERB
dpc-1945	288	4	.	.	PUNCT
dpc-1945	289	1	doi	doi	NOUN
dpc-1945	289	2	:	:	PUNCT
dpc-1945	289	3	10.1136	10.1136	NUM
dpc-1945	289	4	/	/	SYM
dpc-1945	289	5	bmj.f6153	bmj.f6153	NOUN
dpc-1945	289	6	.	.	PUNCT
dpc-1945	290	1	pmid	pmid	NOUN
dpc-1945	290	2	:	:	PUNCT
dpc-1945	290	3	24191270	24191270	NUM
dpc-1945	290	4	.	.	PUNCT
dpc-1945	291	1	10	10	NUM
dpc-1945	291	2	.	.	PUNCT
dpc-1945	292	1	kim	kim	PROPN
dpc-1945	292	2	jys	jys	PROPN
dpc-1945	292	3	,	,	PUNCT
dpc-1945	292	4	kozlow	kozlow	PROPN
dpc-1945	292	5	jh	jh	PROPN
dpc-1945	292	6	,	,	PUNCT
dpc-1945	292	7	mittal	mittal	PROPN
dpc-1945	292	8	b	b	PROPN
dpc-1945	292	9	,	,	PUNCT
dpc-1945	292	10	et	et	PROPN
dpc-1945	292	11	al	al	PROPN
dpc-1945	292	12	.	.	PUNCT
dpc-1945	293	1	guidelines	guideline	NOUN
dpc-1945	293	2	of	of	ADP
dpc-1945	293	3	care	care	NOUN
dpc-1945	293	4	for	for	ADP
dpc-1945	293	5	the	the	DET
dpc-1945	293	6	management	management	NOUN
dpc-1945	293	7	of	of	ADP
dpc-1945	293	8	cutaneous	cutaneous	ADJ
dpc-1945	293	9	squamous	squamous	ADJ
dpc-1945	293	10	cell	cell	NOUN
dpc-1945	293	11	carcinoma	carcinoma	NOUN
dpc-1945	293	12	.	.	PUNCT
dpc-1945	294	1	j	j	PROPN
dpc-1945	294	2	am	be	AUX
dpc-1945	294	3	acad	acad	ADJ
dpc-1945	294	4	dermatol	dermatol	NOUN
dpc-1945	294	5	.	.	PUNCT
dpc-1945	295	1	2018;78(3):560	2018;78(3):560	PROPN
dpc-1945	295	2	-	-	PUNCT
dpc-1945	295	3	578	578	NUM
dpc-1945	295	4	.	.	PUNCT
dpc-1945	296	1	doi	doi	NOUN
dpc-1945	296	2	:	:	PUNCT
dpc-1945	296	3	10.1016	10.1016	NUM
dpc-1945	296	4	/	/	SYM
dpc-1945	296	5	j.	j.	PROPN
dpc-1945	296	6	jaad.2017.10.007	jaad.2017.10.007	PROPN
dpc-1945	296	7	.	.	PUNCT
dpc-1945	297	1	pmid	pmid	PROPN
dpc-1945	297	2	:	:	PUNCT
dpc-1945	297	3	29331386	29331386	NUM
dpc-1945	297	4	.	.	PUNCT
dpc-1945	298	1	11	11	NUM
dpc-1945	298	2	.	.	PUNCT
dpc-1945	299	1	schmults	schmults	PROPN
dpc-1945	299	2	cd	cd	PROPN
dpc-1945	299	3	,	,	PUNCT
dpc-1945	299	4	karia	karia	PROPN
dpc-1945	299	5	ps	ps	PROPN
dpc-1945	299	6	,	,	PUNCT
dpc-1945	299	7	carter	carter	PROPN
dpc-1945	299	8	jb	jb	PROPN
dpc-1945	299	9	,	,	PUNCT
dpc-1945	299	10	han	han	PROPN
dpc-1945	299	11	j	j	PROPN
dpc-1945	299	12	,	,	PUNCT
dpc-1945	299	13	qureshi	qureshi	PROPN
dpc-1945	299	14	aa	aa	PROPN
dpc-1945	299	15	.	.	PUNCT
dpc-1945	300	1	factors	factor	NOUN
dpc-1945	300	2	predictive	predictive	ADJ
dpc-1945	300	3	of	of	ADP
dpc-1945	300	4	recurrence	recurrence	NOUN
dpc-1945	300	5	and	and	CCONJ
dpc-1945	300	6	death	death	NOUN
dpc-1945	300	7	from	from	ADP
dpc-1945	300	8	cutaneous	cutaneous	ADJ
dpc-1945	300	9	squamous	squamous	ADJ
dpc-1945	300	10	cell	cell	NOUN
dpc-1945	300	11	carcinoma	carcinoma	NOUN
dpc-1945	300	12	:	:	PUNCT
dpc-1945	300	13	a	a	DET
dpc-1945	300	14	10	10	NUM
dpc-1945	300	15	-	-	PUNCT
dpc-1945	300	16	year	year	NOUN
dpc-1945	300	17	,	,	PUNCT
dpc-1945	300	18	single	single	ADJ
dpc-1945	300	19	-	-	PUNCT
dpc-1945	300	20	institution	institution	NOUN
dpc-1945	300	21	cohort	cohort	NOUN
dpc-1945	300	22	study	study	NOUN
dpc-1945	300	23	.	.	PUNCT
dpc-1945	301	1	jama	jama	PROPN
dpc-1945	301	2	dermatol	dermatol	NOUN
dpc-1945	301	3	.	.	PUNCT
dpc-1945	302	1	2013;149(5):541	2013;149(5):541	NUM
dpc-1945	302	2	-	-	SYM
dpc-1945	302	3	7	7	NUM
dpc-1945	302	4	.	.	PUNCT
dpc-1945	302	5	doi	doi	NOUN
dpc-1945	302	6	:	:	PUNCT
dpc-1945	302	7	10.1001	10.1001	NUM
dpc-1945	302	8	/	/	SYM
dpc-1945	302	9	jamadermatol.2013.2139	jamadermatol.2013.2139	PROPN
dpc-1945	302	10	.	.	PUNCT
dpc-1945	303	1	pmid	pmid	NOUN
dpc-1945	303	2	:	:	PUNCT
dpc-1945	303	3	23677079	23677079	NUM
dpc-1945	303	4	.	.	PUNCT
dpc-1945	304	1	12	12	NUM
dpc-1945	304	2	.	.	PUNCT
dpc-1945	305	1	deconti	deconti	PROPN
dpc-1945	305	2	rc	rc	PROPN
dpc-1945	305	3	.	.	PUNCT
dpc-1945	306	1	chemotherapy	chemotherapy	NOUN
dpc-1945	306	2	of	of	ADP
dpc-1945	306	3	squamous	squamous	ADJ
dpc-1945	306	4	cell	cell	NOUN
dpc-1945	306	5	carcinoma	carcinoma	NOUN
dpc-1945	306	6	of	of	ADP
dpc-1945	306	7	the	the	DET
dpc-1945	306	8	skin	skin	NOUN
dpc-1945	306	9	.	.	PUNCT
dpc-1945	307	1	semin	semin	PROPN
dpc-1945	307	2	oncol	oncol	PROPN
dpc-1945	307	3	.	.	PUNCT
dpc-1945	308	1	2012;39(2):145	2012;39(2):145	NUM
dpc-1945	308	2	-	-	SYM
dpc-1945	308	3	9	9	NUM
dpc-1945	308	4	.	.	PUNCT
dpc-1945	308	5	doi	doi	NOUN
dpc-1945	308	6	:	:	PUNCT
dpc-1945	308	7	10.1053	10.1053	NUM
dpc-1945	308	8	/	/	SYM
dpc-1945	308	9	j.seminoncol.2012.01.002	j.seminoncol.2012.01.002	PROPN
dpc-1945	308	10	.	.	PUNCT
dpc-1945	309	1	pmid	pmid	NOUN
dpc-1945	309	2	:	:	PUNCT
dpc-1945	309	3	22484186	22484186	NUM
dpc-1945	309	4	.	.	PUNCT
dpc-1945	310	1	13	13	NUM
dpc-1945	310	2	.	.	X
dpc-1945	311	1	sadek	sadek	PROPN
dpc-1945	311	2	h	h	PROPN
dpc-1945	311	3	,	,	PUNCT
dpc-1945	311	4	azli	azli	NOUN
dpc-1945	311	5	n	n	CCONJ
dpc-1945	311	6	,	,	PUNCT
dpc-1945	311	7	wendling	wendle	VERB
dpc-1945	311	8	jl	jl	NOUN
dpc-1945	311	9	,	,	PUNCT
dpc-1945	311	10	et	et	PROPN
dpc-1945	311	11	al	al	PROPN
dpc-1945	311	12	.	.	PROPN
dpc-1945	312	1	treatment	treatment	NOUN
dpc-1945	312	2	of	of	ADP
dpc-1945	312	3	advanced	advanced	ADJ
dpc-1945	312	4	squamous	squamous	ADJ
dpc-1945	312	5	cell	cell	NOUN
dpc-1945	312	6	carcinoma	carcinoma	NOUN
dpc-1945	312	7	of	of	ADP
dpc-1945	312	8	the	the	DET
dpc-1945	312	9	skin	skin	NOUN
dpc-1945	312	10	with	with	ADP
dpc-1945	312	11	cisplatin	cisplatin	NOUN
dpc-1945	312	12	,	,	PUNCT
dpc-1945	312	13	5	5	NUM
dpc-1945	312	14	-	-	PUNCT
dpc-1945	312	15	fluorouracil	fluorouracil	NOUN
dpc-1945	312	16	,	,	PUNCT
dpc-1945	312	17	and	and	CCONJ
dpc-1945	312	18	bleomycin	bleomycin	PROPN
dpc-1945	312	19	.	.	PUNCT
dpc-1945	313	1	cancer	cancer	NOUN
dpc-1945	313	2	.	.	PUNCT
dpc-1945	314	1	1990;66(8):1692	1990;66(8):1692	NUM
dpc-1945	314	2	-	-	SYM
dpc-1945	314	3	6	6	NUM
dpc-1945	314	4	.	.	PUNCT
dpc-1945	314	5	doi	doi	NOUN
dpc-1945	314	6	:	:	PUNCT
dpc-1945	314	7	10.1002/1097	10.1002/1097	NUM
dpc-1945	314	8	-	-	SYM
dpc-1945	314	9	0142(19901015)66:8<1692::aid	0142(19901015)66:8<1692::aid	NOUN
dpc-1945	314	10	-	-	ADJ
dpc-1945	314	11	cncr2820660807>3.0.co;2	cncr2820660807>3.0.co;2	ADJ
dpc-1945	314	12	-	-	PUNCT
dpc-1945	314	13	y.	y.	NOUN
dpc-1945	314	14	pmid	pmid	PROPN
dpc-1945	314	15	:	:	PUNCT
dpc-1945	314	16	1698529	1698529	NUM
dpc-1945	314	17	.	.	PUNCT
dpc-1945	315	1	14	14	NUM
dpc-1945	315	2	.	.	PUNCT
dpc-1945	316	1	guthrie	guthrie	PROPN
dpc-1945	316	2	th	th	PROPN
dpc-1945	316	3	jr	jr	PROPN
dpc-1945	316	4	,	,	PUNCT
dpc-1945	316	5	porubsky	porubsky	NOUN
dpc-1945	316	6	es	es	PROPN
dpc-1945	316	7	,	,	PUNCT
dpc-1945	316	8	luxenberg	luxenberg	PROPN
dpc-1945	316	9	mn	mn	PROPN
dpc-1945	316	10	,	,	PUNCT
dpc-1945	316	11	shah	shah	PROPN
dpc-1945	316	12	kj	kj	PROPN
dpc-1945	316	13	,	,	PUNCT
dpc-1945	316	14	wurtz	wurtz	PROPN
dpc-1945	316	15	kl	kl	PROPN
dpc-1945	316	16	,	,	PUNCT
dpc-1945	316	17	watson	watson	PROPN
dpc-1945	316	18	pr	pr	PROPN
dpc-1945	316	19	.	.	PUNCT
dpc-1945	317	1	cisplatin	cisplatin	NOUN
dpc-1945	317	2	-	-	PUNCT
dpc-1945	317	3	based	base	VERB
dpc-1945	317	4	chemotherapy	chemotherapy	NOUN
dpc-1945	317	5	in	in	ADP
dpc-1945	317	6	advanced	advanced	ADJ
dpc-1945	317	7	basal	basal	NOUN
dpc-1945	317	8	and	and	CCONJ
dpc-1945	317	9	squamous	squamous	ADJ
dpc-1945	317	10	cell	cell	NOUN
dpc-1945	317	11	carcinomas	carcinoma	NOUN
dpc-1945	317	12	of	of	ADP
dpc-1945	317	13	the	the	DET
dpc-1945	317	14	skin	skin	NOUN
dpc-1945	317	15	:	:	PUNCT
dpc-1945	317	16	results	result	NOUN
dpc-1945	317	17	in	in	ADP
dpc-1945	317	18	28	28	NUM
dpc-1945	317	19	patients	patient	NOUN
dpc-1945	317	20	including	include	VERB
dpc-1945	317	21	13	13	NUM
dpc-1945	317	22	patients	patient	NOUN
dpc-1945	317	23	receiving	receive	VERB
dpc-1945	317	24	multimodality	multimodality	NOUN
dpc-1945	317	25	therapy	therapy	NOUN
dpc-1945	317	26	.	.	PUNCT
dpc-1945	318	1	j	j	PROPN
dpc-1945	318	2	clin	clin	PROPN
dpc-1945	318	3	oncol	oncol	PROPN
dpc-1945	318	4	.	.	PUNCT
dpc-1945	319	1	1990;8(2):342	1990;8(2):342	NUM
dpc-1945	319	2	-	-	SYM
dpc-1945	319	3	6	6	NUM
dpc-1945	319	4	.	.	PUNCT
dpc-1945	319	5	doi	doi	NOUN
dpc-1945	319	6	:	:	PUNCT
dpc-1945	319	7	10.1200	10.1200	NUM
dpc-1945	319	8	/	/	SYM
dpc-1945	319	9	jco.1990.8.2.342	jco.1990.8.2.342	NOUN
dpc-1945	319	10	.	.	PUNCT
dpc-1945	320	1	pmid	pmid	NOUN
dpc-1945	320	2	:	:	PUNCT
dpc-1945	320	3	2405109	2405109	NUM
dpc-1945	320	4	.	.	PUNCT
dpc-1945	321	1	15	15	NUM
dpc-1945	321	2	.	.	PUNCT
dpc-1945	321	3	nottage	nottage	NOUN
dpc-1945	321	4	mk	mk	PROPN
dpc-1945	321	5	,	,	PUNCT
dpc-1945	321	6	lin	lin	PROPN
dpc-1945	321	7	c	c	PROPN
dpc-1945	321	8	,	,	PUNCT
dpc-1945	321	9	hughes	hughes	PROPN
dpc-1945	321	10	bg	bg	PROPN
dpc-1945	321	11	,	,	PUNCT
dpc-1945	321	12	et	et	PROPN
dpc-1945	321	13	al	al	PROPN
dpc-1945	321	14	.	.	PROPN
dpc-1945	321	15	prospective	prospective	ADJ
dpc-1945	321	16	study	study	NOUN
dpc-1945	321	17	of	of	ADP
dpc-1945	321	18	definitive	definitive	ADJ
dpc-1945	321	19	chemoradiation	chemoradiation	NOUN
dpc-1945	321	20	in	in	ADP
dpc-1945	321	21	locally	locally	ADV
dpc-1945	321	22	or	or	CCONJ
dpc-1945	321	23	regionally	regionally	ADV
dpc-1945	321	24	advanced	advanced	ADJ
dpc-1945	321	25	squamous	squamous	ADJ
dpc-1945	321	26	cell	cell	NOUN
dpc-1945	321	27	carcinoma	carcinoma	NOUN
dpc-1945	321	28	of	of	ADP
dpc-1945	321	29	the	the	DET
dpc-1945	321	30	skin	skin	NOUN
dpc-1945	321	31	.	.	PUNCT
dpc-1945	322	1	head	head	NOUN
dpc-1945	322	2	neck	neck	NOUN
dpc-1945	322	3	.	.	PUNCT
dpc-1945	323	1	2017;39(4):679	2017;39(4):679	NUM
dpc-1945	323	2	-	-	PUNCT
dpc-1945	323	3	683	683	NUM
dpc-1945	323	4	.	.	PUNCT
dpc-1945	324	1	doi	doi	NOUN
dpc-1945	324	2	:	:	PUNCT
dpc-1945	324	3	10.1002	10.1002	NUM
dpc-1945	324	4	/	/	SYM
dpc-1945	324	5	hed.24662	hed.24662	PROPN
dpc-1945	324	6	.	.	PUNCT
dpc-1945	325	1	pmid	pmid	NOUN
dpc-1945	325	2	:	:	PUNCT
dpc-1945	325	3	28032670	28032670	NUM
dpc-1945	325	4	.	.	PUNCT
dpc-1945	326	1	16	16	NUM
dpc-1945	326	2	.	.	PUNCT
dpc-1945	327	1	chatelut	chatelut	PROPN
dpc-1945	327	2	e	e	NOUN
dpc-1945	327	3	,	,	PUNCT
dpc-1945	327	4	delord	delord	NOUN
dpc-1945	327	5	jp	jp	NOUN
dpc-1945	327	6	,	,	PUNCT
dpc-1945	327	7	canal	canal	ADJ
dpc-1945	327	8	p.	p.	NOUN
dpc-1945	327	9	toxicity	toxicity	NOUN
dpc-1945	327	10	patterns	pattern	NOUN
dpc-1945	327	11	of	of	ADP
dpc-1945	327	12	cytotoxic	cytotoxic	ADJ
dpc-1945	327	13	drugs	drug	NOUN
dpc-1945	327	14	.	.	PUNCT
dpc-1945	327	15	invest	invest	VERB
dpc-1945	327	16	new	new	ADJ
dpc-1945	327	17	drugs	drug	NOUN
dpc-1945	327	18	.	.	PUNCT
dpc-1945	328	1	2003;21(2):141	2003;21(2):141	NUM
dpc-1945	328	2	-	-	SYM
dpc-1945	328	3	8	8	NUM
dpc-1945	328	4	.	.	PUNCT
dpc-1945	328	5	doi	doi	NOUN
dpc-1945	328	6	:	:	PUNCT
dpc-1945	328	7	10.1023	10.1023	NUM
dpc-1945	328	8	/	/	SYM
dpc-1945	328	9	a:1023565227808	a:1023565227808	PROPN
dpc-1945	328	10	.	.	PUNCT
dpc-1945	329	1	pmid	pmid	NOUN
dpc-1945	329	2	:	:	PUNCT
dpc-1945	329	3	12889735	12889735	NUM
dpc-1945	329	4	.	.	PUNCT
dpc-1945	330	1	17	17	NUM
dpc-1945	330	2	.	.	PUNCT
dpc-1945	331	1	galbiati	galbiati	PROPN
dpc-1945	331	2	d	d	PROPN
dpc-1945	331	3	,	,	PUNCT
dpc-1945	331	4	cavalieri	cavalieri	PROPN
dpc-1945	331	5	s	s	PROPN
dpc-1945	331	6	,	,	PUNCT
dpc-1945	331	7	alfieri	alfieri	PROPN
dpc-1945	331	8	s	s	PROPN
dpc-1945	331	9	,	,	PUNCT
dpc-1945	331	10	et	et	PROPN
dpc-1945	331	11	al	al	PROPN
dpc-1945	331	12	.	.	PUNCT
dpc-1945	331	13	activity	activity	NOUN
dpc-1945	331	14	of	of	ADP
dpc-1945	331	15	platinum	platinum	NOUN
dpc-1945	331	16	and	and	CCONJ
dpc-1945	331	17	cetuximab	cetuximab	NOUN
dpc-1945	331	18	in	in	ADP
dpc-1945	331	19	cutaneous	cutaneous	ADJ
dpc-1945	331	20	squamous	squamous	ADJ
dpc-1945	331	21	cell	cell	NOUN
dpc-1945	331	22	cancer	cancer	NOUN
dpc-1945	331	23	not	not	PART
dpc-1945	331	24	amenable	amenable	ADJ
dpc-1945	331	25	to	to	PART
dpc-1945	331	26	curative	curative	ADJ
dpc-1945	331	27	treatment	treatment	NOUN
dpc-1945	331	28	.	.	PUNCT
dpc-1945	332	1	drugs	drug	NOUN
dpc-1945	332	2	context	context	VERB
dpc-1945	332	3	.	.	PUNCT
dpc-1945	333	1	2019;8:212611	2019;8:212611	NOUN
dpc-1945	333	2	.	.	PUNCT
dpc-1945	334	1	doi	doi	NOUN
dpc-1945	334	2	:	:	PUNCT
dpc-1945	334	3	10.7573/	10.7573/	NUM
dpc-1945	334	4	dic.212611	dic.212611	NOUN
dpc-1945	334	5	.	.	PUNCT
dpc-1945	335	1	pmid	pmid	NOUN
dpc-1945	335	2	:	:	PUNCT
dpc-1945	335	3	32158481	32158481	NUM
dpc-1945	335	4	.	.	PUNCT
dpc-1945	336	1	18	18	NUM
dpc-1945	336	2	.	.	PUNCT
dpc-1945	337	1	sabbah	sabbah	PROPN
dpc-1945	337	2	da	da	PROPN
dpc-1945	337	3	,	,	PUNCT
dpc-1945	337	4	hajjo	hajjo	NOUN
dpc-1945	337	5	r	r	NOUN
dpc-1945	337	6	,	,	PUNCT
dpc-1945	337	7	sweidan	sweidan	PROPN
dpc-1945	337	8	k.	k.	PROPN
dpc-1945	337	9	review	review	PROPN
dpc-1945	337	10	on	on	ADP
dpc-1945	337	11	epidermal	epidermal	ADJ
dpc-1945	337	12	growth	growth	NOUN
dpc-1945	337	13	factor	factor	NOUN
dpc-1945	337	14	receptor	receptor	NOUN
dpc-1945	337	15	(	(	PUNCT
dpc-1945	337	16	egfr	egfr	ADJ
dpc-1945	337	17	)	)	PUNCT
dpc-1945	337	18	structure	structure	NOUN
dpc-1945	337	19	,	,	PUNCT
dpc-1945	337	20	signaling	signal	VERB
dpc-1945	337	21	pathways	pathway	NOUN
dpc-1945	337	22	,	,	PUNCT
dpc-1945	337	23	interactions	interaction	NOUN
dpc-1945	337	24	,	,	PUNCT
dpc-1945	337	25	and	and	CCONJ
dpc-1945	337	26	recent	recent	ADJ
dpc-1945	337	27	updates	update	NOUN
dpc-1945	337	28	of	of	ADP
dpc-1945	337	29	egfr	egfr	ADJ
dpc-1945	337	30	inhibitors	inhibitor	NOUN
dpc-1945	337	31	.	.	PUNCT
dpc-1945	338	1	curr	curr	PROPN
dpc-1945	338	2	top	top	ADJ
dpc-1945	338	3	med	med	ADJ
dpc-1945	338	4	chem	chem	NOUN
dpc-1945	338	5	.	.	PUNCT
dpc-1945	339	1	2020;20(10):815	2020;20(10):815	NUM
dpc-1945	339	2	-	-	PUNCT
dpc-1945	339	3	834	834	NUM
dpc-1945	339	4	.	.	PUNCT
dpc-1945	340	1	doi	doi	NOUN
dpc-1945	340	2	:	:	PUNCT
dpc-1945	340	3	10.2174/156802662066620	10.2174/156802662066620	NUM
dpc-1945	340	4	0303123102	0303123102	NUM
dpc-1945	340	5	.	.	PUNCT
dpc-1945	341	1	pmid	pmid	NOUN
dpc-1945	341	2	:	:	PUNCT
dpc-1945	341	3	32124699	32124699	NUM
dpc-1945	341	4	.	.	PUNCT
dpc-1945	342	1	19	19	NUM
dpc-1945	342	2	.	.	PUNCT
dpc-1945	343	1	chen	chen	PROPN
dpc-1945	343	2	j	j	PROPN
dpc-1945	343	3	,	,	PUNCT
dpc-1945	343	4	zeng	zeng	PROPN
dpc-1945	343	5	f	f	PROPN
dpc-1945	343	6	,	,	PUNCT
dpc-1945	343	7	forrester	forrester	PROPN
dpc-1945	343	8	sj	sj	PROPN
dpc-1945	343	9	,	,	PUNCT
dpc-1945	343	10	eguchi	eguchi	NOUN
dpc-1945	343	11	s	s	PROPN
dpc-1945	343	12	,	,	PUNCT
dpc-1945	343	13	zhang	zhang	PROPN
dpc-1945	343	14	mz	mz	PROPN
dpc-1945	343	15	,	,	PUNCT
dpc-1945	343	16	harris	harris	PROPN
dpc-1945	343	17	rc	rc	PROPN
dpc-1945	343	18	.	.	PUNCT
dpc-1945	343	19	expression	expression	NOUN
dpc-1945	343	20	and	and	CCONJ
dpc-1945	343	21	function	function	NOUN
dpc-1945	343	22	of	of	ADP
dpc-1945	343	23	the	the	DET
dpc-1945	343	24	epidermal	epidermal	ADJ
dpc-1945	343	25	growth	growth	NOUN
dpc-1945	343	26	factor	factor	NOUN
dpc-1945	343	27	receptor	receptor	NOUN
dpc-1945	343	28	in	in	ADP
dpc-1945	343	29	physiology	physiology	NOUN
dpc-1945	343	30	and	and	CCONJ
dpc-1945	343	31	disease	disease	NOUN
dpc-1945	343	32	.	.	PUNCT
dpc-1945	344	1	physiol	physiol	PROPN
dpc-1945	344	2	rev	rev	VERB
dpc-1945	344	3	.	.	PUNCT
dpc-1945	345	1	2016;96(3):1025	2016;96(3):1025	NUM
dpc-1945	345	2	-	-	SYM
dpc-1945	345	3	1069	1069	NUM
dpc-1945	345	4	.	.	PUNCT
dpc-1945	346	1	doi	doi	NOUN
dpc-1945	346	2	:	:	PUNCT
dpc-1945	346	3	10.1152	10.1152	NUM
dpc-1945	346	4	/	/	SYM
dpc-1945	346	5	physrev.00030.2015	physrev.00030.2015	NOUN
dpc-1945	346	6	.	.	PUNCT
dpc-1945	347	1	pmid	pmid	NOUN
dpc-1945	347	2	:	:	PUNCT
dpc-1945	347	3	33003261	33003261	NUM
dpc-1945	347	4	.	.	PUNCT
dpc-1945	348	1	20	20	NUM
dpc-1945	348	2	.	.	X
dpc-1945	348	3	oda	oda	PROPN
dpc-1945	349	1	k	k	PROPN
dpc-1945	349	2	,	,	PUNCT
dpc-1945	349	3	matsuoka	matsuoka	VERB
dpc-1945	349	4	y	y	PROPN
dpc-1945	349	5	,	,	PUNCT
dpc-1945	349	6	funahashi	funahashi	PROPN
dpc-1945	349	7	a	a	PRON
dpc-1945	349	8	,	,	PUNCT
dpc-1945	349	9	kitano	kitano	PROPN
dpc-1945	349	10	h.	h.	PROPN
dpc-1945	350	1	a	a	DET
dpc-1945	350	2	comprehensive	comprehensive	ADJ
dpc-1945	350	3	pathway	pathway	NOUN
dpc-1945	350	4	map	map	NOUN
dpc-1945	350	5	of	of	ADP
dpc-1945	350	6	epidermal	epidermal	ADJ
dpc-1945	350	7	growth	growth	NOUN
dpc-1945	350	8	factor	factor	NOUN
dpc-1945	350	9	receptor	receptor	NOUN
dpc-1945	350	10	signaling	signal	VERB
dpc-1945	350	11	.	.	PUNCT
dpc-1945	351	1	mol	mol	ADP
dpc-1945	351	2	syst	syst	PROPN
dpc-1945	351	3	biol	biol	PROPN
dpc-1945	351	4	.	.	PUNCT
dpc-1945	352	1	2005;1:2005.0010	2005;1:2005.0010	NUM
dpc-1945	352	2	.	.	PUNCT
dpc-1945	353	1	doi	doi	NOUN
dpc-1945	353	2	:	:	PUNCT
dpc-1945	353	3	10.1038	10.1038	NUM
dpc-1945	353	4	/	/	SYM
dpc-1945	353	5	msb4100014	msb4100014	NOUN
dpc-1945	353	6	.	.	PUNCT
dpc-1945	354	1	pmid	pmid	NOUN
dpc-1945	354	2	:	:	PUNCT
dpc-1945	354	3	16729045	16729045	NUM
dpc-1945	354	4	.	.	PUNCT
dpc-1945	355	1	21	21	NUM
dpc-1945	355	2	.	.	PUNCT
dpc-1945	356	1	uribe	uribe	PROPN
dpc-1945	356	2	p	p	PROPN
dpc-1945	356	3	,	,	PUNCT
dpc-1945	356	4	gonzalez	gonzalez	PROPN
dpc-1945	356	5	s.	s.	PROPN
dpc-1945	356	6	epidermal	epidermal	ADJ
dpc-1945	356	7	growth	growth	NOUN
dpc-1945	356	8	factor	factor	NOUN
dpc-1945	356	9	receptor	receptor	NOUN
dpc-1945	356	10	(	(	PUNCT
dpc-1945	356	11	egfr	egfr	X
dpc-1945	356	12	)	)	PUNCT
dpc-1945	356	13	and	and	CCONJ
dpc-1945	356	14	squamous	squamous	ADJ
dpc-1945	356	15	cell	cell	NOUN
dpc-1945	356	16	carcinoma	carcinoma	NOUN
dpc-1945	356	17	of	of	ADP
dpc-1945	356	18	the	the	DET
dpc-1945	356	19	skin	skin	NOUN
dpc-1945	356	20	:	:	PUNCT
dpc-1945	356	21	molecular	molecular	ADJ
dpc-1945	356	22	bases	basis	NOUN
dpc-1945	356	23	for	for	ADP
dpc-1945	356	24	egfr	egfr	ADV
dpc-1945	356	25	-	-	PUNCT
dpc-1945	356	26	targeted	target	VERB
dpc-1945	356	27	therapy	therapy	NOUN
dpc-1945	356	28	.	.	PUNCT
dpc-1945	357	1	pathol	pathol	VERB
dpc-1945	357	2	res	re	NOUN
dpc-1945	357	3	pract	pract	NOUN
dpc-1945	357	4	.	.	PUNCT
dpc-1945	358	1	2011;207(6):337	2011;207(6):337	NUM
dpc-1945	358	2	-	-	SYM
dpc-1945	358	3	42	42	NUM
dpc-1945	358	4	.	.	PUNCT
dpc-1945	359	1	doi	doi	NOUN
dpc-1945	359	2	:	:	PUNCT
dpc-1945	359	3	10.1016	10.1016	NUM
dpc-1945	359	4	/	/	SYM
dpc-1945	359	5	j.prp.2011.03.002	j.prp.2011.03.002	NOUN
dpc-1945	359	6	.	.	PUNCT
dpc-1945	360	1	pmid	pmid	NOUN
dpc-1945	360	2	:	:	PUNCT
dpc-1945	360	3	21531084	21531084	NUM
dpc-1945	360	4	.	.	PUNCT
dpc-1945	361	1	22	22	NUM
dpc-1945	361	2	.	.	PUNCT
dpc-1945	362	1	shimizu	shimizu	PROPN
dpc-1945	362	2	t	t	PROPN
dpc-1945	362	3	,	,	PUNCT
dpc-1945	362	4	izumi	izumi	PROPN
dpc-1945	362	5	h	h	PROPN
dpc-1945	362	6	,	,	PUNCT
dpc-1945	362	7	oga	oga	VERB
dpc-1945	362	8	a	a	PRON
dpc-1945	362	9	,	,	PUNCT
dpc-1945	362	10	et	et	PROPN
dpc-1945	362	11	al	al	PROPN
dpc-1945	362	12	.	.	PROPN
dpc-1945	363	1	epidermal	epidermal	ADJ
dpc-1945	363	2	growth	growth	NOUN
dpc-1945	363	3	factor	factor	NOUN
dpc-1945	363	4	receptor	receptor	NOUN
dpc-1945	363	5	overexpression	overexpression	NOUN
dpc-1945	363	6	and	and	CCONJ
dpc-1945	363	7	genetic	genetic	ADJ
dpc-1945	363	8	aberrations	aberration	NOUN
dpc-1945	363	9	in	in	ADP
dpc-1945	363	10	metastatic	metastatic	ADJ
dpc-1945	363	11	squamous	squamous	ADJ
dpc-1945	363	12	-	-	PUNCT
dpc-1945	363	13	cell	cell	NOUN
dpc-1945	363	14	carcinoma	carcinoma	NOUN
dpc-1945	363	15	of	of	ADP
dpc-1945	363	16	the	the	DET
dpc-1945	363	17	skin	skin	NOUN
dpc-1945	363	18	.	.	PUNCT
dpc-1945	364	1	dermatology	dermatology	NOUN
dpc-1945	364	2	.	.	PUNCT
dpc-1945	365	1	2001;202(3):2036	2001;202(3):2036	PROPN
dpc-1945	365	2	.	.	PUNCT
dpc-1945	366	1	doi	doi	PROPN
dpc-1945	366	2	:	:	PUNCT
dpc-1945	366	3	10.1159/000051637	10.1159/000051637	NUM
dpc-1945	366	4	.	.	PUNCT
dpc-1945	367	1	pmid	pmid	NOUN
dpc-1945	367	2	:	:	PUNCT
dpc-1945	367	3	11385224	11385224	NUM
dpc-1945	367	4	.	.	PUNCT
dpc-1945	368	1	23	23	NUM
dpc-1945	368	2	.	.	PUNCT
dpc-1945	369	1	maubec	maubec	PROPN
dpc-1945	369	2	e	e	PROPN
dpc-1945	369	3	,	,	PUNCT
dpc-1945	369	4	petrow	petrow	VERB
dpc-1945	369	5	p	p	NOUN
dpc-1945	369	6	,	,	PUNCT
dpc-1945	369	7	scheer	scheer	PROPN
dpc-1945	369	8	-	-	PUNCT
dpc-1945	369	9	senyarich	senyarich	NOUN
dpc-1945	369	10	i	i	PROPN
dpc-1945	369	11	,	,	PUNCT
dpc-1945	369	12	et	et	PROPN
dpc-1945	369	13	al	al	PROPN
dpc-1945	369	14	.	.	PROPN
dpc-1945	369	15	phase	phase	PROPN
dpc-1945	369	16	ii	ii	PROPN
dpc-1945	369	17	study	study	NOUN
dpc-1945	369	18	of	of	ADP
dpc-1945	369	19	cetuximab	cetuximab	NOUN
dpc-1945	369	20	as	as	ADP
dpc-1945	369	21	first	first	ADJ
dpc-1945	369	22	-	-	PUNCT
dpc-1945	369	23	line	line	NOUN
dpc-1945	369	24	single	single	ADJ
dpc-1945	369	25	-	-	PUNCT
dpc-1945	369	26	drug	drug	NOUN
dpc-1945	369	27	therapy	therapy	NOUN
dpc-1945	369	28	in	in	ADP
dpc-1945	369	29	patients	patient	NOUN
dpc-1945	369	30	with	with	ADP
dpc-1945	369	31	unresectable	unresectable	ADJ
dpc-1945	369	32	squamous	squamous	ADJ
dpc-1945	369	33	cell	cell	NOUN
dpc-1945	369	34	carcinoma	carcinoma	NOUN
dpc-1945	369	35	of	of	ADP
dpc-1945	369	36	the	the	DET
dpc-1945	369	37	skin	skin	NOUN
dpc-1945	369	38	.	.	PUNCT
dpc-1945	370	1	j	j	PROPN
dpc-1945	370	2	clin	clin	PROPN
dpc-1945	370	3	oncol	oncol	PROPN
dpc-1945	370	4	.	.	PUNCT
dpc-1945	371	1	2011;29(25):3419	2011;29(25):3419	NUM
dpc-1945	371	2	-	-	SYM
dpc-1945	371	3	26	26	NUM
dpc-1945	372	1	.	.	PUNCT
dpc-1945	372	2	doi	doi	NOUN
dpc-1945	372	3	:	:	PUNCT
dpc-1945	372	4	10.1200	10.1200	NUM
dpc-1945	372	5	/	/	SYM
dpc-1945	372	6	jco.2010.34.1735	jco.2010.34.1735	PROPN
dpc-1945	372	7	.	.	PUNCT
dpc-1945	373	1	pmid	pmid	PROPN
dpc-1945	373	2	:	:	PUNCT
dpc-1945	373	3	21810686	21810686	NUM
dpc-1945	373	4	.	.	PUNCT
dpc-1945	374	1	24	24	NUM
dpc-1945	374	2	.	.	PUNCT
dpc-1945	375	1	montaudié	montaudié	PROPN
dpc-1945	375	2	h	h	PROPN
dpc-1945	375	3	,	,	PUNCT
dpc-1945	375	4	viotti	viotti	PROPN
dpc-1945	375	5	j	j	PROPN
dpc-1945	375	6	,	,	PUNCT
dpc-1945	375	7	combemale	combemale	NOUN
dpc-1945	375	8	p	p	X
dpc-1945	375	9	,	,	PUNCT
dpc-1945	375	10	et	et	PROPN
dpc-1945	375	11	al	al	PROPN
dpc-1945	375	12	.	.	PROPN
dpc-1945	375	13	cetuximab	cetuximab	NOUN
dpc-1945	375	14	is	be	AUX
dpc-1945	375	15	efficient	efficient	ADJ
dpc-1945	375	16	and	and	CCONJ
dpc-1945	375	17	safe	safe	ADJ
dpc-1945	375	18	in	in	ADP
dpc-1945	375	19	patients	patient	NOUN
dpc-1945	375	20	with	with	ADP
dpc-1945	375	21	advanced	advanced	ADJ
dpc-1945	375	22	cutaneous	cutaneous	ADJ
dpc-1945	375	23	squamous	squamous	ADJ
dpc-1945	375	24	cell	cell	NOUN
dpc-1945	375	25	carcinoma	carcinoma	NOUN
dpc-1945	375	26	:	:	PUNCT
dpc-1945	375	27	a	a	DET
dpc-1945	375	28	retrospective	retrospective	ADJ
dpc-1945	375	29	,	,	PUNCT
dpc-1945	375	30	multicentre	multicentre	NOUN
dpc-1945	375	31	study	study	NOUN
dpc-1945	375	32	.	.	PUNCT
dpc-1945	376	1	oncotarget	oncotarget	NOUN
dpc-1945	376	2	.	.	PUNCT
dpc-1945	377	1	2020;11(4):378385	2020;11(4):378385	NUM
dpc-1945	377	2	.	.	PUNCT
dpc-1945	378	1	doi	doi	PROPN
dpc-1945	378	2	:	:	PUNCT
dpc-1945	378	3	10.18632	10.18632	NUM
dpc-1945	378	4	/	/	SYM
dpc-1945	378	5	oncotarget.27434	oncotarget.27434	PROPN
dpc-1945	378	6	.	.	PUNCT
dpc-1945	378	7	pmid	pmid	NOUN
dpc-1945	378	8	:	:	PUNCT
dpc-1945	378	9	32064041	32064041	NUM
dpc-1945	378	10	.	.	PUNCT
dpc-1945	379	1	25	25	NUM
dpc-1945	379	2	.	.	PUNCT
dpc-1945	379	3	foote	foote	PROPN
dpc-1945	379	4	mc	mc	PROPN
dpc-1945	379	5	,	,	PUNCT
dpc-1945	379	6	mcgrath	mcgrath	PROPN
dpc-1945	379	7	m	m	PROPN
dpc-1945	379	8	,	,	PUNCT
dpc-1945	379	9	guminski	guminski	PROPN
dpc-1945	379	10	a	a	ADV
dpc-1945	379	11	,	,	PUNCT
dpc-1945	379	12	et	et	PROPN
dpc-1945	379	13	al	al	PROPN
dpc-1945	379	14	.	.	PROPN
dpc-1945	379	15	phase	phase	PROPN
dpc-1945	379	16	ii	ii	PROPN
dpc-1945	379	17	study	study	NOUN
dpc-1945	379	18	of	of	ADP
dpc-1945	379	19	single	single	ADJ
dpc-1945	379	20	-	-	PUNCT
dpc-1945	379	21	agent	agent	NOUN
dpc-1945	379	22	panitumumab	panitumumab	NOUN
dpc-1945	379	23	in	in	ADP
dpc-1945	379	24	patients	patient	NOUN
dpc-1945	379	25	with	with	ADP
dpc-1945	379	26	incurable	incurable	ADJ
dpc-1945	379	27	cutaneous	cutaneous	ADJ
dpc-1945	379	28	squamous	squamous	ADJ
dpc-1945	379	29	cell	cell	NOUN
dpc-1945	379	30	carcinoma	carcinoma	NOUN
dpc-1945	379	31	.	.	PUNCT
dpc-1945	380	1	ann	ann	PROPN
dpc-1945	380	2	oncol	oncol	PROPN
dpc-1945	380	3	.	.	PUNCT
dpc-1945	381	1	2014;25(10):2047	2014;25(10):2047	NUM
dpc-1945	381	2	-	-	SYM
dpc-1945	381	3	2052	2052	NUM
dpc-1945	381	4	.	.	PUNCT
dpc-1945	382	1	doi	doi	NOUN
dpc-1945	382	2	:	:	PUNCT
dpc-1945	382	3	10.1093	10.1093	NUM
dpc-1945	382	4	/	/	SYM
dpc-1945	382	5	annonc	annonc	ADJ
dpc-1945	382	6	/	/	SYM
dpc-1945	382	7	mdu368	mdu368	PROPN
dpc-1945	382	8	.	.	PUNCT
dpc-1945	383	1	pmid	pmid	NOUN
dpc-1945	383	2	:	:	PUNCT
dpc-1945	383	3	25091317	25091317	NUM
dpc-1945	383	4	.	.	PUNCT
dpc-1945	384	1	26	26	NUM
dpc-1945	384	2	.	.	PUNCT
dpc-1945	385	1	william	william	PROPN
dpc-1945	385	2	wn	wn	PROPN
dpc-1945	385	3	jr	jr	PROPN
dpc-1945	385	4	,	,	PUNCT
dpc-1945	385	5	feng	feng	PROPN
dpc-1945	385	6	l	l	PROPN
dpc-1945	385	7	,	,	PUNCT
dpc-1945	385	8	ferrarotto	ferrarotto	ADJ
dpc-1945	385	9	r	r	NOUN
dpc-1945	385	10	,	,	PUNCT
dpc-1945	385	11	et	et	PROPN
dpc-1945	385	12	al	al	PROPN
dpc-1945	385	13	.	.	PUNCT
dpc-1945	385	14	gefitinib	gefitinib	NOUN
dpc-1945	385	15	for	for	ADP
dpc-1945	385	16	patients	patient	NOUN
dpc-1945	385	17	with	with	ADP
dpc-1945	385	18	incurable	incurable	ADJ
dpc-1945	385	19	cutaneous	cutaneous	ADJ
dpc-1945	385	20	squamous	squamous	ADJ
dpc-1945	385	21	cell	cell	NOUN
dpc-1945	385	22	carcinoma	carcinoma	NOUN
dpc-1945	385	23	:	:	PUNCT
dpc-1945	385	24	a	a	DET
dpc-1945	385	25	single	single	ADJ
dpc-1945	385	26	-	-	PUNCT
dpc-1945	385	27	arm	arm	NOUN
dpc-1945	385	28	phase	phase	NOUN
dpc-1945	385	29	ii	ii	NOUN
dpc-1945	385	30	clinical	clinical	ADJ
dpc-1945	385	31	trial	trial	NOUN
dpc-1945	385	32	.	.	PUNCT
dpc-1945	386	1	j	j	PROPN
dpc-1945	386	2	am	be	AUX
dpc-1945	386	3	acad	acad	ADJ
dpc-1945	386	4	dermatol	dermatol	NOUN
dpc-1945	386	5	.	.	PUNCT
dpc-1945	387	1	2017;77(6):11101113.e2	2017;77(6):11101113.e2	NUM
dpc-1945	387	2	.	.	PUNCT
dpc-1945	388	1	doi	doi	NOUN
dpc-1945	388	2	:	:	PUNCT
dpc-1945	388	3	10.1016	10.1016	NUM
dpc-1945	388	4	/	/	SYM
dpc-1945	388	5	j.jaad.2017.07.048	j.jaad.2017.07.048	PROPN
dpc-1945	388	6	.	.	PUNCT
dpc-1945	389	1	pmid	pmid	NOUN
dpc-1945	389	2	:	:	PUNCT
dpc-1945	389	3	28964539	28964539	NUM
dpc-1945	389	4	.	.	PUNCT
dpc-1945	390	1	27	27	NUM
dpc-1945	390	2	.	.	PUNCT
dpc-1945	390	3	lewis	lewis	PROPN
dpc-1945	390	4	cm	cm	PROPN
dpc-1945	390	5	,	,	PUNCT
dpc-1945	390	6	glisson	glisson	NOUN
dpc-1945	390	7	bs	bs	PROPN
dpc-1945	390	8	,	,	PUNCT
dpc-1945	390	9	feng	feng	PROPN
dpc-1945	390	10	l	l	PROPN
dpc-1945	390	11	,	,	PUNCT
dpc-1945	390	12	et	et	PROPN
dpc-1945	390	13	al	al	PROPN
dpc-1945	390	14	.	.	PUNCT
dpc-1945	391	1	a	a	DET
dpc-1945	391	2	phase	phase	NOUN
dpc-1945	391	3	ii	ii	NOUN
dpc-1945	391	4	study	study	NOUN
dpc-1945	391	5	of	of	ADP
dpc-1945	391	6	gefitinib	gefitinib	NOUN
dpc-1945	391	7	for	for	ADP
dpc-1945	391	8	aggressive	aggressive	ADJ
dpc-1945	391	9	cutaneous	cutaneous	ADJ
dpc-1945	391	10	squamous	squamous	ADJ
dpc-1945	391	11	cell	cell	NOUN
dpc-1945	391	12	carcinoma	carcinoma	NOUN
dpc-1945	391	13	of	of	ADP
dpc-1945	391	14	the	the	DET
dpc-1945	391	15	head	head	NOUN
dpc-1945	391	16	and	and	CCONJ
dpc-1945	391	17	neck	neck	NOUN
dpc-1945	391	18	.	.	PUNCT
dpc-1945	392	1	clin	clin	PROPN
dpc-1945	392	2	cancer	cancer	NOUN
dpc-1945	392	3	res	re	NOUN
dpc-1945	392	4	.	.	PUNCT
dpc-1945	393	1	2012;18(5):1435	2012;18(5):1435	NUM
dpc-1945	393	2	-	-	SYM
dpc-1945	393	3	46	46	NUM
dpc-1945	393	4	.	.	PUNCT
dpc-1945	394	1	doi	doi	NOUN
dpc-1945	394	2	:	:	PUNCT
dpc-1945	394	3	10.1158/10780432.ccr-11	10.1158/10780432.ccr-11	NUM
dpc-1945	394	4	-	-	SYM
dpc-1945	394	5	1951	1951	NUM
dpc-1945	394	6	.	.	PUNCT
dpc-1945	395	1	pmid	pmid	NOUN
dpc-1945	395	2	:	:	PUNCT
dpc-1945	395	3	22261807	22261807	NUM
dpc-1945	395	4	10	10	NUM
dpc-1945	395	5	review	review	NOUN
dpc-1945	395	6	|	|	ADV
dpc-1945	395	7	dermatol	dermatol	ADJ
dpc-1945	395	8	pract	pract	NOUN
dpc-1945	395	9	concept	concept	NOUN
dpc-1945	395	10	.	.	PUNCT
dpc-1945	396	1	2021	2021	NUM
dpc-1945	396	2	;	;	PUNCT
dpc-1945	397	1	11(s2	11(s2	NUM
dpc-1945	397	2	):	):	PUNCT
dpc-1945	397	3	e2021169s	e2021169s	PROPN
dpc-1945	397	4	28	28	NUM
dpc-1945	397	5	.	.	PUNCT
dpc-1945	398	1	gold	gold	PROPN
dpc-1945	398	2	ka	ka	PROPN
dpc-1945	398	3	,	,	PUNCT
dpc-1945	398	4	kies	kies	PROPN
dpc-1945	398	5	ms	ms	PROPN
dpc-1945	398	6	,	,	PUNCT
dpc-1945	398	7	william	william	PROPN
dpc-1945	398	8	wn	wn	PROPN
dpc-1945	398	9	jr	jr	PROPN
dpc-1945	398	10	,	,	PUNCT
dpc-1945	398	11	johnson	johnson	PROPN
dpc-1945	398	12	fm	fm	PROPN
dpc-1945	398	13	,	,	PUNCT
dpc-1945	398	14	lee	lee	PROPN
dpc-1945	398	15	jj	jj	PROPN
dpc-1945	398	16	,	,	PUNCT
dpc-1945	398	17	glisson	glisson	NOUN
dpc-1945	398	18	bs	bs	PROPN
dpc-1945	398	19	.	.	PUNCT
dpc-1945	398	20	erlotinib	erlotinib	PROPN
dpc-1945	398	21	in	in	ADP
dpc-1945	398	22	the	the	DET
dpc-1945	398	23	treatment	treatment	NOUN
dpc-1945	398	24	of	of	ADP
dpc-1945	398	25	recurrent	recurrent	ADJ
dpc-1945	398	26	or	or	CCONJ
dpc-1945	398	27	metastatic	metastatic	ADJ
dpc-1945	398	28	cutaneous	cutaneous	ADJ
dpc-1945	398	29	squamous	squamous	ADJ
dpc-1945	398	30	cell	cell	NOUN
dpc-1945	398	31	carcinoma	carcinoma	NOUN
dpc-1945	398	32	:	:	PUNCT
dpc-1945	398	33	a	a	DET
dpc-1945	398	34	single	single	ADJ
dpc-1945	398	35	-	-	PUNCT
dpc-1945	398	36	arm	arm	NOUN
dpc-1945	398	37	phase	phase	NOUN
dpc-1945	398	38	2	2	NUM
dpc-1945	398	39	clinical	clinical	ADJ
dpc-1945	398	40	trial	trial	NOUN
dpc-1945	398	41	.	.	PUNCT
dpc-1945	399	1	cancer	cancer	NOUN
dpc-1945	399	2	.	.	PUNCT
dpc-1945	400	1	2018;124(10):2169	2018;124(10):2169	X
dpc-1945	400	2	-	-	SYM
dpc-1945	400	3	2173	2173	NUM
dpc-1945	400	4	.	.	PUNCT
dpc-1945	401	1	doi	doi	NOUN
dpc-1945	401	2	:	:	PUNCT
dpc-1945	401	3	10.1002	10.1002	NUM
dpc-1945	401	4	/	/	SYM
dpc-1945	401	5	cncr.31346	cncr.31346	PROPN
dpc-1945	401	6	.	.	PUNCT
dpc-1945	402	1	pmid	pmid	NOUN
dpc-1945	402	2	:	:	PUNCT
dpc-1945	402	3	29579331	29579331	NUM
dpc-1945	402	4	;	;	PUNCT
dpc-1945	402	5	pmcid	pmcid	ADJ
dpc-1945	402	6	:	:	PUNCT
dpc-1945	402	7	pmc5935588	pmc5935588	NOUN
dpc-1945	402	8	.	.	PUNCT
dpc-1945	403	1	29	29	NUM
dpc-1945	403	2	.	.	PUNCT
dpc-1945	404	1	heath	heath	PROPN
dpc-1945	404	2	ch	ch	PROPN
dpc-1945	404	3	,	,	PUNCT
dpc-1945	404	4	deep	deep	ADJ
dpc-1945	404	5	nl	nl	PROPN
dpc-1945	404	6	,	,	PUNCT
dpc-1945	404	7	nabell	nabell	PROPN
dpc-1945	404	8	l	l	NOUN
dpc-1945	404	9	,	,	PUNCT
dpc-1945	404	10	et	et	PROPN
dpc-1945	404	11	al	al	PROPN
dpc-1945	404	12	.	.	PROPN
dpc-1945	404	13	phase	phase	NOUN
dpc-1945	404	14	1	1	NUM
dpc-1945	404	15	study	study	NOUN
dpc-1945	404	16	of	of	ADP
dpc-1945	404	17	erlotinib	erlotinib	NOUN
dpc-1945	404	18	plus	plus	CCONJ
dpc-1945	404	19	radiation	radiation	NOUN
dpc-1945	404	20	therapy	therapy	NOUN
dpc-1945	404	21	in	in	ADP
dpc-1945	404	22	patients	patient	NOUN
dpc-1945	404	23	with	with	ADP
dpc-1945	404	24	advanced	advanced	ADJ
dpc-1945	404	25	cutaneous	cutaneous	ADJ
dpc-1945	404	26	squamous	squamous	ADJ
dpc-1945	404	27	cell	cell	NOUN
dpc-1945	404	28	carcinoma	carcinoma	NOUN
dpc-1945	404	29	.	.	PUNCT
dpc-1945	405	1	int	int	NOUN
dpc-1945	405	2	j	j	PROPN
dpc-1945	405	3	radiat	radiat	PROPN
dpc-1945	405	4	oncol	oncol	ADJ
dpc-1945	405	5	biol	biol	PROPN
dpc-1945	405	6	phys	phy	NOUN
dpc-1945	405	7	.	.	PUNCT
dpc-1945	406	1	2013;85(5):1275	2013;85(5):1275	NUM
dpc-1945	406	2	-	-	SYM
dpc-1945	406	3	81	81	NUM
dpc-1945	406	4	.	.	PUNCT
dpc-1945	407	1	doi	doi	NOUN
dpc-1945	407	2	:	:	PUNCT
dpc-1945	407	3	10.1016	10.1016	NUM
dpc-1945	407	4	/	/	SYM
dpc-1945	407	5	j.ijrobp.2012.09.030	j.ijrobp.2012.09.030	PROPN
dpc-1945	407	6	.	.	PUNCT
dpc-1945	408	1	pmid	pmid	NOUN
dpc-1945	408	2	:	:	PUNCT
dpc-1945	408	3	23182701	23182701	NUM
dpc-1945	408	4	.	.	PUNCT
dpc-1945	409	1	30	30	NUM
dpc-1945	409	2	.	.	PUNCT
dpc-1945	410	1	strickley	strickley	PROPN
dpc-1945	410	2	jd	jd	PROPN
dpc-1945	410	3	,	,	PUNCT
dpc-1945	410	4	spalding	spalding	PROPN
dpc-1945	410	5	ac	ac	PROPN
dpc-1945	410	6	,	,	PUNCT
dpc-1945	410	7	haeberle	haeberle	PROPN
dpc-1945	410	8	mt	mt	PROPN
dpc-1945	410	9	,	,	PUNCT
dpc-1945	410	10	brown	brown	PROPN
dpc-1945	410	11	t	t	PROPN
dpc-1945	410	12	,	,	PUNCT
dpc-1945	410	13	stevens	stevens	PROPN
dpc-1945	410	14	da	da	PROPN
dpc-1945	410	15	,	,	PUNCT
dpc-1945	410	16	jung	jung	PROPN
dpc-1945	410	17	j.	j.	PROPN
dpc-1945	410	18	metastatic	metastatic	PROPN
dpc-1945	410	19	squamous	squamous	ADJ
dpc-1945	410	20	cell	cell	NOUN
dpc-1945	410	21	carcinoma	carcinoma	NOUN
dpc-1945	410	22	of	of	ADP
dpc-1945	410	23	the	the	DET
dpc-1945	410	24	skin	skin	NOUN
dpc-1945	410	25	with	with	ADP
dpc-1945	410	26	clinical	clinical	ADJ
dpc-1945	410	27	response	response	NOUN
dpc-1945	410	28	to	to	AUX
dpc-1945	410	29	lapatinib	lapatinib	NOUN
dpc-1945	410	30	.	.	PUNCT
dpc-1945	411	1	exp	exp	NOUN
dpc-1945	411	2	hematol	hematol	PROPN
dpc-1945	411	3	oncol	oncol	ADJ
dpc-1945	411	4	.	.	PUNCT
dpc-1945	412	1	2018;7:20	2018;7:20	PROPN
dpc-1945	412	2	.	.	PUNCT
dpc-1945	413	1	doi	doi	NOUN
dpc-1945	413	2	:	:	PUNCT
dpc-1945	413	3	10.1186	10.1186	NUM
dpc-1945	413	4	/	/	SYM
dpc-1945	413	5	s40164	s40164	NOUN
dpc-1945	413	6	-	-	PUNCT
dpc-1945	413	7	018	018	NUM
dpc-1945	413	8	-	-	PUNCT
dpc-1945	413	9	0111	0111	NUM
dpc-1945	413	10	-	-	PUNCT
dpc-1945	413	11	z.	z.	PROPN
dpc-1945	413	12	pmid	pmid	PROPN
dpc-1945	413	13	:	:	PUNCT
dpc-1945	413	14	30181930	30181930	NUM
dpc-1945	413	15	.	.	PUNCT
dpc-1945	414	1	31	31	NUM
dpc-1945	414	2	.	.	PUNCT
dpc-1945	415	1	jenni	jenni	PROPN
dpc-1945	415	2	d	d	PROPN
dpc-1945	415	3	,	,	PUNCT
dpc-1945	415	4	karpova	karpova	PROPN
dpc-1945	415	5	mb	mb	ADP
dpc-1945	415	6	,	,	PUNCT
dpc-1945	415	7	mühleisen	mühleisen	VERB
dpc-1945	415	8	b	b	NOUN
dpc-1945	415	9	,	,	PUNCT
dpc-1945	415	10	et	et	PROPN
dpc-1945	415	11	al	al	PROPN
dpc-1945	415	12	.	.	PUNCT
dpc-1945	416	1	a	a	DET
dpc-1945	416	2	prospective	prospective	ADJ
dpc-1945	416	3	clinical	clinical	ADJ
dpc-1945	416	4	trial	trial	NOUN
dpc-1945	416	5	to	to	PART
dpc-1945	416	6	assess	assess	VERB
dpc-1945	416	7	lapatinib	lapatinib	NOUN
dpc-1945	416	8	effects	effect	NOUN
dpc-1945	416	9	on	on	ADP
dpc-1945	416	10	cutaneous	cutaneous	ADJ
dpc-1945	416	11	squamous	squamous	ADJ
dpc-1945	416	12	cell	cell	NOUN
dpc-1945	416	13	carcinoma	carcinoma	NOUN
dpc-1945	416	14	and	and	CCONJ
dpc-1945	416	15	actinic	actinic	ADJ
dpc-1945	416	16	keratosis	keratosis	NOUN
dpc-1945	416	17	.	.	PUNCT
dpc-1945	417	1	esmo	esmo	NOUN
dpc-1945	417	2	open	open	ADJ
dpc-1945	417	3	.	.	PUNCT
dpc-1945	418	1	2016;1(1):e000003	2016;1(1):e000003	NOUN
dpc-1945	418	2	.	.	PUNCT
dpc-1945	419	1	doi	doi	NOUN
dpc-1945	419	2	:	:	PUNCT
dpc-1945	419	3	10.1136	10.1136	NUM
dpc-1945	419	4	/	/	SYM
dpc-1945	419	5	esmoopen-2015	esmoopen-2015	NOUN
dpc-1945	419	6	-	-	PUNCT
dpc-1945	419	7	000003	000003	NUM
dpc-1945	419	8	.	.	PUNCT
dpc-1945	420	1	pmid	pmid	NOUN
dpc-1945	420	2	:	:	PUNCT
dpc-1945	420	3	27843579	27843579	NUM
dpc-1945	420	4	.	.	PUNCT
dpc-1945	421	1	32	32	NUM
dpc-1945	421	2	.	.	PUNCT
dpc-1945	422	1	chanprapaph	chanprapaph	PROPN
dpc-1945	422	2	k	k	PROPN
dpc-1945	422	3	,	,	PUNCT
dpc-1945	422	4	vachiramon	vachiramon	NOUN
dpc-1945	422	5	v	v	NOUN
dpc-1945	422	6	,	,	PUNCT
dpc-1945	422	7	rattanakaemakorn	rattanakaemakorn	ADJ
dpc-1945	422	8	p.	p.	NOUN
dpc-1945	422	9	epidermal	epidermal	ADJ
dpc-1945	422	10	growth	growth	NOUN
dpc-1945	422	11	factor	factor	NOUN
dpc-1945	422	12	receptor	receptor	NOUN
dpc-1945	422	13	inhibitors	inhibitor	NOUN
dpc-1945	422	14	:	:	PUNCT
dpc-1945	422	15	a	a	DET
dpc-1945	422	16	review	review	NOUN
dpc-1945	422	17	of	of	ADP
dpc-1945	422	18	cutaneous	cutaneous	ADJ
dpc-1945	422	19	adverse	adverse	ADJ
dpc-1945	422	20	events	event	NOUN
dpc-1945	422	21	and	and	CCONJ
dpc-1945	422	22	management	management	NOUN
dpc-1945	422	23	.	.	PUNCT
dpc-1945	423	1	dermatol	dermatol	NOUN
dpc-1945	423	2	res	re	NOUN
dpc-1945	423	3	pract	pract	NOUN
dpc-1945	423	4	.	.	PUNCT
dpc-1945	424	1	2014;2014:734249	2014;2014:734249	NUM
dpc-1945	424	2	.	.	PUNCT
dpc-1945	425	1	doi	doi	NOUN
dpc-1945	425	2	:	:	PUNCT
dpc-1945	425	3	10.1155/2014/734249	10.1155/2014/734249	NUM
dpc-1945	425	4	.	.	PUNCT
dpc-1945	426	1	pmid	pmid	NOUN
dpc-1945	426	2	:	:	PUNCT
dpc-1945	426	3	2472394	2472394	NUM
dpc-1945	426	4	.	.	PUNCT
dpc-1945	427	1	33	33	NUM
dpc-1945	427	2	.	.	PUNCT
dpc-1945	427	3	wacker	wacker	PROPN
dpc-1945	427	4	b	b	PROPN
dpc-1945	427	5	,	,	PUNCT
dpc-1945	427	6	nagrani	nagrani	PROPN
dpc-1945	427	7	t	t	PROPN
dpc-1945	427	8	,	,	PUNCT
dpc-1945	427	9	weinberg	weinberg	PROPN
dpc-1945	427	10	j	j	PROPN
dpc-1945	427	11	,	,	PUNCT
dpc-1945	427	12	witt	witt	PROPN
dpc-1945	427	13	k	k	PROPN
dpc-1945	427	14	,	,	PUNCT
dpc-1945	427	15	clark	clark	PROPN
dpc-1945	427	16	g	g	PROPN
dpc-1945	427	17	,	,	PUNCT
dpc-1945	427	18	cagnoni	cagnoni	VERB
dpc-1945	427	19	pj	pj	PROPN
dpc-1945	427	20	.	.	PUNCT
dpc-1945	427	21	correlation	correlation	NOUN
dpc-1945	427	22	between	between	ADP
dpc-1945	427	23	development	development	NOUN
dpc-1945	427	24	of	of	ADP
dpc-1945	427	25	rash	rash	NOUN
dpc-1945	427	26	and	and	CCONJ
dpc-1945	427	27	efficacy	efficacy	NOUN
dpc-1945	427	28	in	in	ADP
dpc-1945	427	29	patients	patient	NOUN
dpc-1945	427	30	treated	treat	VERB
dpc-1945	427	31	with	with	ADP
dpc-1945	427	32	the	the	DET
dpc-1945	427	33	epidermal	epidermal	ADJ
dpc-1945	427	34	growth	growth	NOUN
dpc-1945	427	35	factor	factor	NOUN
dpc-1945	427	36	receptor	receptor	NOUN
dpc-1945	427	37	tyrosine	tyrosine	PROPN
dpc-1945	427	38	kinase	kinase	PROPN
dpc-1945	427	39	inhibitor	inhibitor	NOUN
dpc-1945	427	40	erlotinib	erlotinib	PROPN
dpc-1945	427	41	in	in	ADP
dpc-1945	427	42	two	two	NUM
dpc-1945	427	43	large	large	ADJ
dpc-1945	427	44	phase	phase	NOUN
dpc-1945	427	45	iii	iii	NUM
dpc-1945	427	46	studies	study	NOUN
dpc-1945	427	47	.	.	PUNCT
dpc-1945	428	1	clin	clin	PROPN
dpc-1945	428	2	cancer	cancer	NOUN
dpc-1945	428	3	res	re	NOUN
dpc-1945	428	4	.	.	PUNCT
dpc-1945	429	1	2007;13(13):3913	2007;13(13):3913	NUM
dpc-1945	429	2	-	-	SYM
dpc-1945	429	3	21	21	NUM
dpc-1945	429	4	.	.	PUNCT
dpc-1945	430	1	doi	doi	NOUN
dpc-1945	430	2	:	:	PUNCT
dpc-1945	430	3	10.1158/1078	10.1158/1078	NUM
dpc-1945	430	4	-	-	PUNCT
dpc-1945	430	5	0432.ccr-06	0432.ccr-06	NOUN
dpc-1945	430	6	-	-	PUNCT
dpc-1945	430	7	2610	2610	NUM
dpc-1945	430	8	.	.	PUNCT
dpc-1945	431	1	pmid	pmid	NOUN
dpc-1945	431	2	:	:	PUNCT
dpc-1945	431	3	17606725	17606725	NUM
dpc-1945	431	4	.	.	PUNCT
dpc-1945	432	1	34	34	NUM
dpc-1945	432	2	.	.	PUNCT
dpc-1945	433	1	hirsh	hirsh	PROPN
dpc-1945	433	2	v.	v.	ADP
dpc-1945	433	3	managing	manage	VERB
dpc-1945	433	4	treatment	treatment	NOUN
dpc-1945	433	5	-	-	PUNCT
dpc-1945	433	6	related	relate	VERB
dpc-1945	433	7	adverse	adverse	ADJ
dpc-1945	433	8	events	event	NOUN
dpc-1945	433	9	associated	associate	VERB
dpc-1945	433	10	with	with	ADP
dpc-1945	433	11	egfr	egfr	ADJ
dpc-1945	433	12	tyrosine	tyrosine	PROPN
dpc-1945	433	13	kinase	kinase	PROPN
dpc-1945	433	14	inhibitors	inhibitor	NOUN
dpc-1945	433	15	in	in	ADP
dpc-1945	433	16	advanced	advanced	ADJ
dpc-1945	433	17	non	non	ADJ
dpc-1945	433	18	-	-	ADJ
dpc-1945	433	19	small	small	ADJ
dpc-1945	433	20	-	-	PUNCT
dpc-1945	433	21	cell	cell	NOUN
dpc-1945	433	22	lung	lung	NOUN
dpc-1945	433	23	cancer	cancer	NOUN
dpc-1945	433	24	.	.	PUNCT
dpc-1945	434	1	curr	curr	PROPN
dpc-1945	434	2	oncol	oncol	PROPN
dpc-1945	434	3	.	.	PUNCT
dpc-1945	435	1	2011;18(3):126	2011;18(3):126	NUM
dpc-1945	435	2	-	-	SYM
dpc-1945	435	3	38	38	NUM
dpc-1945	435	4	.	.	PUNCT
dpc-1945	436	1	doi	doi	NOUN
dpc-1945	436	2	:	:	PUNCT
dpc-1945	436	3	10.3747/	10.3747/	NUM
dpc-1945	436	4	co.v18i3.877	co.v18i3.877	NOUN
dpc-1945	436	5	.	.	PUNCT
dpc-1945	437	1	pmid	pmid	NOUN
dpc-1945	437	2	:	:	PUNCT
dpc-1945	437	3	21655159	21655159	NUM
dpc-1945	437	4	.	.	PUNCT
dpc-1945	438	1	35	35	NUM
dpc-1945	438	2	.	.	X
dpc-1945	438	3	wheeler	wheeler	PROPN
dpc-1945	438	4	dl	dl	PROPN
dpc-1945	438	5	,	,	PUNCT
dpc-1945	438	6	dunn	dunn	PROPN
dpc-1945	438	7	ef	ef	PROPN
dpc-1945	438	8	,	,	PUNCT
dpc-1945	438	9	harari	harari	ADJ
dpc-1945	438	10	pm	pm	NOUN
dpc-1945	438	11	.	.	PUNCT
dpc-1945	439	1	understanding	understand	VERB
dpc-1945	439	2	resistance	resistance	NOUN
dpc-1945	439	3	to	to	ADP
dpc-1945	439	4	egfr	egfr	VERB
dpc-1945	439	5	inhibitors	inhibitor	NOUN
dpc-1945	439	6	-	-	PUNCT
dpc-1945	439	7	impact	impact	NOUN
dpc-1945	439	8	on	on	ADP
dpc-1945	439	9	future	future	ADJ
dpc-1945	439	10	treatment	treatment	NOUN
dpc-1945	439	11	strategies	strategy	NOUN
dpc-1945	439	12	.	.	PUNCT
dpc-1945	440	1	nat	nat	PROPN
dpc-1945	440	2	rev	rev	VERB
dpc-1945	440	3	clin	clin	PROPN
dpc-1945	440	4	oncol	oncol	PROPN
dpc-1945	440	5	.	.	PUNCT
dpc-1945	441	1	2010;7(9):493	2010;7(9):493	NUM
dpc-1945	441	2	-	-	SYM
dpc-1945	441	3	507	507	NUM
dpc-1945	441	4	.	.	PUNCT
dpc-1945	442	1	doi	doi	NOUN
dpc-1945	442	2	:	:	PUNCT
dpc-1945	442	3	10.1038	10.1038	NUM
dpc-1945	442	4	/	/	SYM
dpc-1945	442	5	nrclinonc.2010.97	nrclinonc.2010.97	NOUN
dpc-1945	442	6	.	.	PUNCT
dpc-1945	443	1	pmid	pmid	NOUN
dpc-1945	443	2	:	:	PUNCT
dpc-1945	443	3	20551942	20551942	NUM
dpc-1945	443	4	.	.	PUNCT
dpc-1945	444	1	36	36	NUM
dpc-1945	444	2	.	.	PUNCT
dpc-1945	445	1	zhao	zhao	PROPN
dpc-1945	445	2	b	b	PROPN
dpc-1945	445	3	,	,	PUNCT
dpc-1945	445	4	wang	wang	PROPN
dpc-1945	445	5	l	l	PROPN
dpc-1945	445	6	,	,	PUNCT
dpc-1945	445	7	qiu	qiu	PROPN
dpc-1945	445	8	h	h	PROPN
dpc-1945	445	9	,	,	PUNCT
dpc-1945	445	10	et	et	PROPN
dpc-1945	445	11	al	al	PROPN
dpc-1945	445	12	.	.	PROPN
dpc-1945	445	13	mechanisms	mechanism	NOUN
dpc-1945	445	14	of	of	ADP
dpc-1945	445	15	resistance	resistance	NOUN
dpc-1945	445	16	to	to	ADP
dpc-1945	445	17	anti	anti	ADJ
dpc-1945	445	18	-	-	ADJ
dpc-1945	445	19	egfr	egfr	ADJ
dpc-1945	445	20	therapy	therapy	NOUN
dpc-1945	445	21	in	in	ADP
dpc-1945	445	22	colorectal	colorectal	ADJ
dpc-1945	445	23	cancer	cancer	NOUN
dpc-1945	445	24	.	.	PUNCT
dpc-1945	446	1	oncotarget	oncotarget	NOUN
dpc-1945	446	2	.	.	PUNCT
dpc-1945	447	1	2017;8(3):39804000	2017;8(3):39804000	NUM
dpc-1945	447	2	.	.	PUNCT
dpc-1945	447	3	doi	doi	NOUN
dpc-1945	447	4	:	:	PUNCT
dpc-1945	447	5	10.18632	10.18632	NUM
dpc-1945	447	6	/	/	SYM
dpc-1945	447	7	oncotarget.14012	oncotarget.14012	PROPN
dpc-1945	447	8	.	.	PUNCT
dpc-1945	448	1	pmid	pmid	NOUN
dpc-1945	448	2	:	:	PUNCT
dpc-1945	448	3	28002810	28002810	NUM
dpc-1945	448	4	.	.	PUNCT
dpc-1945	449	1	37	37	NUM
dpc-1945	449	2	.	.	PUNCT
dpc-1945	450	1	sforza	sforza	NOUN
dpc-1945	450	2	v	v	PROPN
dpc-1945	450	3	,	,	PUNCT
dpc-1945	450	4	martinelli	martinelli	PROPN
dpc-1945	450	5	e	e	PROPN
dpc-1945	450	6	,	,	PUNCT
dpc-1945	450	7	ciardiello	ciardiello	PROPN
dpc-1945	450	8	f	f	NOUN
dpc-1945	450	9	,	,	PUNCT
dpc-1945	451	1	et	et	PROPN
dpc-1945	451	2	al	al	PROPN
dpc-1945	451	3	.	.	PROPN
dpc-1945	451	4	mechanisms	mechanism	NOUN
dpc-1945	451	5	of	of	ADP
dpc-1945	451	6	resistance	resistance	NOUN
dpc-1945	451	7	to	to	ADP
dpc-1945	451	8	anti	anti	ADJ
dpc-1945	451	9	-	-	ADJ
dpc-1945	451	10	epidermal	epidermal	ADJ
dpc-1945	451	11	growth	growth	NOUN
dpc-1945	451	12	factor	factor	NOUN
dpc-1945	451	13	receptor	receptor	NOUN
dpc-1945	451	14	inhibitors	inhibitor	NOUN
dpc-1945	451	15	in	in	ADP
dpc-1945	451	16	metastatic	metastatic	ADJ
dpc-1945	451	17	colorectal	colorectal	ADJ
dpc-1945	451	18	cancer	cancer	NOUN
dpc-1945	451	19	.	.	PUNCT
dpc-1945	452	1	world	world	PROPN
dpc-1945	452	2	j	j	PROPN
dpc-1945	452	3	gastroenterol	gastroenterol	PROPN
dpc-1945	452	4	.	.	PUNCT
dpc-1945	453	1	2016;22(28):6345	2016;22(28):6345	NUM
dpc-1945	453	2	-	-	SYM
dpc-1945	453	3	61	61	NUM
dpc-1945	453	4	.	.	PUNCT
dpc-1945	454	1	doi	doi	NOUN
dpc-1945	454	2	:	:	PUNCT
dpc-1945	454	3	10.3748	10.3748	NUM
dpc-1945	454	4	/	/	SYM
dpc-1945	454	5	wjg.v22.i28.6345	wjg.v22.i28.6345	PROPN
dpc-1945	454	6	.	.	PUNCT
dpc-1945	455	1	pmid	pmid	NOUN
dpc-1945	455	2	:	:	PUNCT
dpc-1945	455	3	27605871	27605871	NUM
dpc-1945	455	4	.	.	PUNCT
dpc-1945	456	1	38	38	NUM
dpc-1945	456	2	.	.	PUNCT
dpc-1945	457	1	lovly	lovly	PROPN
dpc-1945	457	2	cm	cm	PROPN
dpc-1945	457	3	,	,	PUNCT
dpc-1945	457	4	horn	horn	NOUN
dpc-1945	457	5	l.	l.	NOUN
dpc-1945	457	6	strategies	strategy	NOUN
dpc-1945	457	7	for	for	ADP
dpc-1945	457	8	overcoming	overcome	VERB
dpc-1945	457	9	egfr	egfr	ADJ
dpc-1945	457	10	resistance	resistance	NOUN
dpc-1945	457	11	in	in	ADP
dpc-1945	457	12	the	the	DET
dpc-1945	457	13	treatment	treatment	NOUN
dpc-1945	457	14	of	of	ADP
dpc-1945	457	15	advanced	advanced	ADJ
dpc-1945	457	16	-	-	PUNCT
dpc-1945	457	17	stage	stage	NOUN
dpc-1945	457	18	nsclc	nsclc	NOUN
dpc-1945	457	19	.	.	PUNCT
dpc-1945	458	1	curr	curr	PROPN
dpc-1945	458	2	treat	treat	PROPN
dpc-1945	458	3	options	option	NOUN
dpc-1945	458	4	oncol	oncol	ADJ
dpc-1945	458	5	.	.	PUNCT
dpc-1945	459	1	2012;13(4):516	2012;13(4):516	NUM
dpc-1945	459	2	-	-	SYM
dpc-1945	459	3	26	26	NUM
dpc-1945	459	4	.	.	PUNCT
dpc-1945	460	1	doi	doi	NOUN
dpc-1945	460	2	:	:	PUNCT
dpc-1945	460	3	10.1007	10.1007	NUM
dpc-1945	460	4	/	/	SYM
dpc-1945	460	5	s11864	s11864	PROPN
dpc-1945	460	6	-	-	PUNCT
dpc-1945	460	7	012	012	NUM
dpc-1945	460	8	-	-	PUNCT
dpc-1945	460	9	0204	0204	NUM
dpc-1945	460	10	-	-	PUNCT
dpc-1945	460	11	6	6	NUM
dpc-1945	460	12	.	.	PUNCT
dpc-1945	461	1	pmid	pmid	NOUN
dpc-1945	461	2	:	:	PUNCT
dpc-1945	461	3	22833206	22833206	NUM
dpc-1945	461	4	.	.	PUNCT
dpc-1945	462	1	39	39	NUM
dpc-1945	462	2	.	.	PUNCT
dpc-1945	463	1	euvrard	euvrard	PROPN
dpc-1945	463	2	s	s	PROPN
dpc-1945	463	3	,	,	PUNCT
dpc-1945	463	4	kanitakis	kanitakis	PROPN
dpc-1945	463	5	j	j	PROPN
dpc-1945	463	6	,	,	PUNCT
dpc-1945	463	7	claudy	claudy	ADJ
dpc-1945	463	8	a.	a.	NOUN
dpc-1945	463	9	skin	skin	NOUN
dpc-1945	463	10	cancers	cancer	NOUN
dpc-1945	463	11	after	after	ADP
dpc-1945	463	12	organ	organ	NOUN
dpc-1945	463	13	transplantation	transplantation	NOUN
dpc-1945	463	14	.	.	PUNCT
dpc-1945	464	1	n	n	CCONJ
dpc-1945	464	2	engl	engl	PROPN
dpc-1945	464	3	j	j	PROPN
dpc-1945	464	4	med	med	PROPN
dpc-1945	464	5	.	.	PUNCT
dpc-1945	465	1	2003;348(17):1681	2003;348(17):1681	NUM
dpc-1945	465	2	-	-	SYM
dpc-1945	465	3	91	91	NUM
dpc-1945	465	4	.	.	PUNCT
dpc-1945	466	1	doi	doi	NOUN
dpc-1945	466	2	:	:	PUNCT
dpc-1945	466	3	10.1056/	10.1056/	NUM
dpc-1945	466	4	nejmra022137	nejmra022137	PROPN
dpc-1945	466	5	.	.	PUNCT
dpc-1945	467	1	pmid	pmid	NOUN
dpc-1945	467	2	:	:	PUNCT
dpc-1945	467	3	12711744	12711744	NUM
dpc-1945	467	4	.	.	PUNCT
dpc-1945	468	1	40	40	NUM
dpc-1945	468	2	.	.	PUNCT
dpc-1945	469	1	berg	berg	PROPN
dpc-1945	469	2	d	d	PROPN
dpc-1945	469	3	,	,	PUNCT
dpc-1945	469	4	otley	otley	PROPN
dpc-1945	469	5	cc	cc	PROPN
dpc-1945	469	6	.	.	PROPN
dpc-1945	469	7	skin	skin	NOUN
dpc-1945	469	8	cancer	cancer	NOUN
dpc-1945	469	9	in	in	ADP
dpc-1945	469	10	organ	organ	NOUN
dpc-1945	469	11	transplant	transplant	NOUN
dpc-1945	469	12	recipients	recipient	NOUN
dpc-1945	469	13	:	:	PUNCT
dpc-1945	469	14	epidemiology	epidemiology	NOUN
dpc-1945	469	15	,	,	PUNCT
dpc-1945	469	16	pathogenesis	pathogenesis	NOUN
dpc-1945	469	17	,	,	PUNCT
dpc-1945	469	18	and	and	CCONJ
dpc-1945	469	19	management	management	NOUN
dpc-1945	469	20	.	.	PUNCT
dpc-1945	470	1	j	j	PROPN
dpc-1945	470	2	am	be	AUX
dpc-1945	470	3	acad	acad	ADJ
dpc-1945	470	4	dermatol	dermatol	NOUN
dpc-1945	470	5	.	.	PUNCT
dpc-1945	471	1	2002;47(1):1	2002;47(1):1	NOUN
dpc-1945	471	2	-	-	SYM
dpc-1945	471	3	17	17	NUM
dpc-1945	471	4	;	;	PUNCT
dpc-1945	471	5	quiz	quiz	NOUN
dpc-1945	471	6	18	18	NUM
dpc-1945	471	7	-	-	SYM
dpc-1945	471	8	20	20	NUM
dpc-1945	471	9	.	.	PUNCT
dpc-1945	472	1	doi	doi	NOUN
dpc-1945	472	2	:	:	PUNCT
dpc-1945	472	3	10.1067	10.1067	NUM
dpc-1945	472	4	/	/	SYM
dpc-1945	472	5	mjd.2002.125579	mjd.2002.125579	ADJ
dpc-1945	472	6	.	.	PUNCT
dpc-1945	473	1	pmid	pmid	NOUN
dpc-1945	473	2	:	:	PUNCT
dpc-1945	473	3	12077575	12077575	NUM
dpc-1945	473	4	.	.	PUNCT
dpc-1945	474	1	41	41	NUM
dpc-1945	474	2	.	.	PUNCT
dpc-1945	475	1	kripke	kripke	PROPN
dpc-1945	475	2	ml	ml	PROPN
dpc-1945	475	3	.	.	PUNCT
dpc-1945	476	1	ultraviolet	ultraviolet	ADJ
dpc-1945	476	2	radiation	radiation	NOUN
dpc-1945	476	3	and	and	CCONJ
dpc-1945	476	4	immunology	immunology	NOUN
dpc-1945	476	5	:	:	PUNCT
dpc-1945	476	6	something	something	PRON
dpc-1945	476	7	new	new	ADJ
dpc-1945	476	8	under	under	ADP
dpc-1945	476	9	the	the	DET
dpc-1945	476	10	sun	sun	NOUN
dpc-1945	476	11	--	--	PUNCT
dpc-1945	476	12	presidential	presidential	ADJ
dpc-1945	476	13	address	address	NOUN
dpc-1945	476	14	.	.	PUNCT
dpc-1945	477	1	cancer	cancer	NOUN
dpc-1945	477	2	res	re	NOUN
dpc-1945	477	3	.	.	PUNCT
dpc-1945	478	1	1994;54(23):6102	1994;54(23):6102	NUM
dpc-1945	478	2	-	-	SYM
dpc-1945	478	3	5	5	NUM
dpc-1945	478	4	.	.	PUNCT
dpc-1945	479	1	pmid	pmid	NOUN
dpc-1945	479	2	:	:	PUNCT
dpc-1945	479	3	7954455	7954455	NUM
dpc-1945	479	4	.	.	PUNCT
dpc-1945	480	1	42	42	NUM
dpc-1945	480	2	.	.	PUNCT
dpc-1945	481	1	pickering	pickere	VERB
dpc-1945	481	2	cr	cr	PROPN
dpc-1945	481	3	,	,	PUNCT
dpc-1945	481	4	zhou	zhou	PROPN
dpc-1945	481	5	jh	jh	PROPN
dpc-1945	481	6	,	,	PUNCT
dpc-1945	481	7	lee	lee	PROPN
dpc-1945	481	8	jj	jj	PROPN
dpc-1945	481	9	,	,	PUNCT
dpc-1945	481	10	et	et	PROPN
dpc-1945	481	11	al	al	PROPN
dpc-1945	481	12	.	.	PROPN
dpc-1945	481	13	mutational	mutational	ADJ
dpc-1945	481	14	landscape	landscape	NOUN
dpc-1945	481	15	of	of	ADP
dpc-1945	481	16	aggressive	aggressive	ADJ
dpc-1945	481	17	cutaneous	cutaneous	ADJ
dpc-1945	481	18	squamous	squamous	ADJ
dpc-1945	481	19	cell	cell	NOUN
dpc-1945	481	20	carcinoma	carcinoma	NOUN
dpc-1945	481	21	.	.	PUNCT
dpc-1945	482	1	clin	clin	PROPN
dpc-1945	482	2	cancer	cancer	NOUN
dpc-1945	482	3	res	re	NOUN
dpc-1945	482	4	.	.	PUNCT
dpc-1945	483	1	2014;20(24):6582	2014;20(24):6582	NUM
dpc-1945	483	2	-	-	SYM
dpc-1945	483	3	92	92	NUM
dpc-1945	483	4	.	.	PUNCT
dpc-1945	483	5	doi	doi	NOUN
dpc-1945	483	6	:	:	PUNCT
dpc-1945	483	7	10.1158/1078	10.1158/1078	NUM
dpc-1945	483	8	-	-	SYM
dpc-1945	483	9	0432.ccr-14	0432.ccr-14	NUM
dpc-1945	483	10	-	-	PUNCT
dpc-1945	483	11	1768	1768	NUM
dpc-1945	483	12	.	.	PUNCT
dpc-1945	484	1	pmid	pmid	NOUN
dpc-1945	484	2	:	:	PUNCT
dpc-1945	484	3	25303977	25303977	NUM
dpc-1945	484	4	.	.	PUNCT
dpc-1945	485	1	43	43	NUM
dpc-1945	485	2	.	.	PUNCT
dpc-1945	486	1	wu	wu	PROPN
dpc-1945	486	2	y	y	PROPN
dpc-1945	486	3	,	,	PUNCT
dpc-1945	486	4	xu	xu	PROPN
dpc-1945	486	5	j	j	PROPN
dpc-1945	486	6	,	,	PUNCT
dpc-1945	486	7	du	du	PROPN
dpc-1945	486	8	c	c	X
dpc-1945	486	9	,	,	PUNCT
dpc-1945	486	10	et	et	PROPN
dpc-1945	486	11	al	al	PROPN
dpc-1945	486	12	.	.	PUNCT
dpc-1945	487	1	the	the	DET
dpc-1945	487	2	predictive	predictive	ADJ
dpc-1945	487	3	value	value	NOUN
dpc-1945	487	4	of	of	ADP
dpc-1945	487	5	tumor	tumor	NOUN
dpc-1945	487	6	mutation	mutation	NOUN
dpc-1945	487	7	burden	burden	NOUN
dpc-1945	487	8	on	on	ADP
dpc-1945	487	9	efficacy	efficacy	NOUN
dpc-1945	487	10	of	of	ADP
dpc-1945	487	11	immune	immune	ADJ
dpc-1945	487	12	checkpoint	checkpoint	NOUN
dpc-1945	487	13	inhibitors	inhibitor	NOUN
dpc-1945	487	14	in	in	ADP
dpc-1945	487	15	cancers	cancer	NOUN
dpc-1945	487	16	:	:	PUNCT
dpc-1945	487	17	a	a	DET
dpc-1945	487	18	systematic	systematic	ADJ
dpc-1945	487	19	review	review	NOUN
dpc-1945	487	20	and	and	CCONJ
dpc-1945	487	21	meta	meta	ADJ
dpc-1945	487	22	-	-	PUNCT
dpc-1945	487	23	analysis	analysis	NOUN
dpc-1945	487	24	.	.	PUNCT
dpc-1945	488	1	front	front	ADJ
dpc-1945	488	2	oncol	oncol	ADJ
dpc-1945	488	3	.	.	PUNCT
dpc-1945	489	1	2019;9:1161	2019;9:1161	NUM
dpc-1945	489	2	.	.	PUNCT
dpc-1945	490	1	doi	doi	NOUN
dpc-1945	490	2	:	:	PUNCT
dpc-1945	490	3	10.3389	10.3389	NUM
dpc-1945	490	4	/	/	SYM
dpc-1945	490	5	fonc.2019.01161	fonc.2019.01161	NOUN
dpc-1945	490	6	.	.	PUNCT
dpc-1945	491	1	pmid	pmid	NOUN
dpc-1945	491	2	:	:	PUNCT
dpc-1945	491	3	31750249	31750249	NUM
dpc-1945	491	4	.	.	PUNCT
dpc-1945	492	1	44	44	NUM
dpc-1945	492	2	.	.	PUNCT
dpc-1945	493	1	bottomley	bottomley	PROPN
dpc-1945	493	2	mj	mj	PROPN
dpc-1945	493	3	,	,	PUNCT
dpc-1945	493	4	thomson	thomson	PROPN
dpc-1945	493	5	j	j	PROPN
dpc-1945	493	6	,	,	PUNCT
dpc-1945	493	7	harwood	harwood	NOUN
dpc-1945	493	8	c	c	NOUN
dpc-1945	493	9	,	,	PUNCT
dpc-1945	493	10	leigh	leigh	PROPN
dpc-1945	493	11	i.	i.	PROPN
dpc-1945	493	12	the	the	DET
dpc-1945	493	13	role	role	NOUN
dpc-1945	493	14	of	of	ADP
dpc-1945	493	15	the	the	DET
dpc-1945	493	16	immune	immune	ADJ
dpc-1945	493	17	system	system	NOUN
dpc-1945	493	18	in	in	ADP
dpc-1945	493	19	cutaneous	cutaneous	ADJ
dpc-1945	493	20	squamous	squamous	ADJ
dpc-1945	493	21	cell	cell	NOUN
dpc-1945	493	22	carcinoma	carcinoma	NOUN
dpc-1945	493	23	.	.	PUNCT
dpc-1945	494	1	int	int	PROPN
dpc-1945	494	2	j	j	PROPN
dpc-1945	494	3	mol	mol	ADP
dpc-1945	494	4	sci	sci	PROPN
dpc-1945	494	5	.	.	PUNCT
dpc-1945	495	1	2019;20(8):2009	2019;20(8):2009	NUM
dpc-1945	495	2	.	.	PUNCT
dpc-1945	496	1	doi	doi	NOUN
dpc-1945	496	2	:	:	PUNCT
dpc-1945	496	3	10.3390	10.3390	NUM
dpc-1945	496	4	/	/	SYM
dpc-1945	496	5	ijms20082009	ijms20082009	PROPN
dpc-1945	496	6	.	.	PUNCT
dpc-1945	497	1	pmid	pmid	NOUN
dpc-1945	497	2	:	:	PUNCT
dpc-1945	497	3	31022866	31022866	NUM
dpc-1945	497	4	.	.	PUNCT
dpc-1945	498	1	45	45	NUM
dpc-1945	498	2	.	.	PUNCT
dpc-1945	499	1	chraa	chraa	PROPN
dpc-1945	499	2	d	d	PROPN
dpc-1945	499	3	,	,	PUNCT
dpc-1945	499	4	naim	naim	PROPN
dpc-1945	499	5	a	a	PRON
dpc-1945	499	6	,	,	PUNCT
dpc-1945	499	7	olive	olive	NOUN
dpc-1945	499	8	d	d	NOUN
dpc-1945	499	9	,	,	PUNCT
dpc-1945	499	10	badou	badou	PROPN
dpc-1945	499	11	a.	a.	PROPN
dpc-1945	499	12	t	t	PROPN
dpc-1945	499	13	lymphocyte	lymphocyte	NOUN
dpc-1945	499	14	subsets	subset	NOUN
dpc-1945	499	15	in	in	ADP
dpc-1945	499	16	cancer	cancer	NOUN
dpc-1945	499	17	immunity	immunity	NOUN
dpc-1945	499	18	:	:	PUNCT
dpc-1945	499	19	friends	friend	NOUN
dpc-1945	499	20	or	or	CCONJ
dpc-1945	499	21	foes	foe	NOUN
dpc-1945	499	22	.	.	PUNCT
dpc-1945	500	1	j	j	PROPN
dpc-1945	500	2	leukoc	leukoc	VERB
dpc-1945	500	3	biol	biol	PROPN
dpc-1945	500	4	.	.	PUNCT
dpc-1945	501	1	2019;105(2):243255	2019;105(2):243255	NUM
dpc-1945	501	2	.	.	PUNCT
dpc-1945	501	3	doi	doi	NOUN
dpc-1945	501	4	:	:	PUNCT
dpc-1945	501	5	10.1002	10.1002	NUM
dpc-1945	501	6	/	/	SYM
dpc-1945	501	7	jlb.mr0318	jlb.mr0318	PROPN
dpc-1945	501	8	-	-	PUNCT
dpc-1945	501	9	097r	097r	PROPN
dpc-1945	501	10	.	.	PUNCT
dpc-1945	502	1	pmid	pmid	NOUN
dpc-1945	502	2	:	:	PUNCT
dpc-1945	502	3	30387907	30387907	NUM
dpc-1945	502	4	.	.	PUNCT
dpc-1945	503	1	46	46	NUM
dpc-1945	503	2	.	.	PUNCT
dpc-1945	504	1	brahmer	brahmer	PROPN
dpc-1945	504	2	jr	jr	PROPN
dpc-1945	504	3	,	,	PUNCT
dpc-1945	504	4	tykodi	tykodi	PROPN
dpc-1945	504	5	ss	ss	PROPN
dpc-1945	504	6	,	,	PUNCT
dpc-1945	504	7	chow	chow	PROPN
dpc-1945	504	8	lq	lq	PROPN
dpc-1945	504	9	,	,	PUNCT
dpc-1945	504	10	et	et	PROPN
dpc-1945	504	11	al	al	PROPN
dpc-1945	504	12	.	.	PROPN
dpc-1945	504	13	safety	safety	NOUN
dpc-1945	504	14	and	and	CCONJ
dpc-1945	504	15	activity	activity	NOUN
dpc-1945	504	16	of	of	ADP
dpc-1945	504	17	anti	anti	ADJ
dpc-1945	504	18	-	-	ADJ
dpc-1945	504	19	pd	pd	ADJ
dpc-1945	504	20	-	-	PUNCT
dpc-1945	504	21	l1	l1	PROPN
dpc-1945	504	22	antibody	antibody	NOUN
dpc-1945	504	23	in	in	ADP
dpc-1945	504	24	patients	patient	NOUN
dpc-1945	504	25	with	with	ADP
dpc-1945	504	26	advanced	advanced	ADJ
dpc-1945	504	27	cancer	cancer	NOUN
dpc-1945	504	28	.	.	PUNCT
dpc-1945	505	1	n	n	PROPN
dpc-1945	505	2	engl	engl	PROPN
dpc-1945	505	3	j	j	PROPN
dpc-1945	505	4	med	med	PROPN
dpc-1945	505	5	.	.	PUNCT
dpc-1945	506	1	2012;366(26):2455	2012;366(26):2455	NUM
dpc-1945	506	2	-	-	SYM
dpc-1945	506	3	65	65	NUM
dpc-1945	506	4	.	.	PUNCT
dpc-1945	506	5	doi	doi	NOUN
dpc-1945	506	6	:	:	PUNCT
dpc-1945	506	7	10.1056	10.1056	NUM
dpc-1945	506	8	/	/	SYM
dpc-1945	506	9	nejmoa1200694	nejmoa1200694	PROPN
dpc-1945	506	10	.	.	PUNCT
dpc-1945	507	1	pmid	pmid	NOUN
dpc-1945	507	2	:	:	PUNCT
dpc-1945	507	3	22658128	22658128	NUM
dpc-1945	507	4	.	.	PUNCT
dpc-1945	508	1	47	47	NUM
dpc-1945	508	2	.	.	PUNCT
dpc-1945	509	1	robainas	robainas	PROPN
dpc-1945	509	2	m	m	PRON
dpc-1945	509	3	,	,	PUNCT
dpc-1945	509	4	otano	otano	ADJ
dpc-1945	509	5	r	r	NOUN
dpc-1945	509	6	,	,	PUNCT
dpc-1945	509	7	bueno	bueno	PROPN
dpc-1945	509	8	s	s	PROPN
dpc-1945	509	9	,	,	PUNCT
dpc-1945	509	10	ait	ait	ADJ
dpc-1945	509	11	-	-	ADJ
dpc-1945	509	12	oudhia	oudhia	PROPN
dpc-1945	509	13	s.	s.	PROPN
dpc-1945	509	14	understanding	understand	VERB
dpc-1945	509	15	the	the	DET
dpc-1945	509	16	role	role	NOUN
dpc-1945	509	17	of	of	ADP
dpc-1945	509	18	pd	pd	PROPN
dpc-1945	509	19	-	-	PUNCT
dpc-1945	509	20	l1	l1	NOUN
dpc-1945	509	21	/	/	SYM
dpc-1945	509	22	pd1	pd1	VERB
dpc-1945	509	23	pathway	pathway	NOUN
dpc-1945	509	24	blockade	blockade	NOUN
dpc-1945	509	25	and	and	CCONJ
dpc-1945	509	26	autophagy	autophagy	VERB
dpc-1945	509	27	in	in	ADP
dpc-1945	509	28	cancer	cancer	NOUN
dpc-1945	509	29	therapy	therapy	NOUN
dpc-1945	509	30	.	.	PUNCT
dpc-1945	510	1	onco	onco	PROPN
dpc-1945	510	2	targets	target	NOUN
dpc-1945	510	3	ther	ther	ADV
dpc-1945	510	4	.	.	PUNCT
dpc-1945	511	1	2017;10:1803	2017;10:1803	NUM
dpc-1945	511	2	-	-	SYM
dpc-1945	511	3	1807	1807	NUM
dpc-1945	511	4	.	.	PUNCT
dpc-1945	512	1	doi	doi	NOUN
dpc-1945	512	2	:	:	PUNCT
dpc-1945	512	3	10.2147/	10.2147/	NUM
dpc-1945	512	4	ott.s132508	ott.s132508	NUM
dpc-1945	512	5	.	.	PUNCT
dpc-1945	513	1	pmid	pmid	NOUN
dpc-1945	513	2	:	:	PUNCT
dpc-1945	513	3	28367063	28367063	NUM
dpc-1945	513	4	.	.	PUNCT
dpc-1945	514	1	48	48	NUM
dpc-1945	514	2	.	.	PUNCT
dpc-1945	515	1	akinleye	akinleye	PROPN
dpc-1945	515	2	a	a	PRON
dpc-1945	515	3	,	,	PUNCT
dpc-1945	515	4	rasool	rasool	PROPN
dpc-1945	515	5	z.	z.	PROPN
dpc-1945	515	6	immune	immune	PROPN
dpc-1945	515	7	checkpoint	checkpoint	NOUN
dpc-1945	515	8	inhibitors	inhibitor	NOUN
dpc-1945	515	9	of	of	ADP
dpc-1945	515	10	pd	pd	PROPN
dpc-1945	515	11	-	-	PROPN
dpc-1945	515	12	l1	l1	PROPN
dpc-1945	515	13	as	as	ADP
dpc-1945	515	14	cancer	cancer	NOUN
dpc-1945	515	15	therapeutics	therapeutic	NOUN
dpc-1945	515	16	.	.	PUNCT
dpc-1945	516	1	j	j	PROPN
dpc-1945	516	2	hematol	hematol	PROPN
dpc-1945	516	3	oncol	oncol	ADJ
dpc-1945	516	4	.	.	PUNCT
dpc-1945	517	1	2019;12(1):92	2019;12(1):92	X
dpc-1945	517	2	.	.	PUNCT
dpc-1945	517	3	doi	doi	NOUN
dpc-1945	517	4	:	:	PUNCT
dpc-1945	517	5	10.1186	10.1186	NUM
dpc-1945	517	6	/	/	SYM
dpc-1945	517	7	s13045	s13045	ADV
dpc-1945	517	8	-	-	PUNCT
dpc-1945	517	9	019	019	NUM
dpc-1945	517	10	-	-	PUNCT
dpc-1945	517	11	0779	0779	NUM
dpc-1945	517	12	-	-	PUNCT
dpc-1945	517	13	5	5	NUM
dpc-1945	517	14	.	.	PUNCT
dpc-1945	518	1	pmid	pmid	NOUN
dpc-1945	518	2	:	:	PUNCT
dpc-1945	518	3	31488176	31488176	NUM
dpc-1945	518	4	.	.	PUNCT
dpc-1945	519	1	49	49	NUM
dpc-1945	519	2	.	.	PUNCT
dpc-1945	520	1	riley	riley	PROPN
dpc-1945	520	2	jl	jl	PROPN
dpc-1945	520	3	.	.	PUNCT
dpc-1945	521	1	pd-1	pd-1	VERB
dpc-1945	521	2	signaling	signal	VERB
dpc-1945	521	3	in	in	ADP
dpc-1945	521	4	primary	primary	ADJ
dpc-1945	521	5	t	t	NOUN
dpc-1945	521	6	cells	cell	NOUN
dpc-1945	521	7	.	.	PUNCT
dpc-1945	522	1	immunol	immunol	PROPN
dpc-1945	522	2	rev	rev	PROPN
dpc-1945	522	3	.	.	PROPN
dpc-1945	522	4	2009;229(1):114	2009;229(1):114	NUM
dpc-1945	522	5	-	-	SYM
dpc-1945	522	6	25	25	NUM
dpc-1945	522	7	.	.	PUNCT
dpc-1945	523	1	doi	doi	NOUN
dpc-1945	523	2	:	:	PUNCT
dpc-1945	523	3	10.1111	10.1111	NUM
dpc-1945	523	4	/	/	SYM
dpc-1945	523	5	j.1600	j.1600	PROPN
dpc-1945	523	6	-	-	PUNCT
dpc-1945	523	7	065x.2009.00767.x	065x.2009.00767.x	NOUN
dpc-1945	523	8	.	.	PUNCT
dpc-1945	524	1	pmid	pmid	NOUN
dpc-1945	524	2	:	:	PUNCT
dpc-1945	524	3	19426218	19426218	NUM
dpc-1945	524	4	.	.	PUNCT
dpc-1945	525	1	50	50	NUM
dpc-1945	525	2	.	.	X
dpc-1945	525	3	migden	migden	PROPN
dpc-1945	525	4	mr	mr	PROPN
dpc-1945	525	5	,	,	PUNCT
dpc-1945	525	6	rischin	rischin	PROPN
dpc-1945	525	7	d	d	PROPN
dpc-1945	525	8	,	,	PUNCT
dpc-1945	525	9	schmults	schmults	PROPN
dpc-1945	525	10	cd	cd	PROPN
dpc-1945	525	11	,	,	PUNCT
dpc-1945	525	12	et	et	PROPN
dpc-1945	525	13	al	al	PROPN
dpc-1945	525	14	.	.	PROPN
dpc-1945	525	15	pd-1	pd-1	ADP
dpc-1945	525	16	blockade	blockade	NOUN
dpc-1945	525	17	with	with	ADP
dpc-1945	525	18	cemiplimab	cemiplimab	NOUN
dpc-1945	525	19	in	in	ADP
dpc-1945	525	20	advanced	advanced	ADJ
dpc-1945	525	21	cutaneous	cutaneous	ADJ
dpc-1945	525	22	squamous	squamous	ADJ
dpc-1945	525	23	-	-	PUNCT
dpc-1945	525	24	cell	cell	NOUN
dpc-1945	525	25	carcinoma	carcinoma	NOUN
dpc-1945	525	26	.	.	PUNCT
dpc-1945	526	1	n	n	PRON
dpc-1945	526	2	engl	engl	PROPN
dpc-1945	526	3	j	j	PROPN
dpc-1945	526	4	med	med	PROPN
dpc-1945	526	5	.	.	PUNCT
dpc-1945	527	1	2018;379(4):341	2018;379(4):341	NUM
dpc-1945	527	2	-	-	SYM
dpc-1945	527	3	351	351	NUM
dpc-1945	527	4	.	.	PUNCT
dpc-1945	527	5	doi	doi	NOUN
dpc-1945	527	6	:	:	PUNCT
dpc-1945	527	7	10.1056/	10.1056/	NUM
dpc-1945	527	8	nejmoa1805131	nejmoa1805131	PROPN
dpc-1945	527	9	.	.	PUNCT
dpc-1945	528	1	pmid	pmid	NOUN
dpc-1945	528	2	:	:	PUNCT
dpc-1945	528	3	29863979	29863979	NUM
dpc-1945	528	4	.	.	PUNCT
dpc-1945	529	1	51	51	NUM
dpc-1945	529	2	.	.	PUNCT
dpc-1945	530	1	rischin	rischin	PROPN
dpc-1945	530	2	d	d	PROPN
dpc-1945	530	3	,	,	PUNCT
dpc-1945	530	4	migden	migden	PROPN
dpc-1945	530	5	mr	mr	PROPN
dpc-1945	530	6	,	,	PUNCT
dpc-1945	530	7	lim	lim	PROPN
dpc-1945	530	8	am	be	AUX
dpc-1945	530	9	,	,	PUNCT
dpc-1945	530	10	et	et	PROPN
dpc-1945	530	11	al	al	PROPN
dpc-1945	530	12	.	.	PROPN
dpc-1945	530	13	phase	phase	NOUN
dpc-1945	530	14	2	2	NUM
dpc-1945	530	15	study	study	NOUN
dpc-1945	530	16	of	of	ADP
dpc-1945	530	17	cemiplimab	cemiplimab	NOUN
dpc-1945	530	18	in	in	ADP
dpc-1945	530	19	patients	patient	NOUN
dpc-1945	530	20	with	with	ADP
dpc-1945	530	21	metastatic	metastatic	ADJ
dpc-1945	530	22	cutaneous	cutaneous	ADJ
dpc-1945	530	23	squamous	squamous	ADJ
dpc-1945	530	24	cell	cell	NOUN
dpc-1945	530	25	carcinoma	carcinoma	NOUN
dpc-1945	530	26	:	:	PUNCT
dpc-1945	530	27	primary	primary	ADJ
dpc-1945	530	28	analysis	analysis	NOUN
dpc-1945	530	29	of	of	ADP
dpc-1945	530	30	fixed	fix	VERB
dpc-1945	530	31	-	-	PUNCT
dpc-1945	530	32	dosing	dosing	ADJ
dpc-1945	530	33	,	,	PUNCT
dpc-1945	530	34	long	long	ADJ
dpc-1945	530	35	-	-	PUNCT
dpc-1945	530	36	term	term	NOUN
dpc-1945	530	37	outcome	outcome	NOUN
dpc-1945	530	38	of	of	ADP
dpc-1945	530	39	weight	weight	NOUN
dpc-1945	530	40	-	-	PUNCT
dpc-1945	530	41	based	base	VERB
dpc-1945	530	42	dosing	dosing	NOUN
dpc-1945	530	43	.	.	PUNCT
dpc-1945	531	1	j	j	PROPN
dpc-1945	531	2	immunother	immunother	ADJ
dpc-1945	531	3	cancer	cancer	NOUN
dpc-1945	531	4	.	.	PUNCT
dpc-1945	532	1	2020;8(1):e000775	2020;8(1):e000775	NOUN
dpc-1945	532	2	.	.	PUNCT
dpc-1945	533	1	doi	doi	NOUN
dpc-1945	533	2	:	:	PUNCT
dpc-1945	533	3	10.1136	10.1136	NUM
dpc-1945	533	4	/	/	SYM
dpc-1945	533	5	jitc-2020	jitc-2020	NOUN
dpc-1945	533	6	-	-	NOUN
dpc-1945	533	7	000775	000775	NUM
dpc-1945	533	8	.	.	PUNCT
dpc-1945	534	1	pmid	pmid	NOUN
dpc-1945	534	2	:	:	PUNCT
dpc-1945	534	3	32554615	32554615	NUM
dpc-1945	534	4	.	.	PUNCT
dpc-1945	535	1	52	52	NUM
dpc-1945	535	2	.	.	PUNCT
dpc-1945	535	3	migden	migden	PROPN
dpc-1945	535	4	mr	mr	PROPN
dpc-1945	535	5	,	,	PUNCT
dpc-1945	535	6	khushalani	khushalani	PROPN
dpc-1945	535	7	ni	ni	PROPN
dpc-1945	535	8	,	,	PUNCT
dpc-1945	535	9	chang	chang	PROPN
dpc-1945	535	10	als	als	PROPN
dpc-1945	535	11	,	,	PUNCT
dpc-1945	535	12	et	et	PROPN
dpc-1945	535	13	al	al	PROPN
dpc-1945	535	14	.	.	PROPN
dpc-1945	535	15	cemiplimab	cemiplimab	NOUN
dpc-1945	535	16	in	in	ADP
dpc-1945	535	17	locally	locally	ADV
dpc-1945	535	18	advanced	advance	VERB
dpc-1945	535	19	cutaneous	cutaneous	ADJ
dpc-1945	535	20	squamous	squamous	ADJ
dpc-1945	535	21	cell	cell	NOUN
dpc-1945	535	22	carcinoma	carcinoma	NOUN
dpc-1945	535	23	:	:	PUNCT
dpc-1945	535	24	results	result	NOUN
dpc-1945	535	25	from	from	ADP
dpc-1945	535	26	an	an	DET
dpc-1945	535	27	open	open	ADJ
dpc-1945	535	28	-	-	PUNCT
dpc-1945	535	29	label	label	NOUN
dpc-1945	535	30	,	,	PUNCT
dpc-1945	535	31	phase	phase	NOUN
dpc-1945	535	32	2	2	NUM
dpc-1945	535	33	,	,	PUNCT
dpc-1945	535	34	single	single	ADJ
dpc-1945	535	35	-	-	PUNCT
dpc-1945	535	36	arm	arm	NOUN
dpc-1945	535	37	trial	trial	NOUN
dpc-1945	535	38	.	.	PUNCT
dpc-1945	536	1	lancet	lancet	PROPN
dpc-1945	536	2	oncol	oncol	PROPN
dpc-1945	536	3	.	.	PUNCT
dpc-1945	537	1	2020;21(2):294	2020;21(2):294	NUM
dpc-1945	537	2	-	-	SYM
dpc-1945	537	3	305	305	NUM
dpc-1945	537	4	.	.	PUNCT
dpc-1945	538	1	doi	doi	NOUN
dpc-1945	538	2	:	:	PUNCT
dpc-1945	538	3	10.1016	10.1016	NUM
dpc-1945	538	4	/	/	SYM
dpc-1945	538	5	s1470	s1470	PROPN
dpc-1945	538	6	-	-	PUNCT
dpc-1945	538	7	2045(19)30728	2045(19)30728	NUM
dpc-1945	538	8	-	-	PUNCT
dpc-1945	538	9	4	4	NUM
dpc-1945	538	10	.	.	PUNCT
dpc-1945	539	1	pmid	pmid	NOUN
dpc-1945	539	2	:	:	PUNCT
dpc-1945	539	3	31952975	31952975	NUM
dpc-1945	539	4	.	.	PUNCT
dpc-1945	540	1	53	53	NUM
dpc-1945	540	2	.	.	PUNCT
dpc-1945	541	1	grob	grob	PROPN
dpc-1945	541	2	jj	jj	PROPN
dpc-1945	541	3	,	,	PUNCT
dpc-1945	541	4	gonzalez	gonzalez	PROPN
dpc-1945	541	5	r	r	PROPN
dpc-1945	541	6	,	,	PUNCT
dpc-1945	541	7	basset	basset	NOUN
dpc-1945	541	8	-	-	PUNCT
dpc-1945	541	9	seguin	seguin	NOUN
dpc-1945	541	10	n	n	CCONJ
dpc-1945	541	11	,	,	PUNCT
dpc-1945	541	12	et	et	PROPN
dpc-1945	541	13	al	al	PROPN
dpc-1945	541	14	.	.	PROPN
dpc-1945	541	15	pembrolizumab	pembrolizumab	NOUN
dpc-1945	541	16	monotherapy	monotherapy	NOUN
dpc-1945	541	17	for	for	ADP
dpc-1945	541	18	recurrent	recurrent	ADJ
dpc-1945	541	19	or	or	CCONJ
dpc-1945	541	20	metastatic	metastatic	ADJ
dpc-1945	541	21	cutaneous	cutaneous	ADJ
dpc-1945	541	22	squamous	squamous	ADJ
dpc-1945	541	23	cell	cell	NOUN
dpc-1945	541	24	carcinoma	carcinoma	NOUN
dpc-1945	541	25	:	:	PUNCT
dpc-1945	541	26	a	a	DET
dpc-1945	541	27	single	single	ADJ
dpc-1945	541	28	-	-	PUNCT
dpc-1945	541	29	arm	arm	NOUN
dpc-1945	541	30	phase	phase	NOUN
dpc-1945	541	31	ii	ii	NOUN
dpc-1945	541	32	trial	trial	NOUN
dpc-1945	541	33	(	(	PUNCT
dpc-1945	541	34	keynote-629	keynote-629	NOUN
dpc-1945	541	35	)	)	PUNCT
dpc-1945	541	36	.	.	PUNCT
dpc-1945	542	1	j	j	PROPN
dpc-1945	542	2	clin	clin	PROPN
dpc-1945	542	3	oncol	oncol	PROPN
dpc-1945	542	4	.	.	PUNCT
dpc-1945	543	1	2020;38(25):2916	2020;38(25):2916	NUM
dpc-1945	543	2	-	-	SYM
dpc-1945	543	3	2925	2925	NUM
dpc-1945	543	4	.	.	PUNCT
dpc-1945	544	1	doi	doi	NOUN
dpc-1945	544	2	:	:	PUNCT
dpc-1945	544	3	10.1200/	10.1200/	NUM
dpc-1945	544	4	jco.19.03054	jco.19.03054	PROPN
dpc-1945	544	5	.	.	PUNCT
dpc-1945	545	1	epub	epub	PROPN
dpc-1945	545	2	2020	2020	NUM
dpc-1945	545	3	jul	jul	PROPN
dpc-1945	545	4	16	16	NUM
dpc-1945	545	5	.	.	PUNCT
dpc-1945	546	1	pmid	pmid	NOUN
dpc-1945	546	2	:	:	PUNCT
dpc-1945	546	3	32673170	32673170	NUM
dpc-1945	546	4	.	.	PUNCT
dpc-1945	547	1	54	54	NUM
dpc-1945	547	2	.	.	PUNCT
dpc-1945	548	1	maubec	maubec	PROPN
dpc-1945	548	2	e	e	PROPN
dpc-1945	548	3	,	,	PUNCT
dpc-1945	548	4	boubaya	boubaya	PROPN
dpc-1945	548	5	m	m	PROPN
dpc-1945	548	6	,	,	PUNCT
dpc-1945	548	7	petrow	petrow	VERB
dpc-1945	548	8	p	p	NOUN
dpc-1945	548	9	,	,	PUNCT
dpc-1945	548	10	et	et	PROPN
dpc-1945	548	11	al	al	PROPN
dpc-1945	548	12	.	.	PROPN
dpc-1945	548	13	phase	phase	PROPN
dpc-1945	548	14	ii	ii	PROPN
dpc-1945	548	15	study	study	NOUN
dpc-1945	548	16	of	of	ADP
dpc-1945	548	17	pembrolizumab	pembrolizumab	NOUN
dpc-1945	548	18	as	as	ADP
dpc-1945	548	19	first	first	ADJ
dpc-1945	548	20	-	-	PUNCT
dpc-1945	548	21	line	line	NOUN
dpc-1945	548	22	,	,	PUNCT
dpc-1945	548	23	single	single	ADJ
dpc-1945	548	24	-	-	PUNCT
dpc-1945	548	25	drug	drug	NOUN
dpc-1945	548	26	therapy	therapy	NOUN
dpc-1945	548	27	for	for	ADP
dpc-1945	548	28	patients	patient	NOUN
dpc-1945	548	29	with	with	ADP
dpc-1945	548	30	unresectable	unresectable	ADJ
dpc-1945	548	31	cutaneous	cutaneous	ADJ
dpc-1945	548	32	squamous	squamous	ADJ
dpc-1945	548	33	cell	cell	NOUN
dpc-1945	548	34	carcinomas	carcinoma	NOUN
dpc-1945	548	35	.	.	PUNCT
dpc-1945	549	1	j	j	PROPN
dpc-1945	549	2	clin	clin	PROPN
dpc-1945	549	3	oncol	oncol	PROPN
dpc-1945	549	4	.	.	PUNCT
dpc-1945	550	1	2020;38(26):3051	2020;38(26):3051	PROPN
dpc-1945	550	2	-	-	PROPN
dpc-1945	550	3	3061	3061	NUM
dpc-1945	550	4	.	.	PUNCT
dpc-1945	551	1	doi	doi	NOUN
dpc-1945	551	2	:	:	PUNCT
dpc-1945	551	3	10.1200	10.1200	NUM
dpc-1945	551	4	/	/	SYM
dpc-1945	551	5	jco.19.03357	jco.19.03357	PROPN
dpc-1945	551	6	.	.	PUNCT
dpc-1945	552	1	pmid	pmid	NOUN
dpc-1945	552	2	:	:	PUNCT
dpc-1945	552	3	32730186	32730186	NUM
dpc-1945	552	4	.	.	PUNCT
dpc-1945	553	1	55	55	NUM
dpc-1945	553	2	.	.	PUNCT
dpc-1945	554	1	spiers	spiers	PROPN
dpc-1945	554	2	l	l	PROPN
dpc-1945	554	3	,	,	PUNCT
dpc-1945	554	4	coupe	coupe	NOUN
dpc-1945	554	5	n	n	CCONJ
dpc-1945	554	6	,	,	PUNCT
dpc-1945	554	7	payne	payne	PROPN
dpc-1945	554	8	m.	m.	NOUN
dpc-1945	554	9	toxicities	toxicity	NOUN
dpc-1945	554	10	associated	associate	VERB
dpc-1945	554	11	with	with	ADP
dpc-1945	554	12	checkpoint	checkpoint	NOUN
dpc-1945	554	13	inhibitors	inhibitor	NOUN
dpc-1945	554	14	-	-	PUNCT
dpc-1945	554	15	an	an	DET
dpc-1945	554	16	overview	overview	NOUN
dpc-1945	554	17	.	.	PUNCT
dpc-1945	555	1	rheumatology	rheumatology	NOUN
dpc-1945	555	2	.	.	PUNCT
dpc-1945	556	1	2019;58(suppl	2019;58(suppl	NOUN
dpc-1945	557	1	7):vii7	7):vii7	ADJ
dpc-1945	557	2	-	-	PUNCT
dpc-1945	557	3	vii16	vii16	NOUN
dpc-1945	557	4	.	.	PUNCT
dpc-1945	558	1	doi	doi	NOUN
dpc-1945	558	2	:	:	PUNCT
dpc-1945	558	3	10.1093	10.1093	NUM
dpc-1945	558	4	/	/	SYM
dpc-1945	558	5	rheumatology	rheumatology	NOUN
dpc-1945	558	6	/	/	SYM
dpc-1945	558	7	kez418	kez418	PROPN
dpc-1945	558	8	.	.	PUNCT
dpc-1945	559	1	pmid	pmid	NOUN
dpc-1945	559	2	:	:	PUNCT
dpc-1945	559	3	31816085	31816085	NUM
dpc-1945	559	4	.	.	PUNCT
dpc-1945	560	1	56	56	NUM
dpc-1945	560	2	.	.	PUNCT
dpc-1945	561	1	ribas	ribas	PROPN
dpc-1945	561	2	a	a	X
dpc-1945	561	3	,	,	PUNCT
dpc-1945	561	4	hamid	hamid	PROPN
dpc-1945	561	5	o	o	PROPN
dpc-1945	561	6	,	,	PUNCT
dpc-1945	561	7	daud	daud	PROPN
dpc-1945	561	8	a	a	X
dpc-1945	561	9	,	,	PUNCT
dpc-1945	561	10	et	et	PROPN
dpc-1945	561	11	al	al	PROPN
dpc-1945	561	12	.	.	PROPN
dpc-1945	561	13	association	association	PROPN
dpc-1945	561	14	of	of	ADP
dpc-1945	561	15	pembrolizumab	pembrolizumab	NOUN
dpc-1945	561	16	with	with	ADP
dpc-1945	561	17	tumor	tumor	NOUN
dpc-1945	561	18	response	response	NOUN
dpc-1945	561	19	and	and	CCONJ
dpc-1945	561	20	survival	survival	NOUN
dpc-1945	561	21	among	among	ADP
dpc-1945	561	22	patients	patient	NOUN
dpc-1945	561	23	with	with	ADP
dpc-1945	561	24	advanced	advanced	ADJ
dpc-1945	561	25	melanoma	melanoma	NOUN
dpc-1945	561	26	.	.	PUNCT
dpc-1945	562	1	jama	jama	PROPN
dpc-1945	562	2	.	.	PUNCT
dpc-1945	563	1	2016;315(15):1600	2016;315(15):1600	NUM
dpc-1945	563	2	-	-	SYM
dpc-1945	563	3	9	9	NUM
dpc-1945	563	4	.	.	PUNCT
dpc-1945	563	5	doi	doi	NOUN
dpc-1945	563	6	:	:	PUNCT
dpc-1945	563	7	10.1001/	10.1001/	NUM
dpc-1945	563	8	jama.2016.4059	jama.2016.4059	PROPN
dpc-1945	563	9	.	.	PUNCT
dpc-1945	564	1	pmid	pmid	NOUN
dpc-1945	564	2	:	:	PUNCT
dpc-1945	564	3	27092830	27092830	NUM
dpc-1945	564	4	.	.	PUNCT
dpc-1945	565	1	57	57	NUM
dpc-1945	565	2	.	.	X
dpc-1945	565	3	nowicki	nowicki	PROPN
dpc-1945	565	4	ts	ts	PROPN
dpc-1945	565	5	,	,	PUNCT
dpc-1945	565	6	hu	hu	PROPN
dpc-1945	565	7	-	-	PROPN
dpc-1945	565	8	lieskovan	lieskovan	PROPN
dpc-1945	565	9	s	s	PROPN
dpc-1945	565	10	,	,	PUNCT
dpc-1945	565	11	ribas	ribas	PROPN
dpc-1945	565	12	a.	a.	NOUN
dpc-1945	565	13	mechanisms	mechanism	NOUN
dpc-1945	565	14	of	of	ADP
dpc-1945	565	15	resistance	resistance	NOUN
dpc-1945	565	16	to	to	ADP
dpc-1945	565	17	pd-1	pd-1	ADJ
dpc-1945	565	18	and	and	CCONJ
dpc-1945	565	19	pd	pd	PROPN
dpc-1945	565	20	-	-	PUNCT
dpc-1945	565	21	l1	l1	PROPN
dpc-1945	565	22	blockade	blockade	NOUN
dpc-1945	565	23	.	.	PUNCT
dpc-1945	566	1	cancer	cancer	NOUN
dpc-1945	566	2	j.	j.	PROPN
dpc-1945	566	3	2018;24(1):47	2018;24(1):47	PROPN
dpc-1945	566	4	-	-	PROPN
dpc-1945	566	5	53	53	NUM
dpc-1945	566	6	.	.	PUNCT
dpc-1945	567	1	doi	doi	NOUN
dpc-1945	567	2	:	:	PUNCT
dpc-1945	567	3	10.1097	10.1097	NUM
dpc-1945	567	4	/	/	SYM
dpc-1945	567	5	ppo.0000000000000303	ppo.0000000000000303	NOUN
dpc-1945	567	6	.	.	PUNCT
dpc-1945	568	1	pmid	pmid	NOUN
dpc-1945	568	2	:	:	PUNCT
dpc-1945	568	3	29360728	29360728	NUM
dpc-1945	568	4	.	.	PUNCT
dpc-1945	569	1	review	review	VERB
dpc-1945	569	2	|	|	ADV
dpc-1945	569	3	dermatol	dermatol	ADJ
dpc-1945	569	4	pract	pract	NOUN
dpc-1945	569	5	concept	concept	NOUN
dpc-1945	569	6	.	.	PUNCT
dpc-1945	570	1	2021	2021	NUM
dpc-1945	570	2	;	;	PUNCT
dpc-1945	570	3	11(s2	11(s2	NUM
dpc-1945	570	4	):	):	PUNCT
dpc-1945	570	5	e2021169s	e2021169s	PROPN
dpc-1945	570	6	11	11	NUM
dpc-1945	570	7	58	58	NUM
dpc-1945	570	8	.	.	PUNCT
dpc-1945	571	1	clinicaltrials.gov	clinicaltrials.gov	X
dpc-1945	571	2	[	[	X
dpc-1945	571	3	internet	internet	NOUN
dpc-1945	571	4	]	]	PUNCT
dpc-1945	571	5	.	.	PUNCT
dpc-1945	572	1	baltimore	baltimore	PROPN
dpc-1945	572	2	(	(	PUNCT
dpc-1945	572	3	md):national	md):national	ADJ
dpc-1945	572	4	library	library	NOUN
dpc-1945	572	5	of	of	ADP
dpc-1945	572	6	medicine	medicine	NOUN
dpc-1945	572	7	(	(	PUNCT
dpc-1945	572	8	us	us	PROPN
dpc-1945	572	9	)	)	PUNCT
dpc-1945	572	10	.	.	PUNCT
dpc-1945	573	1	2000	2000	NUM
dpc-1945	573	2	feb	feb	NOUN
dpc-1945	573	3	29	29	NUM
dpc-1945	573	4	-	-	PUNCT
dpc-1945	573	5	.	.	PUNCT
dpc-1945	573	6	identifier	identifier	PROPN
dpc-1945	573	7	nct03889912	nct03889912	PROPN
dpc-1945	573	8	,	,	PUNCT
dpc-1945	573	9	  	  	SPACE
dpc-1945	573	10	pre	pre	ADJ
dpc-1945	573	11	-	-	ADJ
dpc-1945	573	12	operative	operative	ADJ
dpc-1945	573	13	cemiplimab	cemiplimab	NOUN
dpc-1945	573	14	administered	administer	VERB
dpc-1945	573	15	intralesionally	intralesionally	ADV
dpc-1945	573	16	for	for	ADP
dpc-1945	573	17	patients	patient	NOUN
dpc-1945	573	18	with	with	ADP
dpc-1945	573	19	recurrent	recurrent	ADJ
dpc-1945	573	20	cutaneous	cutaneous	ADJ
dpc-1945	573	21	squamous	squamous	ADJ
dpc-1945	573	22	cell	cell	NOUN
dpc-1945	573	23	carcinoma	carcinoma	NOUN
dpc-1945	573	24	;	;	PUNCT
dpc-1945	574	1	2019	2019	NUM
dpc-1945	574	2	march	march	NOUN
dpc-1945	574	3	26	26	NUM
dpc-1945	574	4	.	.	PUNCT
dpc-1945	574	5	accessed	access	VERB
dpc-1945	574	6	april	april	PROPN
dpc-1945	574	7	15,2021	15,2021	NUM
dpc-1945	574	8	;	;	PUNCT
dpc-1945	574	9	https://clinicaltrials.gov/ct2/show/	https://clinicaltrials.gov/ct2/show/	PROPN
dpc-1945	574	10	nct03889912	nct03889912	NOUN
dpc-1945	574	11	.	.	PUNCT
dpc-1945	575	1	59	59	NUM
dpc-1945	575	2	.	.	X
dpc-1945	575	3	taube	taube	PROPN
dpc-1945	575	4	jm	jm	PROPN
dpc-1945	575	5	,	,	PUNCT
dpc-1945	575	6	klein	klein	PROPN
dpc-1945	575	7	a	a	PROPN
dpc-1945	575	8	,	,	PUNCT
dpc-1945	575	9	brahmer	brahmer	PROPN
dpc-1945	575	10	jr	jr	PROPN
dpc-1945	575	11	,	,	PUNCT
dpc-1945	575	12	et	et	PROPN
dpc-1945	575	13	al	al	PROPN
dpc-1945	575	14	.	.	PROPN
dpc-1945	575	15	association	association	PROPN
dpc-1945	575	16	of	of	ADP
dpc-1945	575	17	pd-1	pd-1	ADV
dpc-1945	575	18	,	,	PUNCT
dpc-1945	575	19	pd-1	pd-1	ADV
dpc-1945	575	20	ligands	ligand	NOUN
dpc-1945	575	21	,	,	PUNCT
dpc-1945	575	22	and	and	CCONJ
dpc-1945	575	23	other	other	ADJ
dpc-1945	575	24	features	feature	NOUN
dpc-1945	575	25	of	of	ADP
dpc-1945	575	26	the	the	DET
dpc-1945	575	27	tumor	tumor	NOUN
dpc-1945	575	28	immune	immune	ADJ
dpc-1945	575	29	microenvironment	microenvironment	NOUN
dpc-1945	575	30	with	with	ADP
dpc-1945	575	31	response	response	NOUN
dpc-1945	575	32	to	to	ADP
dpc-1945	575	33	anti	anti	ADJ
dpc-1945	575	34	-	-	ADJ
dpc-1945	575	35	pd-1	pd-1	ADJ
dpc-1945	575	36	therapy	therapy	NOUN
dpc-1945	575	37	.	.	PUNCT
dpc-1945	576	1	clin	clin	PROPN
dpc-1945	576	2	cancer	cancer	NOUN
dpc-1945	576	3	res	re	NOUN
dpc-1945	576	4	.	.	PUNCT
dpc-1945	577	1	2014;20(19):5064	2014;20(19):5064	NUM
dpc-1945	577	2	-	-	SYM
dpc-1945	577	3	74	74	NUM
dpc-1945	578	1	.	.	PUNCT
dpc-1945	578	2	doi	doi	NOUN
dpc-1945	578	3	:	:	PUNCT
dpc-1945	578	4	10.1158/1078	10.1158/1078	NUM
dpc-1945	578	5	-	-	SYM
dpc-1945	578	6	0432.ccr-13	0432.ccr-13	NOUN
dpc-1945	578	7	-	-	PUNCT
dpc-1945	578	8	3271	3271	NUM
dpc-1945	578	9	.	.	PUNCT
dpc-1945	579	1	pmid	pmid	NOUN
dpc-1945	579	2	:	:	PUNCT
dpc-1945	579	3	24714771	24714771	NUM
dpc-1945	579	4	.	.	PUNCT
dpc-1945	580	1	60	60	NUM
dpc-1945	580	2	.	.	PUNCT
dpc-1945	581	1	tsoukalas	tsoukalas	PROPN
dpc-1945	581	2	n	n	CCONJ
dpc-1945	581	3	,	,	PUNCT
dpc-1945	581	4	kiakou	kiakou	PROPN
dpc-1945	581	5	m	m	PROPN
dpc-1945	581	6	,	,	PUNCT
dpc-1945	581	7	tsapakidis	tsapakidis	PROPN
dpc-1945	581	8	k	k	PROPN
dpc-1945	581	9	,	,	PUNCT
dpc-1945	581	10	et	et	PROPN
dpc-1945	581	11	al	al	PROPN
dpc-1945	581	12	.	.	PROPN
dpc-1945	581	13	pd-1	pd-1	ADP
dpc-1945	581	14	and	and	CCONJ
dpc-1945	581	15	pd	pd	PROPN
dpc-1945	581	16	-	-	PROPN
dpc-1945	581	17	l1	l1	PROPN
dpc-1945	581	18	as	as	ADP
dpc-1945	581	19	immunotherapy	immunotherapy	NOUN
dpc-1945	581	20	targets	target	NOUN
dpc-1945	581	21	and	and	CCONJ
dpc-1945	581	22	biomarkers	biomarker	NOUN
dpc-1945	581	23	in	in	ADP
dpc-1945	581	24	non	non	ADJ
dpc-1945	581	25	-	-	ADJ
dpc-1945	581	26	small	small	ADJ
dpc-1945	581	27	cell	cell	NOUN
dpc-1945	581	28	lung	lung	NOUN
dpc-1945	581	29	cancer	cancer	NOUN
dpc-1945	581	30	.	.	PUNCT
dpc-1945	582	1	j	j	PROPN
dpc-1945	582	2	buon	buon	VERB
dpc-1945	582	3	.	.	PUNCT
dpc-1945	583	1	2019;24(3):883	2019;24(3):883	NUM
dpc-1945	583	2	-	-	PUNCT
dpc-1945	583	3	888	888	NUM
dpc-1945	583	4	.	.	PUNCT
dpc-1945	584	1	pmid	pmid	NOUN
dpc-1945	584	2	:	:	PUNCT
dpc-1945	584	3	31424637	31424637	NUM
dpc-1945	584	4	.	.	PUNCT
dpc-1945	585	1	61	61	NUM
dpc-1945	585	2	.	.	PUNCT
dpc-1945	586	1	fischer	fischer	PROPN
dpc-1945	586	2	s	s	PROPN
dpc-1945	586	3	,	,	PUNCT
dpc-1945	586	4	hasan	hasan	PROPN
dpc-1945	586	5	ali	ali	PROPN
dpc-1945	586	6	o	o	PROPN
dpc-1945	586	7	,	,	PUNCT
dpc-1945	586	8	jochum	jochum	PROPN
dpc-1945	586	9	w	w	PROPN
dpc-1945	586	10	,	,	PUNCT
dpc-1945	586	11	kluckert	kluckert	PROPN
dpc-1945	586	12	t	t	PROPN
dpc-1945	586	13	,	,	PUNCT
dpc-1945	586	14	flatz	flatz	PROPN
dpc-1945	586	15	l	l	PROPN
dpc-1945	586	16	,	,	PUNCT
dpc-1945	586	17	siano	siano	PROPN
dpc-1945	586	18	m.	m.	NOUN
dpc-1945	586	19	anti	anti	ADJ
dpc-1945	586	20	-	-	ADJ
dpc-1945	586	21	pd-1	pd-1	ADJ
dpc-1945	586	22	therapy	therapy	NOUN
dpc-1945	586	23	leads	lead	VERB
dpc-1945	586	24	to	to	ADP
dpc-1945	586	25	near	near	ADJ
dpc-1945	586	26	-	-	PUNCT
dpc-1945	586	27	complete	complete	ADJ
dpc-1945	586	28	remission	remission	NOUN
dpc-1945	586	29	in	in	ADP
dpc-1945	586	30	a	a	DET
dpc-1945	586	31	patient	patient	NOUN
dpc-1945	586	32	with	with	ADP
dpc-1945	586	33	metastatic	metastatic	ADJ
dpc-1945	586	34	basal	basal	NOUN
dpc-1945	586	35	cell	cell	NOUN
dpc-1945	586	36	carcinoma	carcinoma	NOUN
dpc-1945	586	37	.	.	PUNCT
dpc-1945	587	1	oncol	oncol	ADJ
dpc-1945	587	2	res	re	NOUN
dpc-1945	587	3	treat	treat	NOUN
dpc-1945	587	4	.	.	PUNCT
dpc-1945	588	1	2018;41(6):391	2018;41(6):391	NUM
dpc-1945	588	2	-	-	SYM
dpc-1945	588	3	394	394	NUM
dpc-1945	588	4	.	.	PUNCT
dpc-1945	589	1	doi	doi	NOUN
dpc-1945	589	2	:	:	PUNCT
dpc-1945	589	3	10.1159/000487084	10.1159/000487084	NUM
dpc-1945	589	4	.	.	PUNCT
dpc-1945	590	1	pmid	pmid	NOUN
dpc-1945	590	2	:	:	PUNCT
dpc-1945	590	3	29734143	29734143	NUM
dpc-1945	590	4	.	.	PUNCT
dpc-1945	591	1	62	62	NUM
dpc-1945	591	2	.	.	PUNCT
dpc-1945	592	1	shen	shen	PROPN
dpc-1945	593	1	x	x	X
dpc-1945	593	2	,	,	PUNCT
dpc-1945	593	3	zhao	zhao	PROPN
dpc-1945	593	4	b.	b.	PROPN
dpc-1945	593	5	efficacy	efficacy	PROPN
dpc-1945	593	6	of	of	ADP
dpc-1945	593	7	pd-1	pd-1	ADJ
dpc-1945	593	8	or	or	CCONJ
dpc-1945	593	9	pd	pd	PROPN
dpc-1945	593	10	-	-	PUNCT
dpc-1945	593	11	l1	l1	PROPN
dpc-1945	593	12	inhibitors	inhibitor	NOUN
dpc-1945	593	13	and	and	CCONJ
dpc-1945	593	14	pd	pd	PROPN
dpc-1945	593	15	-	-	PUNCT
dpc-1945	593	16	l1	l1	PROPN
dpc-1945	593	17	expression	expression	NOUN
dpc-1945	593	18	status	status	NOUN
dpc-1945	593	19	in	in	ADP
dpc-1945	593	20	cancer	cancer	NOUN
dpc-1945	593	21	:	:	PUNCT
dpc-1945	593	22	meta	meta	ADJ
dpc-1945	593	23	-	-	PUNCT
dpc-1945	593	24	analysis	analysis	NOUN
dpc-1945	593	25	.	.	PUNCT
dpc-1945	594	1	bmj	bmj	PROPN
dpc-1945	594	2	.	.	PUNCT
dpc-1945	595	1	2018;362	2018;362	NUM
dpc-1945	595	2	:	:	PUNCT
dpc-1945	595	3	k3529	k3529	NOUN
dpc-1945	595	4	.	.	PUNCT
dpc-1945	596	1	doi	doi	NOUN
dpc-1945	596	2	:	:	PUNCT
dpc-1945	596	3	10.1136	10.1136	NUM
dpc-1945	596	4	/	/	SYM
dpc-1945	596	5	bmj.k3529	bmj.k3529	NOUN
dpc-1945	596	6	.	.	PUNCT
dpc-1945	597	1	pmid	pmid	NOUN
dpc-1945	597	2	:	:	PUNCT
dpc-1945	597	3	30201790	30201790	NUM
dpc-1945	597	4	.	.	PUNCT
dpc-1945	598	1	63	63	NUM
dpc-1945	598	2	.	.	PUNCT
dpc-1945	599	1	gerlinger	gerlinger	PROPN
dpc-1945	599	2	m	m	PROPN
dpc-1945	599	3	,	,	PUNCT
dpc-1945	599	4	rowan	rowan	PROPN
dpc-1945	599	5	aj	aj	PROPN
dpc-1945	599	6	,	,	PUNCT
dpc-1945	599	7	horswell	horswell	PROPN
dpc-1945	599	8	s	s	PROPN
dpc-1945	599	9	,	,	PUNCT
dpc-1945	599	10	et	et	PROPN
dpc-1945	599	11	al	al	PROPN
dpc-1945	599	12	.	.	PROPN
dpc-1945	599	13	intratumor	intratumor	PROPN
dpc-1945	599	14	heterogeneity	heterogeneity	PROPN
dpc-1945	599	15	and	and	CCONJ
dpc-1945	599	16	branched	branched	ADJ
dpc-1945	599	17	evolution	evolution	NOUN
dpc-1945	599	18	revealed	reveal	VERB
dpc-1945	599	19	by	by	ADP
dpc-1945	599	20	multiregion	multiregion	NOUN
dpc-1945	599	21	sequencing	sequence	VERB
dpc-1945	599	22	.	.	PUNCT
dpc-1945	600	1	n	n	CCONJ
dpc-1945	600	2	engl	engl	PROPN
dpc-1945	600	3	j	j	PROPN
dpc-1945	600	4	med	med	PROPN
dpc-1945	600	5	.	.	PUNCT
dpc-1945	601	1	2012;366(10):883	2012;366(10):883	NUM
dpc-1945	601	2	-	-	SYM
dpc-1945	601	3	892	892	NUM
dpc-1945	601	4	.	.	PUNCT
dpc-1945	602	1	doi	doi	NOUN
dpc-1945	602	2	:	:	PUNCT
dpc-1945	602	3	10.1056/	10.1056/	NUM
dpc-1945	602	4	nejmoa1113205	nejmoa1113205	PROPN
dpc-1945	602	5	.	.	PUNCT
dpc-1945	602	6	2012	2012	NUM
dpc-1945	602	7	sep	sep	PROPN
dpc-1945	602	8	6;367(10):976	6;367(10):976	NOUN
dpc-1945	602	9	.	.	PUNCT
dpc-1945	603	1	pmid	pmid	NOUN
dpc-1945	603	2	:	:	PUNCT
dpc-1945	603	3	22397650	22397650	NUM
dpc-1945	603	4	.	.	PUNCT
dpc-1945	604	1	64	64	NUM
dpc-1945	604	2	.	.	PUNCT
dpc-1945	605	1	krishnamurthy	krishnamurthy	PROPN
dpc-1945	605	2	a	a	PRON
dpc-1945	605	3	,	,	PUNCT
dpc-1945	605	4	jimeno	jimeno	PROPN
dpc-1945	605	5	a.	a.	PROPN
dpc-1945	605	6	atezolizumab	atezolizumab	PROPN
dpc-1945	605	7	:	:	PUNCT
dpc-1945	605	8	a	a	DET
dpc-1945	605	9	novel	novel	ADJ
dpc-1945	605	10	pd	pd	ADJ
dpc-1945	605	11	-	-	PUNCT
dpc-1945	605	12	l1	l1	PROPN
dpc-1945	605	13	inhibitor	inhibitor	NOUN
dpc-1945	605	14	in	in	ADP
dpc-1945	605	15	cancer	cancer	NOUN
dpc-1945	605	16	therapy	therapy	NOUN
dpc-1945	605	17	with	with	ADP
dpc-1945	605	18	a	a	DET
dpc-1945	605	19	focus	focus	NOUN
dpc-1945	605	20	in	in	ADP
dpc-1945	605	21	bladder	bladder	NOUN
dpc-1945	605	22	and	and	CCONJ
dpc-1945	605	23	non	non	ADJ
dpc-1945	605	24	-	-	ADJ
dpc-1945	605	25	small	small	ADJ
dpc-1945	605	26	cell	cell	NOUN
dpc-1945	605	27	lung	lung	NOUN
dpc-1945	605	28	cancers	cancer	NOUN
dpc-1945	605	29	.	.	PUNCT
dpc-1945	606	1	drugs	drug	NOUN
dpc-1945	606	2	today	today	NOUN
dpc-1945	606	3	.	.	PUNCT
dpc-1945	607	1	2017;53(4):217	2017;53(4):217	NUM
dpc-1945	607	2	-	-	SYM
dpc-1945	607	3	237	237	NUM
dpc-1945	607	4	.	.	PUNCT
dpc-1945	608	1	doi	doi	NOUN
dpc-1945	608	2	:	:	PUNCT
dpc-1945	608	3	10.1358/	10.1358/	NUM
dpc-1945	608	4	dot.2017.53.4.2589163	dot.2017.53.4.2589163	NOUN
dpc-1945	608	5	.	.	PUNCT
dpc-1945	609	1	pmid	pmid	NOUN
dpc-1945	609	2	:	:	PUNCT
dpc-1945	609	3	28492290	28492290	NUM
dpc-1945	609	4	.	.	PUNCT
dpc-1945	610	1	65	65	NUM
dpc-1945	610	2	.	.	PUNCT
dpc-1945	611	1	lipson	lipson	PROPN
dpc-1945	611	2	ej	ej	PROPN
dpc-1945	611	3	,	,	PUNCT
dpc-1945	611	4	forde	forde	PROPN
dpc-1945	611	5	pm	pm	PROPN
dpc-1945	611	6	,	,	PUNCT
dpc-1945	611	7	hammers	hammers	PROPN
dpc-1945	611	8	hj	hj	PROPN
dpc-1945	611	9	,	,	PUNCT
dpc-1945	611	10	emens	emen	NOUN
dpc-1945	611	11	la	la	PROPN
dpc-1945	611	12	,	,	PUNCT
dpc-1945	611	13	taube	taube	PROPN
dpc-1945	611	14	jm	jm	PROPN
dpc-1945	611	15	,	,	PUNCT
dpc-1945	611	16	topalian	topalian	PROPN
dpc-1945	611	17	sl	sl	PROPN
dpc-1945	611	18	.	.	PUNCT
dpc-1945	611	19	antagonists	antagonist	NOUN
dpc-1945	611	20	of	of	ADP
dpc-1945	611	21	pd-1	pd-1	ADP
dpc-1945	611	22	and	and	CCONJ
dpc-1945	611	23	pd	pd	PROPN
dpc-1945	611	24	-	-	PROPN
dpc-1945	611	25	l1	l1	PROPN
dpc-1945	611	26	in	in	ADP
dpc-1945	611	27	cancer	cancer	NOUN
dpc-1945	611	28	treatment	treatment	NOUN
dpc-1945	611	29	.	.	PUNCT
dpc-1945	612	1	semin	semin	PROPN
dpc-1945	612	2	oncol	oncol	PROPN
dpc-1945	612	3	.	.	PUNCT
dpc-1945	613	1	2015;42(4):587	2015;42(4):587	NUM
dpc-1945	613	2	-	-	SYM
dpc-1945	613	3	600	600	NUM
dpc-1945	613	4	.	.	PUNCT
dpc-1945	614	1	doi	doi	NOUN
dpc-1945	614	2	:	:	PUNCT
dpc-1945	614	3	10.1053	10.1053	NUM
dpc-1945	614	4	/	/	SYM
dpc-1945	614	5	j.seminoncol.2015.05.013	j.seminoncol.2015.05.013	PROPN
dpc-1945	614	6	.	.	PUNCT
dpc-1945	615	1	pmid	pmid	NOUN
dpc-1945	615	2	:	:	PUNCT
dpc-1945	615	3	26320063	26320063	NUM
dpc-1945	615	4	.	.	PUNCT
dpc-1945	616	1	66	66	NUM
dpc-1945	616	2	.	.	PUNCT
dpc-1945	616	3	bayan	bayan	PROPN
dpc-1945	616	4	cy	cy	PROPN
dpc-1945	616	5	,	,	PUNCT
dpc-1945	616	6	lopez	lopez	PROPN
dpc-1945	616	7	at	at	ADP
dpc-1945	616	8	,	,	PUNCT
dpc-1945	616	9	gartrell	gartrell	PROPN
dpc-1945	616	10	rd	rd	PROPN
dpc-1945	616	11	,	,	PUNCT
dpc-1945	616	12	et	et	PROPN
dpc-1945	616	13	al	al	PROPN
dpc-1945	616	14	.	.	PUNCT
dpc-1945	617	1	the	the	DET
dpc-1945	617	2	role	role	NOUN
dpc-1945	617	3	of	of	ADP
dpc-1945	617	4	oncolytic	oncolytic	ADJ
dpc-1945	617	5	viruses	virus	NOUN
dpc-1945	617	6	in	in	ADP
dpc-1945	617	7	the	the	DET
dpc-1945	617	8	treatment	treatment	NOUN
dpc-1945	617	9	of	of	ADP
dpc-1945	617	10	melanoma	melanoma	NOUN
dpc-1945	617	11	.	.	PUNCT
dpc-1945	618	1	curr	curr	PROPN
dpc-1945	618	2	oncol	oncol	PROPN
dpc-1945	618	3	rep	rep	PROPN
dpc-1945	618	4	.	.	PROPN
dpc-1945	618	5	2018;20(10):80	2018;20(10):80	PROPN
dpc-1945	618	6	.	.	PUNCT
dpc-1945	619	1	doi	doi	NOUN
dpc-1945	619	2	:	:	PUNCT
dpc-1945	619	3	10.1007	10.1007	NUM
dpc-1945	619	4	/	/	SYM
dpc-1945	619	5	s11912	s11912	NOUN
dpc-1945	619	6	-	-	PUNCT
dpc-1945	619	7	018	018	NUM
dpc-1945	619	8	-	-	PUNCT
dpc-1945	619	9	0729	0729	NUM
dpc-1945	619	10	-	-	PUNCT
dpc-1945	619	11	3	3	NUM
dpc-1945	619	12	.	.	PUNCT
dpc-1945	620	1	pmid	pmid	NOUN
dpc-1945	620	2	:	:	PUNCT
dpc-1945	620	3	30145781	30145781	NUM
dpc-1945	620	4	.	.	PUNCT
dpc-1945	621	1	67	67	NUM
dpc-1945	621	2	.	.	PUNCT
dpc-1945	622	1	middleton	middleton	PROPN
dpc-1945	622	2	mr	mr	PROPN
dpc-1945	622	3	,	,	PUNCT
dpc-1945	622	4	sacco	sacco	PROPN
dpc-1945	622	5	jj	jj	PROPN
dpc-1945	622	6	,	,	PUNCT
dpc-1945	622	7	merchan	merchan	PROPN
dpc-1945	622	8	jr	jr	PROPN
dpc-1945	622	9	,	,	PUNCT
dpc-1945	622	10	et	et	PROPN
dpc-1945	622	11	al	al	PROPN
dpc-1945	622	12	.	.	PUNCT
dpc-1945	623	1	an	an	DET
dpc-1945	623	2	open	open	ADJ
dpc-1945	623	3	label	label	NOUN
dpc-1945	623	4	,	,	PUNCT
dpc-1945	623	5	multicenter	multicenter	NOUN
dpc-1945	623	6	,	,	PUNCT
dpc-1945	623	7	phase	phase	NOUN
dpc-1945	623	8	i	i	PRON
dpc-1945	623	9	/	/	SYM
dpc-1945	623	10	ii	ii	PROPN
dpc-1945	623	11	study	study	NOUN
dpc-1945	623	12	of	of	ADP
dpc-1945	623	13	rp1	rp1	PROPN
dpc-1945	623	14	as	as	ADP
dpc-1945	623	15	a	a	DET
dpc-1945	623	16	single	single	ADJ
dpc-1945	623	17	agent	agent	NOUN
dpc-1945	623	18	and	and	CCONJ
dpc-1945	623	19	in	in	ADP
dpc-1945	623	20	combination	combination	NOUN
dpc-1945	623	21	with	with	ADP
dpc-1945	623	22	pd1	pd1	NOUN
dpc-1945	623	23	blockade	blockade	NOUN
dpc-1945	623	24	in	in	ADP
dpc-1945	623	25	patients	patient	NOUN
dpc-1945	623	26	with	with	ADP
dpc-1945	623	27	solid	solid	ADJ
dpc-1945	623	28	tumors	tumor	NOUN
dpc-1945	623	29	.	.	PUNCT
dpc-1945	623	30	  	  	SPACE
dpc-1945	624	1	journal	journal	NOUN
dpc-1945	624	2	of	of	ADP
dpc-1945	624	3	clinical	clinical	ADJ
dpc-1945	624	4	oncology	oncology	NOUN
dpc-1945	624	5	2019:15_suppl	2019:15_suppl	NUM
dpc-1945	624	6	,	,	PUNCT
dpc-1945	624	7	tps2671	tps2671	NOUN
dpc-1945	624	8	-	-	PUNCT
dpc-1945	624	9	tps2671	tps2671	NOUN
dpc-1945	624	10	.	.	PUNCT
dpc-1945	625	1	68	68	NUM
dpc-1945	625	2	.	.	PUNCT
dpc-1945	625	3	phan	phan	PROPN
dpc-1945	625	4	gq	gq	PROPN
dpc-1945	625	5	,	,	PUNCT
dpc-1945	625	6	yang	yang	PROPN
dpc-1945	625	7	jc	jc	PROPN
dpc-1945	625	8	,	,	PUNCT
dpc-1945	625	9	sherry	sherry	PROPN
dpc-1945	625	10	rm	rm	PROPN
dpc-1945	625	11	,	,	PUNCT
dpc-1945	625	12	et	et	PROPN
dpc-1945	625	13	al	al	PROPN
dpc-1945	625	14	.	.	PUNCT
dpc-1945	625	15	cancer	cancer	NOUN
dpc-1945	625	16	regression	regression	NOUN
dpc-1945	625	17	and	and	CCONJ
dpc-1945	625	18	autoimmunity	autoimmunity	NOUN
dpc-1945	625	19	induced	induce	VERB
dpc-1945	625	20	by	by	ADP
dpc-1945	625	21	cytotoxic	cytotoxic	ADJ
dpc-1945	625	22	t	t	PROPN
dpc-1945	625	23	lymphocyte	lymphocyte	NOUN
dpc-1945	625	24	-	-	PUNCT
dpc-1945	625	25	associated	associate	VERB
dpc-1945	625	26	antigen	antigen	ADJ
dpc-1945	625	27	4	4	NUM
dpc-1945	625	28	blockade	blockade	NOUN
dpc-1945	625	29	in	in	ADP
dpc-1945	625	30	patients	patient	NOUN
dpc-1945	625	31	with	with	ADP
dpc-1945	625	32	metastatic	metastatic	ADJ
dpc-1945	625	33	melanoma	melanoma	NOUN
dpc-1945	625	34	.	.	PUNCT
dpc-1945	626	1	proc	proc	PROPN
dpc-1945	626	2	natl	natl	PROPN
dpc-1945	626	3	acad	acad	PROPN
dpc-1945	626	4	sci	sci	PROPN
dpc-1945	626	5	u	u	PROPN
dpc-1945	626	6	s	s	PART
dpc-1945	626	7	a.	a.	NOUN
dpc-1945	626	8	2003;100(14):8372	2003;100(14):8372	NUM
dpc-1945	626	9	-	-	SYM
dpc-1945	626	10	7	7	NUM
dpc-1945	626	11	.	.	PUNCT
dpc-1945	626	12	doi	doi	NOUN
dpc-1945	626	13	:	:	PUNCT
dpc-1945	626	14	10.1073/	10.1073/	NUM
dpc-1945	626	15	pnas.1533209100	pnas.1533209100	PROPN
dpc-1945	626	16	.	.	PUNCT
dpc-1945	627	1	pmid	pmid	NOUN
dpc-1945	627	2	:	:	PUNCT
dpc-1945	627	3	12826605	12826605	NUM
dpc-1945	627	4	.	.	PUNCT
dpc-1945	628	1	69	69	NUM
dpc-1945	628	2	.	.	PUNCT
dpc-1945	629	1	middleton	middleton	PROPN
dpc-1945	629	2	g.	g.	PROPN
dpc-1945	629	3	beyond	beyond	ADP
dpc-1945	629	4	ipilimumab	ipilimumab	NOUN
dpc-1945	629	5	:	:	PUNCT
dpc-1945	629	6	a	a	DET
dpc-1945	629	7	review	review	NOUN
dpc-1945	629	8	of	of	ADP
dpc-1945	629	9	immunotherapeutic	immunotherapeutic	ADJ
dpc-1945	629	10	approaches	approach	NOUN
dpc-1945	629	11	in	in	ADP
dpc-1945	629	12	clinical	clinical	ADJ
dpc-1945	629	13	trials	trial	NOUN
dpc-1945	629	14	in	in	ADP
dpc-1945	629	15	melanoma	melanoma	NOUN
dpc-1945	629	16	,	,	PUNCT
dpc-1945	629	17	  	  	SPACE
dpc-1945	629	18	immunotherapy	immunotherapy	NOUN
dpc-1945	629	19	advances	advance	NOUN
dpc-1945	629	20	.	.	PUNCT
dpc-1945	630	1	ltaa010.2021;1(1	ltaa010.2021;1(1	ADJ
dpc-1945	630	2	)	)	PUNCT
dpc-1945	630	3	.	.	PUNCT
dpc-1945	631	1	doi:10.1093	doi:10.1093	NOUN
dpc-1945	631	2	/	/	SYM
dpc-1945	631	3	immadv	immadv	ADJ
dpc-1945	631	4	/	/	SYM
dpc-1945	631	5	ltaa010	ltaa010	PROPN
dpc-1945	631	6	.	.	PUNCT
dpc-1945	632	1	70	70	NUM
dpc-1945	632	2	.	.	PUNCT
dpc-1945	632	3	day	day	NOUN
dpc-1945	633	1	f	f	X
dpc-1945	633	2	,	,	PUNCT
dpc-1945	633	3	kumar	kumar	PROPN
dpc-1945	633	4	m	m	PROPN
dpc-1945	633	5	,	,	PUNCT
dpc-1945	633	6	fenton	fenton	PROPN
dpc-1945	633	7	l	l	PROPN
dpc-1945	633	8	,	,	PUNCT
dpc-1945	633	9	gedye	gedye	PROPN
dpc-1945	633	10	c.	c.	PROPN
dpc-1945	633	11	durable	durable	ADJ
dpc-1945	633	12	response	response	NOUN
dpc-1945	633	13	of	of	ADP
dpc-1945	633	14	metastatic	metastatic	ADJ
dpc-1945	633	15	squamous	squamous	ADJ
dpc-1945	633	16	cell	cell	NOUN
dpc-1945	633	17	carcinoma	carcinoma	NOUN
dpc-1945	633	18	of	of	ADP
dpc-1945	633	19	the	the	DET
dpc-1945	633	20	skin	skin	NOUN
dpc-1945	633	21	to	to	PART
dpc-1945	633	22	ipilimumab	ipilimumab	VERB
dpc-1945	633	23	immunotherapy	immunotherapy	NOUN
dpc-1945	633	24	.	.	PUNCT
dpc-1945	634	1	j	j	PROPN
dpc-1945	634	2	immunother	immunother	PROPN
dpc-1945	634	3	.	.	PUNCT
dpc-1945	635	1	2017;40(1):36	2017;40(1):36	NUM
dpc-1945	635	2	-	-	SYM
dpc-1945	635	3	38	38	NUM
dpc-1945	635	4	.	.	PUNCT
dpc-1945	636	1	doi	doi	NOUN
dpc-1945	636	2	:	:	PUNCT
dpc-1945	636	3	10.1097/	10.1097/	NUM
dpc-1945	636	4	cji.0000000000000146	cji.0000000000000146	NOUN
dpc-1945	636	5	.	.	PUNCT
dpc-1945	637	1	pmid	pmid	NOUN
dpc-1945	637	2	:	:	PUNCT
dpc-1945	637	3	27684455	27684455	NUM
dpc-1945	637	4	.	.	PUNCT
dpc-1945	638	1	71	71	NUM
dpc-1945	638	2	.	.	PUNCT
dpc-1945	639	1	chen	chen	PROPN
dpc-1945	639	2	j	j	PROPN
dpc-1945	639	3	,	,	PUNCT
dpc-1945	639	4	li	li	PROPN
dpc-1945	639	5	s	s	PROPN
dpc-1945	639	6	,	,	PUNCT
dpc-1945	639	7	yao	yao	PROPN
dpc-1945	639	8	q	q	AUX
dpc-1945	639	9	,	,	PUNCT
dpc-1945	639	10	et	et	PROPN
dpc-1945	639	11	al	al	PROPN
dpc-1945	639	12	.	.	PUNCT
dpc-1945	640	1	the	the	DET
dpc-1945	640	2	efficacy	efficacy	NOUN
dpc-1945	640	3	and	and	CCONJ
dpc-1945	640	4	safety	safety	NOUN
dpc-1945	640	5	of	of	ADP
dpc-1945	640	6	combined	combined	ADJ
dpc-1945	640	7	immune	immune	ADJ
dpc-1945	640	8	checkpoint	checkpoint	NOUN
dpc-1945	640	9	inhibitors	inhibitor	NOUN
dpc-1945	640	10	(	(	PUNCT
dpc-1945	640	11	nivolumab	nivolumab	NOUN
dpc-1945	640	12	plus	plus	CCONJ
dpc-1945	640	13	ipilimumab	ipilimumab	ADV
dpc-1945	640	14	):	):	PUNCT
dpc-1945	640	15	a	a	DET
dpc-1945	640	16	systematic	systematic	ADJ
dpc-1945	640	17	review	review	NOUN
dpc-1945	640	18	and	and	CCONJ
dpc-1945	640	19	meta	meta	ADJ
dpc-1945	640	20	-	-	PUNCT
dpc-1945	640	21	analysis	analysis	NOUN
dpc-1945	640	22	.	.	PUNCT
dpc-1945	641	1	world	world	PROPN
dpc-1945	641	2	j	j	PROPN
dpc-1945	641	3	surg	surg	PROPN
dpc-1945	641	4	oncol	oncol	PROPN
dpc-1945	641	5	.	.	PUNCT
dpc-1945	642	1	2020;18(1):150	2020;18(1):150	NUM
dpc-1945	642	2	.	.	PUNCT
dpc-1945	643	1	doi	doi	NOUN
dpc-1945	643	2	:	:	PUNCT
dpc-1945	643	3	10.1186	10.1186	NUM
dpc-1945	643	4	/	/	SYM
dpc-1945	643	5	s12957	s12957	NOUN
dpc-1945	643	6	-	-	PUNCT
dpc-1945	643	7	020	020	NUM
dpc-1945	643	8	-	-	PUNCT
dpc-1945	643	9	01933	01933	NUM
dpc-1945	643	10	-	-	SYM
dpc-1945	643	11	5	5	NUM
dpc-1945	643	12	.	.	PUNCT
dpc-1945	644	1	pmid	pmid	NOUN
dpc-1945	644	2	:	:	PUNCT
dpc-1945	644	3	32620130	32620130	NUM
dpc-1945	644	4	.	.	PUNCT
dpc-1945	645	1	72	72	NUM
dpc-1945	645	2	.	.	PUNCT
dpc-1945	646	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
dpc-1945	646	2	[	[	X
dpc-1945	646	3	internet	internet	NOUN
dpc-1945	646	4	]	]	PUNCT
dpc-1945	646	5	.	.	PUNCT
dpc-1945	647	1	baltimore	baltimore	PROPN
dpc-1945	647	2	(	(	PUNCT
dpc-1945	647	3	md):national	md):national	ADJ
dpc-1945	647	4	library	library	NOUN
dpc-1945	647	5	of	of	ADP
dpc-1945	647	6	medicine	medicine	NOUN
dpc-1945	647	7	(	(	PUNCT
dpc-1945	647	8	us	us	PROPN
dpc-1945	647	9	)	)	PUNCT
dpc-1945	647	10	.	.	PUNCT
dpc-1945	648	1	2000	2000	NUM
dpc-1945	648	2	feb	feb	NOUN
dpc-1945	648	3	29	29	NUM
dpc-1945	648	4	-	-	PUNCT
dpc-1945	648	5	.	.	PUNCT
dpc-1945	649	1	identifier	identifier	PROPN
dpc-1945	649	2	nct04620200	nct04620200	PROPN
dpc-1945	649	3	,	,	PUNCT
dpc-1945	649	4	neo	neo	NOUN
dpc-1945	649	5	-	-	PUNCT
dpc-1945	649	6	adjuvant	adjuvant	ADJ
dpc-1945	649	7	nivolumab	nivolumab	NOUN
dpc-1945	649	8	or	or	CCONJ
dpc-1945	649	9	nivolumab	nivolumab	NOUN
dpc-1945	649	10	with	with	ADP
dpc-1945	649	11	ipilimumab	ipilimumab	NOUN
dpc-1945	649	12	in	in	ADP
dpc-1945	649	13	advanced	advanced	ADJ
dpc-1945	649	14	cutaneous	cutaneous	ADJ
dpc-1945	649	15	squamous	squamous	ADJ
dpc-1945	649	16	cell	cell	NOUN
dpc-1945	649	17	carcinoma	carcinoma	NOUN
dpc-1945	649	18	prior	prior	ADV
dpc-1945	649	19	to	to	ADP
dpc-1945	649	20	surgery	surgery	NOUN
dpc-1945	649	21	(	(	PUNCT
dpc-1945	649	22	matisse	matisse	PROPN
dpc-1945	649	23	)	)	PUNCT
dpc-1945	649	24	;	;	PUNCT
dpc-1945	649	25	2020	2020	NUM
dpc-1945	649	26	,	,	PUNCT
dpc-1945	649	27	november	november	PROPN
dpc-1945	649	28	6	6	NUM
dpc-1945	649	29	.	.	PUNCT
dpc-1945	649	30	accessed	access	VERB
dpc-1945	649	31	april	april	PROPN
dpc-1945	649	32	15,2021	15,2021	NUM
dpc-1945	649	33	.	.	PUNCT
dpc-1945	650	1	https://	https://	PROPN
dpc-1945	650	2	clinicaltrials.gov/ct2/show/nct04620200	clinicaltrials.gov/ct2/show/nct04620200	PROPN
dpc-1945	650	3	.	.	PUNCT
dpc-1945	651	1	73	73	NUM
dpc-1945	651	2	.	.	PUNCT
dpc-1945	652	1	picard	picard	PROPN
dpc-1945	652	2	a	a	PROPN
dpc-1945	652	3	,	,	PUNCT
dpc-1945	652	4	pedeutour	pedeutour	NOUN
dpc-1945	652	5	f	f	NOUN
dpc-1945	652	6	,	,	PUNCT
dpc-1945	652	7	peyrade	peyrade	NOUN
dpc-1945	652	8	f	f	PROPN
dpc-1945	652	9	,	,	PUNCT
dpc-1945	652	10	et	et	PROPN
dpc-1945	652	11	al	al	PROPN
dpc-1945	652	12	.	.	PROPN
dpc-1945	652	13	association	association	PROPN
dpc-1945	652	14	of	of	ADP
dpc-1945	652	15	oncogenic	oncogenic	ADJ
dpc-1945	652	16	mutations	mutation	NOUN
dpc-1945	652	17	in	in	ADP
dpc-1945	652	18	patients	patient	NOUN
dpc-1945	652	19	with	with	ADP
dpc-1945	652	20	advanced	advanced	ADJ
dpc-1945	652	21	cutaneous	cutaneous	ADJ
dpc-1945	652	22	squamous	squamous	ADJ
dpc-1945	652	23	cell	cell	NOUN
dpc-1945	652	24	carcinomas	carcinoma	NOUN
dpc-1945	652	25	treated	treat	VERB
dpc-1945	652	26	with	with	ADP
dpc-1945	652	27	cetuximab	cetuximab	NOUN
dpc-1945	652	28	.	.	PUNCT
dpc-1945	653	1	jama	jama	PROPN
dpc-1945	653	2	dermatol	dermatol	NOUN
dpc-1945	653	3	.	.	PUNCT
dpc-1945	654	1	2017;153(4):291	2017;153(4):291	NUM
dpc-1945	654	2	-	-	PUNCT
dpc-1945	654	3	298	298	NUM
dpc-1945	654	4	.	.	PUNCT
dpc-1945	654	5	doi	doi	NOUN
dpc-1945	654	6	:	:	PUNCT
dpc-1945	654	7	10.1001	10.1001	NUM
dpc-1945	654	8	/	/	SYM
dpc-1945	654	9	jamadermatol.2017.0270	jamadermatol.2017.0270	PROPN
dpc-1945	654	10	.	.	PUNCT
dpc-1945	655	1	pmid	pmid	NOUN
dpc-1945	655	2	:	:	PUNCT
dpc-1945	655	3	28259104	28259104	NUM
dpc-1945	655	4	.	.	PUNCT
dpc-1945	656	1	74	74	NUM
dpc-1945	656	2	.	.	PUNCT
dpc-1945	657	1	nishino	nishino	PROPN
dpc-1945	657	2	m	m	PROPN
dpc-1945	657	3	,	,	PUNCT
dpc-1945	657	4	ramaiya	ramaiya	PROPN
dpc-1945	657	5	nh	nh	PROPN
dpc-1945	657	6	,	,	PUNCT
dpc-1945	657	7	hatabu	hatabu	PROPN
dpc-1945	657	8	h	h	PROPN
dpc-1945	657	9	,	,	PUNCT
dpc-1945	657	10	hodi	hodi	PROPN
dpc-1945	657	11	fs	fs	PROPN
dpc-1945	657	12	.	.	PROPN
dpc-1945	658	1	monitoring	monitor	VERB
dpc-1945	658	2	immune	immune	NOUN
dpc-1945	658	3	-	-	PUNCT
dpc-1945	658	4	checkpoint	checkpoint	NOUN
dpc-1945	658	5	blockade	blockade	NOUN
dpc-1945	658	6	:	:	PUNCT
dpc-1945	658	7	response	response	NOUN
dpc-1945	658	8	evaluation	evaluation	NOUN
dpc-1945	658	9	and	and	CCONJ
dpc-1945	658	10	biomarker	biomarker	NOUN
dpc-1945	658	11	development	development	NOUN
dpc-1945	658	12	.	.	PUNCT
dpc-1945	659	1	nat	nat	PROPN
dpc-1945	659	2	rev	rev	VERB
dpc-1945	659	3	clin	clin	PROPN
dpc-1945	659	4	oncol	oncol	PROPN
dpc-1945	659	5	.	.	PUNCT
dpc-1945	660	1	2017;14(11):655	2017;14(11):655	NOUN
dpc-1945	660	2	-	-	PUNCT
dpc-1945	660	3	668	668	NUM
dpc-1945	660	4	.	.	PUNCT
dpc-1945	660	5	doi	doi	NOUN
dpc-1945	660	6	:	:	PUNCT
dpc-1945	660	7	10.1038	10.1038	NUM
dpc-1945	660	8	/	/	SYM
dpc-1945	660	9	nrclinonc.2017.88	nrclinonc.2017.88	PROPN
dpc-1945	660	10	.	.	PUNCT
dpc-1945	661	1	pmid	pmid	NOUN
dpc-1945	661	2	:	:	PUNCT
dpc-1945	661	3	28653677	28653677	NUM
dpc-1945	661	4	.	.	PUNCT
dpc-1945	662	1	75	75	NUM
dpc-1945	662	2	.	.	PUNCT
dpc-1945	663	1	guthrie	guthrie	PROPN
dpc-1945	663	2	th	th	PROPN
dpc-1945	663	3	jr	jr	PROPN
dpc-1945	663	4	,	,	PUNCT
dpc-1945	663	5	mcelveen	mcelveen	PROPN
dpc-1945	663	6	lj	lj	PROPN
dpc-1945	663	7	,	,	PUNCT
dpc-1945	663	8	porubsky	porubsky	NOUN
dpc-1945	663	9	es	es	PROPN
dpc-1945	663	10	,	,	PUNCT
dpc-1945	663	11	harmon	harmon	PROPN
dpc-1945	663	12	jd	jd	PROPN
dpc-1945	663	13	.	.	PROPN
dpc-1945	663	14	cisplatin	cisplatin	PROPN
dpc-1945	663	15	and	and	CCONJ
dpc-1945	663	16	doxorubicin	doxorubicin	PROPN
dpc-1945	663	17	.	.	PUNCT
dpc-1945	664	1	an	an	DET
dpc-1945	664	2	effective	effective	ADJ
dpc-1945	664	3	chemotherapy	chemotherapy	NOUN
dpc-1945	664	4	combination	combination	NOUN
dpc-1945	664	5	in	in	ADP
dpc-1945	664	6	the	the	DET
dpc-1945	664	7	treatment	treatment	NOUN
dpc-1945	664	8	of	of	ADP
dpc-1945	664	9	advanced	advanced	ADJ
dpc-1945	664	10	basal	basal	NOUN
dpc-1945	664	11	cell	cell	NOUN
dpc-1945	664	12	and	and	CCONJ
dpc-1945	664	13	squamous	squamous	ADJ
dpc-1945	664	14	carcinoma	carcinoma	NOUN
dpc-1945	664	15	of	of	ADP
dpc-1945	664	16	the	the	DET
dpc-1945	664	17	skin	skin	NOUN
dpc-1945	664	18	.	.	PUNCT
dpc-1945	665	1	cancer	cancer	NOUN
dpc-1945	665	2	.	.	PUNCT
dpc-1945	666	1	1985;55(8):1629	1985;55(8):1629	NUM
dpc-1945	666	2	-	-	SYM
dpc-1945	666	3	32	32	NUM
dpc-1945	666	4	.	.	PUNCT
dpc-1945	667	1	doi	doi	NOUN
dpc-1945	667	2	:	:	PUNCT
dpc-1945	667	3	10.1002/1097	10.1002/1097	NUM
dpc-1945	667	4	-	-	PUNCT
dpc-1945	667	5	0142(19850415)55:8<1629::aid	0142(19850415)55:8<1629::aid	NUM
dpc-1945	667	6	-	-	PUNCT
dpc-1945	667	7	cncr2820550802>3.0.co;2	cncr2820550802>3.0.co;2	NOUN
dpc-1945	667	8	-	-	PUNCT
dpc-1945	667	9	i.	i.	NOUN
dpc-1945	667	10	pmid	pmid	PROPN
dpc-1945	667	11	:	:	PUNCT
dpc-1945	667	12	4038911	4038911	NUM
dpc-1945	667	13	.	.	PUNCT
dpc-1945	668	1	76	76	NUM
dpc-1945	668	2	.	.	PUNCT
dpc-1945	669	1	khansur	khansur	PROPN
dpc-1945	669	2	t	t	PROPN
dpc-1945	669	3	,	,	PUNCT
dpc-1945	669	4	kennedy	kennedy	PROPN
dpc-1945	669	5	a.	a.	PROPN
dpc-1945	669	6	cisplatin	cisplatin	PROPN
dpc-1945	669	7	and	and	CCONJ
dpc-1945	669	8	5	5	NUM
dpc-1945	669	9	-	-	PUNCT
dpc-1945	669	10	fluorouracil	fluorouracil	NOUN
dpc-1945	669	11	for	for	ADP
dpc-1945	669	12	advanced	advanced	ADJ
dpc-1945	669	13	locoregional	locoregional	ADJ
dpc-1945	669	14	and	and	CCONJ
dpc-1945	669	15	metastatic	metastatic	ADJ
dpc-1945	669	16	squamous	squamous	ADJ
dpc-1945	669	17	cell	cell	NOUN
dpc-1945	669	18	carcinoma	carcinoma	NOUN
dpc-1945	669	19	of	of	ADP
dpc-1945	669	20	the	the	DET
dpc-1945	669	21	skin	skin	NOUN
dpc-1945	669	22	.	.	PUNCT
dpc-1945	670	1	cancer	cancer	NOUN
dpc-1945	670	2	.	.	PUNCT
dpc-1945	671	1	1991;67(8):2030	1991;67(8):2030	NUM
dpc-1945	671	2	-	-	SYM
dpc-1945	671	3	2	2	NUM
dpc-1945	671	4	.	.	PUNCT
dpc-1945	671	5	doi	doi	NOUN
dpc-1945	671	6	:	:	PUNCT
dpc-1945	671	7	10	10	NUM
dpc-1945	671	8	.1002	.1002	NOUN
dpc-1945	671	9	/1097	/1097	NOUN
dpc-1945	671	10	-	-	PUNCT
dpc-1945	671	11	0142(19910415)67	0142(19910415)67	NOUN
dpc-1945	671	12	:	:	PUNCT
dpc-1945	671	13	8<2030	8<2030	NUM
dpc-1945	671	14	:	:	PUNCT
dpc-1945	671	15	:	:	PUNCT
dpc-1945	671	16	a	a	DET
dpc-1945	671	17	i	i	PROPN
dpc-1945	671	18	d	d	PROPN
dpc-1945	671	19	cn	cn	PROPN
dpc-1945	671	20	cr2820670803>3.0.co;2	cr2820670803>3.0.co;2	PROPN
dpc-1945	671	21	-	-	PUNCT
dpc-1945	671	22	k.	k.	NOUN
dpc-1945	671	23	pmid	pmid	PROPN
dpc-1945	671	24	:	:	PUNCT
dpc-1945	671	25	2004320	2004320	NUM
dpc-1945	671	26	.	.	PUNCT
dpc-1945	672	1	77	77	NUM
dpc-1945	672	2	.	.	PUNCT
dpc-1945	673	1	merimsky	merimsky	ADJ
dpc-1945	673	2	o	o	NOUN
dpc-1945	673	3	,	,	PUNCT
dpc-1945	673	4	neudorfer	neudorfer	PROPN
dpc-1945	673	5	m	m	PROPN
dpc-1945	673	6	,	,	PUNCT
dpc-1945	673	7	spitzer	spitzer	PROPN
dpc-1945	673	8	e	e	PROPN
dpc-1945	673	9	,	,	PUNCT
dpc-1945	673	10	chaitchik	chaitchik	PROPN
dpc-1945	673	11	s.	s.	PROPN
dpc-1945	673	12	salvage	salvage	PROPN
dpc-1945	673	13	cisplatin	cisplatin	NOUN
dpc-1945	673	14	and	and	CCONJ
dpc-1945	673	15	adriamycin	adriamycin	NOUN
dpc-1945	673	16	for	for	ADP
dpc-1945	673	17	advanced	advanced	ADJ
dpc-1945	673	18	or	or	CCONJ
dpc-1945	673	19	recurrent	recurrent	ADJ
dpc-1945	673	20	basal	basal	NOUN
dpc-1945	673	21	or	or	CCONJ
dpc-1945	673	22	squamous	squamous	ADJ
dpc-1945	673	23	cell	cell	NOUN
dpc-1945	673	24	carcinoma	carcinoma	NOUN
dpc-1945	673	25	of	of	ADP
dpc-1945	673	26	the	the	DET
dpc-1945	673	27	face	face	NOUN
dpc-1945	673	28	.	.	PUNCT
dpc-1945	674	1	anticancer	anticancer	NOUN
dpc-1945	674	2	drugs	drug	NOUN
dpc-1945	674	3	.	.	PUNCT
dpc-1945	675	1	1992;3(5):481	1992;3(5):481	NUM
dpc-1945	675	2	-	-	SYM
dpc-1945	675	3	4	4	NUM
dpc-1945	675	4	.	.	PUNCT
dpc-1945	675	5	doi	doi	NOUN
dpc-1945	675	6	:	:	PUNCT
dpc-1945	675	7	10.1097/00001813	10.1097/00001813	NUM
dpc-1945	675	8	-	-	SYM
dpc-1945	675	9	199210000	199210000	NUM
dpc-1945	675	10	-	-	PUNCT
dpc-1945	675	11	00006	00006	NUM
dpc-1945	675	12	.	.	PUNCT
dpc-1945	676	1	pmid	pmid	NOUN
dpc-1945	676	2	:	:	PUNCT
dpc-1945	676	3	1450442	1450442	NUM
dpc-1945	676	4	.	.	PUNCT
dpc-1945	677	1	78	78	NUM
dpc-1945	677	2	.	.	PUNCT
dpc-1945	678	1	cartei	cartei	NOUN
dpc-1945	678	2	g	g	NOUN
dpc-1945	678	3	,	,	PUNCT
dpc-1945	678	4	cartei	cartei	NOUN
dpc-1945	678	5	f	f	PROPN
dpc-1945	678	6	,	,	PUNCT
dpc-1945	678	7	interlandi	interlandi	NOUN
dpc-1945	678	8	g	g	PROPN
dpc-1945	678	9	,	,	PUNCT
dpc-1945	678	10	et	et	PROPN
dpc-1945	678	11	al	al	PROPN
dpc-1945	678	12	.	.	PROPN
dpc-1945	679	1	oral	oral	ADJ
dpc-1945	679	2	5	5	NUM
dpc-1945	679	3	-	-	PUNCT
dpc-1945	679	4	fluorouracil	fluorouracil	NOUN
dpc-1945	679	5	in	in	ADP
dpc-1945	679	6	squamous	squamous	ADJ
dpc-1945	679	7	cell	cell	NOUN
dpc-1945	679	8	carcinoma	carcinoma	NOUN
dpc-1945	679	9	of	of	ADP
dpc-1945	679	10	the	the	DET
dpc-1945	679	11	skin	skin	NOUN
dpc-1945	679	12	in	in	ADP
dpc-1945	679	13	the	the	DET
dpc-1945	679	14	aged	age	VERB
dpc-1945	679	15	.	.	PUNCT
dpc-1945	680	1	am	be	AUX
dpc-1945	680	2	j	j	PROPN
dpc-1945	680	3	clin	clin	PROPN
dpc-1945	680	4	oncol	oncol	PROPN
dpc-1945	680	5	.	.	PUNCT
dpc-1945	681	1	2000;23(2):181	2000;23(2):181	NUM
dpc-1945	681	2	-	-	SYM
dpc-1945	681	3	4	4	NUM
dpc-1945	681	4	.	.	PUNCT
dpc-1945	681	5	doi	doi	NOUN
dpc-1945	681	6	:	:	PUNCT
dpc-1945	681	7	10.1097/00000421	10.1097/00000421	NUM
dpc-1945	681	8	-	-	SYM
dpc-1945	681	9	200004000	200004000	NUM
dpc-1945	681	10	-	-	PUNCT
dpc-1945	681	11	00015	00015	NUM
dpc-1945	681	12	.	.	PUNCT
dpc-1945	682	1	pmid	pmid	NOUN
dpc-1945	682	2	:	:	PUNCT
dpc-1945	682	3	10776981	10776981	NUM
dpc-1945	682	4	.	.	PUNCT
dpc-1945	683	1	79	79	NUM
dpc-1945	683	2	.	.	PUNCT
dpc-1945	684	1	shin	shin	PROPN
dpc-1945	684	2	dm	dm	PROPN
dpc-1945	684	3	,	,	PUNCT
dpc-1945	684	4	glisson	glisson	NOUN
dpc-1945	684	5	bs	bs	NOUN
dpc-1945	684	6	,	,	PUNCT
dpc-1945	684	7	khuri	khuri	PROPN
dpc-1945	684	8	fr	fr	PROPN
dpc-1945	684	9	,	,	PUNCT
dpc-1945	684	10	et	et	PROPN
dpc-1945	684	11	al	al	PROPN
dpc-1945	684	12	.	.	PROPN
dpc-1945	684	13	phase	phase	PROPN
dpc-1945	684	14	ii	ii	PROPN
dpc-1945	684	15	and	and	CCONJ
dpc-1945	684	16	biologic	biologic	NOUN
dpc-1945	684	17	study	study	NOUN
dpc-1945	684	18	of	of	ADP
dpc-1945	684	19	interferon	interferon	ADJ
dpc-1945	684	20	alfa	alfa	PROPN
dpc-1945	684	21	,	,	PUNCT
dpc-1945	684	22	retinoic	retinoic	PROPN
dpc-1945	684	23	acid	acid	NOUN
dpc-1945	684	24	,	,	PUNCT
dpc-1945	684	25	and	and	CCONJ
dpc-1945	684	26	cisplatin	cisplatin	NOUN
dpc-1945	684	27	in	in	ADP
dpc-1945	684	28	advanced	advanced	ADJ
dpc-1945	684	29	squamous	squamous	ADJ
dpc-1945	684	30	skin	skin	NOUN
dpc-1945	684	31	cancer	cancer	NOUN
dpc-1945	684	32	.	.	PUNCT
dpc-1945	685	1	j	j	PROPN
dpc-1945	685	2	clin	clin	PROPN
dpc-1945	685	3	oncol	oncol	PROPN
dpc-1945	685	4	.	.	PUNCT
dpc-1945	686	1	2002;20(2):364	2002;20(2):364	NOUN
dpc-1945	686	2	-	-	SYM
dpc-1945	686	3	70	70	NUM
dpc-1945	686	4	.	.	PUNCT
dpc-1945	687	1	doi	doi	NOUN
dpc-1945	687	2	:	:	PUNCT
dpc-1945	687	3	10.1200	10.1200	NUM
dpc-1945	687	4	/	/	SYM
dpc-1945	687	5	jco.2002.20.2.364	jco.2002.20.2.364	PROPN
dpc-1945	687	6	.	.	PUNCT
dpc-1945	688	1	pmid	pmid	NOUN
dpc-1945	688	2	:	:	PUNCT
dpc-1945	688	3	11786562	11786562	NUM
dpc-1945	688	4	.	.	PUNCT
dpc-1945	689	1	80	80	NUM
dpc-1945	689	2	.	.	PUNCT
dpc-1945	690	1	fujisawa	fujisawa	PROPN
dpc-1945	690	2	y	y	PROPN
dpc-1945	690	3	,	,	PUNCT
dpc-1945	690	4	umebayashi	umebayashi	PROPN
dpc-1945	690	5	y	y	PROPN
dpc-1945	690	6	,	,	PUNCT
dpc-1945	690	7	ichikawa	ichikawa	PROPN
dpc-1945	690	8	e	e	NOUN
dpc-1945	690	9	,	,	PUNCT
dpc-1945	690	10	kawachi	kawachi	PROPN
dpc-1945	690	11	y	y	PROPN
dpc-1945	690	12	,	,	PUNCT
dpc-1945	690	13	otsuka	otsuka	PROPN
dpc-1945	690	14	f.	f.	PROPN
dpc-1945	690	15	chemoradiation	chemoradiation	PROPN
dpc-1945	690	16	using	use	VERB
dpc-1945	690	17	low	low	ADJ
dpc-1945	690	18	-	-	PUNCT
dpc-1945	690	19	dose	dose	NOUN
dpc-1945	690	20	cisplatin	cisplatin	NOUN
dpc-1945	690	21	and	and	CCONJ
dpc-1945	690	22	5	5	NUM
dpc-1945	690	23	-	-	PUNCT
dpc-1945	690	24	fluorouracil	fluorouracil	NOUN
dpc-1945	690	25	in	in	ADP
dpc-1945	690	26	locally	locally	ADV
dpc-1945	690	27	advanced	advance	VERB
dpc-1945	690	28	squamous	squamous	ADJ
dpc-1945	690	29	cell	cell	NOUN
dpc-1945	690	30	carcinoma	carcinoma	NOUN
dpc-1945	690	31	of	of	ADP
dpc-1945	690	32	the	the	DET
dpc-1945	690	33	skin	skin	NOUN
dpc-1945	690	34	:	:	PUNCT
dpc-1945	690	35	a	a	DET
dpc-1945	690	36	report	report	NOUN
dpc-1945	690	37	of	of	ADP
dpc-1945	690	38	two	two	NUM
dpc-1945	690	39	cases	case	NOUN
dpc-1945	690	40	.	.	PUNCT
dpc-1945	691	1	j	j	PROPN
dpc-1945	691	2	am	be	AUX
dpc-1945	691	3	acad	acad	ADJ
dpc-1945	691	4	dermatol	dermatol	NOUN
dpc-1945	691	5	.	.	PUNCT
dpc-1945	692	1	2006;55(5	2006;55(5	NUM
dpc-1945	692	2	suppl):s81	suppl):s81	NOUN
dpc-1945	692	3	-	-	PUNCT
dpc-1945	692	4	5	5	NUM
dpc-1945	692	5	.	.	PUNCT
dpc-1945	692	6	doi	doi	NOUN
dpc-1945	692	7	:	:	PUNCT
dpc-1945	692	8	10.1016	10.1016	NUM
dpc-1945	692	9	/	/	SYM
dpc-1945	692	10	j.jaad.2005.12.035	j.jaad.2005.12.035	PROPN
dpc-1945	692	11	.	.	PUNCT
dpc-1945	693	1	pmid	pmid	NOUN
dpc-1945	693	2	:	:	PUNCT
dpc-1945	693	3	17052540	17052540	NUM
dpc-1945	693	4	.	.	PUNCT
dpc-1945	694	1	81	81	NUM
dpc-1945	694	2	.	.	PUNCT
dpc-1945	695	1	hillen	hillen	PROPN
dpc-1945	695	2	u	u	PROPN
dpc-1945	695	3	,	,	PUNCT
dpc-1945	695	4	leiter	leiter	PROPN
dpc-1945	695	5	u	u	PROPN
dpc-1945	695	6	,	,	PUNCT
dpc-1945	695	7	haase	haase	PROPN
dpc-1945	695	8	s	s	PROPN
dpc-1945	695	9	,	,	PUNCT
dpc-1945	695	10	et	et	PROPN
dpc-1945	695	11	al	al	PROPN
dpc-1945	695	12	.	.	PUNCT
dpc-1945	696	1	dermatologic	dermatologic	ADJ
dpc-1945	696	2	cooperative	cooperative	ADJ
dpc-1945	696	3	oncology	oncology	NOUN
dpc-1945	696	4	group	group	NOUN
dpc-1945	696	5	(	(	PUNCT
dpc-1945	696	6	decog	decog	VERB
dpc-1945	696	7	)	)	PUNCT
dpc-1945	696	8	.	.	PUNCT
dpc-1945	697	1	advanced	advanced	ADJ
dpc-1945	697	2	cutaneous	cutaneous	ADJ
dpc-1945	697	3	squamous	squamous	ADJ
dpc-1945	697	4	cell	cell	NOUN
dpc-1945	697	5	carcinoma	carcinoma	NOUN
dpc-1945	697	6	:	:	PUNCT
dpc-1945	697	7	a	a	DET
dpc-1945	697	8	retrospective	retrospective	ADJ
dpc-1945	697	9	analysis	analysis	NOUN
dpc-1945	697	10	of	of	ADP
dpc-1945	697	11	patient	patient	ADJ
dpc-1945	697	12	profiles	profile	NOUN
dpc-1945	697	13	and	and	CCONJ
dpc-1945	697	14	treatment	treatment	NOUN
dpc-1945	697	15	patterns	pattern	NOUN
dpc-1945	697	16	-	-	PUNCT
dpc-1945	697	17	results	result	NOUN
dpc-1945	697	18	of	of	ADP
dpc-1945	697	19	a	a	DET
dpc-1945	697	20	non	non	ADJ
dpc-1945	697	21	-	-	ADJ
dpc-1945	697	22	interventional	interventional	ADJ
dpc-1945	697	23	study	study	NOUN
dpc-1945	697	24	of	of	ADP
dpc-1945	697	25	the	the	DET
dpc-1945	697	26	decog	decog	VERB
dpc-1945	697	27	.	.	PUNCT
dpc-1945	698	1	eur	eur	PROPN
dpc-1945	698	2	j	j	PROPN
dpc-1945	698	3	cancer	cancer	NOUN
dpc-1945	698	4	.	.	PUNCT
dpc-1945	699	1	2018;96:34	2018;96:34	NUM
dpc-1945	699	2	-	-	SYM
dpc-1945	699	3	43	43	NUM
dpc-1945	699	4	.	.	PUNCT
dpc-1945	700	1	doi	doi	NOUN
dpc-1945	700	2	:	:	PUNCT
dpc-1945	700	3	10.1016	10.1016	NUM
dpc-1945	700	4	/	/	SYM
dpc-1945	700	5	j.ejca.2018.01.075	j.ejca.2018.01.075	PROPN
dpc-1945	700	6	.	.	PUNCT
dpc-1945	701	1	pmid	pmid	NOUN
dpc-1945	701	2	:	:	PUNCT
dpc-1945	701	3	29665511	29665511	NUM
dpc-1945	701	4	.	.	PUNCT
dpc-1945	702	1	82	82	NUM
dpc-1945	702	2	.	.	PUNCT
dpc-1945	703	1	preneau	preneau	PROPN
dpc-1945	703	2	s	s	PROPN
dpc-1945	703	3	,	,	PUNCT
dpc-1945	703	4	rio	rio	PROPN
dpc-1945	703	5	e	e	PROPN
dpc-1945	703	6	,	,	PUNCT
dpc-1945	703	7	brocard	brocard	VERB
dpc-1945	703	8	a	a	PRON
dpc-1945	703	9	,	,	PUNCT
dpc-1945	703	10	et	et	PROPN
dpc-1945	703	11	al	al	PROPN
dpc-1945	703	12	.	.	PROPN
dpc-1945	703	13	efficacy	efficacy	NOUN
dpc-1945	703	14	of	of	ADP
dpc-1945	703	15	cetuximab	cetuximab	NOUN
dpc-1945	703	16	in	in	ADP
dpc-1945	703	17	the	the	DET
dpc-1945	703	18	treatment	treatment	NOUN
dpc-1945	703	19	of	of	ADP
dpc-1945	703	20	squamous	squamous	ADJ
dpc-1945	703	21	cell	cell	NOUN
dpc-1945	703	22	carcinoma	carcinoma	NOUN
dpc-1945	703	23	.	.	PUNCT
dpc-1945	704	1	j	j	PROPN
dpc-1945	704	2	dermatolog	dermatolog	PROPN
dpc-1945	704	3	treat	treat	NOUN
dpc-1945	704	4	.	.	PUNCT
dpc-1945	705	1	2014;25(5):424	2014;25(5):424	NUM
dpc-1945	705	2	-	-	SYM
dpc-1945	705	3	7	7	NUM
dpc-1945	705	4	.	.	PUNCT
dpc-1945	705	5	doi	doi	NOUN
dpc-1945	705	6	:	:	PUNCT
dpc-1945	705	7	10.3109/09546634.2012.751481	10.3109/09546634.2012.751481	NUM
dpc-1945	705	8	.	.	PUNCT
dpc-1945	706	1	pmid	pmid	NOUN
dpc-1945	706	2	:	:	PUNCT
dpc-1945	706	3	23167307	23167307	NUM
dpc-1945	706	4	.	.	PUNCT
dpc-1945	707	1	83	83	NUM
dpc-1945	707	2	.	.	PUNCT
dpc-1945	708	1	reigneau	reigneau	PROPN
dpc-1945	708	2	m	m	PROPN
dpc-1945	708	3	,	,	PUNCT
dpc-1945	708	4	robert	robert	PROPN
dpc-1945	708	5	c	c	PROPN
dpc-1945	708	6	,	,	PUNCT
dpc-1945	708	7	routier	routier	X
dpc-1945	708	8	e	e	PROPN
dpc-1945	708	9	,	,	PUNCT
dpc-1945	708	10	et	et	PROPN
dpc-1945	708	11	al	al	PROPN
dpc-1945	708	12	.	.	PROPN
dpc-1945	708	13	efficacy	efficacy	PROPN
dpc-1945	708	14	of	of	ADP
dpc-1945	708	15	neoadjuvant	neoadjuvant	ADJ
dpc-1945	708	16	cetuximab	cetuximab	NOUN
dpc-1945	708	17	alone	alone	ADJ
dpc-1945	708	18	or	or	CCONJ
dpc-1945	708	19	with	with	ADP
dpc-1945	708	20	platinum	platinum	NOUN
dpc-1945	708	21	salt	salt	NOUN
dpc-1945	708	22	for	for	ADP
dpc-1945	708	23	the	the	DET
dpc-1945	708	24	treatment	treatment	NOUN
dpc-1945	708	25	of	of	ADP
dpc-1945	708	26	unresectable	unresectable	ADJ
dpc-1945	708	27	advanced	advanced	ADJ
dpc-1945	708	28	nonmetastatic	nonmetastatic	ADJ
dpc-1945	708	29	cutaneous	cutaneous	ADJ
dpc-1945	708	30	squamous	squamous	ADJ
dpc-1945	708	31	cell	cell	NOUN
dpc-1945	708	32	carcinomas	carcinoma	NOUN
dpc-1945	708	33	.	.	PUNCT
dpc-1945	709	1	br	br	PROPN
dpc-1945	709	2	j	j	PROPN
dpc-1945	709	3	dermatol	dermatol	NOUN
dpc-1945	709	4	.	.	PUNCT
dpc-1945	710	1	2015	2015	NUM
dpc-1945	710	2	aug;173(2):527	aug;173(2):527	NOUN
dpc-1945	710	3	-	-	PUNCT
dpc-1945	710	4	34	34	NUM
dpc-1945	710	5	.	.	PUNCT
dpc-1945	711	1	doi	doi	NOUN
dpc-1945	711	2	:	:	PUNCT
dpc-1945	711	3	10.1111/	10.1111/	NUM
dpc-1945	711	4	bjd.13741	bjd.13741	PROPN
dpc-1945	711	5	.	.	PUNCT
dpc-1945	712	1	pmid	pmid	NOUN
dpc-1945	712	2	:	:	PUNCT
dpc-1945	712	3	25704233	25704233	NUM
dpc-1945	712	4	.	.	PUNCT
dpc-1945	713	1	84	84	NUM
dpc-1945	713	2	.	.	PUNCT
dpc-1945	714	1	in	in	ADP
dpc-1945	714	2	gk	gk	PROPN
dpc-1945	714	3	,	,	PUNCT
dpc-1945	714	4	vaidya	vaidya	PROPN
dpc-1945	714	5	p	p	PROPN
dpc-1945	714	6	,	,	PUNCT
dpc-1945	714	7	filkins	filkin	VERB
dpc-1945	714	8	a	a	PRON
dpc-1945	714	9	,	,	PUNCT
dpc-1945	714	10	et	et	PROPN
dpc-1945	714	11	al	al	PROPN
dpc-1945	714	12	.	.	PROPN
dpc-1945	714	13	pd-1	pd-1	ADP
dpc-1945	714	14	inhibition	inhibition	NOUN
dpc-1945	714	15	therapy	therapy	NOUN
dpc-1945	714	16	for	for	ADP
dpc-1945	714	17	advanced	advanced	ADJ
dpc-1945	714	18	cutaneous	cutaneous	ADJ
dpc-1945	714	19	squamous	squamous	ADJ
dpc-1945	714	20	cell	cell	NOUN
dpc-1945	714	21	carcinoma	carcinoma	NOUN
dpc-1945	714	22	:	:	PUNCT
dpc-1945	714	23	a	a	DET
dpc-1945	714	24	retrospective	retrospective	ADJ
dpc-1945	714	25	analysis	analysis	NOUN
dpc-1945	714	26	from	from	ADP
dpc-1945	714	27	the	the	DET
dpc-1945	714	28	university	university	PROPN
dpc-1945	714	29	of	of	ADP
dpc-1945	714	30	southern	southern	PROPN
dpc-1945	714	31	california	california	PROPN
dpc-1945	714	32	.	.	PUNCT
dpc-1945	715	1	j	j	PROPN
dpc-1945	715	2	cancer	cancer	NOUN
dpc-1945	715	3	res	re	VERB
dpc-1945	715	4	clin	clin	PROPN
dpc-1945	715	5	oncol	oncol	PROPN
dpc-1945	715	6	.	.	PUNCT
dpc-1945	716	1	2021;147(6):1803	2021;147(6):1803	NUM
dpc-1945	716	2	-	-	SYM
dpc-1945	716	3	1811	1811	NUM
dpc-1945	716	4	.	.	PUNCT
dpc-1945	717	1	doi	doi	NOUN
dpc-1945	717	2	:	:	PUNCT
dpc-1945	717	3	10.1007	10.1007	NUM
dpc-1945	717	4	/	/	SYM
dpc-1945	717	5	s00432	s00432	NOUN
dpc-1945	717	6	-	-	PUNCT
dpc-1945	717	7	02003458	02003458	NUM
dpc-1945	717	8	-	-	PUNCT
dpc-1945	717	9	6	6	NUM
dpc-1945	717	10	.	.	PUNCT
dpc-1945	718	1	pmid	pmid	NOUN
dpc-1945	718	2	:	:	PUNCT
dpc-1945	718	3	33210210	33210210	NUM
dpc-1945	718	4	.	.	PUNCT
dpc-1945	719	1	12	12	NUM
dpc-1945	719	2	review	review	NOUN
dpc-1945	719	3	|	|	ADV
dpc-1945	719	4	dermatol	dermatol	ADJ
dpc-1945	719	5	pract	pract	NOUN
dpc-1945	719	6	concept	concept	NOUN
dpc-1945	719	7	.	.	PUNCT
dpc-1945	720	1	2021	2021	NUM
dpc-1945	720	2	;	;	PUNCT
dpc-1945	720	3	11(s2	11(s2	NUM
dpc-1945	720	4	):	):	PUNCT
dpc-1945	720	5	e2021169s	e2021169s	PROPN
dpc-1945	720	6	85	85	NUM
dpc-1945	720	7	.	.	PUNCT
dpc-1945	721	1	salzmann	salzmann	PROPN
dpc-1945	721	2	m	m	PROPN
dpc-1945	721	3	,	,	PUNCT
dpc-1945	721	4	leiter	leiter	PROPN
dpc-1945	721	5	u	u	PROPN
dpc-1945	721	6	,	,	PUNCT
dpc-1945	721	7	loquai	loquai	PROPN
dpc-1945	721	8	c	c	NOUN
dpc-1945	721	9	,	,	PUNCT
dpc-1945	721	10	et	et	PROPN
dpc-1945	721	11	al	al	PROPN
dpc-1945	721	12	.	.	PROPN
dpc-1945	721	13	programmed	program	VERB
dpc-1945	721	14	cell	cell	NOUN
dpc-1945	721	15	death	death	NOUN
dpc-1945	721	16	protein	protein	NOUN
dpc-1945	721	17	1	1	NUM
dpc-1945	721	18	inhibitors	inhibitor	NOUN
dpc-1945	721	19	in	in	ADP
dpc-1945	721	20	advanced	advanced	ADJ
dpc-1945	721	21	cutaneous	cutaneous	ADJ
dpc-1945	721	22	squamous	squamous	ADJ
dpc-1945	721	23	cell	cell	NOUN
dpc-1945	721	24	carcinoma	carcinoma	NOUN
dpc-1945	721	25	:	:	PUNCT
dpc-1945	721	26	real	real	ADJ
dpc-1945	721	27	-	-	PUNCT
dpc-1945	721	28	world	world	NOUN
dpc-1945	721	29	data	datum	NOUN
dpc-1945	721	30	of	of	ADP
dpc-1945	721	31	a	a	DET
dpc-1945	721	32	retrospective	retrospective	ADJ
dpc-1945	721	33	,	,	PUNCT
dpc-1945	721	34	multicenter	multicenter	ADJ
dpc-1945	721	35	study	study	NOUN
dpc-1945	721	36	.	.	PUNCT
dpc-1945	722	1	eur	eur	PROPN
dpc-1945	722	2	j	j	PROPN
dpc-1945	722	3	cancer	cancer	NOUN
dpc-1945	722	4	.	.	PUNCT
dpc-1945	723	1	2020;138:125	2020;138:125	NUM
dpc-1945	723	2	-	-	SYM
dpc-1945	723	3	132	132	NUM
dpc-1945	724	1	.	.	PUNCT
dpc-1945	724	2	doi	doi	NOUN
dpc-1945	724	3	:	:	PUNCT
dpc-1945	724	4	10.1016	10.1016	NUM
dpc-1945	724	5	/	/	SYM
dpc-1945	724	6	j.ejca.2020.07.029	j.ejca.2020.07.029	PROPN
dpc-1945	724	7	.	.	PUNCT
dpc-1945	725	1	pmid	pmid	NOUN
dpc-1945	725	2	:	:	PUNCT
dpc-1945	725	3	32882466	32882466	NUM
dpc-1945	725	4	.	.	PUNCT
dpc-1945	726	1	86	86	NUM
dpc-1945	726	2	.	.	PUNCT
dpc-1945	727	1	eton	eton	PROPN
dpc-1945	727	2	o	o	PROPN
dpc-1945	727	3	,	,	PUNCT
dpc-1945	727	4	hsu	hsu	PROPN
dpc-1945	727	5	e	e	PROPN
dpc-1945	727	6	,	,	PUNCT
dpc-1945	727	7	patel	patel	PROPN
dpc-1945	727	8	a	a	PRON
dpc-1945	727	9	,	,	PUNCT
dpc-1945	727	10	et	et	PROPN
dpc-1945	727	11	al	al	PROPN
dpc-1945	727	12	.	.	PUNCT
dpc-1945	727	13	anti	anti	ADJ
dpc-1945	727	14	-	-	ADJ
dpc-1945	727	15	egfr	egfr	ADJ
dpc-1945	727	16	antibody	antibody	NOUN
dpc-1945	727	17	added	add	VERB
dpc-1945	727	18	to	to	ADP
dpc-1945	727	19	ongoing	ongoing	ADJ
dpc-1945	727	20	anti	anti	ADJ
dpc-1945	727	21	-	-	ADJ
dpc-1945	727	22	pd-1	pd-1	ADJ
dpc-1945	727	23	antibody	antibody	NOUN
dpc-1945	727	24	treatment	treatment	NOUN
dpc-1945	727	25	for	for	ADP
dpc-1945	727	26	metastatic	metastatic	ADJ
dpc-1945	727	27	cutaneous	cutaneous	ADJ
dpc-1945	727	28	squamous	squamous	ADJ
dpc-1945	727	29	cell	cell	NOUN
dpc-1945	727	30	carcinoma	carcinoma	NOUN
dpc-1945	727	31	of	of	ADP
dpc-1945	727	32	the	the	DET
dpc-1945	727	33	face	face	NOUN
dpc-1945	727	34	:	:	PUNCT
dpc-1945	727	35	two	two	NUM
dpc-1945	727	36	case	case	NOUN
dpc-1945	727	37	reports	report	VERB
dpc-1945	727	38	.	.	PUNCT
dpc-1945	728	1	journal	journal	NOUN
dpc-1945	728	2	for	for	ADP
dpc-1945	728	3	immunotherapy	immunotherapy	NOUN
dpc-1945	728	4	of	of	ADP
dpc-1945	728	5	cancer	cancer	NOUN
dpc-1945	728	6	.	.	PUNCT
dpc-1945	729	1	2020;8	2020;8	NOUN
dpc-1945	729	2	.	.	PUNCT
dpc-1945	730	1	doi	doi	NOUN
dpc-1945	730	2	:	:	PUNCT
dpc-1945	730	3	10.1136	10.1136	NUM
dpc-1945	730	4	/	/	SYM
dpc-1945	730	5	jitc-2020sitc2020.0467	jitc-2020sitc2020.0467	NUM
dpc-1945	730	6	.	.	PUNCT